



(86) Date de dépôt PCT/PCT Filing Date: 2003/05/02
(87) Date publication PCT/PCT Publication Date: 2004/02/05
(85) Entrée phase nationale/National Entry: 2004/11/02
(86) N° demande PCT/PCT Application No.: US 2003/013743
(87) N° publication PCT/PCT Publication No.: 2004/010925
(30) Priorité/Priority: 2002/05/02 (60/377,136) US

(51) Cl.Int.⁷/Int.Cl.⁷ C12N 15/12, A61K 31/7088, A61K 48/00,
A61K 39/395, C12Q 1/02, C07K 14/47, C07K 14/435,
C12Q 1/68
(71) Demandeur/Applicant:
VANDERBILT UNIVERSITY, US
(72) Inventeur/Inventor:
RUBIN, DONALD H., US
(74) Agent: GOWLING LAFLEUR HENDERSON LLP

(54) Titre : GENES DE MAMMIFERE IMPLIQUES DANS LA SUPPRESSION DES INFECTIONS VIRALES ET DES
TUMEURS

(54) Title: MAMMALIAN GENES INVOLVED IN VIRAL INFECTION AND TUMOR SUPPRESSION

(57) **Abrégé/Abstract:**

The present invention provides methods of identifying cellular genes used for viral, bacterial or parasitic growth. Also provided by the present invention are nucleic acids related to and methods of reducing or preventing viral, bacterial or parasitic infection.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
5 February 2004 (05.02.2004)

PCT

(10) International Publication Number
WO 2004/010925 A2

(51) International Patent Classification⁷: **A61K**
(21) International Application Number: PCT/US2003/013743
(22) International Filing Date: 2 May 2003 (02.05.2003)
(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data: 60/377,136 2 May 2002 (02.05.2002) US
(71) Applicant (for all designated States except US): **VAN-
DERBILT UNIVERSITY** [US/US]; Office of Technology
Transfer, 1207 17th Avenue South, Suite 105, Nashville,
TN 37212 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.
(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventor; and
(75) Inventor/Applicant (for US only): **RUBIN, Donald, H.**
[US/US]; 1937 Edenbridge Way, Nashville, TN 37215
(US).
(74) Agents: **NEEDLE & ROSENBERG, P.C.** et al.; The
Candler Building, 127 Peachtree Street, Atlanta, GA
30303-1811 (US).

Published:
— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: MAMMALIAN GENES INVOLVED IN VIRAL INFECTION AND TUMOR SUPPRESSION

(57) Abstract: The present invention provides methods of identifying cellular genes used for viral, bacterial or parasitic growth. Also provided by the present invention are nucleic acids related to and methods of reducing or preventing viral, bacterial or parasitic infection.

WO 2004/010925 A2

DEMANDE OU BREVET VOLUMINEUX

LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND PLUS D'UN TOME.

CECI EST LE TOME 1 DE 2
CONTENANT LES PAGES 1 À 244

NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets

JUMBO APPLICATIONS/PATENTS

THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE VOLUME

THIS IS VOLUME 1 OF 2
CONTAINING PAGES 1 TO 244

NOTE: For additional volumes, please contact the Canadian Patent Office

NOM DU FICHER / FILE NAME :

NOTE POUR LE TOME / VOLUME NOTE:

MAMMALIAN GENES INVOLVED IN VIRAL INFECTION AND TUMOR SUPPRESSION

This application claims priority to U. S. Provisional Application Serial No.
5 60/377,136, filed May 2, 2002 which is hereby incorporated in its entirety by this reference.

BACKGROUND

Field of the Invention

10 The present invention provides methods of identifying cellular genes used for viral, bacterial or parasitic growth or for tumor progression. Thus, the present invention relates to nucleic acids related to and methods of reducing or preventing viral, bacterial or parasitic infection and for suppressing tumor progression. The invention also relates to methods for screening for additional such genes.

15 Background art

Various projects have been directed toward isolating and sequencing the genome of various animals, notably the human. However, most methodologies provide nucleotide sequences for which no function is linked or even suggested, thus limiting the immediate usefulness of such data.

20 The present invention, in contrast, provides methods of screening only for nucleic acids that are involved in a specific process, *i.e.*, viral infection, bacterial or parasitic or tumor progression, and further, for nucleic acids useful in treatments for these processes because by this method only nucleic acids which are also nonessential to the cell are isolated. Such methods are highly useful, since they ascribe a function
25 to each isolated gene, and thus the isolated nucleic acids can immediately be utilized in various specific methods and procedures.

For, example, the present invention provides methods of isolating nucleic acids encoding gene products used for viral infection, but nonessential to the cell. Viral infections of the intestine and liver are significant causes of human morbidity
30 and mortality. Understanding the molecular mechanisms of such infections will lead to new approaches in their treatment and control.

Viruses can establish a variety of types of infection. These infections can be generally classified as lytic or persistent, though some lytic infections are considered persistent. Generally, persistent infections fall into two categories: (1) chronic

(productive) infection, *i.e.*, infection wherein infectious virus is present and can be recovered by traditional biological methods and (2) latent infection, *i.e.*, infection wherein viral genome is present in the cell but infectious virus is generally not produced except during intermittent episodes of reactivation. Persistence generally involves stages of both productive and latent infection.

Lytic infections can also persist under conditions where only a small fraction of the total cells are infected (smoldering (cycling) infection). The few infected cells release virus and are killed, but the progeny virus again only infect a small number of the total cells. Examples of such smoldering infections include the persistence of lactic dehydrogenase virus in mice (Mahy, B.W.J., *Br. Med. Bull.* 41: 50-55 (1985)) and adenovirus infection in humans (Porter, D.D. pp. 784-790 in Baron, S., ed. *Medical Microbiology* 2d ed. (Addison-Wesley, Menlo Park, CA 1985)).

Furthermore, a virus may be lytic for some cell types but not for others. For example, evidence suggests that human immunodeficiency virus (HIV) is more lytic for T cells than for monocytes/macrophages, and therefore can result in a productive infection of T cells that can result in cell death, whereas HIV-infected mononuclear phagocytes may produce virus for considerable periods of time without cell lysis. (Klatzmann, et al. *Science* 225:59-62 (1984); Koyanagi, et al. *Science* 241:1673-1675 (1988); Sattentau, et al. *Cell* 52:631-633 (1988)).

Traditional treatments for viral infection include pharmaceuticals aimed at specific virus derived proteins, such as HIV protease or reverse transcriptase, or recombinant (cloned) immune modulators (host derived), such as the interferons. However, the current methods have several limitations and drawbacks which include high rates of viral mutations which render anti-viral pharmaceuticals ineffective. For immune modulators, limited effectiveness, limiting side effects, a lack of specificity all limit the general applicability of these agents. Also the rate of success with current antivirals and immune-modulators has been disappointing.

The current invention focuses on isolating genes that are not essential for cellular survival when disrupted in one or both alleles, but which are required for virus replication. This may occur with a dose effect, in which one allele knock-out may confer the phenotype of virus resistance for the cell. As targets for therapeutic intervention, inhibition of these cellular gene products, including: proteins, parts of proteins (modification enzymes that include, but are not restricted to glycosylation, lipid modifiers [myriolate, etc.]), lipids, transcription elements and RNA regulatory

molecules, may be less likely to have profound toxic side effects and virus mutation is less likely to overcome the 'block' to replicate successfully.

The present invention provides a significant improvement over previous methods of attempted therapeutic intervention against viral infection by addressing
5 the cellular genes required by the virus for growth. Therefore, the present invention also provides an innovative therapeutic approach to intervention in viral infection by providing methods to treat viruses by inhibiting the cellular genes necessary for viral infection. Because these genes, by virtue of the means by which they are originally detected, are nonessential to the cell's survival, these treatment methods can be used
10 in a subject without serious detrimental effects to the subject, as has been found with previous methods. The present invention also provides the surprising discovery that virally infected cells are dependent upon a factor in serum to survive. Therefore, the present invention also provides a method for treating viral infection by inhibiting this serum survival factor. Finally, these discoveries also provide a novel method for
15 removing virally infected cells from a cell culture by removing, inhibiting or disrupting this serum survival factor in the culture so that non-infected cells selectively survive.

The methods provided herein can also be used against bacterial and/or parasitic infections. Specifically, the same methods are employed but a parasite or
20 bacteria replaces the virus.

The selection of tumor suppressor gene(s) has become an important area in the discovery of new target for therapeutic intervention of cancer. Since the discovery that cells are restricted from promiscuous entry into the cell cycle by specific genes that are capable of suppressing a 'transformed' phenotype, considerable time has been
25 invested in the discovery of such genes. Some of these genes include the gene associated by rhabdomyosarcoma (Rb) and the p53 (apoptosis related) encoding gene. The present invention provides a method, using gene-trapping, to select cell lines that have transformed phenotype from cells that are not transformed and to isolate from these cells a gene that either participates in or can suppress a malignant phenotype.
30 Thus, by the nature of the isolation process, a function is associated with the isolated genes. The capacity to select quickly tumor suppressor genes or oncogenes can provide unique targets in the process of treating or preventing, and even for diagnostic testing of, cancer.

DETAILED DESCRIPTION OF THE INVENTION

The present invention utilizes a "gene trap" method along with a selection process to identify and isolate nucleic acids from genes associated with a particular function. Specifically, it provides a means of isolating cellular genes necessary for viral infection but not essential for the cell's survival, and it provides a means of isolating cellular genes that suppress tumor progression.

The present invention also provides a core discovery that virally infected cells become dependent upon at least one factor present in serum for survival, whereas non-infected cells do not exhibit this dependence. This core discovery has been utilized in the present invention in several ways. First, inhibition of the "serum survival factor" can be utilized to eradicate persistently virally infected cells from populations of non-infected cells. Inhibition of this factor can also be used to treat virus infection in a subject, as further described herein. Additionally, inhibition of or withdrawal of the serum survival factor in tissue culture allows for the detection of cellular genes required for viral replication yet nonessential for an uninfected cell to survive.^y The present invention further provides several such cellular genes, as well as methods of treating viral infections by inhibiting the functioning of such genes.

As used herein, "replication" and "infection" can include any of the processes for viral success in a cell, e.g. infection, growth, replication, and lysis.

Furthermore, the present invention provides a method for isolation of cellular genes utilized in tumor progression.

The invention also provides cellular genes whose overexpression is associated with inhibition of viral growth and/or reproduction.

The present method provides several cellular genes that are necessary for viral growth in the cell but are not essential for the cell to survive. These genes are important for lytic and persistent infection by viruses. These genes were isolated by generating gene trap libraries by infecting cells with a retrovirus gene trap vector, selecting for cells in which a gene trap event occurred (*i.e.*, in which the vector had inserted such that the promoterless marker gene was inserted such that a cellular promoter promotes transcription of the marker gene, *i.e.*, inserted into a functioning gene), starving the cells of serum, infecting the selected cells with the virus of choice while continuing serum starvation, and adding back serum to allow visible colonies to develop, which colonies were cloned by limiting dilution. Genes into which the

retrovirus gene trap vector inserted were then isolated from the colonies using probes specific for the retrovirus gene trap vector. Thus nucleic acids isolated by this method are isolated portions of genes. Additionally, utilizing this method, several cellular genes were isolated whose overexpression prevents viral infection or tumor growth, and they provide methods of treating viral infection or tumor growth/suppression by overexpression of these genes.

The present invention identifies the genomic loci of genes required for viral replication or responsible for a malignant phenotype by providing genomic sequences disrupted by the present gene trap method. Providing the sequence of the disrupted locus identifies the gene that is disrupted. Thus, the invention provides the gene at the locus disrupted by the present gene trap vector. By identifying the gene that is disrupted, the invention provides both the gene and its product(s) as targets for antiviral therapies.

As targets for anti-viral or anti-cancer therapies, the invention provides several examples of regulatory sequences (e.g., transcription factors). In some cases, disruption of the transcription factor has a direct impact on viral growth. In other cases disruption of the transcription factor affects viral growth by affecting transcription or translation of the gene or genes that are under its control. Examples of multi-gene pathways controlled by a transcription factor that is disrupted by the present vectors, such as the CTCF pathway, are provided herein.

Thus the present invention provides a method of identifying a cellular gene necessary for viral growth in a cell and nonessential for cellular survival, comprising (a) transferring into a cell culture growing in serum-containing medium a vector encoding a selective marker gene lacking a functional promoter, (b) selecting cells expressing the marker gene, (c) removing serum from the culture medium, (d) infecting the cell culture with the virus, and (e) isolating from the surviving cells a cellular gene within which the marker gene is inserted, thereby identifying a gene necessary for viral growth in a cell and nonessential for cellular survival. The present invention also provides a method of identifying a cellular gene used for viral growth in a cell and nonessential for cellular survival, comprising (a) transferring into a cell culture growing in serum-containing medium a vector encoding a selective marker gene lacking a functional promoter, (b) selecting cells expressing the marker gene, (c) removing serum from the culture medium, (d) infecting the cell culture with the virus, and (e) isolating from the surviving cells a cellular gene within which the

marker gene is inserted, thereby identifying a gene necessary for viral growth in a cell and nonessential for cellular survival. In any selected cell type, such as Chinese hamster ovary cells, one can readily determine if serum starvation is required for selection. If it is not, serum starvation may be eliminated from the steps.

5 Thus the present invention provides a method of identifying a cellular gene necessary for viral growth in a cell and nonessential for cellular survival, comprising (a) transferring into a cell culture growing in serum-containing medium a vector encoding a selective marker gene lacking a functional promoter, (b) selecting cells expressing the marker gene, (c) infecting the cell culture with the virus, and (d)
10 isolating from the surviving cells a cellular gene within which the marker gene is inserted, thereby identifying a gene necessary for viral growth in a cell and nonessential for cellular survival. The present invention also provides a method of identifying a cellular gene used for viral growth in a cell and nonessential for cellular survival, comprising (a) transferring into a cell culture growing in serum-containing
15 medium a vector encoding a selective marker gene lacking a functional promoter, (b) selecting cells expressing the marker gene, (c) infecting the cell culture with the virus, and (d) isolating from the surviving cells a cellular gene within which the marker gene is inserted, thereby identifying a gene necessary for viral growth in a cell and nonessential for cellular survival.

20 Alternatively, instead of removing serum from the culture medium, a serum factor required by the virus for growth can be inhibited, such as by the administration of an antibody that specifically binds that factor. Furthermore, if it is believed that there are no or few persistently infected cells in the culture, the serum starvation step can be eliminated and the cells grown in usual medium for the cell type. Thus, the
25 method can be used without regard for the serum survival factor where the virus is lytic to the selection cell. If serum starvation is used, it can be continued for a time after the culture is infected with the virus. Serum can then be added back to the culture. If some other method is used to inactivate the factor, it can be discontinued, inactivated or removed (such as removing the anti-factor antibody, *e.g.*, with a bound
30 antibody directed against that antibody) prior to adding fresh serum back to the culture. Cells that survive are mutants having an inactivating insertion in a gene necessary for growth of the virus. The genes having the insertions can then be isolated by isolating sequences having the marker gene sequences. This mutational process disturbs a wild type function. A mutant gene may produce at a lower level a

normal product, it may produce a normal product not normally found in these cells, it may cause the overproduction of a normal product, it may produce an altered product that has some functions but not others, or it may completely disrupt a gene function. Additionally, the mutation may disrupt an RNA that has a function but is never
5 translated into a protein. For example, the alpha-tropomyosin gene has a 3' RNA that is very important in cell regulation but never is translated into protein. (*Cell* 75 pg 1107-1117, 12/17/93).

As used herein, a cellular gene "nonessential for cellular survival" means a gene for which disruption of one or both alleles results in a cell viable for at least a
10 period of time which allows viral replication to be inhibited for preventative or therapeutic uses or use in research. A gene "necessary for viral growth" means the gene product, either protein or RNA, secreted or not, is necessary, either directly or indirectly in some way for the virus to grow, and therefore, in the absence of that gene product (*i.e.*, a functionally available gene product), at least some of the cells
15 containing the virus die. For example, such genes can encode cell cycle regulatory proteins, proteins affecting the vacuolar hydrogen pump, or proteins involved in protein folding and protein modification, including but not limited to: phosphorylation, methylation, glycosylation, myristylation or other lipid moiety, or protein processing via enzymatic processing. Some examples of such genes are
20 exemplified herein, wherein some of the isolated nucleic acids correspond to genes such as vacuolar H⁺-ATPase, alpha tropomyosin, gas5 gene, ras complex, N-acetylglucosaminyltransferase I mRNA, and calcyclin.

Any virus capable of infecting the cell can be used for this method. Virus can be selected based upon the particular infection desired to study. However, it is
25 contemplated by the present invention that many viruses will be dependent upon the same cellular genes for survival; thus a cellular gene isolated using one virus can be used as a target for therapy for other viruses as well. All viruses that can be sorted using lytic infection, or that can be selected through multiple rounds of robotic infection (if the cell line is not totally lytic), can be sorted against PI cells by using
30 multiple rounds of selection in the same library. During this process the inserts in PI cells should be random, unless the disrupted gene is important for the establishment of the PI state. Other genes selected should be in cells that are resistant to infection; thus, this process is facilitated by robotic selection, as multiple rounds of selection can be achieved.

- Any cellular gene can be tested for relevancy to any desired virus using the methods set forth herein, *i.e.*, in general, by inhibiting the gene or its gene product in a cell and determining if the desired virus can grow in that cell. Some examples of viruses include HIV (including HIV-1 and HIV-2); parvovirus; papillomaviruses;
- 5 SARS (severe acute respiratory syndrome) virus; hantaviruses; influenza viruses (*e.g.*, influenza A, B and C viruses); hepatitis viruses A to G; caliciviruses; astroviruses; rotaviruses; coronaviruses, such as human respiratory coronavirus; picornaviruses, such as human rhinovirus and enterovirus; ebola virus; human herpesvirus (*e.g.*, HSV-1-9) including zoster, epstein-bar, and human cytomegalovirus; human
- 10 cytomegalovirus; human adenovirus; hantaviruses; for animal, the animal counterpart to any above listed human virus, animal retroviruses, such as simian immunodeficiency virus, avian immunodeficiency virus, bovine immunodeficiency virus, feline immunodeficiency virus, equine infectious anemia virus, caprine arthritis encephalitis virus or visna virus.
- 15 The methods of the present invention can be used to indentify and target bacteria. Examples of bacteria that can be targeted include, but are not limited to, the following: *Listeria* (sp.), *Mycobacterium tuberculosis*, *Rickettsia* (all types), *Ehrlichia*, *Chylamida*. Further examples of bacteria that can be targeted by the present methods include *M. tuberculosis*, *M. bovis*, *M. bovis* strain BCG, BCG
- 20 substrains, *M. avium*, *M. intracellulare*, *M. africanum*, *M. kansasii*, *M. marinum*, *M. ulcerans*, *M. avium* subspecies *paratuberculosis*, *Nocardia asteroides*, other *Nocardia* species, *Legionella pneumophila*, other *Legionella* species, *Salmonella typhi*, other *Salmonella* species, *Shigella* species, *Yersinia pestis*, *Pasteurella haemolytica*, *Pasteurella multocida*, other *Pasteurella* species, *Actinobacillus pleuropneumoniae*,
- 25 *Listeria monocytogenes*, *Listeria ivanovii*, *Brucella abortus*, other *Brucella* species, *Cowdria ruminantium*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Chlamydia psittaci*, *Coxiella burnetti*, other *Rickettsial* species, *Ehrlichia* species, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Streptococcus pyogenes*, *Streptococcus agalactiae*, *Bacillus anthracis*, *Escherichia coli*, *Vibrio cholerae*, *Campylobacter*
- 30 species, *Neisseria meningitidis*, *Neisseria gonorrhea*, *Pseudomonas aeruginosa*, other *Pseudomonas* species, *Haemophilus influenzae*, *Haemophilus ducreyi*, other *Hemophilus* species, *Clostridium tetani*, other *Clostridium* species, *Yersinia enterolitica*, and other *Yersinia* species.

The methods of the present invention can be used to indentify and target parasites. Examples of parasites that can be targeted include, but are not limited to, the following: Cryptosporidium, Plasmodium (all species), American trypanosomes (T. cruzi). Furthermore, examples of protozoan and fungal species contemplated

5 within the present methods include, but are not limited to, *Plasmodium falciparum*, other *Plasmodium* species, *Toxoplasma gondii*, *Pneumocystis carinii*, *Trypanosoma cruzi*, other trypanosomal species, *Leishmania donovani*, other *Leishmania* species, *Theileria annulata*, other *Theileria* species, *Eimeria tenella*, other *Eimeria* species, *Histoplasma capsulatum*, *Cryptococcus neoformans*, *Blastomyces dermatitidis*,

10 *Coccidioides immitis*, *Paracoccidioides brasiliensis*, *Pneumocystis carinii*, *Penicillium marneffeii*, and *Candida* species.

The nucleic acids comprising cellular genes of this invention were isolated by the above method and as set forth in the examples. The invention includes a nucleic

15 acid comprising the nucleotide sequence set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ

20 ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ

25 ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ

30 ID NO:73, SEQ ID NO:74 or SEQ ID NO:75, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO:95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO:104, SEQ ID NO: 105, SEQ ID

NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 113, SEQ ID NO: 114
 SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID
 NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124,
 SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID
 5 NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133,
 SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO:
 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ
 ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147,
 SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID
 10 NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156,
 SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID
 NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165,
 SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID
 NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174,
 15 SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 178, SEQ ID NO: 179,
 SEQ ID NO: 180, SEQ ID NO: 181, SEQ ID NO: 182, SEQ ID NO: 183, SEQ ID
 NO: 184, SEQ ID NO: 185, SEQ ID NO: 186, SEQ ID NO: 187, SEQ ID NO: 188,
 SEQ ID NO: 189, SEQ ID NO: 190, SEQ ID NO: 191, SEQ ID NO: 192, SEQ ID
 NO: 193, SEQ ID NO: 194, SEQ ID NO: 195, SEQ ID NO: 196, SEQ ID NO: 197,
 20 SEQ ID NO: 198, SEQ ID NO: 199, SEQ ID NO: 200, SEQ ID NO: 201, SEQ ID
 NO: 202, SEQ ID NO: 203, SEQ ID NO: 204, SEQ ID NO: 205, SEQ ID NO: 207,
 SEQ ID NO: 208, SEQ ID NO: 209, SEQ ID NO: 210, SEQ ID NO: 211, SEQ ID
 NO: 212, SEQ ID NO: 213, SEQ ID NO: 214, SEQ ID NO: 215, SEQ ID NO: 216,
 SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID
 25 NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225,
 SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID
 NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, SEQ ID NO: 234
 SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID NO: 238, SEQ ID
 NO: 239, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 244, SEQ ID NO: 245,
 30 SEQ ID NO: 246, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO:
 251, SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 254, SEQ ID NO: 255, SEQ ID
 NO: 256, SEQ ID NO: 257, SEQ ID NO: 258, SEQ ID NO: 259, SEQ ID NO: 260,
 SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO:
 265, SEQ ID NO: 266, SEQ ID NO: 267, SEQ ID NO: 268, SEQ ID NO: 269, SEQ

ID NO: 270, SEQ ID NO: 271, SEQ ID NO: 272, SEQ ID NO: 273, SEQ ID NO: 274
 SEQ ID NO: 275, SEQ ID NO: 276, SEQ ID NO: 277, SEQ ID NO: 278, SEQ ID
 NO: 279, SEQ ID NO: 280, SEQ ID NO: 281, SEQ ID NO: 282, SEQ ID NO: 283,
 SEQ ID NO: 284, SEQ ID NO: 285, SEQ ID NO: 286, SEQ ID NO: 287, SEQ ID
 5 NO: 288, SEQ ID NO: 289, SEQ ID NO: 290, SEQ ID NO: 291, SEQ ID NO: 292,
 SEQ ID NO: 293, SEQ ID NO: 294, SEQ ID NO: 295, SEQ ID NO: 296, SEQ ID NO:
 297, SEQ ID NO: 298, SEQ ID NO: 299, SEQ ID NO: 300, SEQ ID NO: 301, SEQ ID
 NO: 302, SEQ ID NO: 303, SEQ ID NO: 304, SEQ ID NO: 305, SEQ ID NO: 306,
 SEQ ID NO: 307, SEQ ID NO: 308, SEQ ID NO: 309, SEQ ID NO: 310, SEQ ID
 10 NO: 311, SEQ ID NO: 312, SEQ ID NO: 313, SEQ ID NO: 314, SEQ ID NO: 315,
 SEQ ID NO: 316, SEQ ID NO: 317, SEQ ID NO: 318, SEQ ID NO: 319, SEQ ID
 NO: 320, SEQ ID NO: 321, SEQ ID NO: 322, SEQ ID NO: 323, SEQ ID NO: 324,
 SEQ ID NO: 325, SEQ ID NO: 326, SEQ ID NO: 327, SEQ ID NO: 328, SEQ ID
 NO: 329, SEQ ID NO: 330, SEQ ID NO: 331, SEQ ID NO: 332, SEQ ID
 NO: 333, SEQ ID NO: 334, SEQ ID NO: 335, SEQ ID NO: 336, SEQ ID NO: 337,
 15 SEQ ID NO: 338, SEQ ID NO: 339, SEQ ID NO: 340, SEQ ID NO: 341, SEQ ID NO: 342,
 SEQ ID NO: 343, SEQ ID NO: 344, SEQ ID NO: 345, SEQ ID NO: 346, SEQ ID NO: 347,
 SEQ ID NO: 348, SEQ ID NO: 349, SEQ ID NO: 350, SEQ ID NO: 351, SEQ ID NO: 352,
 SEQ ID NO: 353, SEQ ID NO: 354, SEQ ID NO: 355, SEQ ID NO: 356, SEQ ID NO: 357,
 SEQ ID NO: 358, SEQ ID NO: 359, SEQ ID NO: 360, SEQ ID NO: 361, SEQ ID NO: 362,
 SEQ ID NO: 363, SEQ ID NO: 364, SEQ ID NO: 365, SEQ ID NO: 366, SEQ ID NO: 367,
 20 SEQ ID NO: 368, SEQ ID NO: 369, SEQ ID NO: 370, SEQ ID NO: 371, SEQ ID NO: 372,
 SEQ ID NO: 373, SEQ ID NO: 374, SEQ ID NO: 375, SEQ ID NO: 376, SEQ ID NO:
 377, SEQ ID NO: 378, SEQ ID NO: 379, SEQ ID NO: 380, SEQ ID NO: 381, SEQ
 ID NO: 382, SEQ ID NO: 383, SEQ ID NO: 384, SEQ ID NO: 385, SEQ ID NO: 386,
 25 SEQ ID NO: 387, SEQ ID NO: 388, SEQ ID NO: 389, SEQ ID NO: 390, SEQ ID
 NO: 391, SEQ ID NO: 392, SEQ ID NO: 393, SEQ ID NO: 394, SEQ ID NO: 395,
 SEQ ID NO: 396, SEQ ID NO: 397, SEQ ID NO: 398, SEQ ID NO: 399, SEQ ID
 NO: 400, SEQ ID NO: 401, SEQ ID NO: 402, SEQ ID NO: 403, SEQ ID NO: 404,
 SEQ ID NO: 405, SEQ ID NO: 406, SEQ ID NO: 407, SEQ ID NO: 408, SEQ ID
 30 NO: 409, SEQ ID NO: 410, SEQ ID NO: 411, SEQ ID NO: 412, SEQ ID NO: 413,
 SEQ ID NO: 414, SEQ ID NO: 415, SEQ ID NO: 416, SEQ ID NO: 417, SEQ ID NO: 418,
 SEQ ID NO: 419, SEQ ID NO: 420, SEQ ID NO: 421, SEQ ID NO: 422, SEQ ID
 NO: 423, SEQ ID NO: 424, SEQ ID NO: 425, SEQ ID NO: 426, SEQ ID NO: 427
 SEQ ID NO: 428 (this list is sometimes referred to herein as SEQ ID LIST 1 for
 brevity). Thus these nucleic acids can contain, in addition to the nucleotides set forth

in each SEQ ID NO in the sequence listing, additional nucleotides at either end of the molecule. Such additional nucleotides can be added by any standard method, as known in the art, such as recombinant methods and synthesis methods. Examples of such nucleic acids comprising the nucleotide sequence set forth in any entry of the sequence listing contemplated by this invention include, but are not limited to, for example, the nucleic acid placed into a vector; a nucleic acid having one or more regulatory region (*e.g.*, promoter, enhancer, polyadenylation site) linked to it, particularly in functional manner, *i.e.* such that an mRNA or a protein can be produced; a nucleic acid including additional nucleic acids of the gene, such as a larger or even full length genomic fragment of the gene, a partial or full length cDNA, a partial or full length RNA. Making and/or isolating such larger nucleic acids is further described below and is well known and standard in the art.

The invention also provides a nucleic acid encoding the protein encoded by the gene comprising the nucleotide sequence set forth in SEQ ID NO: 1 to 428 (SEQ ID List 1), as well as allelic variants and homologs of each such gene. The gene is readily obtained using standard methods, as described below and as is known and standard in the art. The present invention also contemplates any unique fragment of these genes or of the nucleic acids set forth in any of the sequences listed in SEQ ID LIST 1. Examples of inventive fragments of the inventive genes are the nucleic acids whose sequence is set forth in any of the sequences set forth in SEQ ID LIST 1 (SEQ IDs 1-428). To be unique, the fragment must be of sufficient size to distinguish it from other known sequences, most readily determined by comparing any nucleic acid fragment to the nucleotide sequences of nucleic acids in computer databases, such as GenBank. Such comparative searches are standard in the art. Typically, a unique fragment useful as a primer or probe will be at least about 20 to about 25 nucleotides in length, depending upon the specific nucleotide content of the sequence. Additionally, fragments can be, for example, at least about 30, 40, 50, 75, 100, 200 or 500 nucleotides in length. The nucleic acids can be single or double stranded, depending upon the purpose for which it is intended.

The present invention further provides a nucleic acid comprising the regulatory region of a gene comprising the nucleotide sequences set forth in SEQ ID NO: 1 to 428 (SEQ ID List 1). Additionally provided is a construct comprising such a regulatory region functionally linked to a reporter gene. Such reporter gene constructs can be used to screen for compounds and compositions that affect

expression of the gene comprising the nucleic acids whose sequence is set forth in any of the sequences listed above or in SEQ ID LIST 1.

The nucleic acids set forth in the sequence listing are typically gene fragments; the entire coding sequence and the entire gene that comprises each fragment are both contemplated herein and are readily obtained by standard methods, given the nucleotide sequences presented in the sequence listing (*see, e.g.,* Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989; *DNA cloning: A Practical Approach*, Volumes I and II, Glover, D.M. ed., IRL Press Limited, Oxford, 1985). To obtain the entire genomic gene, briefly, a nucleic acid whose sequence is set forth in any of the sequences set forth above, or a smaller fragment thereof, is utilized as a probe to screen a genomic library under high stringency conditions, and isolated clones are sequenced. Therefore, once a genomic locus has been disrupted by the methods of the present invention, and a partial sequence for the disrupted gene is obtained, one of skilled in the art would know how to isolate the entire gene comprising the partial sequence and thus would be in possession of the full length sequence of the gene, including its regulatory regions. For example, once the sequence of the new clone is determined, a probe can be devised from a portion of the new clone not present in the previous fragment and hybridized to the library to isolate more clones containing fragments of the gene. In this manner, by repeating this process in organized fashion, one can "walk" along the chromosome and eventually obtain nucleotide sequence for the entire gene. Similarly, one can use portions of the present fragments, or additional fragments obtained from the genomic library, that contain open reading frames to screen a cDNA library to obtain a cDNA having the entire coding sequence of the gene. Repeated screens can be utilized as described above to obtain the complete sequence from several clones if necessary. The isolates can then be sequenced to determine the nucleotide sequence by standard means such as dideoxynucleotide sequencing methods (*see, e.g.,* Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989).

The present genes were isolated from rat; however, homologs in any desired species, preferably mammalian, such as human, are provided or can readily be obtained by screening a human library, genomic or cDNA, with a probe comprising sequences of the nucleic acids set forth in the sequence listing herein, or fragments

thereof, and isolating genes specifically hybridizing with the probe under preferably relatively high stringency hybridization conditions. For example, high salt conditions (*e.g.*, in 6X SSC or 6X SSPE) and/or high temperatures of hybridization can be used. For example, the stringency of hybridization is typically about 5°C to 20°C below the

5 T_m (the melting temperature at which half of the molecules dissociate from its partner) for the given chain length. As is known in the art, the nucleotide composition of the hybridizing region factors in determining the melting temperature of the hybrid. For 20mer probes, for example, the recommended hybridization temperature is typically about 55-58°C. Additionally, the rat sequence can be utilized to devise a probe for a

10 homolog in any specific animal by determining the amino acid sequence for a portion of the rat protein, and selecting a probe with optimized codon usage to encode the amino acid sequence of the homolog in that particular animal. Any isolated gene can be confirmed as the targeted gene by sequencing the gene to determine it contains the nucleotide sequence listed herein as comprising the gene. Any homolog can be

15 confirmed as a homolog by its functionality. Homologs can also be obtained by comparing the rat sequences to sequences from other species on readily available databases. For example, the rat sequence can be compared with mouse sequences to obtain a homolog. The homolog obtained from this comparison can then be compared to human sequences or other mammalian sequences to obtain additional homologs.

20 The rat sequences can also be compared directly with human sequences or any other mammalian sequences on databases.

Additionally contemplated by the present invention are nucleic acids, from any desired species, preferably mammalian and more preferably human, having 98%, 95%, 90%, 85%, 80%, 70%, 60%, or 50% homology, or greater, in the region of

25 homology, to a region in an exon of a nucleic acid encoding the protein encoded by the gene comprising the nucleotide sequence set forth in any of SEQ ID NO:1 through SEQ ID 428 of the sequence listing or to homologs thereof. Also contemplated by the present invention are nucleic acids, from any desired species, preferably mammalian and more preferably human, having 98%, 95%, 90%, 85%, 80%, 70%, 60%, or 50%

30 homology, or greater, in the region of homology, to a region in an exon of a nucleic acid comprising the nucleotide sequence set forth in any of SEQ ID NO:1 through SEQ ID 418 of the sequence listing or to homologs thereof. These genes can be synthesized or obtained by the same methods used to isolate homologs, with

stringency of hybridization and washing, if desired, reduced accordingly as homology desired is decreased, and further, depending upon the G-C or A-T richness of any area wherein variability is searched for. Allelic variants of any of the present genes or of their homologs can readily be isolated and sequenced by screening additional libraries following the protocol above. Methods of making synthetic genes are described in U.S. Patent No. 5,503,995 and the references cited therein.

The nucleic acid encoding any selected protein of the present invention can be any nucleic acid that functionally encodes that protein. For example, to functionally encode, *i.e.*, allow the nucleic acid to be expressed, the nucleic acid can include, for example, exogenous or endogenous expression control sequences, such as an origin of replication, a promoter, an enhancer, and necessary information processing sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcriptional terminator sequences. Preferred expression control sequences can be promoters derived from metallothioneine genes, actin genes, immunoglobulin genes, CMV, SV40, adenovirus, bovine papilloma virus, etc. Expression control sequences can be selected for functionality in the cells in which the nucleic acid will be placed. A nucleic acid encoding a selected protein can readily be determined based upon the amino acid sequence of the selected protein, and, clearly, many nucleic acids will encode any selected protein.

The present invention additionally provides a nucleic acid that selectively hybridizes under stringent conditions with a nucleic acid encoding the protein encoded by the gene comprising the nucleotide sequence set forth in any sequence listed herein (*i.e.*, any of SEQ ID NO:1 through SEQ ID NO:428). This hybridization can be specific. The degree of complementarity between the hybridizing nucleic acid and the sequence to which it hybridizes should be at least enough to exclude hybridization with a nucleic acid encoding an unrelated protein. Thus, a nucleic acid that selectively hybridizes with a nucleic acid of the present protein coding sequence will not selectively hybridize under stringent conditions with a nucleic acid for a different, unrelated protein, and vice versa. Typically, the stringency of hybridization to achieve selective hybridization involves hybridization in high ionic strength solution (6X SSC or 6X SSPE) at a temperature that is about 12-25°C below the T_m (the melting temperature at which half of the molecules dissociate from its partner) followed by washing at a combination of temperature and salt concentration chosen so

that the washing temperature is about 5°C to 20°C below the T_m of the hybrid molecule. The temperature and salt conditions are readily determined empirically in preliminary experiments in which samples of reference DNA immobilized on filters are hybridized to a labeled nucleic acid of interest and then washed under conditions of different stringencies. Hybridization temperatures are typically higher for DNA-RNA and RNA-RNA hybridizations. The washing temperatures can be used as described above to achieve selective stringency, as is known in the art. (Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989; Kunkel et al. *Methods Enzymol.* 10 1987:154:367, 1987). Nucleic acid fragments that selectively hybridize to any given nucleic acid can be used, e.g., as primers and or probes for further hybridization or for amplification methods (e.g., polymerase chain reaction (PCR), ligase chain reaction (LCR)). A preferable stringent hybridization condition for a DNA:DNA hybridization can be at about 68°C (in aqueous solution) in 6X SSC or 6X SSPE followed by washing at 68°C.

The present invention additionally provides a protein encoded by a nucleic acid encoding the protein encoded by the gene comprising any of the nucleotide sequences set forth herein (i.e., any of SEQ ID NO: 1 through SEQ ID NO:428). The protein can be readily obtained by any of several means. For example, the nucleotide sequence of coding regions of the gene can be translated and then the corresponding polypeptide can be synthesized mechanically by standard methods. Additionally, the coding regions of the genes can be expressed or synthesized, an antibody specific for the resulting polypeptide can be raised by standard methods (see, e.g., Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1988), and the protein can be isolated from other cellular proteins by selective hybridization with the antibody. This protein can be purified to the extent desired by standard methods of protein purification (see, e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989). The amino acid sequence of any protein, polypeptide or peptide of this invention can be deduced from the nucleic acid sequence, or it can be determined by sequencing an isolated or recombinantly produced protein.

The terms "peptide," "polypeptide" and "protein" are used interchangeably herein and refer to a polymer of amino acids and includes full-length proteins and fragments thereof. As used in the specification and in the claims, "a" can mean one or more, depending upon the context in which it is used. An amino acid residue is an amino acid formed upon chemical digestion (hydrolysis) of a polypeptide at its peptide linkages. The amino acid residues described herein are preferably in the L-isomeric form. However, residues in the D-isomeric form can be substituted for any L-amino acid residue, as long as the desired functional property is retained by the polypeptide. Standard polypeptide nomenclature (described in *J. Biol. Chem.*, 243:3552-59 (1969) and adopted at 37 CFR § 1.822(b)) is used herein.

As will be appreciated by those skilled in the art, the invention also includes those polypeptides having slight variations in amino acid sequences or other properties. Amino acid substitutions can be selected by known parameters to be neutral (*see, e.g.*, Robinson WE Jr, and Mitchell WM., AIDS 4:S151-S162(1990)). Such variations may arise naturally as allelic variations (*e.g.*, due to genetic polymorphism) or may be produced by human intervention (*e.g.*, by mutagenesis of cloned DNA sequences), such as induced point, deletion, insertion and substitution mutants. Minor changes in amino acid sequence are generally preferred, such as conservative amino acid replacements, small internal deletions or insertions, and additions or deletions at the ends of the molecules. Substitutions may be designed based on, for example, the model of Dayhoff, *et al.* (in *Atlas of Protein Sequence and Structure 1978*, Nat'l Biomed. Res. Found., Washington, D.C.). These modifications can result in changes in the amino acid sequence, provide silent mutations, modify a restriction site, or provide other specific mutations. Likewise, such amino acid changes result in a different nucleic acid encoding the polypeptides and proteins. Thus, alternative nucleic acids are also contemplated by such modifications.

The present invention also provides cells containing a nucleic acid of the invention. A cell containing a nucleic acid encoding a protein typically can replicate the DNA and, further, typically can express the encoded protein. The cell can be a prokaryotic cell, particularly for the purpose of producing quantities of the nucleic acid, or a eukaryotic cell, particularly a mammalian cell. The cell is preferably a mammalian cell for the purpose of expressing the encoded protein so that the resultant produced protein has mammalian protein processing modifications.

Nucleic acids of the present invention can be delivered into cells by any selected means, in particular depending upon the purpose of the delivery of the compound and the target cells. Many delivery means are well-known in the art. For example, electroporation, calcium phosphate precipitation, microinjection, cationic or anionic liposomes, and liposomes in combination with a nuclear localization signal peptide for delivery to the nucleus can be utilized, as is known in the art.

The present invention also contemplates that the mutated cellular genes necessary for viral growth, produced by the present method, as well as cells containing these mutants can also be useful. These mutated genes and cells containing them can be isolated and/or produced according to the methods herein described and using standard methods.

It should be recognized that the sequences set forth herein may contain minor sequencing errors. Such errors can be corrected, for example, by using the hybridization procedure described above with various probes derived from the described sequences such that the coding sequence can be reisolated and resequenced.

As described in the examples, the present invention provides the discovery of a "serum survival factor" present in serum that is necessary for the survival of certain persistently virally infected cells. Isolation and characterization of this factor have shown it to be a protein, to have a molecular weight of between about 50 kD and 100 kD, to resist inactivation in low pH (*e.g.*, pH2) and chloroform extraction, to be inactivated by boiling for about 5 minutes and in low ionic strength solution (*e.g.*, about 10 mM to about 50 mM). The present invention thus provides a purified mammalian serum protein having a molecular weight of between about 50 kD and 100 kD which resists inactivation in low pH and resists inactivation by chloroform extraction, which inactivates when boiled and inactivates in low ionic strength solution, and which when removed from a cell culture comprising cells persistently infected with reovirus selectively substantially prevents survival of cells persistently infected with reovirus. The factor, fitting the physical characteristics described above, can readily be verified by adding it to non-serum-containing medium (which previously could not support survival of persistently virally infected cells) and determining whether this medium with the added putative factor can now support persistently virally infected cells, particularly cells persistently infected with reovirus. As used herein, a "purified" protein means the protein is at least of sufficient purity such that an approximate molecular weight can be determined.

The amino acid sequence of the protein can be elucidated by standard methods. For example, an antibody to the protein can be raised and used to screen an expression library to obtain nucleic acid sequence coding the protein. This nucleic acid sequence is then simply translated into the corresponding amino acid sequence.

5 Alternatively, a portion of the protein can be directly sequenced by standard amino acid sequencing methods (amino-terminus sequencing). This amino acid sequence can then be used to generate an array of nucleic acid probes that encompasses all possible coding sequences for a portion of the amino acid sequence. The array of probes is used to screen a cDNA library to obtain the remainder of the coding

10 sequence and thus ultimately the corresponding amino acid sequence.

The present invention also provides methods of detecting and isolating additional serum survival factors. For example, to determine if any known serum components are necessary for viral growth, the known components can be inhibited in, or eliminated from, the culture medium, and it can be observed whether viral

15 growth is inhibited by determining if persistently infected cells do not survive. One can add the factor back (or remove the inhibition) and determine whether the factor allows for viral growth.

Additionally, other, unknown serum components can also be found to be essential for viral growth. Serum can be fractionated by various standard means, and

20 fractions added to serum free medium to determine if a factor is present in a reaction that allows viral growth previously inhibited by the lack of serum. Fractions having this activity can then be further fractionated until the factor is relatively free of other components. The factor can then be characterized by standard methods, such as size fractionation, denaturation and/or inactivation by various means, etc. Preferably, once

25 the factor has been purified to a desired level of purity, it is added to cells in serum free medium to confirm that it bestows the function of allowing virus to grow when serum-free medium alone did not. This method can be repeated to confirm the requirement for the specific factor for any desired virus, since each serum factor found to be required by any one virus can also be required by many other viruses. In

30 general, the closer the viruses are related and the more similar the infection modes of the viruses, the more likely that a factor required by one virus will be required by the other.

The present invention also provides methods of treating virus infections utilizing applicants' discoveries. The subject of any of the herein described methods

can be any animal, preferably a mammal, such as a human, a veterinary animal, such as a cat, dog, horse, pig, goat, sheep, or cow, or a laboratory animal, such as a mouse, rat, rabbit, or guinea pig, depending upon the virus.

The present invention provides a method of reducing or inhibiting, and thereby
5 treating, a viral infection in a subject, comprising administering to the subject an
inhibiting amount of a composition that inhibits functioning of the serum protein
described herein, *i.e.* the serum protein having a molecular weight of between about
50 kD and 100 kD which resists inactivation in low pH and resists inactivation by
chloroform extraction, which inactivates when boiled and inactivates in low ionic
10 strength solution, and which when removed from a cell culture comprising cells
persistently infected with the virus prevents survival of at least some cells persistently
infected with the virus, thereby treating the viral infection. The composition can
comprise, for example, an antibody that specifically binds the serum protein, or an
antisense RNA that binds an RNA encoded by a gene functionally encoding the serum
15 protein.

The method of reducing or inhibiting viral infection in a subject, can use a
vector that is targeted to one of the genes (or loci) identified herein as associate with
viral growth (e.g., SEQ ID NOS: 1-428). The method call for administration of a
vector targeted to the sequence, whereby the vector can disrupt the gene and thereby
20 inhibit the viral growth that is dependent on the disrupted gene. The vector can be
targeted by containing homologous sequences such that an insertional or deletional
mutation takes place at the target site upon administration of the vector.

Any virus capable of infecting the selected subject to be treated can be treated
by the present method. As described above, any serum protein or survival factor
25 found by the present methods to be necessary for growth of any one virus can be
found to be necessary for growth of many other viruses. For any given virus, the
serum protein or factor can be confirmed to be required for growth by the methods
described herein. The cellular genes identified by the examples using reovirus, a
mammalian pathogen, and a rat cell system have general applicability to other virus
30 infections that include all of the known as well as yet to be discovered human
pathogens, including, but not limited to: human immunodeficiency viruses (*e.g.*,
HIV-1, HIV-2); parvovirus; papillomaviruses; hantaviruses; SARS (severe acute
respiratory syndrome) virus influenza viruses (*e.g.*, influenza A, B and C viruses);
hepatitis viruses A to G; caliciviruses; astroviruses; rotaviruses; coronaviruses, such

as human respiratory coronavirus; picornaviruses, such as human rhinovirus and enterovirus; ebola virus; human herpesvirus (*e.g.*, HSV-1-9); human cytomegalovirus; human adenovirus; Epstein-Barr virus; hantaviruses; for animal, the animal counterpart to any above listed human virus, animal retroviruses, such as
5 simian immunodeficiency virus, avian immunodeficiency virus, bovine immunodeficiency virus, feline immunodeficiency virus, equine infectious anemia virus, caprine arthritis encephalitis virus or visna virus.

A protein inhibiting amount of the composition can be readily determined, such as by administering varying amounts to cells or to a subject and then adjusting
10 the effective amount for inhibiting the protein according to the volume of blood or weight of the subject. Compositions that bind to the protein can be readily determined by running the putatively bound protein on a protein gel and observing an alteration in the protein's migration through the gel. Inhibition of the protein can be determined by any desired means such as adding the inhibitor to complete media used
15 to maintain persistently infected cells and observing the cells' viability. The composition can comprise, for example, an antibody that specifically binds the serum protein. Specific binding by an antibody means that the antibody can be used to selectively remove the factor from serum or inhibit the factor's biological activity and can readily be determined by radio immune assay (RIA), bioassay, or enzyme-linked
20 immunosorbant (ELISA) technology.

The identification of cellular genes that are associated with the propagation of intracellular pathogens allows for effective targeting at the level of transcription, translation, processing, or protein function (phosphorylation, glycosylation, protein-protein interactions, etc.). There are examples of each. Many of these are aimed at
25 the viral proteins or their untranslated DNA, or RNA. As there is greater genetic instability in the pathogen than the host, these targets are more prone to mutation and escape from the effect of the therapeutic approach. Host targets are more likely to be stable and therefore may be more practical, if the target is not conditionally lethal when mutant. As the process of selection utilized in the approach taken in this patent
30 relies upon cellular proliferation after the mutation has been made, the target for a therapeutic is unlikely to be lethal when mutant. Thus, the composition can comprise, for example, an antisense RNA or an siRNA (small interfering RNA (siRNA)) that specifically binds an RNA encoded by the gene encoding the serum protein. Antisense RNAs can be synthesized and used by standard methods (*e.g.*, *Antisense*

RNA and DNA, D. A. Melton, Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1988)).

Antisense molecules against nucleic acids encoding the ANNEXIN I, ANNEXIN II and ANNEXIN III proteins are provided and can be used to inhibit the expression of the targeted protein. As will be understood by those of skill in the art, antisense molecules are oligonucleotides that are complements or partial complements to nucleic acid sequence that encodes or is necessary for the expression of the protein whose expression is to be inhibited. For example, antisense molecules that can be used to inhibit the expression of these proteins include any oligonucleotide that is complementary to the nucleic acid encoding the particular protein. For example, for inhibiting the expression of ANNEXIN I, an antisense oligonucleotide complementary or partially complementary to, but not limited to, SEQ ID NO: 65 or a portion thereof can be used to inhibit ANNEXIN I expression. Particular antisense oligonucleotides can form duplexes that persist at an appreciable level, thereby reducing the expression of the targeted gene, under selected conditions. Examples of antisense targeting ANNEXIN I protein expression can include an oligonucleotide comprising the complement of SEQ ID NO:65 or portions of the complement to SEQ ID NO:65. Particular examples of such antisense molecules for ANNEXIN I protein would include; ACAAGTCAAATGCT, ACAAGTCAAATGCTTTATA, GTCAAATGCTTTATA, TTATATATTTGAGT T, TTATATATTTGAGTTAGGGA, TTTGAGTTAGGGAACATGTATAT, CATGTATATGTCAAAAATAAAAAT, TGCACATTGAAACCCTTATG, TTCCACGTTTATCTATTTT, and GGAAACGTTAATGACAGAAAC. Similarly, for inhibiting the expression of ANNEXIN II protein, antisense molecules that inhibit the expression of ANNEXIN II protein can include any oligonucleotide that is complementary to the nucleic acid encoding ANNEXIN II protein such as, but not limited to, SEQ ID NO: 41. Particular examples of such antisense molecules for ANNEXIN II protein would include; AAAAGGCGGACAAGGG, CTTCCNGACNCCCCNAAGCC, CGAANCGGAAGGGC, GCCCGCCCGAA, GGCCGACTCTCTGCCCGCC, and CCCGGAAAGAGGACAGCG.

Similarly, for inhibiting the expression of ANNEXIN III protein, antisense molecules that inhibit the expression of ANNEXIN III protein can include any

oligonucleotide that is complementary to the nucleic acid encoding ANNEXIN II protein such as, but not limited to, SEQ ID NO: 188. Particular examples of such antisense molecules for ANNEXIN III protein would include;

GGTTGGGCCAAAAA, TTAANAAACCGTTCACCCC,
 5 AACCGGTGGTTTGTGCGG, GATAACTCACTGCTG,
 CTTCTCTTGAACACACCTCCTGGGG, and GCGAAAGGCCCTAACAATAG.

Similarly, for any other protein encoding genes, such as, but not limited to, the IGF2BP 5 protease (prss11) genes, antisense molecules can be designed as is
 10 illustrated above for the ANNEXIN I, II and III proteins by those of skill in the art. For example, the antisense molecule to be used can be greater than 14, 15, 16, 17, 18, 20, 22, 24, 26, 28, 30, 34, 38, 42, 50, 60, 70, 80 or 90 nucleotides in length. The antisense molecule to be used can be less than 150, 125, 100, 90, 80, 70, 60, 50, 42, 38, 34, 30, 28, 26, 24, 22, 20, 18, 17, 16, or 15 nucleotides in length. Antisense
 15 molecules can include mismatches or non-Watson-Crick base pairings with the target sequence of the targeted gene. The number of mismatches can be greater than 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18 or 20 nucleotides. The number of mismatches can be less than 20, 18, 16, 14, 12, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 nucleotides. The level of mismatches in the sequence of the antisense molecule can be more than 0.5, 1, 2, 3, 4,
 20 5, or 7% of the total number of base pairs. The level of mismatches in the sequence of the antisense molecule can be less than 10, 7, 5, 4, 3, 2, or 1% of the total number of base pairs. Further, antisense sequences can include further contiguous sequence on either the 5' or 3' ends of the molecules in addition to that corresponding to complementary or partially complementary sequence as described herein. For
 25 example, an antisense molecule can be linked to further sequence that is not a complement to the target sequence.

In other embodiments, oligonucleotides that function in a manner different from antisense can be used. For example, an RNA for use as an interfering RNA such
 30 as siRNA can be designed based on the sequence of the encoded protein whose expression is to be inhibited or reduced. The resulting interfering RNA can be used in a manner similar to that of the antisense molecules to reduce or inhibit the expression of particular proteins such as, but not limited to, those described herein, particularly those noted in the Table 2 and their human homologs. The following

references relating to the phenomenon of RNA interference and its use to silence gene
 expression are incorporated herein for their teachings, particularly their teachings of
 how to silence expression of genes, putative genes, or potential genes, by transfecting
 or transforming cells with RNA molecules; Fire et al., "Potent and specific genetic
 5 interference by double-stranded RNA in *Caenorhabditis elegans*," *Nature* 391: 806-
 811 (1998); Kennerdell and Carthew, "Use of dsRNA-mediated interference to
 demonstrate that *frizzled* and *frizzled 2* act in the wingless pathway," *Cell* 95: 1017-
 1026 (1998); Ngo et al., "Double-stranded RNA induces mRNA degradation in
Trypanosoma brucei," *Proc. Natl. Acad. Sci. USA* 95: 14687-14692 (1998); Timmons
 10 and Fire, "Specific interference by ingested dsRNA," *Nature* 395: 854 (1998); Yang
 et al., "Specific double-stranded RNA interference in undifferentiated mouse
 embryonic stem cells," *Mol. Cell Biol.* 21: 7807-7816 (2001); Caplen et al., "Specific
 inhibition of gene expression by small double-stranded RNAs in invertebrate and
 vertebrate systems," *Proc. Natl. Acad. Sci. USA* 98: 9742-9747 (2001); Elbashir et al.,
 15 "Duplexes of 21-nucleotide RNAs mediate RNA interference in mammalian cell
 culture," *Nature* 411: 494-498 (2001); Hammond et al., "An RNA-directed nuclease
 mediates post-transcriptional gene silencing in *Drosophila* cells," *Nature* 404: 293-
 296 (2000); Zamore et al., "RNAi: double-stranded RNA directs the ATP-dependent
 cleavage of mRNA at 21-33 nucleotide intervals," *Cell* 101: 25-33 (2000); Bernstein
 20 et al., "Role for a bidentate ribonuclease in the initiation step of RNA interference,"
Nature 409: 363-366 (2001); Nykanen et al., "ATP requirements and small interfering
 RNA structure in the RNA interference pathway," *Cell* 107: 309-321 (2001); Elbashir
 et al., "RNA interference is mediated by 21 and 22-nucleotide RNAs," *Genes Dev.*
 15:188-200 (2001); Lipardi et al., "RNAi as random degradative PCR, siRNA primers
 25 convert mRNA into dsRNAs that are degraded to generate new siRNAs," *Cell* 107:
 297-307 (2001); Sijen et al., "On the role of RNA amplification in dsRNA-triggered
 gene silencing," *Cell* 107: 465-476 (2001); Grishok et al., "Genes and mechanisms
 related to RNA interference regulate expression of the small temporal RNAs that
 control *C. elegans* developmental timing," *Cell* 106: 23-34 (2001); Aravin et al.,
 30 "Double-stranded RNA-mediated silencing of genomic tandem repeats and
 transposable elements in the *D. melanogaster* germline," *Curr. Biol.* 11: 1017-1027
 (2001); and Hutvagner and Zamore, "RNAi: nature abhors a double-strand," *Curr.*
Opinion Genetics Develop. 12: 225-232 (2002). Examples of effective therapies
 include the following.

CCR5 has a target for siRNA. CCR5 is a co-receptor (cellular gene product) necessary for HIV entry into macrophage cell lines (Qin XF, An DS, Chen IS, Baltimore D., Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5, Proc Natl Acad Sci U S A 2003 Jan 5 7;100(1):183-8). Double-stranded RNAs, approximately 21 nucleotides long, are recognized as powerful reagents to reduce the expression of specific genes. To use them as reagents to protect cells against viral infection, effective methods for introducing siRNAs into primary cells are required. Here, we describe success in constructing a lentivirus-based vector to introduce siRNAs against the HIV-1 10 coreceptor, CCR5, into human peripheral blood T lymphocytes. With high-titer vector stocks, >40% of the peripheral blood T lymphocytes could be transduced, and the expression of a potent CCR5-siRNA resulted in up to 10-fold inhibition of CCR5 expression on the cell surface over a period of 2 weeks in the absence of selection. In contrast, the expression of another major HIV-1 coreceptor, CXCR4, was not 15 affected. Importantly, blocking CCR5 expression by siRNAs provided a substantial protection for the lymphocyte populations from CCR5-tropic HIV-1 virus infection, dropping infected cells by 3- to 7-fold; only a minimal effect on infection by a CXCR4-tropic virus was observed. Thus, our studies demonstrate the feasibility and potential of lentiviral vector-mediated delivery of siRNAs as a general means of 20 intracellular immunization for the treatment of HIV-1 and other viral diseases.

A viral target for Influenza A: Ge Q, McManus MT, Nguyen T, Shen CH, Sharp PA, Eisen HN and Chen, J. (Proc Natl Acad Sci U S A 2003 Mar 4;100(5):2718-23, RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription) 25 disclose that Influenza A virus causes widespread infection in the human respiratory tract, but existing vaccines and drug therapy are of limited value. Here we show that short interfering RNAs (siRNAs) specific for conserved regions of the viral genome can potently inhibit influenza virus production in both cell lines and embryonated chicken eggs. The inhibition depends on the presence of a functional antisense strand 30 in the siRNA duplex, suggesting that viral mRNA is the target of RNA interference. However, siRNA specific for nucleocapsid (NP) or a component of the RNA transcriptase (PA) abolished the accumulation of not only the corresponding mRNA but also virion RNA and its complementary RNA. These siRNAs also broadly inhibited the accumulation of other viral, but not cellular, RNAs. The findings reveal

that newly synthesized NP and PA proteins are required for influenza virus transcription and replication and provide a basis for the development of siRNAs as prophylaxis and therapy for influenza infection in humans.

The present application shows the disruption of KLF6. Yoon HS, Chen X and
5 Yang VW (J Biol Chem 2003 Jan 24;278(4):2101-5, Kruppel-like factor 4 mediates p53-dependent G1/S cell cycle arrest in response to DNA damage) show siRNA effectiveness on a related protein KLF4. The tumor suppressor p53 is required for the maintenance of genomic integrity following DNA damage. One mechanism by which p53 functions is to induce a block in the transition between the G(1) and S phase of
10 the cell cycle. Previous studies indicate that the Kruppel-like factor 4 (KLF4) gene is activated following DNA damage and that such activation depends on p53. In addition, enforced expression of KLF4 causes G(1)/S arrest. The present study examines the requirement of KLF4 in mediating the p53-dependent cell cycle arrest process in response to DNA damage. We show that the G(1) population of a colon
15 cancer cell line, HCT116, that is null for the p53 alleles (-/-) was abolished following gamma irradiation compared with cells with wild-type p53 (+/+). Conditional expression of KLF4 in irradiated HCT116 p53-/- cells restored the G(1) cell population to a level similar to that seen in irradiated HCT116 p53+/+ cells. Conversely, treatment of HCT116 p53+/+ cells with small interfering RNA (siRNA)
20 specific for KLF4 significantly reduced the number of cells in the G(1) phase following gamma irradiation compared with the untreated control or those treated with a nonspecific siRNA. In each case the increase or decrease in KLF4 level because of conditional induction or siRNA inhibition, respectively, was accompanied by an increase or decrease in the level of p21(WAF1/CIP1). Results of our study
25 indicate that KLF4 is an essential mediator of p53 in controlling G(1)/S progression of the cell cycle following DNA damage.

Once the genes are known, the present approach can be used to protect humans (and other animals from disease (Olson KE, Adelman ZN, Travanty EA, Sanchez-Vargas I, Beaty BJ and Blair CD, Developing arbovirus resistance in
30 mosquitoes, Insect Biochem Mol Biol 2002 Oct;32(10):1333-43). Diseases caused by arthropod-borne viruses are increasingly significant public health problems, and novel methods are needed to control pathogen transmission. The hypothesis underlying the research described here is that genetic manipulation of *Aedes aegypti* mosquitoes can profoundly and permanently reduce their competence to transmit dengue viruses to

human hosts. Recent key findings now allow us to test the genetic control hypothesis. We have identified viral genome-derived RNA segments that can be expressed in mosquito midguts and salivary glands to ablate homologous virus replication and transmission. We have demonstrated that both transient and heritable expression of virus-derived effector RNAs in cultured mosquito cells can silence virus replication, and have characterized the mechanism of RNA-mediated resistance. We are now developing virus-resistant mosquito lines by transformation with transposable elements that express effector RNAs from mosquito-active promoters.

The targeting of IGF2 (one of the genes disrupted in the present method) has produced good results in cancer of the liver (Yao X, Hu JF, Daniels M, Shiran H, Zhou X, Yan H, Lu H, Zeng Z, Wang Q, Li T, Hoffman AR, A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma, J Clin Invest 2003 Jan;111(2):265-73). IGF2 is a mitogenic peptide that has been implicated in hepatocellular oncogenesis. Since the silencing of gene expression is frequently associated with cytosine methylation at cytosine-guanine (CpG) dinucleotides, we designed a methylated oligonucleotide (MON1) complementary to a region encompassing IGF2 promoter P4 in an attempt to induce DNA methylation at that locus and diminish IGF2 mRNA levels. MON1 specifically inhibited IGF2 mRNA accumulation in vitro, whereas an oligonucleotide (ON1) with the same sequence but with nonmethylated cytosines had no effect on IGF2 mRNA abundance. MON1 treatment led to the specific induction of de novo DNA methylation in the region of IGF2 promoter hP4. Cells from a human hepatocellular carcinoma (HCC) cell line, Hep 3B, were implanted into the livers of nude mice, resulting in the growth of large tumors. Animals treated with MON1 had markedly prolonged survival as compared with those animals treated with saline or a truncated methylated oligonucleotide that did not alter IGF2 mRNA levels in vitro. This study demonstrates that a methylated sense oligonucleotide can be used to induce epigenetic changes in the IGF2 gene and that inhibition of IGF2 mRNA accumulation may lead to enhanced survival in a model of HCC.

The present methods provide a method of screening a compound for treating a viral infection, comprising administering the compound to a cell containing a cellular gene functionally encoding a gene product necessary for reproduction of the virus in the cell but not necessary for survival of the cell and detecting level of the gene product produced, a decrease or elimination of the gene product indicating a

compound for treating the viral infection. The present methods also provide a method of screening a compound for effectiveness in treating a viral infection, comprising administering the compound to a cell containing a cellular gene functionally encoding a gene product necessary for reproduction of the virus in the cell but not necessary for survival of the cell and detecting the level of the gene product produced, a decrease or elimination of the gene product indicating a compound effective for treating the viral infection. The cellular gene can be, for example, any gene provided herein, *i.e.*, any of the genes comprising the nucleotide sequences set forth in any of the sequences in SEQ ID LIST 1 or any other gene obtained using the methods provided herein for obtaining such genes. Level of the gene product can be measured by any standard means, such as by detection with an antibody specific for the protein. The level of gene product can be compared to the level of the gene product in a control cell not contacted with the compound. The level of gene product can be compared to the level of the gene product in the same cell prior to addition of the compound. Activity of function, can be measured by any standard means, such as by enzymatic assays that measure the conversion of a substrate to a product or binding assays that measure the binding of a protein to a nucleic acids, for example. Relatedly, the regulatory region of the gene can be functionally linked to a reporter gene and compounds can be screened for inhibition of the reporter gene. Such reporter constructs are described herein.

Examples of gene products whose activity/function can be measured and which are disclosed herein include, but are not limited to tristetraprolin (human ZFP-36), 6-pyruvoyl-tetrahydropterin synthase, a eukaryotic DnaJ-like protein, ID3 (inhibitor of DNA binding 3), N-acetylglucos-aminyltransferase I (mGAT-1), cleavage stimulation factor (CSTF2), TAK1 binding protein, human zinc transcription factor ZPF207, Dlx2, Smad7 (Mad-related protein), and P-glycoprotein (mdr1b). The activity can be compared to the activity in a control cell not contacted with the compound or in the same cell prior to addition of the compound.

The present invention also provides a method of screening a compound for effectiveness in treating or preventing a viral infection comprising contacting the compound with the gene product of a cellular gene comprising a nucleic acid of SEQ ID LIST 1, or any homolog thereof, or a gene identified in Table 1 or 2 or otherwise in this application, and detecting the function of the gene product, a decrease or elimination of the function indicating a compound effective for treating or preventing

viral infection. Examples of gene products that can be utilized in these methods include, but are not limited to tristetraprolin (human ZFP-36), 6-pyruvoyl-tetrahydropterin synthase, a eukaryotic DnaJ-like protein, ID3 (inhibitor of DNA binding 3), N-acetylglucos-aminyltransferase I (mGAT-1), cleavage stimulation
5 factor (CSTF2), TAK1 binding protein, CTCF, human zinc transcription factor ZPF207, Dlx2, Smad7 (Mad-related protein), and P-glycoprotein (mdr1b). The activity can be compared to the activity in a control cell not contacted with the compound or in the same cell prior to addition of the compound.

The present invention provides a method of selectively eliminating cells
10 persistently infected with a virus from an animal cell culture capable of surviving for a first period of time in the absence of serum, comprising propagating the cell culture in the absence of serum for a second time period which a persistently infected cell cannot survive without serum, thereby selectively eliminating from the cell culture cells persistently infected with the virus. The second time period should be shorter
15 than the first time period. Thus one can simply eliminate serum from a standard culture medium composition for a period of time (*e.g.* by removing serum containing medium from the culture container, rinsing the cells, and adding serum-free medium back to the container), then, after a time of serum starvation, return serum to the culture medium. Alternatively, one can inhibit a serum survival factor from the
20 culture in place of the step of serum starvation. Furthermore, one can instead interfere with the virus-factor interaction. Such a viral elimination method can periodically be performed for cultured cells to ensure that they remain virus-free. The time period of serum removal can greatly vary, with a typical range being about 1 to about 30 days; a preferable period can be about 3 to about 10 days, and a more preferable period can
25 be about 5 days to about 7 days. This time period can be selected based upon ability of the specific cell to survive without serum as well as the life cycle of the virus, *e.g.*, for reovirus, which has a life cycle of about 24 hours, 3 days' starvation of cells provides dramatic results.

Furthermore, the time period can be shortened by also passaging the cells
30 during the starvation; in general, increasing the number of passages can decrease the time of serum starvation (or serum factor inhibition) needed to get full clearance of the virus from the culture. While passaging, the cells typically are exposed briefly to serum (typically for about 3 to about 24 hours). This exposure both stops the action of the trypsin used to dislodge the cells and stimulates the cells into another cycle of

growth, thus aiding in this selection process. Thus a starvation/serum cycle can be repeated to optimize the selective effect. Other standard culture parameters, such as confluency of the cultures, pH, temperature, etc. can be varied to alter the needed time period of serum starvation (or serum survival factor inhibition). This time period can readily be determined for any given viral infection by simply removing the serum for various periods of time, then testing the cultures for the presence of the infected cells (*e.g.*, by ability to survive in the absence of serum and confirmed by quantitating virus in cells by standard virus titration and immunohistochemical techniques) at each tested time period, and then detecting at which time periods of serum deprivation the virally infected cells were eliminated. It is preferable that shorter time periods of serum deprivation that still provide elimination of the persistently infected cells be used. Furthermore, the cycle of starvation, then adding back serum and determining amount of virus remaining in the culture can be repeated until no virtually infected cells remain in the culture.

Thus, the present method can further comprise passaging the cells, *i.e.*, transferring the cell culture from a first container to a second container. Such transfer can facilitate the selective lack of survival of virally infected cells. Transfer can be repeated several times. Transfer is achieved by standard methods of tissue culture (*see, e.g.*, Freshney, *Culture of Animal Cells, A Manual of Basic Technique*, 2nd Ed. Alan R. Liss, Inc., New York, 1987).

The present method further provides a method of selectively eliminating from a cell culture cells persistently infected with a virus, comprising propagating the cell culture in the absence of a functional form of the serum protein having a molecular weight of between about 50 kD and 100 kD which resists inactivation in low pH and resists inactivation by chloroform extraction, which inactivates when boiled and inactivates in low ionic strength solution, and which when removed from a cell culture comprising cells persistently infected with reovirus substantially prevents survival of cells persistently infected with reovirus. The absence of the functional form can be achieved by any of several standard means, such as by binding the protein to an antibody selective for it (binding the antibody in serum either before or after the serum is added to the cells; if before, the serum protein can be removed from the serum by, *e.g.*, binding the antibody to a column and passing the serum over the column and then administering the survival protein-free serum to the cells), by

administering a compound that inactivates the protein, or by administering a compound that interferes with the interaction between the virus and the protein.

Thus, the present invention provides a method of selectively eliminating from a cell culture propagated in serum-containing medium cells persistently infected with a virus, comprising inhibiting in the serum the protein having a molecular weight of between about 50 kD and 100 kD which resists inactivation in low pH and resists inactivation by chloroform extraction, which inactivates when boiled and inactivates in low ionic strength solution, and which when removed from a cell culture comprising cells persistently infected with reovirus substantially prevents survival of cells persistently infected with reovirus. Alternatively, the interaction between the virus and the serum protein can be disrupted to selectively eliminate cells persistently infected with the virus.

Any virus capable of some form of persistent infection may be eliminated from a cell culture utilizing the present elimination methods, including removing, inhibiting or otherwise interfering with a serum protein, such as the one exemplified herein, and also including removing, inhibiting or otherwise interfering with a gene product from any cellular gene found by the present method to be necessary for viral growth yet nonessential to the cell. For example, DNA viruses or RNA viruses can be targeted. One can readily determine whether cells infected with a selected virus can be selectively removed from a culture through removal of serum by starving cells permissive to the virus of serum (or inhibiting the serum survival factor), adding the selected virus to the cells, adding serum to the culture, and observing whether infected cells die (*i.e.*, by titering levels of virus in the surviving cells with an antibody specific for the virus).

A culture of any animal cell (*i.e.*, any cell that is typically grown and maintained in culture in serum) that can be maintained for a period of time in the absence of serum, can be purified from viral infection utilizing the present method. For example, primary cultures as well as established cultures and cell lines can be used. Furthermore, cultures of cells from any animal and any tissue or cell type within that animal that can be cultured and that can be maintained for a period of time in the absence of serum can be used. For example, cultures of cells from tissues typically infected, and particularly persistently infected, by an infectious virus could be used.

As used in the claims "in the absence of serum" means at a level at which persistently virally infected cells do not survive. Typically, the threshold level is about 1% serum in the media. Therefore, about 1% serum or less can be used, such as about 1%, 0.75%, 0.50%, 0.25%, 0.1% or no serum can be used.

5 As used herein, "selectively eliminating" cells persistently infected with a virus means that substantially all of the cells persistently infected with the virus are killed such that the presence of virally infected cells cannot be detected in the culture immediately after the elimination procedure has been performed. Furthermore, "selectively eliminating" includes that cells not infected with the virus are generally
10 not killed by the method. Some surviving cells may still produce virus but at a lower level, and some may be defective in pathways that lead to death by the virus. Typically, for cells persistently infected with virus to be substantially all killed, more than about 90% of the cells, and more preferably less than about 95%, 98%, 99%, or 99.99% of virus-containing cells in the culture are killed.

15 The present method also provides a nucleic acid comprising the regulatory region of any of the genes. Such regulatory regions can be isolated from the genomic sequences isolated and sequenced as described above and identified by any characteristics observed that are characteristic for regulatory regions of the species and by their relation to the start codon for the coding region of the gene. The present
20 invention also provides a construct comprising the regulatory region functionally linked to a reporter gene. Such constructs are made by routine subcloning methods, and many vectors are available into which regulatory regions can be subcloned upstream of a marker gene. Marker genes can be chosen for ease of detection of marker gene product.

25 The present method therefore also provides a method of screening a compound for treating a viral infection, comprising administering the compound to a cell containing any of the above-described constructs, comprising a regulatory region of one of the genes comprising the nucleotide sequence set forth in any of the sequences in SEQ ID LIST 1 functionally linked to a reporter gene, and detecting the
30 level of the reporter gene product produced, a decrease or elimination of the reporter gene product indicating a compound for treating the viral infection. Compounds detected by this method would inhibit transcription of the gene from which the regulatory region was isolated, and thus, in treating a subject, would inhibit the

production of the gene product produced by the gene, and thus treat the viral infection.

Some genes when disrupted by the present method of retrovirus insertion, resulted in overexpression of the gene product, and this overexpression inhibited viral replication. Specifically, as described in the Examples, by utilizing the methods of the present invention, the genomic locus comprising the sequence of CTCF was disrupted (clone designated 6BE72_rE (SEQ ID NO: 2) and this resulted in an overexpression of IGF2 which led to decreased viral replication. Therefore, the present invention provides a method of decreasing or inhibiting viral replication by overexpressing IGF2. The present invention also provides a method of increasing the expression of IGF2 by disrupting the CTCF gene, or by inhibiting the gene product of the CTCF gene. The human genomic sequence for IGF2 can be found on the publicly available GenBank Database under Accession No. NT_033238. This sequence, available via GenBank Accession No. NT_033238 is hereby incorporated by reference in its entirety by this reference. The human mRNA sequence for IGF2 can also be found on GenBank under Accession No. NM_00612. This sequence, available via GenBank Accession No. NM_00612 is hereby incorporated by reference in its entirety by this reference. The human mRNA sequence for CTCF can be found on GenBank under Accession No. NM_080618. This sequence, available via GenBank Accession No. NM_080618 is hereby incorporated by reference in its entirety by this reference. The human genomic sequence for CTCF, located on human chromosomal location 16q21-q22.3, can be found on GenBank under Accession No. NT_010478. This sequence available via GenBank Accession No. NT_010478 is hereby incorporated by reference in its entirety.

In another example, the methods of the present invention identified another clone (Lab Designation 14_7#2 SEQ ID NO: 115)) which results in overexpression of N-acetylglucosaminyltransferase I which is encoded by Mgat-1. Overexpression of N-acetylglucosaminyltransferase I resulted in decreased viral replication.

Once a gene is found that upon disruption results in overexpression of another gene, the gene that is overexpressed can be modulated directly, i.e., via the overexpressed gene, or indirectly, i.e., via the gene that was originally disrupted (or its gene product) or via another gene (or its gene product) associated with the overexpressed gene. For example, one of skill in the art can administer a compound that results in the overexpression of IGF2. This compound may interact with the

IGF2 gene, IGF2 mRNA or the IGF2 protein. The compound could also interact with the CTCF gene, CTCF mRNA or the CTCF protein to increase IGF2 expression. The compound can also interact with other genes, mRNAs or proteins involved in the IGF2 pathway, resulting in increased IGF2 expression.

5 Thus, the present invention provides a method of screening a compound for effectiveness in treating a viral infection, comprising administering the compound to a cell containing a cellular gene functionally encoding a gene product whose overexpression inhibits reproduction of the virus, but does not prevent survival of the cell and detecting the level of the gene product produced, an increase in the gene
10 product indicating a compound effective for treating a viral infection. Typically, an increase will be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 125%, 150%, 175%, 200%, 300%, 400%, 500% or higher increase over gene product produced when the compound is not present.

 The present invention additionally provides a method of reducing or inhibiting
15 a viral infection in a subject, comprising administering to the subject an amount of a composition that inhibits expression or functioning of a gene product encoded by a gene comprising the nucleic acid set forth in any of the sequences in the Sequence Listing or a homolog thereof, or a gene identified in Table 1 or 2, or otherwise, in this application, thereby treating the viral infection. The composition can comprise, for
20 example, an antibody that binds a protein encoded by the gene. The composition can also comprise an antibody that binds a receptor for a protein encoded by the gene. Such an antibody can be raised against the selected protein by standard methods, and can be either polyclonal or monoclonal, though monoclonal is preferred. Alternatively, the composition can comprise an antisense RNA that binds an RNA
25 encoded by the gene. Furthermore, the composition can comprise a nucleic acid functionally encoding an antisense RNA that binds an RNA encoded by the gene. Other useful compositions will be readily apparent to the skilled artisan.

 The present invention also provides a method of treating a viral infection in a subject comprising administering to the subject a treatment effective amount of a
30 composition that increases expression of a gene whose overexpression reduces or inhibits viral replication. Typically, an increase in expression will be a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 125%, 150%, 175%, 200%, 300%, 400%, 500% or higher increase over gene product produced when the composition is not present.

The present invention further provides a method of reducing or inhibiting a viral infection in a subject comprising mutating *ex vivo* in a selected cell from the subject an endogenous gene comprising the nucleic acid set forth in any of the sequences listed in SEQ ID LIST 1, or a homolog thereof, to a gene form incapable of producing a functional gene product of the gene or a gene form producing a reduced amount of a functional gene product of the gene, and replacing the cell in the subject, thereby reducing viral infection of cells in the subject. The cell can be selected according to the typical target cell of the specific virus whose infection is to be reduced, prevented or inhibited. A preferred cell for several viruses is a hematopoietic cell. When the selected cell is a hematopoietic cell, viruses which can be reduced or inhibited from infection can include, for example, HIV, including HIV-1 and HIV-2.

The invention also includes a method of reducing or inhibiting viral infection in a subject comprising mutating *ex vivo* in a selected cell, for example from a subject or an allogenic source, an endogenous gene comprising a nucleic acid set forth in SEQ ID LIST 1 whose overexpression causes inhibition of viral replication, or a homolog thereof, to a gene form that expresses the gene at a higher level than the endogenous gene, and placing or replacing the cell in the subject. Typically, a higher level can be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 125%, 150%, 175%, 200%, 300%, 400%, 500% or higher than the non-mutated, endogenous gene. The cell can be selected according to the typical target cell of the specific virus whose infection is to be reduced, prevented or inhibited. A preferred cell for several viruses is a hematopoietic cell. When the selected cell is a hematopoietic cell, viruses which can be reduced or inhibited from infection can include, for example, HIV, including HIV-1 and HIV-2. However, many other virus-cell combinations will be apparent to the skilled artisan.

The present invention additionally provides a method of increasing viral infection resistance in a subject comprising mutating *ex vivo* in a selected cell, for example from the subject or from an allogenic source, an endogenous gene comprising a nucleic acid set forth in SEQ LIST 1, whose inhibition or reduction in expression increases viral infection resistance, said endogenous gene being mutated to a mutated gene form incapable of producing a functional gene product of the gene or a gene form producing a reduced amount of a functional gene product of the gene, and placing the cell in the subject, thereby increasing viral infection resistance of cells in

the subject. The virus can be HIV, particularly when the cell is a hematopoietic cell. However, many other virus-cell combinations will be apparent to the skilled artisan.

The present invention also provides a method of reducing or inhibiting a viral infection in a subject comprising mutating *ex vivo* in a selected cell from the subject
5 an endogenous gene comprising a nucleic acid isolated by a method comprising
(a) transferring into a cell culture growing in serum-containing medium a vector encoding a selective marker gene lacking a functional promoter, (b) selecting cells expressing the marker gene, (c) removing serum from the culture medium, (d) infecting the cell culture with the virus, and (e) isolating from the surviving cells a
10 cellular gene within which the marker gene is inserted, to a mutated gene form incapable of producing a functional gene product of the gene or to a mutated gene form producing a reduced amount of a functional gene product of the gene, and replacing the cell in the subject, thereby reducing viral infection of cells in the subject. Thus the mutated gene form can be one incapable of producing an effective amount of
15 a functional protein or mRNA, or one incapable of producing a functional protein or mRNA, for example. The method can be performed wherein the virus is HIV. The method can be performed in any selected cell in which the virus may infect with deleterious results. For example, the cell can be a hematopoietic cell. However, many other virus-cell combinations will be apparent to the skilled artisan.

20 The present invention additionally provides a method of increasing viral infection resistance in a subject comprising mutating *ex vivo* in a selected cell from the subject an endogenous gene comprising a nucleic acid isolated by a method comprising
(a) transferring into a cell culture growing in serum-containing medium a vector
25 encoding a selective marker gene lacking a functional promoter, (b) selecting cells expressing the marker gene, (c) removing serum from the culture medium, (d) infecting the cell culture with the virus, and (e) isolating from the surviving cells a cellular gene within which the marker gene is inserted, to a mutated gene form incapable of producing a functional gene product of the gene or a gene form
30 producing a reduced amount of a functional gene product of the gene, and replacing the cell in the subject, thereby reducing viral infection of cells in the subject. The virus can be HIV, particularly when the cell is a hematopoietic cell. However, many other virus-cell combinations will be apparent to the skilled artisan.

The present invention also provides a method of reducing or inhibiting a viral infection in a subject comprising mutating *ex vivo* in a selected cell from the subject an endogenous gene comprising a nucleic acid isolated by a method comprising (a) transferring into a cell culture growing in serum-containing medium a vector encoding a selective marker gene lacking a functional promoter, (b) selecting cells expressing the marker gene, (c) infecting the cell culture with the virus, and (d) isolating from the surviving cells a cellular gene within which the marker gene is inserted, to a mutated gene form incapable of producing a functional gene product of the gene or to a mutated gene form producing a reduced amount of a functional gene product of the gene, and replacing the cell in the subject, thereby reducing viral infection of cells in the subject. Thus the mutated gene form can be one incapable of producing an effective amount of a functional protein or mRNA, or one incapable of producing a functional protein or mRNA, for example. The method can be performed wherein the virus is HIV. The method can be performed in any selected cell in which the virus may infect with deleterious results. For example, the cell can be a hematopoietic cell. However, many other virus-cell combinations will be apparent to the skilled artisan.

The present invention additionally provides a method of increasing viral infection resistance in a subject comprising mutating *ex vivo* in a selected cell from the subject an endogenous gene comprising a nucleic acid isolated by a method comprising (a) transferring into a cell culture growing in serum-containing medium a vector encoding a selective marker gene lacking a functional promoter, (b) selecting cells expressing the marker gene, (c) infecting the cell culture with the virus, and (d) isolating from the surviving cells a cellular gene within which the marker gene is inserted, to a mutated gene form incapable of producing a functional gene product of the gene or a gene form producing a reduced amount of a functional gene product of the gene, and replacing the cell in the subject, thereby reducing viral infection of cells in the subject. The virus can be HIV, particularly when the cell is a hematopoietic cell. However, many other virus-cell combinations will be apparent to the skilled artisan.

Furthermore, the present invention provides a method for isolation of cellular genes utilized in tumor progression. The present invention provides a method of identifying a cellular gene that can suppress a malignant phenotype in a cell,

comprising (a) transferring into a cell culture incapable of growing well in soft agar or Matrigel a vector encoding a selective marker gene lacking a functional promoter, (b) selecting cells expressing the marker gene, and (c) isolating from selected cells which are capable of growing in soft agar or Matrigel a cellular gene within which the marker gene is inserted, thereby identifying a gene that can suppress a malignant phenotype in a cell. This method can be performed using any selected non-transformed cell line, of which many are known in the art.

The present invention additionally provides a method of identifying a cellular gene that can suppress a malignant phenotype in a cell, comprising (a) transferring into a cell culture of non-transformed cells a vector encoding a selective marker gene lacking a functional promoter, (b) selecting cells expressing the marker gene, and (c) isolating from selected and transformed cells a cellular gene within which the marker gene is inserted, thereby identifying a gene that can suppress a malignant phenotype in a cell. A non-transformed phenotype can be determined by any of several standard methods in the art, such as the exemplified inability to grow in soft agar, or inability to grow in Matrigel.

The present invention additionally provides a method of identifying a cellular gene that can suppress a malignant phenotype in a cell, comprising (a) transferring into a cell culture of non-transformed cells a vector encoding a selective marker gene lacking a functional promoter, (b) selecting cells expressing the marker gene, and (c) isolating from selected and transformed cells a cellular gene within which the marker gene is inserted, thereby identifying a gene that can suppress a malignant phenotype in a cell. A non-transformed phenotype can be determined by any of several standard methods in the art, such as the exemplified inability to grow in soft agar, or inability to grow in Matrigel. This method can be performed using any selected non-transformed cell line, of which many are known in the art.

The present invention further provides a method of screening for a compound for suppressing a malignant phenotype in a cell comprising administering the compound to a cell containing a cellular gene functionally encoding a gene product involved in establishment of a malignant phenotype in the cell and detecting the level of the gene product produced, a decrease or elimination of the gene product indicating a compound effective for suppressing the malignant phenotype. Detection of the level, or amount, of gene product produced can be measured, directly or indirectly, by any of several methods standard in the art (*e.g.*, protein gel, antibody-based assay,

detecting labeled RNA) for assaying protein levels or amounts, and selected based upon the specific gene product.

The present invention further provides a method of suppressing a malignant phenotype in a cell in a subject, comprising administering to the subject an amount of
5 a composition that inhibits expression or functioning of a gene product encoded by a gene comprising the nucleic acid set forth in SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82 or SEQ ID NO:83, SEQ ID NO: 92, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 119, SEQ ID NO: 177, SEQ ID NO: 206, SEQ ID
10 NO: 240, SEQ ID NO: 243, SEQ ID NO: 247, SEQ ID NO: 321, SEQ ID NO: 328, SEQ ID NO: 329, SEQ ID NO: 330, SEQ ID NO: 331, SEQ ID NO: 334, SEQ ID NO: 335, SEQ ID NO: 336, SEQ ID NO: 408, SEQ ID NO: 411, SEQ ID NO: 412, SEQ ID NO: 413, SEQ ID NO: 414 or a homolog thereof, or any gene whose overexpression is found by the present method to be involved in suppressing a
15 malignant phenotype in the cell (e.g., any clone designated herein with an "x" throughout the application) thereby suppressing a malignant phenotype. The composition can, for example, comprise an antibody that binds a protein encoded by the gene. The composition can, as another example, comprise an antibody that binds a receptor for a protein encoded by the gene. The composition can comprise an
20 antisense RNA that binds an RNA encoded by the gene. Further, the composition can comprise a nucleic acid functionally encoding an antisense RNA that binds an RNA encoded by the gene.

The present invention further provides a method of suppressing a malignant phenotype in a cell in a subject, comprising administering to the subject an amount of
25 a composition that increases expression of a gene product whose overexpression is involved in suppressing a malignant phenotype in the cell. The gene product can be the product of a gene wherein disruption of an upstream gene by the present vector resulted in overexpression of the downstream gene, and the overexpression of the downstream gene demonstrated a transformed phenotype. The composition can be,
30 for example, an inhibitor, such as a small molecule inhibitor, of the COX 2 enzyme.

Diagnostic or therapeutic agents of the present invention can be administered to a subject or an animal model by any of many standard means for administering therapeutics or diagnostics to that selected site or standard for administering that type of functional entity. For example, an agent can be administered orally, parenterally

(e.g., intravenously), by intramuscular injection, by intraperitoneal injection, topically, transdermally, or the like. Agents can be administered, *e.g.*, as a complex with cationic liposomes, or encapsulated in anionic liposomes. Compositions can include various amounts of the selected agent in combination with a pharmaceutically acceptable carrier and, in addition, if desired, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, diluents, etc. Parental administration, if used, is generally characterized by injection. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Depending upon the mode of administration, the agent can be optimized to avoid degradation in the subject, such as by encapsulation, etc.

Dosages will depend upon the mode of administration, the disease or condition to be treated, and the individual subject's condition, but will be that dosage typical for and used in administration of antiviral or anticancer agents. Dosages will also depend upon the composition being administered, *e.g.*, a protein or a nucleic acid. Such dosages are known in the art. Furthermore, the dosage can be adjusted according to the typical dosage for the specific disease or condition to be treated. Furthermore, viral titers in culture cells of the target cell type can be used to optimize the dosage for the target cells *in vivo*, and transformation from varying dosages achieved in culture cells of the same type as the target cell type can be monitored. Often a single dose can be sufficient; however, the dose can be repeated if desirable. The dosage should not be so large as to cause adverse side effects. Generally, the dosage will vary with the age, condition, sex and extent of the disease in the patient and can be determined by one of skill in the art. The dosage can also be adjusted by the individual physician in the event of any complication.

For administration to a cell in a subject, the composition, once in the subject, will of course adjust to the subject's body temperature. For *ex vivo* administration, the composition can be administered by any standard methods that would maintain viability of the cells, such as by adding it to culture medium (appropriate for the target cells) and adding this medium directly to the cells. As is known in the art, any medium used in this method can be aqueous and non-toxic so as not to render the cells non-viable. In addition, it can contain standard nutrients for maintaining viability of cells, if desired. For *in vivo* administration, the complex can be added to, for example, a blood sample or a tissue sample from the patient, or to a pharmaceutically

acceptable carrier, e.g., saline and buffered saline, and administered by any of several means known in the art. Examples of administration include parenteral administration, e.g., by intravenous injection including regional perfusion through a blood vessel supplying the tissues(s) or organ(s) having the target cell(s), or by
5 inhalation of an aerosol, subcutaneous or intramuscular injection, topical administration such as to skin wounds and lesions, direct transfection into, e.g., bone marrow cells prepared for transplantation and subsequent transplantation into the subject, and direct transfection into an organ that is subsequently transplanted into the subject. Further administration methods include oral administration, particularly
10 when the composition is encapsulated, or rectal administration, particularly when the composition is in suppository form. A pharmaceutically acceptable carrier includes any material that is not biologically or otherwise undesirable, i.e., the material may be administered to an individual along with the selected complex without causing any undesirable biological effects or interacting in a deleterious manner with any of the
15 other components of the pharmaceutical composition in which it is contained.

Specifically, if a particular cell type *in vivo* is to be targeted, for example, by regional perfusion of an organ or tumor, cells from the target tissue can be biopsied and optimal dosages for import of the complex into that tissue can be determined *in vitro*, as described herein and as known in the art, to optimize the *in vivo* dosage,
20 including concentration and time length. Alternatively, culture cells of the same cell type can also be used to optimize the dosage for the target cells *in vivo*.

For either *ex vivo* or *in vivo* use, the complex can be administered at any effective concentration. An effective concentration is that amount that results in reduction, inhibition or prevention of the viral infection or in reduction or inhibition
25 of transformed phenotype of the cells

A nucleic acid can be administered in any of several means, which can be selected according to the vector utilized, the organ or tissue, if any, to be targeted, and the characteristics of the subject. The nucleic acids, if desired in a pharmaceutically acceptable carrier such as physiological saline, can be administered systemically, such
30 as intravenously, intraarterially, orally, parenterally, subcutaneously. The nucleic acids can also be administered by direct injection into an organ or by injection into the blood vessel supplying a target tissue. For an infection of cells of the lungs or trachea, it can be administered intratracheally. The nucleic acids can additionally be administered topically, transdermally, etc.

The nucleic acid or protein can be administered in a composition. For example, the composition can comprise other medicinal agents, pharmaceutical agents, carriers, adjuvants, diluents, etc. Furthermore, the composition can comprise, in addition to the vector, lipids such as liposomes, such as cationic liposomes (e.g., DOTMA, DOPE, DC-cholesterol) or anionic liposomes. Liposomes can further comprise proteins to facilitate targeting a particular cell, if desired. Administration of a composition comprising a vector and a cationic liposome can be administered to the blood afferent to a target organ or inhaled into the respiratory tract to target cells of the respiratory tract. Regarding liposomes, see, e.g., Brigham et al. *Am. J. Resp. Cell. Mol. Biol.* 1:95-100 (1989); Felgner et al. *Proc. Natl. Acad. Sci USA* 84:7413-7417 (1987); U.S. Pat. No.4,897,355.

For a viral vector comprising a nucleic acid, the composition can comprise a pharmaceutically acceptable carrier such as phosphate buffered saline or saline. The viral vector can be selected according to the target cell, as known in the art. For example, adenoviral vectors, in particular replication-deficient adenoviral vectors, can be utilized to target any of a number of cells, because of its broad host range. Many other viral vectors are available, and their target cells known..

EXAMPLES

20

Selective elimination of virally infected cells from a cell culture

Rat intestinal cell line-1 cells (RIE-1 cells) were standardly grown in Dulbecco's modified eagle's medium, high glucose, supplemented with 10% fetal bovine serum. To begin the experiment, cells persistently infected with reovirus were grown to near confluence, then serum was removed from the growth medium by removing the medium, washing the cells in PBS, and returning to the flask medium not supplemented with serum. Typically, the serum content was reduced to 1% or less. The cells are starved for serum for several days, or as long as about a month, to bring them to quiescence or growth arrest. Media containing 10% serum is then added to the quiescent cells to stimulate growth of the cells. Surviving cells are found to not to be persistently infected cells by immunohistochemical techniques used to establish whether cells contain any infectious virus (sensitivity to 1 infectious virus per ml of homogenized cells).

Cellular Genomic DNA Isolation

Gene Trap Libraries: The libraries are generated by infecting the RIE-1 cells with a retrovirus vector (U3 gene-trap) at a ratio of less than one retrovirus for every ten cells. When a U3 gene trap retrovirus integrates within an actively transcribed
5 gene, the neomycin resistance gene that the U3 gene trap retrovirus encodes is also transcribed, this confers resistance to the cell to the antibiotic neomycin. Cells with gene trap events are able to survive exposure to neomycin while cells without a gene trap event die. The various cells that survive neomycin selection are then propagated as a library of gene trap events. Such libraries can be generated with any retrovirus
10 vector that has the properties of expressing a reporter gene from a transcriptionally active cellular promoter that tags the gene for later identification.

Reovirus selection: Reovirus infection is typically lethal to RIE-1 cells but can result in the development of persistently infected cells. These cells continue to grow while producing infective reovirus particles. For the identification of gene trap
15 events that confer reovirus resistance to cells, the persistently infected cells must be eliminated or they will be scored as false positives. We have found that RIE-1 cells persistently infected with reovirus are very poorly tolerant to serum starvation, passaging and plating at low density. Thus, we have developed protocols for the screening of the RIE-1 gene trap libraries that select against both reovirus sensitive
20 cells and cells that are persistently infected with reovirus.

1. RIE-1 library cells are grown to near confluence and then the serum is removed from the media. The cells are starved for serum for several days to bring them to quiescent or growth arrest.
2. The library cells are infected with reovirus at a titer of greater than ten
25 reovirus per cell and the serum starvation is continued for several more days.
3. The infected cells are passaged, (a process in which they are exposed to serum for three to six hours) and then starved for serum for several more days.
4. The surviving cells are then allowed to grow in the presence of serum until visible colonies develop at which point they are cloned by limiting dilution.

30 MEDIA: DULBECCO'S MODIFIED EAGLE'S MEDIUM, HIGH GLUCOSE (DME/HIGH) Hyclone Laboratories cat. no. SH30003.02.

NEOMYCIN: The antibiotic used to select against the cells that did not have a U3 gene trap retrovirus. We used GENETICIN, from Sigma. cat. no. G9516.

- RAT INTESTINAL CELL LINE-1 CELLS (RIE-1 CELLS): These cells are from the laboratory of Dr. Ray Dubois (VAMC). They are typically cultured in Dulbecco's Modified Eagle's Medium supplemented with 10% fetal calf serum.
- REOVIRUS: Laboratory strains of either serotype 1 or serotype 3 are used. They were originally obtained from the laboratories of Bernard N. Fields (deceased). These viruses have been described in detail.
- RETROVIRUS: The U3 gene trap retrovirus used here were developed by Dr. Earl Ruley (VAMC) and the libraries were produced using a general protocol suggested by him.
- 10 SERUM: FETAL BOVINE SERUM Hyclone Laboratories cat. no. A-1115-L.

Genes Necessary for Viral Infection

Characteristics of some of the isolated sequences include the following:

- SEQ ID NO:1- rat genomic sequence of vacuolar H⁺ATPase (chemically inhibiting the activity of the gene product results in resistance to influenza virus and reovirus)
- 15 SEQ ID NO:2- rat alpha tropomyosin genomic sequence
- SEQ ID NO:3- rat genomic sequence of murine and rat gas5 gene (cell cycle regulated gene)
- SEQ ID NO:4- rat genomic sequence of p162 of ras complex , mouse, human (cell cycle regulated gene)
- 20 SEQ ID NO:5- similar to N-acetyl-glucosaminyltransferase I mRNA, mouse, human (enzyme located in the Golgi region in the cell; has been found as part of a DNA containing virus)
- SEQ ID NO:6- similar to calcyclin, mouse, human, reverse complement (cell cycle regulated gene)
- 25 SEQ ID NO:7- contains sequence similar to :LOCUS AA254809 364 bp mRNA EST DEFINITION mz75a10.r1 Soares mouse lymph node NbMLN Mus musculus cDNA clone 719226 5'
- SEQ ID NO:8- contains a sequence similar to No SW:RSP1_MOUSE Q01730 RSP-1
- 30 PROTEIN
- SEQ ID NO:9- contains 5' UTR of gb | U25435 | HSU25435 Human transcriptional repressor (CTCF) mRNA, complete cds, Length = 3780
- SEQ ID NO:38- similar to cDNA of retroviral origin

SEQ ID NO: 50- trapped AYU-6 genetic element

Isolation of cellular genes that suppress a malignant phenotype

We have utilized a gene-trap method of selecting cell lines that have a transformed phenotype (are potentially tumor cells) from a population of cells (RIE-1 parentals) that are not transformed. The parental cell line, RIE-1 cells, does not have the capacity to grow in soft agar or to produce tumors in mice. Following gene-trapping, cells were screened for their capacity to grow in soft agar. These cells were cloned and genomic sequences were obtained 5' or 3' of the retrovirus vector SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO: 92, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 119, SEQ ID NO: 177, SEQ ID NO: 206, SEQ ID NO: 240, SEQ ID NO: 243, SEQ ID NO: 247, SEQ ID NO: 321, SEQ ID NO: 328, SEQ ID NO: 329, SEQ ID NO: 330, SEQ ID NO: 331, SEQ ID NO: 334, SEQ ID NO: 335, SEQ ID NO: 336, SEQ ID NO: 408, SEQ ID NO: 411, SEQ ID NO: 412, SEQ ID NO: 413, SEQ ID NO: 414. All of the clones designated with an "x" in the lab designations set forth throughout this application represent genes involved in tumor progression. All of the cell lines behave as if they are tumor cell lines, as they also induce tumors in mice.

Of the cell lines, two are associated with the enhanced expression of the prostaglandin synthetase gene II or COX 2. It has been shown that disruption of gene function by retroviral targeting of an upstream gene has lead to increased expression of a downstream gene product, COX 2. When a small molecule inhibitor of COX 2 enzyme was added, reversion of the transformed phenotype occurred. The COX 2 gene has been found to be increased in pre-malignant adenomas in humans and overexpressed in human colon cancer. Inhibitors of COX 2 expression also arrests the growth of the tumor. One of the cell lines, x18 (SEQ ID NO:177) has disrupted a gene that is represented in the EST (dbest) database.

(SEQ ID NO:76): >02-X18H-t7.., identical to: gb|W55397|W55397 mb13h04.r1 Life Tech mouse brain Mus at 1.0e-114. x18 has also been sequenced from the vector with the same EST being found. (SEQ ID NO:77): >x8_b4_2.. (SEQ ID NO:78): >x7_b4.. (SEQ ID NO:79): >x4-b4.. (SEQ ID NO:80): >x2-b4... (SEQ ID NO:81):

>x15-b4.. (SEQ ID NO:82): >x13-re..., reverse complement. (SEQ ID NO:83):
>x12_b4..

Each of the genes from which the provided nucleotide sequences is isolated represents a tumor suppressor gene. The mechanism by which the disrupted genes other than the gene comprising the nucleic acid which sequence is set forth in SEQ ID NO:76 may suppress a transformed phenotype is at present unknown. However, each one represents a tumor suppressor gene that is potentially unique, as none of the genomic sequences correspond to a known gene. The capacity to select quickly tumor suppressor genes may provide unique targets in the process of treating or preventing (potential for diagnostic testing) cancer.

Isolation of entire genomic genes

An isolated nucleic acid of this invention (whose sequence is set forth in any of SEQ ID NO:1 through SEQ ID NO: 418), or a smaller fragment thereof, is labeled by a detectable label and utilized as a probe to screen a rat genomic library (lambda phage or yeast artificial chromosome vector library) under high stringency conditions, *i.e.*, high salt and high temperatures to create hybridization and wash temperature 5-20°C. Clones are isolated and sequenced by standard Sanger dideoxynucleotide sequencing methods. Once the entire sequence of the new clone is determined, it is aligned with the probe sequence and its orientation relative to the probe sequence determined. A second and third probe is designed using sequences from either end of the combined genomic sequence, respectively. These probes are used to screen the library, isolate new clones, which are sequenced. These sequences are aligned with the previously obtained sequences and new probes designed corresponding to sequences at either end and the entire process repeated until the entire gene is isolated and mapped. When one end of the sequence cannot isolate any new clone, a new library can be screened. The complete sequence includes regulatory regions at the 5' end and a polyadenylation signal at the 3' end.

Isolation of cDNAs

An isolated nucleic acid (whose sequence is set forth in any of SEQ ID NO:1 through SEQ ID NO:418, or a smaller fragment thereof, or additional fragments obtained from the genomic library, that contain open reading frames, is labeled by a

detectable label and utilized as a probe to screen a portions of the present fragments, to screen a cDNA library. A rat cDNA library obtains rat cDNA; a human cDNA library obtains a human cDNA. Repeated screens can be utilized as described above to obtain the complete coding sequence of the gene from several clones if necessary.

- 5 The isolates can then be sequenced to determine the nucleotide sequence by standard means such as dideoxynucleotide sequencing methods.

Serum survival factor isolation and characterization

The lack of tolerance to serum starvation is due to the acquired dependence of
10 the persistently infected cells for a serum factor (survival factor) that is present in serum. The serum survival factor for persistently infected cells has a molecular weight between 50 and 100 kD and resists inactivation in low pH (pH2) and chloroform extraction. It is inactivated by boiling for 5 minutes [once fractionated from whole serum (50 to 100 kD fraction)], and in low ionic strength solution [10 to
15 50 mM].

The factor was isolated from serum by size fraction using centriprep molecular cut-off filters with excluding sizes of 30 and 100 kd (Millipore and Amnicon), and dialysis tubing with a molecular exclusion of 50 kd. Polyacrylamide gel electrophoresis and silver staining was used to determine that all of the resulting
20 material was between 50 and 100 kd, confirming the validity of the initial isolation. Further purification was performed on using ion exchange chromatography, and heparin sulfate adsorption columns, followed by HPLC. Activity was determined following adjusting the pH of the serum fraction (30 to 100 kd fraction) to different pH conditions using HCl and readjusting the pH to pH 7.4 prior to assessment of
25 biologic activity. Low ionic strength sensitivity was determined by dialyzing the fraction containing activity into low ionic strength solution for various lengths of time and readjusting ionic strength to physiologic conditions prior to determining biologic activity by dialyzing the fraction against the media. The biologic activity was maintained in the aqueous solution following chloroform extraction, indicating the
30 factor is not a lipid. The biologic activity was lost after the 30 to 100 kd fraction was placed in a 100°C water bath for 5 minutes.

Isolated nucleic acid

Tagged genomic DIAS isolated were sequenced by standard methods using Sanger dideoxynucleotide sequencing. The nucleotide sequences of these nucleic acids are set forth herein as SEQ ID NO: 1 to 428 (SEQ ID List 1). The sequences were run through computer databanks in a homology search. Sequences for some of the "6b" sequences [obtained from genomic library 6, flask b] (*i.e.*, SEQ ID NO:37, 38, 39, 42, 61, 65, 66, 69) correspond to a known gene, alpha tropomyosin, and some of the others correspond to the vacuolar-H⁺-ATPase. These sequences are associated with both acute and persistent viral infection and the cellular genes which comprise them, *i.e.*, alpha tropomyosin and vacuolar-H⁺-ATPase, can be targets for drug treatments for viral infection using the methods described above. These genes can be therapy targets particularly because disruption of one or both alleles results in a viable cell.

Identification Tags for Isolated Nucleic Acids

Genomic sequences, tagged with a vector, such as the U3 gene trap vector, are given a number corresponding to the genomic library of mutant cells from which the sequence was isolated, and a letter indicating a unique member of the library. More than one sequence with the same number and letter indicates multiple, unique sequences obtained from the genome surrounding the vector insert that "tagged" the gene. Such genomic sequences are obtained using vector-based primers, from which sequencing occurs 3' to 5' or 5' to 3'. In the former case, to recover the orientation of the gene into which the vector inserted, the sequence derived from the vector primer must be reversed and complemented. Such reverse complement sequences are designated "rE". In the case of genome sequencing from a primer that occurs 5' to 3' (*i.e.* the primer is at the 3' end of the vector), no changes are needed, since the derived sequence is the sequence as it appears in the gene disrupted. Such sequences are designated "B4". Homologies indicated below each genomic sequence are in the positive direction, unless explicitly noted to be on the negative strand. As an example, SEQ ID NO. 110 comprises a nucleic acid sequence encoding a novel polypeptide on the positive strand, while the negative strand encodes ferritin.

The SEQ ID NOs and the lab designations for additional genes identified using the methods of the present invention appear below.

84	32-3-2#1E/-rE
85	L191B2E#1-RE

	86	L191B2E#3+-rE
	87	21-5-9E-RE
	homology to: emb/AL021154/HS15005 human DNA sequence	
	88	14A14E-rE
5	89	4cx-b4
	90	5a-b4
	91	6BSA12-B4
	92	X7B/B4
	93	x27b4f_1
10	94	12C#A-rE
	95	10-3b(5/2/96)/-rE
	96	10_4B_4-rE
	97	6BE60-rE
15	homology to: alpha-trophomyosin	
	98	19D3E-rE
	99	L19D16E-rE
	100	2b_rE
	101	14_24_#6-rE
20	102	7A7'-rE
	homology to: annexin II/dynein I	
	103	L12cx#6-rE
25	homology to: gb:X51760 human zinc finger protein ZFP-36	
	104	L12cx#11-rE
	105	19D5E-rE
	homology to: 6-pyruvoyl-tetrahydropterin synthase (gb/M77850/RAT6PTHS)	
30	106	12_3b#7-rE
	107	12_3B#8-RE
	homology to: gb/AA871174/vq32a08.r1 Barskad bowel MPLRBg Mus musculus cDNA clone 10959265'	
35	108	9B27-2-E
	homology to: RAT LOCUS RNU53922 04-MAY-1996; Rattus norvegicus DnaJ-like protein (RDJ1) mRNA, complete Cds, ACCESSION U53922 (on negative strand)	
	109	x15-rE
40	110	X11-rE
	homology to: ferritin H (on the negative strand)	

- 111 X20-rE
homology to: LOCUS RATGL5A Rat NICER element (GL5-14)5' long terminal repeat, Acc.No. M59028 M33535N1D
- 5 112 X4-rE
- 113 14A7E-rE
homology to: MMSMAD7 3681 bp mRNA ROD 31-JUL-1998 DEFINITION Mus musculus mRNA for Mad-related protein Smad7 ,149 bases
- 10 114 14A13E-rE
- 115 14_7#2E-rE
homology to: N-acetylglucosaminyltransferase I
- 15 116 12CX#6-rE
homology to: gb|AA522204|AA522204 vf98g09_r1 Soares mouse mammary gland NbMMG Mus musculus cDNA clone 851872; also 5' similar to gb X51760 zinc finger protein ZFP-36 (HUMAN), gb L20450 Mus musculus DNA-binding protein mRNA, complete cds (MOUSE); Length = 442, 925 bases (shares homology with
- 20 SEQ ID NO:20)
- 117 12C_2B#9E-rE
- 118 12CX#11E-rE
- 119 x5-rE
- 25 120 8C5_11-rE
- 121 191E2E-rE
- 122 19_7AE-rE
- 123 19_9BE-rE
homology to: LOCUS HS347M6 56583 bp DNA PRI 14-JAN-1998 Human DNA sequence from PAC 347M6 on chromosome Xq22, CSTF2 (Cleavage Stimulation Factor, CF-1, Polyadenylation Factor) 64 kD subunit gene
- 30 124 191E9E-rE
- 125 191E8E-rE
- 35 126 14C_2E/-rE
homology to: gb/H31084/EST104778 Rattus sp. cDNA - 5' end similar to signal recognition particle subunit(19kDa) (on negative strand)
- 127 14H1E-rE
- 40 128 14G3E-rE
- 129 14G_2E-rE
- 130 6_3_6_2E/-rE
homology to: Rattus norvegicus cis-golgi gp130 (on negative strand); and

- a HUMAN EST (on positive strand) AI127398; qb70g11.x1 Soares fetal heart NbHH19W Homo sapiens cDNA clone (1705508 3' mRNA sequence)
- 131 14H4E/-rE
- 5 132 18A_8_4E-rE
- 133 18A_8_1E-rE
- 134 SCB2_19E-rE
- 135 L197B3E-rE
- 136 L195C5E-rE
- 10 homology to: H. pylori and C.jejuni
- 137 21_5_7E-rE
- homology to: id3 gene; emb|AL021154|HS150O5 Human DNA sequence from clone 150O5; HTGS phase 1 [Homo sapiens]; containing the E2F2 gene for transcription factor E2F-2 and the ID3 gene for Inhibitor of DNA binding 3 (dominant negative helix-loop-helix protein), 1R2, Length = 133667, 971 bases
- 15
- 138 L195B1E-rE
- homology to: vK72b07.s1 Knowles Solter mouse 2 cell Mus musculus cDNA clone 960181 5'
- 20
- 139 L194c4E-rE
- 140 L193A1E#A-rE
- 141 L192A3E-rE
- 25 142 L1739E-rE
- 143 L192B3E#13-rE
- contains sequence identical to: insulin growth factorII/mannose-6-phosphate receptor
- 144 3 2 4 rE
- 30 located in the same region of the genome as calcyclin, but the gene is "read" in the opposite direction
- 145 36 7 1 a-rE
- 146 36 5 1 4 a-rE
- 147 34 25 5a-rE
- 35 rat satellite DNA (RATRSSID 93 bp, ROD 12-MAR-1984)
- 148 34 24-126/rE
- homology to:
- 40 HSU49928 (3096 bp mRNA) PRI 06-APR-1998, Homo sapiens TAK1 binding protein (TAB1) mRNA, complete cds, ACCESSION U49928 NID g1401125, and HS333H23 (142274 bp DNA) HTG 17-JUL-1998 Human DNA sequence
- 149 34 23-1/rE
- 150 36 5 2-6/rE

	151	36 5 2-196/rE
	152	34 23-3/rE
	homology to: gb L16546 RATAP1X Rat P-glycoprotein (mdr1b) gene	
	153	34 25 23-rE
5	154	36 5 2-196/rE
	155	31 3 9/rE
	homology to: AA798638 568 bp mRNA EST 10-FEB-1998, vw34b06.r1 Soares mouse mammary gland NbMMG Mus musculus cDNA clone1245683 5, mRNA sequence, 824 bases.	
10	156	31 3 6-2-rE
	157	31 3 17-rE
	158	31 3 5-rE
	homology to: AF046001 2347 bp mRNA PRI 19-FEB-1998, Homo sapiens zinc finger transcription factor (ZNF207) mRNA, complete Cds, 833 bases.	
15	159	31 3 15#1/rE
	160	24 3 5#1/rE
	161	31 4 4#1/rE
	162	31 3 19#2/rE
20	163	31 4 5#1/rE
	164	24 9 3#2/rE
	165	L24_26_1-BL
	homology to: AI045472 396 bp mRNA EST 06-JUL-1998, UI-R-C1-jz-h-09-0-UI.s2 UI-R-C1 Rattus norvegicus cDNA cloneUI-R-C1-jz-h-09-0-UI 3', mRNA sequence.	
25	166	L24_26_1-B4
	167	L22_5A1/rE
	168	L24_3_2B/rE
	169	L24 4-2/rE
30	170	L24 5-2/rE
	171	L24 5-3/rE
	172	(15-)L28AP/rE
	173	L24 26-10/rE
35	homology to: LOCUS R06687 403 bp mRNA EST 03-APR-1995; yf10a10.r1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone 126426 5'	
	174	L24 26-2A/rE
	175	L24 26-2B/rE
40	homology to: gb AA590026 AA590026 vm22g03.r1 Knowles Solter mouse blastocyst B1 Mus musculus cDNA clone 990964 , 459 bases, 139A; and Rattus norvegicus Eker rat-associated intracisternal-A particle element	

- 176 14 7#2E-rE
homology to: N-acetylglucosaminyltransferase I; this sequence shares homology with
SEQ ID NO:32.
- 5 177 x18
178 31_3_9-rE
179 31_3_6_2-rE
180 31_3_17-rE
10 181 31_3_15#1-rE
182 24_3_5#1-rE
183 31_4_4#1-rE
184 31_3_19#2-rE
185 31_4_5#1-rE
15 186 24_9_3#2-rE
187 14XD#12E-rE
188 70A-rE
189 31-3-4-rE
190 3_6_9-NeoG-rE
20 191 31_4_2-rE
192 3_2_13-rE
homology to: calcyclin
193 3_2_4-E
25 194 L25-10/-rE
homology to: calcyclin
195 L24-4-3/-rE
30 196 L24-9-1-rE
rat id sequence
197 17-L25-27#7-rE
homology to: calcyclin
35 198 L21C1E-rE
homology to: calcyclin
199 L24-5-3BE-rE.
40 homology to:
LOCUS H32572 310 bp mRNA EST 08-SEP-1995 EST107805 Rat PC-12 cells,
untreated Rattus sp cDNA 5' end, ACCESSION H32572, and

LOCUS AA858747 470 bp mRNA EST 10-MAR-1998 UI-R-A0-bb-e-01-0-UI.s1
 UI-R-A0 Rattus norvegicus cDNA clone UI-R-A0-bb-e-01-0-UI, 3' similar to
 gb|AA473081|AA473081 vd44b07-r1 Barstead MPLRB1 Mus musculus cDNA clone
 803413 5' mRNA sequence

- 5
 200 L24-4-2BE-rE
 homology to: LOCUS MMU51002 6495 bp DNA ROD 16-JAN-1997 Mus
 musculus Dlx-2 gene, complete cds, ACCESSION U51002 NID g1477589
- 10 201 17-3-3B-B4
 202 L24-26-3/-rE
 homology to: RNU23776, DNA ROD 10-AUG-1995, Rattus norvegicus Eker
 rat-associated intracisternal-A particle element
- 15 203 12_2B#2-rE
 204 05-17-3-3He-1-T7
 205 21_5_8E-rE
 homology to: emb|AL021154|HS150O5 Human DNA sequence from clone 150O5;
 1p36_13-36_22, contains the E2F2 gene for transcription factor E2F-2 and the ID3
 20 gene for Inhibitor of DNA binding 3(dominant negative helix-loop-helix protein, 1R2,
 Length = 133667, 971 bases
- 206 X18H-t7
 207 18A_8_4E-rE
- 25 208 L24-5-2BE-rE
 209 L24-4-2AE-rE
 210 L24-10-1BE-rE

Properties of Genes Necessary for Viral Infection

- 30 The methods of the present invention have identified imprinted genes such as
 IFG2r (Lab Designation L192b3E##13-rE (SEQ ID NO: 143)) and CTCF (paternally
 imprinted) which regulates IGF2 transcription (Lab Designation 6BE72_rE (SEQ ID
 NO: 2).

- 35 Also, of 120 clones selected for virus resistance, 6 genes (16 cell clones) were
 selected more than once from separate libraries. Calcyclin was selected 10 times. In
 addition to calcyclin, other clones were disrupted more than once. The statistical
 difference between virus selected and random insertional events by test of proportions
 is $p < 5 \times 10^{-5}$

40

Data also showed that HSV-1 reporter expression is enhanced in two cell clones. S100A6 (Lab Designation 3_2_13_rE (SEQ ID NO: 192)) and Annexin II (Lab Designation 7A7'-rE (SEQ ID NO: 102)) are the sequences disrupted in these clones. They are part of the same pathway and may bind to each other.

5

The present invention has also identified genes whose products are related by binding. For example Lab Designation 6B37H (SEQ ID NO: 65) has the anxI gene disrupted. Lab Designation 6B60 (SEQ ID NO: 237) has the TPM1 gene disrupted. Lab Designation 7A7'-rE (SEQ ID NO: 102)) has the anxII gene disrupted. Lab Designation 3_2_13 (SEQ ID NO: 192) has the S100A6 gene disrupted. Lab Designation 32_3_2#1E (SEQ ID NO: 84) has the cam2 gene disrupted. Lab Designation L24_5_3BE (SEQ ID NO: 199) has the TUSP gene disrupted. Lab Designation 31_3_15#1 (SEQ ID NO: 159) has the fkbp8 gene disrupted. Lab Designation 24_9_3#2 (SEQ ID NO: 164) has the cpr8 gene disrupted.

15

Data also showed that mutant cell clones can have an altered level of expression of the disrupted gene. For example, in the S100A6 clone (Lab Designation 3_2_13_rE (SEQ ID NO: 192)) S100A6 expression is decreased. For another clone, the P162 (eif3s10) (Lab Designation 12PSA#6_rE (SEQ ID NO: 4)) expression is increased. In yet another clone, TPM1 (Lab Designation 6b60_Lac (SEQ ID NO: 237)) expression has altered transcript size.

20

Overall, the genes disrupted by the methods of the present invention are varied and belong to several categories of protein families. This invention provides DNA binding proteins (znf207, HP1-BP74, HAT1); RNA Binding Proteins (zpf36, eif-3, CSTF); Metabolic enzymes (vacuolar H⁺ ATPase [16 and 31 kDa], GnT-1 [N-acetylglucosaminyltransferase); retrotransposons (intracisternal A element rat retroviral sequence); cell surface/matrix proteins (alpha-tropomyosin (TPM1)); signal transduction proteins (TAK1 and smad-7)); and molecular trafficking proteins (gm130, m6p/igf2r, annexin I, annexin II, annexin III, calyculin, JWA, ERBIN, ABC-cassette [mdr1] and DnaJ.

25

30

EXAMPLE II- IDENTIFICATION OF GENES IN IGF2 PATHWAY

To conduct a systematic screen for virus susceptibility genes, a gene entrapment approach, was developed to select intestinal epithelial cells (Blay & Brown (1985a); Blay & Brown (1985b)) resistant to reovirus-induced cell lysis. One of the selected reovirus-resistant clones overexpresses insulin growth factor-2 (IGF2) (Bell et al. (2000)) due to an inserted mutation in the CTCF transcriptional regulators. IGF2 overexpression was found to be sufficient for resistance to reovirus infection. In addition, the selected clone displayed a transformed cell phenotype by its ability to proliferate in soft agar⁶. Thus, gain-of-function mutations in the IGF2 signaling pathway confer resistance to lytic viral infections and potentially contribute to carcinogenesis.

Libraries of RIE-1 cells created by random mutagenesis by a promoter-trap vector⁷ were used to select survivors following lytic reovirus infection. RIE-1 cells were mutagenized by using the U3NeoSV1 gene trap shuttle vector described herein and the resulting libraries of mutagenized cells were infected with reovirus serotype 1/Lang, MOI=35, to select for clones resistant to lytic infection. Persistently-infected (PI) cells (Ahmed (1977)) created following reovirus type 1 infection were found to require a serum survival factor. Since PI cells provide a non-genetic mechanism by which RIE-1 cells can acquire resistance to lytic infection⁹, reovirus-resistant clones were selected in serum free medium to remove PI survivors.

The isolated clones did not express reoviral antigens, and did not produce infectious virus as assessed by plaque assay, suggesting these reovirus resistant clones are not PI. Regions of 3 genomic DNA adjacent to the U3NeoSV1 provirus in each virus resistant clone were isolated by plasmid rescue and sequenced. Altogether, of the 130 isolated clones 62% of flanking sequences matched known or presumptive genes, and an additional 23% were represented in the public databases of expressed sequence tags (dbEST) or non-redundant sequences (nr). From the 90 clones matching known or presumptive genes, 8 genes are represented more than once. Many of the disrupted genes have known or imputed functions, and several are known to function in the same or related pathways. The library included 4 independent mutations of which three genes were associated with the insulin growth factor-2 (IGF2) signaling pathway, namely, the IGF2/mannose-6-phosphate receptor (IGF2/mpr)^{10,11}, the insulin growth factor binding protein (IGFBP) 5 protease (prss11)¹², and the CTCF gene^{13,14} (clone 6b72). CTCF differentially represses maternal IGF2 gene expression, whereas the imprinted paternal gene escapes repression due to methylation of CTCF binding sites.

Levels of CTCF protein in 6b72 cells were reduced by about 50% as assessed by western blot analysis, consistent with the disruption of one allele. Diminished CTCF expression was associated with an increase in IGF2 transcripts as assessed by Northern blot. In addition, two products were amplified from 6b72 cells by RT-PCR using primers that flanked the IGF2 coding sequence. The first product was identical to the rat IGF2 sequence (Genbank Accession No. X17012), whereas, the second contained 14 additional nucleotides due to differential splicing of exon 2 to an alternative splice acceptor located upstream of exon 3. The alternative transcript encodes an abnormal protein consisting of the first 11 amino acids of the E-peptide appended to 60 amino acid residues without homology to any known protein. To examine whether increased expression of IGF2 in the 6b72 clone is associated with cellular resistance to reovirus infection, RIE-1 and 6b72 cells were infected with reovirus type 1, MOI=10. There was approximately a 90% decrease in titer of reovirus obtained from infection of the 6B72 clone compared to RIE-1 cells at 24 hours post-infection (4.5×10^5 versus 5.1×10^6) that was maintained at 48 hours. Additionally, there was a dramatic difference in the survival of 6b72 cells after being exposed to high titers of reovirus type 1. To determine whether IGF2 confers the property of resistance to lysis with reovirus, cell clones overexpressing the IGF2 gene and its splice variant were generated. Cells were examined for their capacity to resist lytic infection with reovirus. Over-expression of wild type, but not the splice variant IGF2 in RIE-1 cells increased the resistance of cells to reovirus infection by over 100 fold. However, when the splice variant IGF2 was transfected into 6b72 cells, the ability of 6b72 cells to survive infection was abolished. Over expression of the IGF2 gene in reverse orientation resulted in a slight difference in the capacity of 6b72 cells to resist infection. These studies suggest that increased IGF2 expression in 6b72 cells is associated with their capacity to resist lysis by reovirus infection, and that the splice variant IGF2 encodes a dominant negative isoform that blocks the effect of IGF2. There is accumulating evidence suggesting that overexpression of IGF2 associated with relaxation of IGF2 genomic imprinting is associated with tumor formation. To determine whether the 6b72 cells differ in their rate of cell cycling compared to wild type cells we examined the incorporation of MTS/PMS. It was found that there was no alteration in cell cycling (data not shown). RIE-1 cells do not have the capacity to proliferate in soft agar, a surrogate for the ability to form invasive tumors in rodents^{6,15}. It was found that 6B72 cells that have a disrupted CTCF gene develop the

capacity to proliferate in soft agar To determine whether IGF2 confers this phenotype, cells that were transfected with the IGF2 wild type and its gene variant were examined. 6b72 cells that overexpress the IGF2 gene were found to grow in soft agar. Forced expression of either the splice variant IGF2 or an antisense IGF2 abrogates the ability of 6b72 cells to grow in soft agar. Thus, the variant IGF2 appears to act as a trans-dominant inhibitor of IGF2 in this assay. Finally, as anticipated, there was no phenotype associated with overexpressing the splice variant IGF2 gene in the parental RIE-1 cells. The capacity to proliferate in soft agar is not a property of other reovirus-resistant clones that contain mutations in the IGF2 pathway Thus, cell clones with disrupted IGF2 receptor (IGF2/mpr) or IGF2BP 5 protease (prss11) genes did not proliferate in soft agar. Annexin II (anxa2) is involved in cytomegalovirus replication¹⁶ and binds to the insulin and insulin growth factor-1 receptors¹⁷. A clone with a disrupted anxa2 was found in our library, also failed to grow in soft agar. Therefore, the capacity to proliferate in soft agar is not a general property of cells that are resistant to reovirus, even in clones that contain genes disrupted in the IGF2 or related pathways.

Insertional mutagenesis provides an approach to identify genes associated with selectable cellular phenotypes. In the present study, one clone resistant to reovirus lytic infection contained a provirus inserted into the CTCF transcriptional regulator and overexpressed IGF2. CTCF binding motifs are present in many genes, including IGF2¹⁸/H19¹⁹, and c-myc²⁰. However, since 3 other clones selected for reovirus resistance contained mutations in the IGF2 pathway, the role of IGF2 in virus-resistance was investigated further. Forced overexpression of the IGF2 gene in the parental RIE-1 cell was sufficient to confer cellular resistance to lytic reovirus infection. By inference, inserts affecting other genes in the IGF signaling pathway suggest that mutations in multiple genes may affect the same phenotype by acting on a common pathway.

As the entry, disassembly, transcription, translation, and repacking of viruses share common features; it is possible that common cellular pathways will influence infection by other virus families. The present study is the first to show a direct connection between IGF2 gene expression and virus infection.

The data presented herein also suggests that the level of IGF2 expression correlates with the capacity of cells to proliferate in soft agar, a surrogate for the establishment of invasive cell growth. In addition, this invention has defined a novel

dominant negative variant that shares virtually the entire sequence of the mature hormone, but lacks a major portion of the E-peptide.

Entrapment mutagenesis and selection of reovirus resistant clones

5 To identify genes that may interfere with reovirus' lytic infection, a gene trap retrovirus shuttle vector, U3NeoSV1, was used to generate mutagnized rat intestinal (RIE-1) cells₁. A library of mutagenized RIE-1 cells were generated following infection of the vector, multiplicity of infection < 0.1, and selection in media containing G418 sulfate (0.7 mg/ml) (Clontech, Palo Alto, CA), 1 mg/ml₁. Twenty
10 libraries of mutant RIE-1 cells, each consisting of 10⁴ independent U3neoSV1 vector insertions, were generated and expanded until each mutational event was represented by a sub line of approximately 10³ sibling cells. These cells were plated at low density and incubated in serum-free media for 3 days until they became quiescent, infected overnight with reovirus serotype 1 at a multiplicity of infection of 30 plaque forming
15 units (pfu) per cell. The infected cells were detached with trypsin, DMEM medium containing 10% fetal bovine serum (FBS) (Hyclone Laboratories, Inc., Logan, Utah) was added and the cells were allowed to reattach. After 4-6 hours the medium was replaced with serum-free medium and the cells incubated for several days until there was microscopic evidence of only a few cells attached to the plastic of the flask. Cells
20 that survived the selection were transferred to cell culture plates in media containing 10% FBS and cells were divided for extraction of DNA and freezing

Identification of genes disrupted by gene entrapment

To identify the gene disrupted by the vector in clones surviving reovirus
25 infection, the shuttlevector property of U3NeoSV1 was utilized. Regions of genomic DNA adjacent to the U3NeoSV1 provirus insertions in clones resistant to reovirus lytic infection were sub cloned by plasmid rescue, and sequenced₁. Sequencing was done using an automated sequencer (ABI 3700 DNA Analyzer, Applied Biosystems, Foster City, CA), and the results obtained were compared to databases available in the
30 public domain (BLAST nr, est, and hgts). The probability of a match to sequences in the databases occurring by chance alone varies due to interspecies conservation and the length of the match. Matches to characterized genes were considered significant if the probability score was $p < 10^{-5}$ and involved non-repetitive sequences. As indicated, virtually all of the genes identified had matches to murine, rat, or human gene

sequences with $p < 10^{-10}$.

IGF2 expression was assessed by Northern Blot hybridization

Total RNA was isolated from cultured cells using Trizole reagent
5 (Gibco/BRL). 5 mg of RNA was separated on 1.2% agarose gel, and transferred to a
Nitrocellulose membrane. Membranes were hybridized with random prime-labeled
(Stratagene) probes corresponding to a full length of IGF2 cDNA and a b-actin
cDNA.

10 IGF2 cDNA isolation and expression

Rat IGF2 cDNAs were obtained using reverse transcriptase PCR (RT-PCR).
Total RNA was extracted from RIE *and* 6B72 cells using Trizole reagent (Life
Technologies, Rockville, MD). RT was performed on 1 mg of total RNA (PTC-100
programmable Thermal Controller, MJ Research, Inc, Watertown, MA). A pair of
15 primers was designed according to rat sequences:
CTTCCAGGTACCAATGGGGATC (forward) (SEQ ID NO: 429) and
TTTGGTTCACTGATGGTTGCTG (reverse) (SEQ ID NO:430). A 500 bp DNA was
amplified under following conditions: 95°C, 1 min; 40 cycles of 95°C 30 seconds,
60°C 30 seconds and 68°C 3minutes; 68°C 10 min; 4°C.

20

Immunoblotting Analysis

Cells were washed with PBS and lysed in SDS Lamelli buffer. Protein
concentration was determined using the bicinchoninc acid protein assay (Sigma, St.
Louis, MO). 20 mg of protein extract was loaded in each lane of a 10% SDS-PAGE
25 and run at 100 V. Protein was transferred to a nitrocellulose membrane at 22V
overnight at 4°C. The membrane was washed three times with TBST (50 mM Tris pH
7.5, 150 mM NaCl, 0.05 % Tween 20) and then incubated in blocking buffer (TBST
and 5% nonfat dry milk, pH 7.5) for 1 hour at room temperature. The membrane was
then incubated with anti-mouse, CTCF (1:500, BD Transduction laboratories) and b-
30 actin (1:3000, Sigma) in blocking buffer overnight at 4°C. Following washing (x3),
the membranes were incubated with goat anti-mouse secondary antibody (1:20,000,
Jackson ImmunoResearch Laboratories, West Grove, Pennsylvania) for 1 hour at
room temperature, followed by three 15-min washings. Immune complexes were

visualized by addition of chemiluminescence reagent (Renaissance, DuPont NEN, Boston, MA) and the membrane was exposed to Kodak XAR-5 film (Eastman Kodak Co., Rochester, NY).

5 Transfection

Cells were cultured to semi-confluence and plasmids expressing wild type and variant IGF2 proteins were transfected into RIE and 6B72 cells using SuperFect Reagent (Qiagen, Inc. Valencia, CA) according to the manufacturer's protocol. After 48 hours, transfected cells were passaged, 1:10, into medium containing hygromycin
10 (selective medium) at a concentration determined to kill 100% of non-transfected cells (150 mg/ml). Cells were maintained in selective medium until clones appeared.

Soft agar colony forming assay

Dual layers of sea plaque agarose were made with the bottom layer consisting of a
15 50:50 mixture of 1.6% agarose solution 1:1 and 2X medium. The bottom layer was allowed to set for 4 hours, and then a 50:25:25 solution consisting of 2X medium, 1.6% stock agarose, and 1X medium containing cells, at a final concentration of 5000 cells/ml, was vortexed in a conical tube, and 2ml was added to each well. Following 30 minutes at room temperature to allow the upper layer to set, plates were incubated
20 at 37°C, 5% CO₂ incubator for 7-10 days and checked for colony formation by microscopy.

Cell Proliferation Assay

RIE-1, 6b72, or IGF2 transfected RIE-1 or 6b72 cells were seeded at 5x10⁴ per well
25 in 96-well plates, incubated at 37°C and 5% CO₂. At 4,6,18,48 hours post plating, MTS/PMS, 20 ml per well (CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay, Promega, Madison, WI) was incubated for 2 hours, and then the absorbance was determined at 490 nm. Each set of conditions was repeated in triplicate.

30

EXAMPLE III

T. cruzi

The methods of the present invention have identified cellular genes involved in the pathogenesis of *Trypanosoma cruzi* infection of mammalian cells. *T. cruzi*

infects many cells including muscle cells and epithelial cells, among others.

Insertional mutagenesis was utilized to isolate positional sequence tags that define regions of DNA that contain DNA that encodes for genes necessary for the infectious cycle of *T. cruzi*. In the process of characterization of genes that have functional
5 roles in the replication of *T. cruzi*, one PST was found that is essential for both *T. cruzi* and reovirus replication.

Chagas' disease affects millions of people in South and Central America. *Trypanosoma cruzi*, the protozoan which causes Chagas' disease must attach to mammalian cells before it can invade them. The disease is acquired when a host is
10 infected by invasive trypomastigotes transmitted by an insect vector or during blood transfusion. Cases of blood transfusion-related Chagas' disease have been reported in the United States where the disease is not common. There are estimated to be more than 100,000 infected persons residing in the United States, and it has been suggested that cases will be encountered in increasing numbers. Trypomastigotes attach to and
15 penetrate mammalian host cell membranes to multiply intracellularly as amastigotes. Amastigotes then transform into trypomastigotes that are released from these cells to infect neighboring cells and disseminate in the body.

The methods of the present invention were used to select cell mutant clones of rat intestinal epithelial cells (RIE-1) that are resistant to *T. cruzi* infection using gene
20 trap retroviruses. For this purpose, RIE-1 cells were randomly mutagenized with a retroviral vector (U3 gene trap) containing neomycin and ampicillin resistance gene markers. A library of gene trapped RIE-1 cells was infected with the highly invasive *T. cruzi* trypomastigote clone 20A at a ratio of 20 parasites per cell. Control monolayers of wild-type RIE-1 cells were also infected with the same density of *T.*
25 *cruzi*. After several cycles of *T. cruzi* infection, cell lines were selected for their ability to be resistant to *T. cruzi* infection and then for their ability to be resistant to G418, a neomycin analogue that is cytotoxic to mammalian cells. These cell lines were cloned by limiting dilution and two clones named A:11:4:C5 and C:8:2:B4 were selected for further studies. It was found that A:11:4:C5 and C:8:2:B4 clones released
30 very few trypanosomas, whereas wild-type RIE cells released many trypanosomas. Kinetics of infection of A:11:4:C5 and C:8:2:B4 clones and wild type-RIE-1 cells with *T. cruzi* indicate that mutant clones A:11:4:C5 and C:8:2:B4 do not support *T. cruzi* infection as indicated by the dramatically low number of intracellular parasites within these cells as compared to high level of infection seen in wild-type RIE-1

cells. This pattern of low *T. cruzi* infection seen in A:11:4:C5 and C:8:2:B4 clones is constant during the cycle of infection of *T. cruzi* in rat epithelial cells observed from 1 to 5 days. Further analysis of two cell clones demonstrate that the block in the parasite's infectious cycle occurs after the binding of the parasite into the mutant
5 cells. It was shown that binding of parasites to the mutant cells is similar to the binding of parasites to the parental cells. However, entry of parasites into each cell line was diminished. For another mutant cell line, entry was similar to the parental cell, but the ability of the parasite to be released from the phagolysosome was dramatically affected.

10 To investigate this hypothesis the features of the gene-trap vector were manipulated to derive a rescued plasmid from each clone. The resistant (R) clone obtained by EcoR1 rescue and BamH1 rescue gave two plasmids representing over 10 kb of DNA. The downstream sequence has significant identity with several rat EST sequences identified and submitted to the gene bank on behalf of NIH's rat genome sequencing project.

15 The second clone is designated most resistant (MR) based on its quantitative resistance to intracellular *T. cruzi* infection as compared to the wild type cell line. The genomic sequence that was rescued from this clone is approximately 4.5kb with significant homology to a protein phosphatase pp2a B' regulatory subunit gene. Because of several anomalies, the MR cell line was subcloned and from a pool of 50 clones MR- 6C2 was
20 selected, which again upon conducting plasmid rescues yielded a sequence with identity to the pp2a B' regulatory subunit. By reverse transcriptase followed by polymerase chain reaction (RT-PCR), using primers designed from the human pp2a B' regulatory subunit homologue, we have been able to show that the RIE wild type cell line expresses a pp2a B' regulatory subunit while the MR-6C2 clone does not amplify a product in parallel
25 experiments. These data indicate that this gene is no longer expressed in the selected clone.

Several other clones have been isolated. One of these, 8B1, has the phenotype of diminished binding of parasites to the cell surface. By plasmid rescue, a sequence of genomic DNA was isolated that has a 100% homology to the rat *lectin-like oxidized LDL receptor gene (LOX-1)*. The 1.6-kb genomic fragment gives 100% identity when sequenced
30 with both Lac (5' distal) and Neo (5' adjacent to the vector) primers. The insertion resides at base #6120 in the reported sequence¹⁹. Our genomic fragment extends 5' to an EcoR1 site just prior to the TATA box of the promoter position (# 4774). This positional sequence tag (PST) is consistent with the published report of the position of this restriction site. Analysis of the clone indicates that insertion has taken place into intronic sequence after the

first exon and the rescued sequence appears to contain the coding sequence contributed by the first exon. The first exon is found at nts 4800-4937 of the rat genomic DNA for exon 1 and the promoter region. The vector resides at nt 6122 and the reporter gene would be expected to be transcribed from the same strand as the LOX-1 gene. The LOX-1 gene is
 5 3.75 kb, and the organization of the downstream exons is not reported to the database.

MR-b4...identity with est: EST230513 Normalized rat lung.
 (SEQ ID NO: 419)

10 GTTAGGCCCTCTGAGTCCNTNACTACCCGTCAGCGGGGGTCTTTCACACC
 CTTTACCTACCCACCCTGCATCCCAACATGTCATGTGGAAAAGTCCTCAT
 TTTTATATTGAGAAGGGTTTTTTGTTTGTTTGATTAATTTTTGATTTTT
 CAGTGAANTCATTTTCTTTGTGTCAATACCTTTTTCTCTACACTTACCAG
 GCTGTTGTAAGAAATAAACTGAGAAACATTTGATCTCTCCTCTTCCTCCA
 15 CCAAGTGCTGACCCTCAGGCTGCACCACCAATAAATAGGGACCTGAAGAA
 AGGAATGGGAGTTGTGTTTATTAAAAAAGATTAGACAGAAGGAATACG
 TTTGGTGGATGTGTATTTCAGG TTTGGTGGATGTGTATTTCAGG

P4c5e/NeoC
 20 (SEQ ID NO: 420)
 CGATCCTCAGCTAGCTTG
 CCAACCTACAGGTGGGGTCTTTCACCCTGTACCTGTTAAGCTCATCTCACC
 TCCCTGCCATTTTCTGGATGAATTCTTTGTCAAACCAATCTCAAGCCGTTG
 GCAAAAATACTCTACAGCACTTCAAAGTGAAGTGCAATCATTTTCTTTTC
 25 TACCCAGGAACACAAAGATTTTCCAGCACAATGTAGAACTGACGAGAAA
 TGGAGCAGGGGAACATCCAGCACACGAGCAGCTCTGAGGTGTGGGTGTGT
 TAGCTCAAACCTNCACTTNCCATAAAGTAGAGGTGAGGAGGACAGGGTAAC
 TTANAGGAGGCAGAAAGAAAACAACAGNATNATAGTTGACCCTGGGAAG
 GGGCTCTACGTGTTGTGGGTGCTNCCAAACCCAGNTGGNCAATNAATGCA
 30 CTNCTACTNCATGGTGGCTTGAGGAAAGGGCTGGAGTNACTAAAGNCGGG
 NTGAGGAGGGTGGATNATNGNGNCTGCAGATNGGNCCTGNTTGNAGGTN
 GNNCTGNTGNGGNNTGTGGGGNAGACAGGATNGGGTGTGGGGGGGGGNTN
 GNTGGGNTGGNANTGNCTGTGGNGNCCAGGNTGGGNTGGGNCTGGCNG
 ATGNTGNTGGCTGTGGNNTGNTGGGGGCTNGGNTTGAANGTGTGGCNCNG
 35 GGNGGCNTNGGNTGNGGGNANGGGGNANGGGNTGNGTGGGGGGGGGAGT
 GGTGGGGGGTGGGTGNNGGTGGGGGGNCCCTTGGGGGGNTNGGGGGTNG
 GNTNACGTGGCNGNGTNGGGGAAGTGNNGNACGACGC

>
 gi|18846965|gb|AC109110.2| Rattus norvegicus clone CH230-28... 688 0.0
 40

P4C5c/LacO >
 (SEQ ID NO: 421)>
 TTTNCACAGAATNCAAGCCAGAGGCTCAAAAGTAAACCTACACATCCTGT
 TCACAAAAGCACTGGGCACAATTGCTAGAGGCTAGAAGAAGCCCAAGTAT
 45 CCACTTAACAGGTAAATGCCACACGCCTGCAGTGCCTTTGCTATTCACCTG
 TCAGAGGGAAGGGAAGCCCGTTCATGCTGCAGCATGGGTGTTCTGCACAG
 TGAAGAATGAACTATGGTGGCTGTGCTTTCCAGTTCCGATGAGTGGGCATT
 TAGGAGGCAAAGAGAGAGAGACACAGCAGACTGAAGCAACCTGTAG

ACAGCAAAAGCTCATCCAGTCAGGGCTCACAATAGCCAACAATAGAGAC
 GACTACCGCAGCCTGATTGAAAGAGGGGAGCAAAAGGCATCAAGTTGGTG
 CTCACAACATCCCCCATGAGTCTGCTGTCGGANCAGTAGTCCTGCTGGAGT
 TCTGAGTGGAGGGTCCTGGGCAGAGCANANCAGTCTCCATGGATGAGCTT
 5 CATAGTCTGTTGCCAATGGTTACCTTCTAGCTGTTGTCAANAGCTTGTTTTT
 ACTGNCAAGATGTGTTGCTGTTGTCAATNCCCANACAANGGCCCTTANAG
 GACAATATGAGATAGGCATGGGTGGGCCTGAAATGGGGGGAAGGAGAGG
 GGTNAATTGCANNTTGGCAAGGAGGGGCANACANCACTTGNTGGCTGCTAC
 ACTNTATNGGGGAGGGGACCAAAGGNGCCATGANGAATGGTNNTGATGG
 10 NANTTGCTTGAGGGGGCGTNGNAAAATANAAATNGGNAAAANGATTGTT
 TNGCNTTTTTTTTAANNNGANGGGTATGAATNNNNNTANACCTNGNGGNG
 GGAAANANCN

> gi|18846965|gb|AC109110.2| Rattus norvegicus clone CH230-28... 605 e-170
 15 P4C5c/NeoC..
 (SEQ ID NO: 422)
 CGATTTCTNAGCTACCTTGCCAACCTACANGTGGGGTCTTTCACCCTGTGC
 CTGTTNAGCTCATCTGACACTGGCCTGCCATTNTNTGGATGAATTCTTNGT
 20 NGAACCAATCTTAAGNCGGNGGATNAAATACTGNTACAGNAGCTNANNA
 GTGAAAGCG
 above sequence- first 46 are vector.

Note: this next gene is a LAC (5' not connected to the vector sequence) of
 25 P8A3- it is in the Rat tryptase 2 gene.>
 >
 P8A3a/LacO., gb|AF011446|AF011446 Mus musculus granzyme K
 gene, complete cds
 Length = 5747,2e_99, and gb|L19694|RATRKNKT2A Rattus
 30 norvegicus tryptase 2 mRNA, complete cds. Length = 884, both
 negative strand.
 >
 (SEQ ID NO: 423)
 TTCACAGAAACCTAGGGTGAAGGGTAAGGCTGGGGAAGTAAGGAATCTG
 35 CAAATCCATCGTGAGTGCATACACGCAGAGTGTCTCTGCAACATATCTGT
 GCTTACTAAATGTGTCAGTTATTCTGAAATACCTTAAAAAATAAAAAACAC
 CAAGTCTCAAAACCGCACCAAGAAAGAGACAGTAACTTTCCTTGCACCC
 AGGCTTCCTTTCAGCAATTGCAGTTGCTTGTGGTCAACTGCTGTTGAAAGA
 TTACATGAAATATTCCAGAGACAAATGATACATGCATTGAAAATTACATA
 40 TTAGAGTAGATTGATTGAATTGTGCTTTGATNGCCATTGTTAATCTTACTG
 TACTCAGGNNCTTGACTAGACTTTATGTTATGCGTGTCAATTTATCCTGGAC
 ATGGACCACCACATACATGGAAAAGCACAGGGGACTGACCGAGAGTAGC
 ANTGGGCCGGCTGNTANCACCCACTGCGGATGGATNANGACTGNCTGCCA
 AATATNCTGGGCGGGGTGCTGGATGGAAGCCATAGAAGGCGTGNAATGN
 45 GGNTNNNCT
 >

gi|3169700|gb|AF011446.1|AF011446 Mus musculus strain 129/SvJ 216 2e-53
 gi|8393512|ref|NM_017119.1| Rattus norvegicus granzyme K (G... 66 4e-08
 50 >

P8A3C/e..., reverse complement, 862 bases, 2600 checksum.

(SEQ ID NO: 424)

```

5  CCCCCCCCNCANNNCCCCACACACCTCCCCCGCCNCCTTCACCCCANCNCA
   GCCCNAGCCCCCNCNCCCACATTTCCACANCCCACCGNGCNTCTTTCCCA
   GNNCGNATNTNTCCAANCAGNTCCCNCCACATCCNCCANCCCCCAGTNCA
   CGGGGCCNCCCCATCCTNNCNGNCCCACAGGCCANCTTTNCCCCTGTCCC
   CATTCCCCACCCTNCCTNTCATGNCCCCTNAGTANCNNTCANCAGCCACN
   CTNCCCCTTNATCCCANCNCTGTGCACACCTTTTATTCCTGTGNCCCN
10  CCAATGTCTCCCACCTTTCTGTTCCATTTTTCCCNCATAGTTCCCAANN
   CNATTCTGGGNAAGAGCAGCCATCAAGGCCCACTTTATAGTCCANAATNC
   TGGNCCTGCCTTNNAATGTCCTCCTATATTNAGTNACCGCACCGCCTTTA
   AATCNACCATCATGCAAAGTGGCAGNATGCANACAAATTGTANAAAAGCT
   CTTCGCCTGAGCAGCACTGTGGATCTCCTAGTNAAGTTGGAGTGTGTACA
15  CTACACCCCAATATCTTAGAAAATTCCCAAGAGAACTTCATCTTTTCC
   TCTATAAATTTGCAAGAGAATAAAAAGGATGGTAAGACAATTATGCCAAAT
   TAGACCTTTAATCAAGAGATTACAAATTATAATGTCTACTACCCTTCCTG
   AATCTATGAAGAAAATTAAAAATACACTATAATAATATTCATAGTTGTTT
   ATTTAGAGCATTTGCTTCTCAACTTTAAATATTAGTCTTTTATTTCTTTA
20  CGCCCATATATCAGGAACCAGTGAAAGACCCACCTGTAGGTTGGCAAG
   CTAGCTGAGNAT
   >

```

P8A3a/E..., reverse complement, 640 bases, 55F checksum.

(SEQ ID NO: 425)

```

25  GGGNNTNANGGAGNCNCGNGGCGCNCGGGCNTNGCCCGNTANCGNGGNG
   NGCGGGGNGNGGAANNNTNAGGNCNGNNAACAGAGGCGGNGNNGCGGCG
   CTGGGNNNNNGGNCCGGNNGGCCCGGNGGGGTANAAGNNGAAGTGNTNAGN
   GGTGGGGAGGNANNNGACGNTGGGNNCGANNNNCGCNGGGGGANGTGAA
30  GCCNGCCNGTGCNNGGNGAGNNGGGCGGNNNTGGGGGNGNGGGGCCANNNN
   CNGNATGAGGNGATGNTGNGGNTGGGCGNAGGNNAGGCGGGCGNGTGGC
   GNGNNGCGGTGGGGNGNGNNGGAANNGANNTGGCGNGCNCNCCGAGGGN
   GNGATNCNNCGCNCNGNGGAGGGNCNGGNGATGNGTCNNAGANGGTCCG
   NGGNNGGCNGGNCAGNNCGTGCNGTNANGNCNTNGNGATCANNGAGGGT
35  GNCCNNNGGNANGAGTCTAGGGGCGGCCCTNTCGTNNATNCNANGNGGG
   CCGATTNCNCGCATNCGCNNATAATCATATTCCATAGTTGNTTATNTAGAGC
   ATNNGCTTGTCACCTTTNAATATTAGTCTTTNATTTCTTNACGCCCATAN
   ATCAGGNACCAGTCGNAGACCCACNTGTAGGTTTGGCAAGGGTNGCGAG
   NA

```

40

P8B1-E..., dbj|AB018097|AB018097S1 Rattus norvegicus gene for lectin_like oxidized low_density lipoprotein receptor, exon 1., rev, 827 bases, 1EA checksum.

(SEQ ID NO: 426)

```

45  TANAAAGANGNCANAAANGCNNCNTTCAGAGNCCCAAANNTATTTTGTGT
   GTNNTNAAGNCTGCAAAAATGGGNAGTGTTTTGTNAGTATNTAAGCAGAT
   TNGGTATATTCAGNCGGCCAAANANACATTAGACTCTTTGTCCATTGTTG
   GCTTTAAAAATTGTAGCTTGTAATTCNCTATCCAGTAAACTTAATTACTT
   ANGCTGAATAGATAACTCGATTCTGTAGAAAACACAGGTAAACATCTA
50  TTATTTTATAAAATCGAGAGAAAAAGGCCAGGTAGGTGCACACCTTTAAG

```

CCCAGCACTTGGGAGGCAGAGGCAGGTCACCTGCTCTACAGGGTGAGCTT
 TAGGTCATCCAGGAATACACAGAGCAACCCTGACTCAGAANCAAACCCAA
 AAAAAAAAAAAAAAAAAAAGGAACAAATTGTAAGAAGAGGAAGAAAGGCAT
 AGTGTGTCTGTAAATAAGCCTGAAATCTCTCAGTGGGTAAGATAAGGCCG
 5 AGTGTGGTGTGATTTAATGTCTGAGTGACTGAACTAGCTCAGAGTCAGGA
 CAGTGCTGGAGCTTGGTAGTAGACCCAGCAGCAGTGGAGCTAGCTTAGTG
 TGAGAAAGTGCTGGTGTTTAGTAGTAGATGTAGGAGCTAGTACCACGTGT
 GAATTTGCTCAACCACTCATTCAATTATTTGTGCAGTAAATATTGTTTTCTAA
 CCTGACTTTTACCATAAATACTAGTTCTTCTTTAGGAGCCCTGGTTAG
 10 ACTATTTACTGTGGTATAAGCTATATACTGAAGTTAGTGTGAAAGACCCCA
 CCTGTAGGTTTGGCAAGCTAGCTAG
 >

15 gi|4008162|dbj|AB018097.1|AB018097S1 Rattus norvegicus gene... 743 0.0
 >
 Sequence of homology with the vector sequence and the LOX-1 genomic fragment.
 dbj|AB018097|AB018097S1 Rattus norvegicus gene for lectin-like oxidized
 low-density

20 lipoprotein receptor, exon 1
 Length = 8960
 602601
 Nucleotide, Related Entries, Protein, PubMed, LinkOut
 LOW DENSITY LIPOPROTEIN, OXIDIZED, RECEPTOR 1; OLR1
 25 >
 LECTIN-LIKE OXIDIZED-LDL RECEPTOR 1; LOX1
 OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1
 Gene map locus 12p13-p12

30 Endothelial cell dysfunction or activation elicited by oxidatively modified
 low density lipoprotein (Ox-LDL) has been implicated in the pathogenesis of
 atherosclerosis. Vascular endothelial cells internalize and degrade Ox-LDL
 through a putative receptor-mediated pathway that does not involve macrophage
 scavenger receptors (see MSR1; 153622). To identify genes encoding Ox-LDL
 35 receptors, Sawamura et al. (1997) transfected mammalian cells with a cDNA
 expression library derived from bovine aortic endothelial cells and assayed
 for uptake of labeled Ox-LDL. They recovered a cDNA encoding an Ox-LDL
 receptor, which they designated lectin-like Ox-LDL receptor-1 (LOX1).
 Immunofluorescence studies showed that bovine LOX1 is expressed on the cell
 40 surface. Sawamura et al. (1997) cloned a cDNA encoding the human homolog of
 LOX1 by screening a human lung cDNA library with the bovine LOX1 cDNA. Cells
 stably expressing human LOX1 showed uptake of labeled Ox-LDL. The predicted
 273-amino acid human LOX1 protein is 72% identical to bovine LOX1. Its

structure is similar to that of C-type lectins such as CD94 (KLRD1) and NKR-P1.
(KLRB1). Northern blot analysis revealed that human LOX1 is expressed as a
2.8-kb mRNA in various tissues, with the most abundant expression in placenta.
Yamanaka et al. (1998) determined that LOX1 is expressed in vascular-rich
5 organs but not in lymphocytes.

Yamanaka et al. (1998) found that the LOX1 gene spans approximately 15 kb
and consists of 6 exons. By fluorescence in situ hybridization, they mapped the
gene to 12p12-p13, where genes of the natural killer cell receptors are
clustered.

10

Ehrlichia

The selection methods of the present invention were used with a highly
susceptible cell line that is commercially available, DH82 cells, that were obtained
from the ATCC. The cells were infected with a vector of the present invention and a
15 library was created of mutant cells. The mutant cell library was selected with
Ehrlichia chaffeensis, Arkansas strain, that was obtained from a laboratory sample
from an infected individual. Surviving cells were re-exposed to the infectious agent,
1:100 infected to naïve cells [infection of naïve cells requires the presence of infected
cells for infection- cell to cell contact]. A single cell clone was derived from a library
20 of approximately 1 to 3000 unique inserts. The clone has a disrupted fastK gene.

The parental cells are susceptible to apoptosis during the course of *Ehrlichia*
chaffeensis infection, whereas the mutant cells are not susceptible. However,
chemically induced apoptosis is preserved in the mutant cell clone (susceptible to
anti-neoplastic drugs). An expression cassette was created using a macrophage
25 specific promoter and enhancer and the human fastK gene. It was found that the
phenotype of *Ehrlichia* susceptibility can be complemented in the cells that express
the transgene in its appropriate (positive) orientation. The transgene expressed in
negative orientation did not have a phenotype with the mutant cell clone used as the
recipient.

30 (SEQ ID NO: 427)

11-d11-erlichia sequence from dog, Rubin.Seq LENGTH: 1101 CHECK: 332 ...,
reverse complement, 919 bases, 2339 checksum.

ACCGGAACCCCGTTTTTTNTTGNNNGGGNTTTAACCCNNATTTGGNGNCC

GGCCCCGGTNCNNGGGNTTNNTGGAAAAATGNCNNNCTCGNTGGCCTTCCNA
 TTAANANGCCNNGGGGAAGCCCGTCTCCCGGNCCCCANNNCNATTAGGA
 ACCACCNTCGCNGGNCTTGGNACCCATTTAGGGGTGGCCCTTCCGGNCGG
 CTTGGAAGGNCGNCGGTAGTTGTTGTTGCCNACCGTTAAGACGGTCTCC
 5 GGGCGTCNCCNGGCTTCCCCGGNCCGGTTGGTTTGGGCCCCTAACACCGC
 CGACTCCGGCCATTNCAAAGCCGCGCGCTCGGGCTTCCACGGGGGCCCCCN
 TGCNANCTGGGCGTTGCGTTCTCGTTTCACGGGCGAGNAGGCTTGGCAAA
 AAGACGAAGCCACTTTGTCCAAGGTCATGCAGTTGGTAAGTGGAAGCGCC
 CCAAGCATTGNAACCCCAAGGTCCCGGCCCGCTTCCCGAAGCCCCGGCGT
 10 TTCCCAACCCCTTCCTTTGCCCGCTGCCCGCCTTCCTTGCGGGNAGGGGAGN
 TTGNTCAAAAAGGGGCGTGTGACAGGCAAGTTGGGNTCCAGGTGGGGCC
 CGACCCACTAACCCGACTCGTTGCCCTGGGGCTTTACCCCCCCCCNTTCC
 TTTTGGNCTTTGGTTTCTCCNCTGTGAAATGNAGGTAGTGCCAGCCCTG
 CCTNCCTCAGAGGCGCGTGCAGGAGCATCAGAGATCCATAGTGATGTGNA
 15 ATTGCTCTGTAAATATCCCTGTGCGAAGNACATGGAAGGTGCTGCTTTAA
 AGGATGGAAGGAGNCAGAGAGGGGGCGGGGTGGGGAAGACTAGAGCAAT
 CACAGAGGAAGGACGAACATGAGTGGGTGTTCTTGAAAGACCCACACNAT
 NGGTTTTCNAAGCAANGGG

(SEQ ID NO: 428)

20 12-d11-Laco.Seq LENGTH: 1159 Mon, Jan 31, 2000 2:51 PM CHECK: 6877 ..., 992 bases, 15A5 checksum.

ATTACNCTTTNNACAAGGCCNNGGACGAGACTCAGTGGATTCTGGGAATCA
 TGGCCTTTGTGTCACAGAAGATGCCCTGNCAGGCGCCTTCAGGGGGTGTT
 NNGGGGATGGGGGGGCACNGCGGTACAGGGTCACTGTTAAGGAAGTTGG
 25 AGCTGGATGGGAATCCAGCTGATTCTGNCCCTCCCTGCTCTGGGAAAGTG
 CTCTGCCGCAAATGTCTTCCCTGCCTCACTCCCTATGTGCCTATNNACCA
 AGGNTGTNACCAAAAGGAGCTNNGGGGTATTTTAGAGCTGATGGGGAACTT
 CTACTTTCTTGNAAGGGCAAAGAATANTCGNTCGNTGTGCCCCACCTGCTT
 NAGATCTAGGAGGAAAATCTGGGNANCTCCNGNNTTTGGGGCCCTNNGCT
 30 CACACAAATGCCAACTTCTGGTCCCCACCCNACGGGTGATTTAGGCCANT
 TACTTAGATCCACGTTAATGAAGTTTTTCTGTTGCCTAAATTAGTTCACAG
 GGAAC TNAGCCTTGGGAAGAAAAANAANCTAAGAGGATTTGNTGAAAGG
 ACACAAGGAAGTTATGTNNGGNATGTTTCAAGANCAAGGGCANGNACTTT
 AGGGTTCAAANNGGGGGTTTTTTACTCCCATCCCAAAAATACTGGAATGG
 35 NTTCTTTNCCCAGGTTGNAGGGGACCCTCCCAAAAGCATAAAAAGGGGGG
 GTGTTTTAGNGTTGAAAAAAGGCCCCCAAAAGCNCTNACANCCAATAATG
 GGGGAATNTGGACCCCTTAAATTGTNAANGGCCCAANAAAATGGGGNC
 NGGGCCCTNNNCCCAAAATTCAATGNTNNTNCCCCNNNNNNNAAAAAA
 ANTTNAANGNNCCCCTTTTAAANAAATNTNTNNGGNCTNNNNANANGT

40 Additional Properties of Genes Necessary for Viral Infection

Table 1 provides a list of all sequences obtained utilizing the methods of the present invention. This table provides, from left to right, the Lab Designation, the gene comprising the Lab Designation sequence, human chromosomal location (if available) and any matches found in three publicly available databases (BLAST nr,

est, and hgts). The database matches appear in the three columns immediately following the chromosomal location designation. Table 2 provides Lab Designations and additional information for a number of the clones isolated utilizing the methods of the present invention. Further description of the identified genes is provided

5 following Table 2.

TABLE 1

06_RA2#E_rE.txt	gjl17456622[	8q11.1	0.23	0.20	0.0 AC090206.3 h
10_2A_3_12-rE.txt	gata4	8p23.1-p22	0.58	none	9e-28 AC099091.2 r
10_3A_2_Lac.txt	PPM1A	14q23.1	0.057	2e-4 AA089094	9e-91 AC107409.2]
10_3b(5-2-96)_rE.txt	na		H	none	H
10_3bE_rE.txt	hp1-bp74[EIF4G3]	1p36.12	5e-05 AL138784	7e-07 AW533300	6e-05 AL606477
10_3b_2_rE.txt	KLHL6	3q27.3	H	8e-10 AW915888	H
10_4A_8_rE.txt	gas5	1q23.3	1e-07 BC004622	8e-08 BI303289	0.41
10_4b_4_rE.txt	KLHL6	3q27.3	h	2e-69 AW915888	0.018 AC069211.12]
11X#17_Lac.txt	na	na	6e-05 satellite S64630	0.17	7e-08 AC107099.2]
12C#A_rE.txt	LOC159772	11p15.3	0.51	4e-04 BF849606	2e-04 AC084304
12CX#11E_rE.txt	LOC168349-[LOC168348+]	7q33	7e-30 AC024913.32]	1.31	H
12CX#6_rE.txt	zfp-36	na	2e-11 AK018350	3e-36 BF548520	e-178
12CXY#7_Lac.txt	prss11	10q25.3-q26.2	2e-17 satellite	5e-11 repetitive 0.0	AC110392.2/AC087063.17
12CXY#7_rE.txt	prss11	10q25.3-q26.2	H	none	7e-13 AC087063.16]
12C_2B#9B-B4.txt	na	na	H	none	H
12C_2B#9E_rE.txt	LOC160196	11q24.1	2e-20	1e-20 BI105708	2e-20 AC016859
12PSA#6_rE.txt	EIF3S10	10q26	9e-47 MMU14172	8e-53 AI597159	1e-30 AC026587
12_3B#10-rE.txt	LOC164360	20p11.22	H	0.18	0.0 AC114195.1]
12_3B#10_Lac.txt	na	h	1e-20 H32702	0.0 AC114195.1]	
12_3B#2_Lac.txt	jwa {UBE1C+}	3p14	0.23	0.18	e-123 AC109665.2]
12_3B#2_rE.txt	GTRAP3-18-arl6 (jwa)	3p14	5e-58 AF240182	2e-53 BF543062	e-111 AC102724.1]
12_3B#7_Lac.txt	DKFZP727C091	17q21.31	8e-68 S82811	2e-40 BE123674	1e-85 AC095637.3]
12_3B#8_rE.txt	Aptx	9p13.3 .14	3e-8 AA871174	H	
12_4b#11_rE.txt	na	na	0.13	na	0.15
12_4B#7-rE.txt	LOC13854	9q31.3	5e-73 AL389915 hu	none	e-102 AC073037 hu
12_4b(#11)-Lac.txt	DKFZP727C091	17q21.31	8e-68	2e-40	1e-85 AC095637.3]
12_4b_9_lac.txt	YWHAE and loc14697	17q21.32	0.20	0.75	7e-14 AC102099.1]
12_4b_9_re.txt			0.037	.031	.042
12_6B#6_Lac.txt	LOC148582	1p31.2	0.066	0.053	4e-13 AL669966.4]
12_6B#6_rE.txt	LOC148582	1p31.2	0.073	0.059	0.002 AL669966.5]
12_L24_5_3-Lac.txt	HCK and KIAA0255	+20q11-q12	e-128 AC078911	0.20	0.001
14A13E_rE.txt	gata4	8p23.1	0.034	1.31	2e-47 AC099091.2]
14A14E_rE.txt			H	none	H
14A7re	smad7	18q21.1	3e-30 NM_030858.1]	2e-37 AI556846	8e-25 ACO24384.4 h
14C_2E_rE.txt	sfp19	5q21-q22	6e-19 ACO91750	2e-12 BA395473	2E-78 ACO99430.2
14G3E_rE.txt			H	none	H
14H1E_rE.txt			H	1.31	H
14H4Erepeatmasker_rE.txt	repeat		1e-04	0.031	5e-08
14H4E_rE.txt	repeats		1e-09	3e-09	3e-16
14XD#12E_rE.txt	CLR-B		4e-49 AF320597	0.17	5e-06 AC117852.1
14XD#12E_T7.txt			1e-83 AF320597	8e-16	1e-24
14XD#18B_B4.txt			H	1.31	H
14_24_#6_Lac.txt			4e-06	1e-05	e-167 AC105467.3
14_7#2E_rE.txt	LOC94765 [fer113-]	10q23.32	2e-69 abo12876	na	0.0 BF392858
17_3_3B_B4.txt	mgat1	5q35	H	0.70	H

72

WO 2004/010925

PCT/US2003/013743

31_3_17_rE.txt			4e-06	5e-05	2e-24
31_3_19#2_Lac.txt			0.004	0.70	e-161
31_3_19#2_rE.txtc lectin-related protein C			8e-72	6e-76	
31_3_4_rE.txt			0.016	0.013	8e-05
31_3_5_rE.txt	znf207	17q11.2	9e-07	1e-54	0
31_3_6_2_Lac.txt	FKBP8		1e-30 CNS00002	0.64	2e-82 AC107272.2
31_3_6_2_rE.txt			3e-34 AC090529.2	6e-35 A1715684	1e-40 AC108331.2
31_3_9_rE.txt	mail	3q12.3	1e-92 030612.1	e-113 AA798638	0.0 AC111450.1
31_4_2_Lac.txt			H	none	H
31_4_2_Laca.txt		22 q12.2	H	6e-4 BF389250	1e-89 AC095192.2
31_4_2_LacO.txt			H	none	H
31_4_2_rE.txt			0.27	none	0.33
31_4_4#1_Lac.txt			4e-33 AK018434	0.0 A1482382	0.0 AL135899
31_4_4#1_rE.txt		10q25.3-q26.2	6e-14 AL583887	3e-12 BB192448	3e-50 AC087063.17
31_4_5#1_LacO.txt	prss11	22 q12.1	0.054	0.17	0.0 AC095192.2
31_4_5#1_rE.txt			0.21	0.67	0.27
32_3_2#1E-Lac.txt			H	0.73	0.0 AC105839.1
32_3_2#1E_rE.txt	CAM2	7p15-p14	H	8e-13 A1021238	0.30
34X23_1-rE.txt	card4	7q21.1		.003 BF509588	5.8
34X23_3-rE.txt	Abcb1b		0.004 AC006027.2	none	2e-91 AC094362.2
34X24_126-rE.txt	MAP3K7IP1	22q13.1	1e-91 AJ312410.1 RNO312410	6e-14 BG717658	0.083
34X25_23_Lac.txt			2e-20 AC000039	0.21	2e-08 AC094592.2
34X25_23_rE.txt	PDE4B	1p31.2-32.1	0.066	.20	0.0 AC094592.2
34x25_5a_rE.txt			9e-17 AL109926.9 HSDJ543C6	1e-18 BE122674	3e-45 AC095096.3
36_5_1_4_rE.txt			5e-40 repeat K00500.1 RATRSSID	2e-04 BF950374	8e-23 AL663067.7
36_5_2_196-rE.txt			5e-05 AF267747	8e-4 A1552849	2e-08 AC116254.1
36_5_2_19a_LacO.txt			3e-4 AC098729.3	1e-30 BI292332	2e-33 repeat AC099104.2
36_5_2_19b_LacO.txt			2e-29 repeat AC091503.2	4e-04 A1552849	2e-13 AC094419.2
36_5_2_6-rE.txt	brd2	6p21.3	8e-10 repeat AL592303.15	5e-17	e-135 AC098547.2
36_5_2_6_LacO.txt	RD2		4e-64 AF100956	e-126 AF100956	2e-29 BI653651 7e-
21 AL671924.2					
36_7_1_a_rE.txt			H	none	H
38_17#2_rE.txt	SCMH1	1p34	5e-12 AK009416	0.054	0.0 AC109561.2
39_2_6-Lac.txt			4e-92	repeat AL645968.6	8e-84 BI289726
39_2_6-rE-repMa.txt			H	none	H
39_2_6-rE.txt			6e-45 AL591207.15	2e-38 repeat BI290754	3e-53 repeat
AC097552.3					
3_2_13_rE.txt	s100A6	1q21	5e-12 repeat AC025910	8e-60 AA267952	2e-73 AC027648.11
3_2_4_rE.txt	s100A6 negative strand	1q21	5e-21 repeat in L47235.1 MUSXPDG1	3e-13 BF566181	7e-55 AC027648.11
3_6_9_teoG_rE.txt			0.28	none	0.35
42_8#3_rE.txt	arhgef3	3p21-p13	5e-49 AK016751	e-49 BB642560	0.0 AC108271.2
49_RA2_A_rE.txt	hnrl	19q13.2	0.0 AC008982	4e-20 BG941347	4e-24 repeat AC069503.21
4ae5_rE.txt	ms4a48b	11q13.1	0.047	none	0.0 AC097387.3
4a_b4.txt			0.011	0.14	9e-04
4cx_b4.txt			H	none	H
4c_lac.txt			H	none	
4c_rE.txt			0.002	none	0.14
5ad4-rE.txt			H	none	H
5ASE_Lac.txt			3e-12 repeat AF260927	5e-10 BG071839	0.0 repeat

74

WO 2004/010925

PCT/US2003/013743

L12cx#11_rE.txt	na	9e-30	none	H	
L14D#18_Lac.txt	na	5e-18	1e-08	1e-15	
L14D#8_Lac.txt	na	0.016		none	
L14XD#18_rE.txt	na	H	none	H	
L14XD#2_rE.txt	na	H	none	H	
L14XD#2_Lac.txt	na	H	none	H	
L14XD#8_rE.txt	na	H	none		
L14XD12E_rN80.txt	na	2e-51	none	0.30	
L14_7_2B_B2.txt	na	6e-11	0.18	2e-05	
L14_7_2B_B4.txt	na	H	1e-08	2e-17	
L1739E_rE.txt	na		none	H	
L191B2E#1_Lac.txt	na	0.22	none	0.070	
L191B2E#1_RE.txt	na	e-139	none	0.063	
L191B2E#3+_rE.txt	rpa16	e-117	none	H	
L192A3E_Lac.txt	na	9e-07	7e-04	0.0	
L192A3E_rE.txt	na	H	none	H	
L192B3E#13_rE.txt	fer1l3	0.20	none	e-167	
L193A1E#A_Lac.txt	m6p/igf2r	2e-60	0.62	1e-55	
L193A1E#A_rE.txt	na	3e-16	none	4e-16	
L194c4E_rE.txt	na 3e-06	e-157	none		
L195B1E_Lac.txt	na	H	none	8e-08	
L195B1E_rE.txt	na	H	1e-54	e-132	
L195C5E-rE	gtf2e1	0.63	5e-41	0.0	
L197B3E-rE	CL2-like 1	20q11.21	3e-16	3e-13	3e-13
L197B3E-rE.txt	na	2e-11	na	0.0	
L197B3E_Lac.txt	na	H	none	e-119	
L19D16E-rE	na	4e-06	3e-06	e-146	
L21C1E_Lac.txt	na	0.004	na	4e-37	
L21_5_7#2_Lac.txt	na	H	none	0.24	
L22_5A1_Lac.txt	na	3e-06	</PRE>	9e-10	
L22_5A1_rE.txt	na	0.064	</PRE>	0.080	
L24_10_1BE_rE.txt	na	0.063	none	0.31	
L24_26_10-Lac.txt	na	H BF525273	none	9e-48	
L24_26_10-rE.txt	na	e-144	0.19	H	
L24_26_1_B4.txt	loc168348	e-168	1e-11	0.27	
L24_26_1_BL-re.txt	na	H	e-134	H	
L24_26_2A-rE.txt	na	e-103	none	3e-35	
L24_26_2B-Lac.txt	na	0.22	4e-24	0.27	
L24_26_2B-rE.txt	na	e-164	</PRE>	0.0	
L24_3_2B_rE.txt	na	e-178	7e-33		
L24_4_2-Lac.txt	na	0.26	8e-33		
L24_4_2-rE.txt	na	1e-05	none	0.32	
L24_4_2AE_rE.txt	na	0.066	0.054	e-107	
L24_4_2BE_rE.txt	na	0.066	0.052		
L24_4_3-Lac.txt	na	2e-23	0.052	0.0	
L24_4_3-rE.txt	na	e-170	none	2e-92	
contamination AC006099	dix2 negative	4e-71 AC078911	2e-91	e-167	
L24_5_2-Lac.txt	na		3e-43 plamsid	4e-47 plasmid	
L24_5_2-rE.txt	kiaa0255				
	na	1e-37	1e-30	5e-40	
	na	0.26	none	0.33	

WO 2004/010925

PCT/US2003/013743

L24_5_2BE_rE.txt	HNF3B	20p11	0.004	0.013	0.0 AC113866.2
L24_5_3BE_rE.txt	kiaa0255-		e-125 AC078911.11	3e-06	6e-06
L24_5_3_rE.txt	KIAA0255-	20q11.21	e-125 AC078911.11	na	3e-06 6e-06
L24_6_3-Lac.txt	na		0.067	0.22	0.0
L24_9_1-Lac.txt	na		0.27	none	8e-67
L24_9_1_rE.txt	na		9e-23	7e-23	1e-25
L25_10-Lac.txt	s100a6		5e-21	2e-13	e-110
L28AP-rE.txt	TCEB3		1p36.1	0.43	0.40 e-102
AL672076.2]					
RA2#C_Lac.txt	na		7e-66	0.0	
RA2#C_Laco.txt	na		0.0	4e-06	0.0
RA2#C_rE.txt	na		0.069	e-119	0.0
RA3_A_rE.txt	dj3240	17.1.2	0.0	0.72	0.0
RA5_A_rE.txt	na		1e-51	0.17	
RA5_B_rE.txt	gamma crystalline		0.0	0.003	0.0
SCA6#1_Lac.txt	loc131020		0.25	e-102 BF289981	6e-64 AC103936.2
SCA6#1_rE.txt	LOC151593	3q24	H	0.68	3e-44 AC103936.2
SCA7#5-Lac.txt	na		H	none	H
SCA7#5_rE.txt	na		H	none	
SCA9#14_Lac.txt	na		6e-45	0.003	7e-05
SCA9#14_rE.txt	7e-23		6e-20	5e-55	
ScB2#19_Lac.txt	erbin		2e-07	4e-09	
ScB2#19_rE.txt	ERBB2IP	5q13.1	H 1e-27	H	
second est of incyte for 6_3_6_	na	0.0	na	0.0	e-149
seq1a_lac.txt	na 7e-80	3e-83	0.46	0.092	0.14
seq1b_lac.txt	znf7 (KOX4)	8q24	0.0	na	0.0 0.0
sequence match for 34X23_1.txt CAR (RFP2)	na	13q14	e-178	8e-84	1e-18
X11_rE.txt	na		H	none	4e-48
X13_rE.txt	na		H	none	
X15_rE.txt	fksg28	10q24.2		none	e-149
X18 estAl647623.txt	kiaa1303	17q25.3	e-167	e-121	
X18H_17.txt	kiaa1303		2e-10	2e-10	0.0
X20_rE.txt	nicer element		e-104	e-103	e-143
X236E1_T3.txt	na		0.018	0.23	
X236E1_T7.txt	na		0.013	none	e-116
X23_7-T3-clean.txt	na		H	H	
X23_7-T3-intact.txt	na		4e-18	1e-11	0.001
X23_7_T7.txt	na		H	none	H
X23_8-T3.txt	na		H <PRE>	0.066	
X24_4_T7.txt	na		H	none	H
x27b4f_1.txt	na		0.38	0.48	
x2_b4.txt	na		H	none	0.16
X3_2_13_Lac.txt	s100a6		5e-15	1e-12	2e-15
X3_2_4_LacO.txts100a6- wrong direction			7e-76	7e-60	6e-83
X4_rE.txt	na		H	1.31	H
x5_rE.txt	na		H	none	2e-34 AC110459.2
X7B-B4.txt	na		H	1.31	H

EST extensions or est match blasts results; 0542234 est of 14a13e_re.txt	8p23.1-p22	H	none	8e-16 AC069185.6
h				
EST 10_3b_2_rE.txt		0.0	1e-43	
est 5ase-lacAA946172.txt		0.002	5e-62	0.0
est for 10_4b_4_rE.txt		0.69	0.0	H
est for scb2#19.txt		e-151	1e-53	
est From 12 4b_9re.txt		0.0	0.0	3e-48
est from 12c#A-re-AA972262.		e-143	6e-86	
est from 12_3B#8_RE.txt	9p13.3	0.0	aa871174	0.0 1e-07
EST from L193A1E#A_rE-AI230550.		3e-04	0.0	0.0
est of 42_8#3_rE.txt		0.0	0.0	5e-77
est of 31_3_9_lac.txt		0.0	0.0	0.0
est of 32_3_2#1E_rE.txt		0.10	0.33	
est of 35_5_2_19b_lac.txt		2e-44	0.0	1e-64
est of 6_3_6_2E-rEa.txt		0.0	0.0	e-166
est of L195B1E-lac.txt	9q34.13	1e-08	0.0	0.0
est of RA2#C_rE.txt	3q21-q24	0.34	e-106 BE089756	e-124
est of sca6#1.txt		e-166		
Est-31-3-9 incyte1056987-1.txt		2e-92		
est-36_5_2_196-rE AI552849.txt		na	0.0	2e-63
est-L24_5_3BE_rE.txt		1e-19	0.0	0.0
est191e9b-rb2-124.txt		2e-20	2e-16	2e-23
EST224186 of x18.txt		e-149		
est_L24_5_3BE_rEa.txt		0.0	0.0	0.0
extension of est-L195B1E_rE.txt	6q25-q26	6e-08	0.0	0.0
gene of 12_3b#8.txt	9p13.3	0.0	0.0	0.003
incyte cDNA for 24-26-10-human.		0.0	e-170	1e-06
incyte est of 6_3_6_2E-rEa est		e-160	0.0	5e-61
na				
na				
LOC169647				
GTF2E1				
id3				
e-121				
TUSP				
GTF2e1				
APTX				
na				
na				

TABLE 2.

	SEQ_NAME	SEQ_NOTES
1	10_2A_3_12-rE	GATA4: GATA binding protein 4 human chromosome 8 10,812K-12,275K
2	10_3A_2_Lac	Ppmla: protein phosphatase 1A, magnesium dependent, alpha isoform murine chromosome 12 67,344K-67,458K
3	10_3bE gene-F113534	Hp1bp3 heterochromatin protein 1 binding protein 3, 1p36.12 HP1-BP74
4	10_3b_2_rE	LOC239743 similar to kelch-like 6 (Drosophila) [Homo sapiens] murine chromosome 16 A3
6	10_46_4-Lac	aprataxin 5 prime of DnaJ Hsp40 homolog, subfamily A, member 1
7	10_4A_8_rE	gas5 murine chr 1
8	10_4b_4_rE	- sits at end of LOC287974 in negative strand - positive strand- upstream maybeB3gnt5 1599 bp mRNA - linear ROD 28-JAN-2003 DEFINITION Rattus norvegicus UDP-GlcNAc:betaGal beta-1, 3-N-acetylglucosaminyltransferase 5 (B3gnt5), mRNA.
9	12C#A_rE	kiaa0750 human chr 11
10	12CX#11E_rE	LOC330280 or Psma3 is listed as being only 853 nts, which seems unlikely murine chromosome 6
11	14A7re	Madh7 MAD homolog 7 (Drosophila)at 18p12 human chr 18 46,230K-46,308K
12	12CX#6_rE	Rattus norvegicus similar to gonadotropin inducible ovarian transcription factor 1
13	12CXY#7_rE	HTRA, PRSS11 murine chromosome 7 119,771K-119,793K, human chromosome 10q25.3-q26.2
14	12C_2B#9E_rE	LOC244819 murine chr 9 993161..1003851 + 99 20888725
15	12PSA#6_rE	ref:NP_003741.1 - eukaryotic translation initiation factor 3, subunit 10 (theta, 150/170kD); eukaryotic murine chr 19 21363609..21370345 - 448 6753740 Eif3 eukaryotic translation initiation factor 3
16	12_3B#10-rE	LOC241690, mouse 5 of rin2- which is likely gene mRNA complement(join(45074453..45074634, 45082032..45082055, 45083667..45083839,45100942..45101235,45140102..45140163))
17	12_3B#2_Lac	LOC241690 /product=similar to ribosomal protein L10 [Rattus norvegicus] /transcript_id=XM_141402.1
18	12_3B#2_rE	Arl6ip5 positive strand chr 4 rat is:ubiquitin-activating enzyme E1C Ubelc and on the other side, similar to Neuronal tropomodulin (N-Tmod) (Tropomodulin 2) LOC312585 negative strand.glutamate transporter EAAC1 interacting protein negative strand.
19	12_3B#8_rE	aprataxin, murine chr 4- this gene is off negative strand, and there may be another rat gene
20	12_4B#7-rE	Peptidyl-prolyl cis-trans isomerase A (PPIase) (Rotamase) (Cyclophilin A) (Cyclosporin A-binding protein NT_039230. Mm3_39270_30 Mus musculus chromosome 3 genomic contig no gene identified in this murine sequence
21	12_4b#11_rE	

22	12_4b_9_rE	LOC211313 NT_039299.1 Mm5_39339_30 Mus musculus chromosome 5 genomic
23	12_6B#6_rE	murine chr 2 closest murine gene is 1723887..1724855 - 323 20340819 LOC241732 TSPY which is probably not the gene
24	12_L24_5_3-Lac	0542234 est of 14a13e_re murine chr 14 52M-55M next to gata 4
25	14A13E_rE	srp19 human chr 5 murine 18
26	14A14E_rE	
27	14C_2E_rE	
28	14G3E_rE	
29	14H1E_rE	
30	14H4E_rE	
31	14XD#12E_rE	CLR-B murine chromosome 6
32	14XD#18B_B4	region of fer113 human chr 10
33	14_24_#6-rE	Mm11_39560_30 Mus musculus chromosome 11 genomic, mgat-1
34	14_7#2E_rE	murine chr 11 E130113K08Rik
35	17_3_3He_1-T7	18992349..19034645 + 126 21312102 1110029A09Rik murine chr 4
36	18A_8_1E_rE	1469944..1479193 - 91 20840505 E130102H24Rik murine chr 4
37	18A_8_3E_rE	
38	18_5#13E_rE	
40	191E2E_rE	
41	191E8E_rE	22749957..22802881 - 337 20877992 LOC239186 closest match murine chr 14
42	191E9E_rN80	CLR-C 4448981..4475825 + 202 28526608 LOC333160 this is C lectin-related protein C murine chr 9
43	19D3E_rE	6982588..6999715 + 162 28523464 LOC3333094 murine chr 6
44	19D5E_rE	Pts 6-pyruvoyl-tetrahydropterin synthase
45	19_7AE_rE	
46	19_9BE_rE	Cstf2: cleavage stimulation factor chr X mouse and man
47	1a_rE	
48	1bw_lac	LOC195700 closest gene murine chr 6 294812..337018 + 438 28523444
49	20_L28AP-lac	loc279232 murine chr 4
50	21_5_8E(2)_rE	E2F-2, murine chr 4 5700649..5721013 + 444 28498372 LOC242705
51	24_3_5#1_rE	murine chr 11 similar to Collagen alpha1 closest known gene LOC217123
52	29A_5_1_lac	s100a6 murine chr 3 lac sequence in s100a5
53	2AE_lac	JNK-binding protein JNKBP1 like murine chr 2 8031390..8107228 - 343 28484974 LOC241298
54	2b_lac	2281090..2321346 + 162 28485837 LOC329423 murine chr 2 next to dlx1 and 2

55	31_3_15#1_Lac	murine chr 8 within gene 8031390..8107228 - 343 28484974 LOC241298 off negative strand and probably disrupts 5790690..5796087 + 356 6857787 Fkbp8
56	31_3_17_rE	cut-like 1 (cutl1) 6647971..6737110 - 1332 7106283 Cutl1 CCAAT displacement protein murine chr 5
57	31_3_19#2_rE	4637984..4643986 + 208 16716407 Ocil-pending C lectin-related protein B murine chr 6
58	31_3_5_rE	murine chr 11 38818453..38830549 + 461 6756051 Zfp207 Zfp207
59	31_3_6_2_Lac	murine chr 12 is equivalent to hu 14 in non-repetitive part 7737091..7806367 + 128 20849473 LOC217541 similar to 3-phosphoglycerate dehydrogenase
60	31_3_9_rE	53077725..53087552 - 729 13447398 Mail-pending definite murine chr 16
61	31_4_2_rE	7424..39696 - 679 28505866 2310047115Rik murine chr 11
62	31_4_4#1_rE	755214..804073 + 481 9625027 Prss11 murine chr 7
63	32_3_2#1E_rE	21171379..21180079 - 149 6680832 Calm2 calmodulin 2 murine chr 17
64	34X23_1-rE	murine chr 12 closest gene is 9807175..9807651 + 159 20849986 LOC238153
65	34X23_3-rE	two genes in opposite orientations- probably share a promoter region 1999682..2066949 - 1277 6755046 Abcb1b ATP-binding cassette, sub-family B (MDR/TAP), member 1B 2067489..2075793 + 142 28501108 LOC330031 vector disrupts loc33031 murine chromosome 5
66	34X24_126-rE	41543381..41569827 + 503 28486603 2310012M03Rik Similar to mitogen-activated protein kinase
67	34X25_23_Lac	kinase kinase 7 interacting protein 1 TAK1 murine chr 15 2377737..2727820 + 722 9790151 Pde4b phosphodiesterase 4B, cAMP specific murine chr 4 2377737..2727820 + 722 9790151 Pde4b phosphodiesterase 4B, cAMP specific
68	34X25_23_rE	murine chr 4 2377737..2727820 + 722 9790151 Pde4b
69	34x25_5a_rE	
70	36_5_2_196-rE	
71	36_5_2_6-rE	murine chr 17 LOC309624
72	36_7_1_a_rE	
73	38_17#2_rE	20744318..20811497 + 665 22095027 Scmh1 sex comb on midleg homolog 1 murine chr 4
74	39_2_6-rE	
75	4a_b4	murine chr 5
76	3_2_13_rE	s100a6 murine chr 3
77	3_2_4_rE	s100a6 murine chr 3
78	42_8#3_rE	murine chr 14 657807..709478 + 1499 28477705 4933409E02Rik which is retinoblastoma-associated protein RAP140
79	4ae5_rE	19q13.13
80	4c_rE	
81	4cx_b4	murine chr 1
82	5_1_Lac0	32168807..32227960 - 625 28521737 LOC238331 murine chr 12 there is a repeat, but not in the first part of the sequence that matches this

83	5a_lac	two ests- perhaps on rat chr 4 gi 20423079 gb BQ206614.1 BQ206614 gi 11381574 gb BF396599.1 BF396599
84	6B37H_T7	10964157..10975247 - 347 6754570 Anxa1 murine chr 19
85	6B52E_rE	4257489..4269990 - 151 28551828 E030042N20Rik 4330462..4335374 + 190 20888893 1200008O12Rik murine chr 19
86	6BE1_Re	R.norvegicus mRNA (pBUS19) highly repetitive sequence of retroviral origin
87	6BE3_lac	697470..702328 - 156 6753144 Atp6v0c murine chr 17
88	6BE60_rE	tpm1, murine chr. 9
89	6BE65_T7	8533246..8538206 + 218 20875728 LOC242198 8546745..8685908 + 2269 6671495 Abca4 murine chr 3 t7 sequence is in abca4 but collaborator could not find expression in rie-1 cells
90	6BE72_rE	CTCF, chr 19- rat
91	6BSA12_rE	adam10 and LIPH Gene map locus 15q21-q23
92	6_3_6_2E-rE	golgi matrix protein GM130 and Mnbk-Dyrk1A- binds to grb2 human gene is GG95
93	6be3_rE	chr 17 697470..702328 - 156 6753144 Atp6v0c
94	6be5_rE	2849866..2876267 + 411 20863400 LOC330758 murine chr 8 Similar to serine/threonine protein kinase TAO1
95	6bh15_T3	13360838..13381657 - 285 13270471 Tpm1 tropomyosin 1, alpha murine chr 9
96	70A-rE	murine chr 5 anxa3
97	7A10_1_rE	LOC269872 Mus musculus chromosome 7 genomic contig, strain C57BL 6J - 618181..664133
98	8C5_11-rE	
99	8C5_6_rE	murine chr 11 8625545..8698887 - 921 6679491 Psa puromycin-sensitive aminopeptidase
100	9A#2_3_rE	LOC289895: similar to Emu1 protein rat 14 Emu1 is restricted to epithelial extracellular binding
101	9B27_2_rE	murine chr 4 17656746..17665179 - 277 27228977 Aptx aprataxin sits at start of dnaj1a
102	L11#17_rE	
103	L12cx#11_rE	closest to 276400..276777 - 126 28523321 LOC330280 in region of AAC12943 3037091 proteasome alpha7/C8 subunit [Mus musculus]
104	L14D#18_Lac	
105	L14D#8_Lac	murine chr 16 negative strand between these two genes 42060678..42085522 + 206 21312810 4833409J19Rik RIKEN cDNA 4833409J19 42212422..42245696 + 950 23956172 Ssg1-pending
106	L14XD#18_rE	Gtpat12
107	L14XD#2-rE	
108	L14XD#8_rE	murine chr 16
109	L14XD12E_rN80	4448981..4475825 + 202 28526608 C lectin-related protein C LOC333160 murine chr 6
110	L1739E_rE	R74726 murine chr 9
111	L191B2E#1_Lac	1224295..1225537 + 134 6677791 Rpol-3 murine chr 5
112	L191B2E#1_RE	

113	L191B2E#3+_rE	64583664..64585839 + 305 20343300 LOC239678 although this gene appears to be on the negative strand murine chr 15 closest positive strand gene is HOXC13
114	L192A3E_rE	in between E030042N20Rik: RIKEN cDNA E030042N20 gene and 1200008012Rik: RIKEN cDNA 1200008012 gene murine chr 19 4257489..4269990 - 151 28551828 E030042N20Rik fer-1 like protein 3 4330462..4335374 + 190 20888893 1200008012Rik
115	L192B3E#13_rE	5058584..5144689 - 2483 23956054 Igf2r murine chr 17
116	L193A1E#A_rE	34316683..34341462 - 441 21312660 Gtf2e1 general transcription factor II E, polypeptide 1 (alpha subunit) murine chr 16
117	L194c4E_rE	similar to E2IG2 murine chr 7 28480555 LOC244162 rat chr 1 LOC308858murine chr 7
118	L195B1E_rE	1287066..1334911 - 234 6753170 Bcl2l murine chr 2
119	L197B3E-rE	6982588..6999715 + 162 28523464 LOC333094 murine chr 6
120	L19D16E-rE	murine chr 14 negative strand maybe similar to PSHD Region Gene 2
121	L22_5A1_rE	loc276970 murine chr 11 Mm11_39561_30
122	L24_10_1BE_rE	276400..276777 - 126 28523321 LOC330280 murine chr 6
123	L24_26_10-rE	repeat shows up on this
124	L24_26_1_BL-re	murine chr 14 7931639..7932322 - 228 20881545 LOC212081
125	L24_26_2A-rE	36668143..36676666 + 254 28524792 LOC332305 murine chr 18
126	L24_26_2B-rE	2175918..2178442 + 256 6753644 Dlx1 distal-less homeobox 1 2190449..2192321 - 333 6753646 Dlx2 distal-less homeobox 2 murine chr 2
127	L24_4_2AE_rE	12387618..12442029 + 1221 28500402 2810442I22Rik 12527560..12529296 + 579 7657112 Galnt4
128	L24_4_2BE_rE	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 4 12544567..12544764 - 66 6679305 ??Phxr2 murine chr 10
129	L24_4_3-rE	47832456..47859226 + 295 20912679 LOC241708 murine chr 2
130	L24_5_2BE_rE	1570784..1576636 + 193 21704056 LOC228788 similar to chromosome 20 open reading
131	L24_5_3BE_rE	frame 160 1623748..1650722 + 504 6754166 Hck hemopoietic cell kinase 1686886..1691690 + 265 28488150 LOC329539 1701920..1708331 + 139 19527062 AU045326 expressed sequence AU045326 1723887..1724855 - 323 20340819 LOC241732 murine chr 2 negative strand
132	L24_6_3-Lac	LOC304968 rat 13q23 similar to RIKEN cDNA 1700009P17 [Mus musculus]
133	L24_9_1-Lac	LOC230761 murine chr 4
134	L24_9_1_rE	12638955..12746974 - 450 28490830 Ddx10 Similar to DEAD/H murine chr 9
135	L25_10-Lac	26660256..26660811 + 90 25048430 S100a6 murine chr 3
136	L28AP-rE	murine chr 4- missing the gene in between 8430427k15 and loc279232
137	SCA6#1_rE	5459137..5476774 - 425 28492548 LOC244982 murine chr 9
138	SCA7#5-Lac	C lectin-related protein B

139	SCA9#14_rE	12018184..12022411 - 161 16519535 Erbb2ip the erbb2ip is in the correct orientation for this vector insert, the vector resides next to this gene-12120524..12120802 + 93 28526912 LOC328330 in the wrong orientation murine chr 13
141	X23_7_T7	
142	X23_8-T3	
143	X24_4_T7	
144	seq1b_lac	murine chr 15 mgc6397, related to zinc finger 7 (human)
145	7A7_rE	chr 9 anxa2
	est12c#A-re-	
146	AA972262	
147	est42_8#3_rE	rap140 retinoblastoma-associated Mm14_39638_30 Mus musculus chromosome 14 genomic contig, strain C57BL/6 657807..709478 + 1499 28477705 4933409E02Rik similar to RETINOBLASTOMA-ASSOCIATED PROTEIN RAP140
148	ESTL193A1E#A_rE- AI230550.	AI326792 and 1300010C19-RAGA (RAS-RELATED GTP-BINDING PROTEIN murine chr 4
150	est32_3_2#1E_rE	murine chr 17
151	est36_5_2_19b_lac	CCr4-NOT complex-transcription factor subunit murine chr 6
152	estL195B1E-lac extension_est-	chr 9 mouse next to loc244982
153	L195B1E_rE	anxa2 murine chr 9
154	7a7_rE	A230053016Rik murine chromosome 2, human chr 20 maybe Bcl2l Unexpectedly, the smaller mRNA species (BCLXS) encodes a protein that inhibits the ability of BCL2 to enhance the survival of growth factor-deprived cells. In vivo, the smaller BCLX mRNA was expressed at high levels in cells that undergo a high rate of turnover, such as developing lymphocytes. murine chr 2
155	36_5_1_4_rE	4637984..4643986 + 208 16716407 Ocil-pending C lectin-related protein B murine chr 6
156	L195C5E-rE	
157	24_9_3#2-re	

Two of the sequences (Lab Designation 10_2A_3_12-rE (SEQ ID NO: 17)) and Lab Designation 14A13E_rE (SEQ ID NO: 114)) isolated utilizing the methods of the present invention comprise sequence encoding GATA-Binding Protein 4 and map to human gene map locus 8p23.1-p22.

5 The GATA-binding proteins are a group of structurally related transcription factors that control gene expression and differentiation in a variety of cell types. Members of this family of DNA-binding proteins recognize a consensus sequence known as the 'GATA' motif, which is an important cis-element in the promoters of many genes. Arceci et al. (1993) cloned the mouse GATA4 cDNA by screening a 6.5-day embryonic library with
10 primers based on the conserved zinc finger domains. The 50-kD predicted protein contains 2 zinc fingers and, when expressed in cell culture, activated appropriate reporter constructs. GATA 4 is associated with apoptosis, however, it was not previously known to be associated with any virus or with infection.

 Another sequence (Lab Designation 10_3A_2_lac (SEQ ID NO: 213)) comprises
15 sequence encoding PROTEIN PHOSPHATASE MAGNESIUM-DEPENDENT, 1A, ALPHA ISOFORM; PPM1A and maps to chromosome 14. This protein is also known as PROTEIN PHOSPHATASE 2C, ALPHA ISOFORM; PP2CA PP2C-ALPHA. Related to 2AE JNK-binding protein JNKBP1 like murine chr 2 8031390..8107228 - 343 28484974 LOC241298.

20 PPM1A is a serine/threonine protein phosphatase that is essential for regulating cellular stress responses in eukaryotes. By screening a human teratocarcinoma cDNA library with rat Pp2c-alpha as the probe, Mann et al. (1992) cloned the human counterpart, PPM1A, which they called PP2C-alpha. The PPM1A cDNA encodes a predicted 382-amino acid peptide that shares 99.7% amino acid identity with rabbit Pp2c-alpha.

25 In a genetic screen to identify protein phosphatases that negatively regulate the p38 (600289) and JNK (see 601158) stress-activated MAPK cascades, Takekawa et al. (1998) obtained a PP2C-alpha cDNA, which they initially called MC4, that encodes a 324-amino acid peptide. The authors hypothesized that MC4 is an alternative splicing product of PP2C-alpha. The 2 proteins, which they termed PP2C-alpha-1 (382 amino acids) and
30 PP2C-alpha-2 (324 amino acids), differ at the C terminus. Northern blot analysis detected 2.8- and 4.4-kb transcripts, which correspond to PP2C-alpha-1 and PP2C-alpha-2, respectively. Both transcripts were expressed at high levels in heart, placenta, skeletal muscle, and pancreas, and the 4.4-kb transcript (PP2C-alpha-2) was detected in brain.

Using immunohistochemical analysis, Das et al. (1996) detected PPM1A in both the cytoplasm and nucleus of mammalian cells, consistent with a role in dephosphorylating components of stress-activated pathways.

By expressing PPM1A in mammalian cells, Takekawa et al. (1998) demonstrated
5 that PPM1A inhibits the activation of the stress-responsive p38 and JNK MAPK cascades. Their in vivo and in vitro observations indicated that PPM1A dephosphorylates and inactivates MAPKKs (MKK6 (601254) and SEK1 (601335)) and a MAPK (p38) in the stress-responsive MAPK cascades. Using coimmunoprecipitation assays, the authors demonstrated that PPM1A directly interacts with p38. MAPK (mitogen-activated protein
10 kinase) cascades are common eukaryotic signaling modules that consist of a MAPK, a MAPK kinase (MAPKK) and a MAPKK kinase (MAPKKK) (Takekawa et al., 2000). Because phosphorylation is essential for the activation of both MAPKKs and MAPKs, protein phosphatases are likely to be important regulators of
15 signaling through MAPK cascades. To identify protein phosphatases that negatively regulate the stress-responsive p38 and JNK MAPK cascades, we screened human cDNA libraries for genes that down-regulated the yeast HOG1 MAPK pathway, which shares similarities with the p38 and JNK pathways, using a hyperactivating yeast mutant. In this screen, the human protein phosphatase type 2C α (PP2C α) was found to negatively
20 regulate the HOG1 pathway in yeast. Moreover, when expressed in mammalian cells, PP2C α inhibited the activation of the p38 and JNK cascades induced by environmental stresses. Both in vivo and in vitro observations indicated that PP2C α dephosphorylated and inactivated MAPKKs (MKK6 and SEK1) and a MAPK (p38) in the stress-responsive MAPK cascades. Furthermore, a direct interaction of PP2C α and p38 was
25 demonstrated by a co-immunoprecipitation assay. This interaction was observed only when cells were stimulated with stresses or when a catalytically inactive PP2C α mutant was used, suggesting that only the phosphorylated form of p38 interacts with PP2C α .

Das et al. (1996) determined the crystal structure of PPM1A, which they called
30 PP2C. The structure revealed a novel protein fold with a catalytic domain composed of a central beta sandwich that binds 2 manganese ions, which is surrounded by alpha helices. The authors stated that the protein architecture and deduced catalytic mechanism are similar to the PP1, PP2A, and PP2B family of protein ser/thr phosphatases.

Ofek et al. (Cell Cycle Regulation and p53 Activation by Protein Phosphatase 2C α , J Biol Chem 2003 Apr 18;278(16):14299-305) note that protein phosphatase 2C (PP2C) dephosphorylates a broad range of substrates, regulating stress response and growth-related pathways in both prokaryotes and eukaryotes. They demonstrate that

5 PP2C α , a major mammalian isoform, inhibits cell growth and activates the p53 pathway. In 293 cell clones, in which PP2C α expression is regulated by a tetracycline-inducible promoter, PP2C α overexpression led to G(2)/M cell cycle arrest and apoptosis. Furthermore, PP2C α induced the expression of endogenous p53 and the p53-responsive gene p21. Activation of the p53 pathway by PP2C α took place both in

10 cells harboring endogenous p53, as well as in p53-null cells transfected with exogenous p53. Induction of PP2C α resulted in an increase in the overall levels of p53 protein as well as an augmentation of p53 transcription activity. The dephosphorylation activity of PP2C α is essential to the described phenomena, as none of these effects was detected when an enzymatically inactive PP2C α mutant was overexpressed. p53 plays an

15 important role in PP2C α -directed cell cycle arrest and apoptosis because perturbation of p53 expression in human 293 cells by human papillomavirus E6 led to a significant increase in cell survival. The role of PP2C α in p53 activation is discussed.

Another sequence (Lab Designation 10_3bE_rE (SEQ ID NO: 15)) comprises sequence encoding EUKARYOTIC TRANSLATION INITIATION FACTOR 4-

20 GAMMA, 3 (EIF4G3).

Mammalian eukaryotic translation initiation factor 4G (eIF4G) is a scaffolding polypeptide that appears to be responsible for recruiting the 43S preinitiation complex to the mRNA through interactions with eIF4E (133440), eIF4A (see 602641), eIF3 (see 602039), and 40S ribosomes. See eIF4GI (600495). Gradi et al. (1998) identified a partial

25 human cDNA encoding a protein with homology to human and rabbit eIF4GI. By screening additional libraries, the authors isolated cDNAs corresponding to the complete coding region of the novel protein, which they designated eIF4GII. The predicted 1,585-amino acid eIF4GII protein is 46% identical to eIF4GI. On Western blots, both eIF4G proteins migrated at approximately 220 kD. Using an in vitro assay, Gradi et al. (1998)

30 showed that eIF4GII, like eIF4GI, was cleaved by the picornavirus rhinovirus 2A(pro). Far Western analysis and coimmunoprecipitation experiments demonstrated that eIF4GII directly interacts with eIF4E, eIF4A, and eIF3. eIF4GII restored cap-dependent translation in a reticulocyte lysate that had been pretreated with rhinovirus 2A(pro) to cleave

endogenous eIF4G, leading the authors to conclude that eIF4GII is a functional homolog of eIF4GI. Northern blot analysis revealed that eIF4GII is expressed ubiquitously as 5.2-kb and 6.0-kb mRNAs. Imataka et al. (1998) demonstrated that the N-terminal regions of both eIF4GI and eIF4GII bind to PABP (604679). EIF4G is associated with poliovirus (Irurzun et al.).

Other sequences (Lab Designation 10_4b_4-rE (SEQ ID NO: 7)) and 10_3b_2-rE (SEQ ID NO: 13)) comprise sequence encoding KLHL6 protein and these sequences map to chromosome 3q27.3. This protein has the same domains as the gata4 protein described above.

Another sequence (Lab Designation 10_4A_8_rE (SEQ ID NO: 3)) comprises sequence encoding the gas 5 protein and this sequence maps to chromosomal location 1q23.3. The murine gas5 gene was originally isolated based on its preferential expression in the growth arrest phase of the cell cycle (Barone et al.) This gene contains 12 exons from which two alternatively spliced transcripts have been initially identified. More recently, it has been reported that both human and murine gas5 genes contain in their introns sequences homologous to the small nucleolar RNAs involved in the processing of ribosomal RNA. Here we report on the identification and analysis of the expression pattern of two novel alternatively spliced mouse gas5 mRNAs which contain no obvious open reading frame (ORF). Using antibodies generated against the putative amino acid sequence deduced from the gas5 cDNAs, we were not able to detect any Gas5 protein in cultured cells or murine tissues extracts. Even more definitive evidence that the gas5 gene may not encode a protein was obtained by cloning and sequencing the rat gas5 gene which revealed that the putative ORF is interrupted by a stop codon after the first 13 amino acids, correspondint or corresponds to the VV region located between genes F9L and A38L. Within the terminal 13 kbp, colinearity is disrupted and multiple poxvirus gene homologues are absent or share a lower percentage of amino acid identity. Most of these differences involve genes and gene families with likely functions involving viral virulence and host range. Three open reading frames (SPV018, SPV019. and SPV020) are unique for SWPV. Phylogenetic analysis, genome organization, and amino acid identity indicate that SWPV is most closely related to the capripoxvirus lumpy skin disease virus, followed by the yatapoxvirus yaba-like disease virus and the leporipoxviruses. The gene complement of SWPV better defines Suipoxvirus within the Chordopoxvirinae subfamily and provides a basis for future genetic comparisons

Another sequence (Lab Designation 12CX#6_rE (SEQ ID NO: 50)) comprises sequence encoding zfp-36. Zfp-36, the gene encoding the putative zinc finger protein tristetraprolin (TTP), is rapidly induced in fibroblasts by a variety of growth factors. Recent gene knockout experiments have shown that TTP-deficient mice developed
5 arthritis, cachexia, and autoimmunity, all apparently mediated by an excess of tumor necrosis factor alpha. Lai et al. showed that full serum inducibility of Zfp-36 requires elements in the promoter; in addition, removal of the single intron strikingly inhibited serum-induced TTP expression. Lai et al also showed that replacement of the intron with unrelated sequences, or removal of 95% of the intron but retention of the splice sites, each
10 resulted in the maintenance of approximately 45 and 19%, respectively, of full serum-induced expression. In addition, deletion of intron sequences base pairs 601-655 decreased the serum-induced expression of TTP by 65%. Sequence base pairs 618-626 bound specifically to the transcription factor Sp1; mutation of this binding motif decreased TTP expression by 70%, suggesting that Sp1 binding to this motif contributes to serum
15 induction of Zfp-36 (Lai et al.).

Another sequence (Lab Designation 12CXY#7_rE (SEQ ID NO: 62)) comprises sequence encoding PROTEASE, SERINE, 11 or PRSS11. This protein is also known as HTRA; HOMOLOG OF E. COLI HTRA; HTRA; HTRA1 and maps to chromosomal location 10q25.3-q26.2.

20 Insulin-like growth factors (IGFs; see 147440) stimulate the proliferation and differentiation of a vast number of cell types. The action of the growth factors is mediated and controlled by a complex system of components, including at least 2 different forms of IGF, 2 IGF receptors (e.g., 147370), 7 different IGF-binding proteins (IGFBPs; see 146730), and several proteases that cleave the IGFBPs.

25 Zumbrunn and Trueb (1996) cloned the cDNA for a human protein, termed L56 by them, that seemed to be part of the IGF signaling system. The predicted protein encodes a 480-amino acid polypeptide with a molecular mass of 51 kD. Zumbrunn and Trueb (1996) found that PRSS11 contains a secretory signal sequence, an IGFBP-binding domain, and a serine protease domain. The serine protease domain is most similar to certain bacterial
30 serine proteases. By Northern blot analysis, Zumbrunn and Trueb (1996) showed that PRSS11 is expressed in a variety of human tissues, with strongest expression in placenta.

Hu et al. (1998) also cloned PRSS11. The deduced 480-amino acid protein is 98% identical to the cow, guinea pig, and rabbit proteins. It contains an N terminus homologous

to MAC25 (IGFBP7; 602867) with a conserved Kazal-type serine protease inhibitor motif, as well as a C-terminal PDZ domain. Semiquantitative RT-PCR and immunoblot analyses showed an approximately 7-fold increase of PRSS11 in osteoarthritis cartilage compared with controls. Functional and mutational analyses indicated that PRS11 is a serine
 5 protease dependent on the presence of a serine at position 328.

Using fluorescence in situ hybridization, Zumbrunn and Trueb (1997) mapped the PRSS11 gene to 10q25.3-q26.2.

Another sequence (Lab Designation 12PSA#6-rE (SEQ ID NO: 4)) comprises sequence encoding EUKARYOTIC TRANSLATION INITIATION FACTOR 3 THETA.
 10 This protein is also known as EIF3-THETA EIF3, p180 SUBUNIT, EIF3, p170 SUBUNIT, CYTOPLASMIC PROTEIN p167, MOUSE HOMOLOG OF CENTROSOMIN B. This sequence maps to chromosomal location 10q26.

Eukaryotic translation initiation factors (EIFs) initiate protein synthesis from mRNAs. EIF3, at 650 kD, is the largest of the EIFs. According to Johnson et al. (1997),
 15 EIF3 has been implicated in several roles, including binding to the 40S ribosomal subunit and to other EIFs, possibly to align the factors for initial binding to the 40S subunit and the subsequent identification of the AUG initiation codon. The EIF3 protein synthesis initiation factor is composed of at least 8 subunits, the largest of which is p180.

Another sequence (Lab Designation 12_3B#2_Lac (SEQ ID NO: 218)) comprises
 20 sequence encoding UBIQUITIN-ACTIVATING ENZYME E1C or UBE1C. This protein is also known as S. CEREVISIAE, HOMOLOG OF UBIQUITIN-ACTIVATING ENZYME 3, UBA3. This sequence maps to human chromosomal location 3p14.

Ubiquitin (191320) is covalently attached to target proteins by a multienzymatic
 25 system consisting of E1 (ubiquitin-activating), E2 (ubiquitin-conjugating), and E3 (ubiquitin-ligating) enzymes. Osaka et al. (1998) found that NEDD8 (603171), a ubiquitin-like protein, is conjugated to proteins in a manner analogous to ubiquitylation. They found that APP-BP1 (beta-amyloid precursor protein-binding protein-1) can bind to NEDD8 in rabbit reticulocyte lysates. However, since APP-BP1 shows similarity to only
 30 the N-terminal domain of an E1 enzyme, the authors reasoned that it must interact with a protein showing similarity to the C-terminal region of E1s. By searching sequence databases, Osaka et al. (1998) identified cDNAs encoding UBA3, the human homolog of yeast Uba3. The predicted 442-amino acid UBA3 protein shares 43% sequence identity

with yeast Uba3. In vitro, UBA3 formed a complex with APP-BP1 and a thioester linkage with NEDD8. Osaka et al. (1998) suggested that the APP-BP1/UBA3 complex functions as an E1-like enzyme for the activation of NEDD8.

Another sequence (Lab Designation 12_4B#7_rE (SEQ ID NO: 21)) comprises
5 sequence encoding PEPTIDYL-PROLYL CIS-TRANS ISOMERASE A (PPIASE) also known as ROTAMASE, CYCLOPHILIN A or CYCLOSPORIN A-BINDING PROTEIN. This protein maps to chromosomal location 9q31.3.

A protein designated chickpea cyclophilin-like antifungal protein (CLAP) was isolated from seeds of the chickpea (*Cicer arietinum*). Chickpea CLAP was characterized
10 by a molecular weight of 18 kDa and an N-terminal sequence homologous to cyclophilins. The protein was isolated with a procedure involving affinity chromatography on Affi-gel blue gel and ion exchange chromatography on CM-Sepharose. In addition to an inhibitory effect on the growth of fungi including *Rhizoctonia solani*, *Mycosphaerella arachidicola* and *Botrytis cinerea*, the protein was capable of inhibiting human immunodeficiency virus-
15 1 reverse transcriptase. Chickpea CLAP did not possess lectin and ribonuclease activities but it weakly inhibited translation in a rabbit reticulocyte lysate system. The protein stimulated 3H-thymidine incorporation by mouse splenocytes.

Cyclophilin A is the target of the immunosuppressant cyclosporin A (CsA) and is encoded by a single unique gene conserved from yeast to humans. In the pathogenic
20 fungus *Cryptococcus neoformans*, two homologous linked genes, CPA1 and CPA2, were found to encode two conserved cyclophilin A proteins. In contrast to *Saccharomyces cerevisiae*, in which cyclophilin A mutations confer CsA resistance but few other phenotypes, cyclophilin A mutations conferred dramatic phenotypes in *C. neoformans*. The Cpa1 and Cpa2 cyclophilin A proteins play a shared role in cell growth, mating,
25 virulence and CsA toxicity. The Cpa1 and Cpa2 proteins also have divergent functions. Cpa1 mutants are inviable at 39 degrees C and attenuated for virulence, whereas Cpa2 mutants are viable at 39 degrees C and fully virulent. Cpa1 Cpa2 double mutants exhibited synthetic defects in growth and virulence. Cyclophilin A active site mutants restored growth of Cpa1 Cpa2 mutants at ambient but not at higher temperatures, suggesting that
30 the prolyl isomerase activity of cyclophilin A has an *in vivo* function.

Another sequence (Lab Designation 12_L24_5_3-Lac (SEQ IDNO: 283)) comprises sequence encoding HEMOPOIETIC CELL KINASE also known as HCK and KIAA0255. This sequence maps to gene map locus 20q11-q12. This gene was also

disrupted off the negative strand in this region and disrupts an unknown gene.

During a search for a cDNA clone representing human SRC (190090), Quintrell et al. (1987) encountered a previously unrecognized gene that appeared to encode a protein-tyrosine kinase similar to SRC. Ziegler et al. (1987) found the same gene by a different route. Expression of this gene may be limited to certain hemopoietic cells and is especially prominent in cells of myeloid lineage, particularly mature granulocytes and monocytes. Therefore, Quintrell et al. (1987) designated the gene HCK (pronounced 'hick') for hemopoietic cell kinase. They described the nucleotide sequence of a cDNA clone that represents most or all of the mRNA for HCK, the deduced amino acid sequence of the protein encoded by HCK, and the distribution of RNA transcribed from HCK among various hemopoietic cells. By spot-blot analysis of sorted chromosomes and by in situ hybridization, Quintrell et al. (1987) assigned the HCK gene to 20q11-q12. Since this region is affected by interstitial deletions in some acute myeloid leukemias and myeloproliferative disorders, they suggested that damage to HCK may contribute to the pathogenesis of these conditions.

Another sequence (Lab Designation L24_5_2BE-rE (SEQ IDNO: 208) comprises sequence encoding HEPATOCYTE NUCLEAR FACTOR 3-BETA (HNF3B) (Kaestner et al.). This sequence maps to gene map locus 20p11.

Deleuze et al. (1994) investigated hepatic nuclear factor-3-beta as a candidate gene for Alagille syndrome (AGS; 118450) because of its pattern of expression during embryogenesis in derivatives of the embryonic gut and because of its localization to mouse chromosome 2 (Avraham et al., 1992) in the region syntenic with human chromosome 20 where AGS is located. They found that the gene was not deleted in a deletion case of AGS. The presence of the HNF3B gene in the deleted cells was established by Southern blot hybridization rather than by fluorescence in situ hybridization; hence, the assignment of the human gene to chromosome 20 was based on homology only.

Mincheva et al. (1997) used fluorescence in situ hybridization to map the HNF3B gene to human chromosome 20p11.

Another sequence comprises sequence encoding DROSOPHILA HOMOLOG OF DISCS LARGE 5; DLG5. This protein is also known as PLACENTA AND PROSTATE DLG and as PDLG. This sequence maps to gene map locus 10q23.

Vertebrate homologs of the Drosophila discs large (dlg) gene are members of the MAGUK (membrane-associated guanylate kinase) family. MAGUK proteins contain PDZ

motifs, an SH3 domain, and a guanylate kinase (GUK)-homologous region. Both the PDZ and GUK domains are thought to contribute to protein-protein interactions. By searching an EST database for sequences related to *Drosophila dlg*, Nakamura et al. (1998) identified cDNAs encoding a novel human homolog. Northern blot analysis revealed that the 9.4-kb transcript was highly expressed in placenta and prostate, as well as in several other tissues, leading the authors to designate the gene PDLG (placenta and prostate DLG). An additional 8.8-kb PDLG mRNA was detected in thyroid. The predicted 859-amino acid PDLG protein contains 3 PDZ domains, an SH3 domain, and a GUK region. PDLG is 45% and 40% identical to DLG1 (601014) and *Drosophila dlg*, respectively. Western blot analysis of extracts of human prostate tissue and various cell lines showed that PDLG has an apparent molecular mass of 105 kD. Immunofluorescence experiments indicated that PDLG is localized at the plasma membrane and cytoplasm, and is expressed in the gland epithelial cells of normal prostate tissue but not in prostate cell lines. Using a yeast 2-hybrid screen, Nakamura et al. (1998) determined that PDLG interacts with the GUK domain of p55 (MPP1; 305360), a palmitoylated erythrocyte membrane MAGUK protein. The authors suggested that PDLG and p55 form a heteromeric MAGUK complex at the plasma membrane and cluster various intracellular molecules to play roles in maintaining the structure of epithelial cells and transmitting extracellular signals to the membrane and cytoskeleton.

Independently, Nagase et al. (1998) identified KIAA0583, a DLG5 cDNA. By radiation hybrid analysis, they mapped the DLG5 gene to chromosome 10. Using the same technique, Nakamura et al. (1998) refined the localization of the DLG5 gene to 10q23.

Another sequence (Lab Designation L28AP_rE (SEQ ID NO: 172)) comprises sequence encoding TRANSCRIPTION ELONGATION FACTOR B, 3 or TCEB3. This protein is also known as ELONGIN A and ELONGIN, 110-KD. This sequence maps to chromosomal location 1p36.1

Eukaryotic transcription and mRNA synthesis are complex biochemical processes controlled in part by the concerted action of a set of general transcription factors that regulate the activity of RNA polymerase II at both the initiation and elongation stages of transcription. Aso et al. (1995) noted that several general initiation factors, including TFIIA (see 600520), TFIIB (189963), TFIID (see 313650), TFIIE (see 189962), and TFIIH (see 189972), and several accessory proteins (e.g., TAFs; see 600475), have been identified in eukaryotic cells and found to promote selective binding of RNA polymerase

II to promoters and to support a basal level of transcription.

Aso et al. (1996) described a full-length cDNA encoding the human homolog. The predicted 722-amino acid protein shares 84% homology with the rat protein. Comparison of the open reading frames of the human cDNA with that of the previously characterized
5 rat cDNA indicated that they are 84% conserved in nucleotide sequence.

Duan et al. (1995) and Kibel et al. (1995) reported results suggesting that the tumor suppression activity of the von Hippel-Lindau tumor suppressor gene product (193300) is a function of its ability to bind to TCEB2 and TCEB1 and inhibit transcription elongation.

By fluorescence in situ hybridization, Aso et al. (1995) mapped the TCEB3 gene to
10 1p36.1. They pointed out that this region has been shown to have deletions in several forms of malignancy.

Another sequence (Lab Designation 14A7rE (SEQ ID NO: 113)) comprises sequence encoding MOTHERS AGAINST DECAPENTAPLEGIC, or DROSOPHILA, HOMOLOG OF, 7 or MADH7. This protein is also known as SMA- AND MAD-
15 RELATED PROTEIN 7; SMAD7. This sequence maps to gene map locus 18q21.1

MAD proteins, originally defined in Drosophila, are essential components of the signaling pathways of the transforming growth factor-beta receptor family (e.g., TGFBR1; 190181). Using a differential display approach in cultured endothelial cells subjected to multiple soluble and biomechanical stimuli, Topper et al. (1997) isolated a human
20 endothelial cell cDNA encoding MADH7, which they called SMAD7. The predicted 426-amino acid MADH7 protein lacks the C-terminal putative phosphorylation sites present in other MAD proteins, suggesting that it may be distinctly regulated. In situ hybridization and immunohistochemical analyses on human tissues showed that MADH7 is expressed predominantly in vascular endothelium. The authors demonstrated that MADH7 and
25 MADH6 (602931) can form complexes in endothelial cells. MADH7 was induced in cultured vascular endothelium by fluid mechanical forces and was capable of modulating endothelial gene expression in response to both humoral and biomechanical stimuli in vitro.

Kavsak et al. (2000) found that the E3 ubiquitin ligase SMURF2 (605532)
30 associates constitutively with SMAD7. SMURF2 is nuclear, but binding to SMAD7 induced export and recruitment to the activated TGFBR, where it caused degradation of receptors and of SMAD7 via proteasomal and lysosomal pathways. Gamma-interferon (IFNG; 147570), which stimulates expression of SMAD7, induced SMAD7-SMURF2

complex formation and increased TGFBR turnover, which was stabilized by blocking SMAD7 or SMURF2 expression. Furthermore, SMAD7 mutants that interfered with recruitment of SMURF2 to the receptors were compromised in their inhibitory activity. These studies defined SMAD7 as an adaptor in an E3 ubiquitin ligase complex that targets
5 TGFBR for degradation.

Lallemand et al. (2001) showed that cells stably expressing SMAD7 had increased susceptibility to apoptosis induced by TGFB (190180), TNFA (191160), serum withdrawal, or loss of cell adhesion (anoikis). SMAD7 decreased NFkB (164011) activity, providing a mechanism for the increased apoptosis. Stable expression of RAS (190020)
10 suppressed SMAD7 inhibition of NFkB and SMAD7 potentiation of apoptosis.

By somatic cell hybrid analysis, Topper et al. (1997) mapped the MADH7 gene to human chromosome 18. By FISH, Roijer et al. (1998) refined the localization to 18q21.1.

Another sequence (Lab Designation 14C_2E/rE (SEQ ID NO: 126)) comprises sequence encoding SIGNAL RECOGNITION PARTICLE, 19-KD (SRP19). This
15 sequence maps to gene map locus 5q21-q22.

The signal recognition particle (SRP) is a ribonucleoprotein complex that mediates the targeting of proteins to the endoplasmic reticulum (ER). The complex consists of a 7S (or 7SL) RNA and 6 different proteins, SRP9 (600707), SRP14 (600708), SRP19, SRP54 (604857), SRP68 (604858), and SRP72 (602122). The proteins are bound to the 7S RNA
20 as monomers (SRP19 and SRP54) or heterodimers (SRP9/SRP14 and SRP68/SRP72). SRP9 and SRP14 constitute the Alu domain of 7S, whereas the other 4 proteins belong to the S domain. SRP has at least 3 distinct functions that can be associated with the protein subunits: signal recognition, translational arrest, and ER membrane targeting by interaction with the docking protein.

25 By screening a liver cDNA library with an anti-SRP19 probe, Lingelbach et al. (1988) isolated a human SRP19 cDNA encoding a 144-amino acid protein. Sequence analysis showed that SRP19 contains a very basic C-terminal domain of 7 lysine residues interrupted by 2 glycine residues. Northern blot analysis revealed expression of a 0.9 kb transcript in HeLa cells. SDS-PAGE analysis showed that SRP19 is expressed as a 19-kD
30 protein, identical in size to canine SRP19. Functional analysis determined that the SRP19 protein binds to 7SL RNA in canine pancreas.

In 2 small nested deletions of 100 to 260 kb identified by Joslyn et al. (1991) in patients with adenomatous polyposis coli (APC; 175100), Groden et al. (1991) identified 3

genes in a span of about 100 kb on chromosome 5. One of these was DP1 (125265); a second was the gene that is mutant in APC (175100), called by them DP2.5. A third was a gene which was found to have the same sequence as that of SRP19. SRP19 was shown to have 5 exons and to lie between DP1 and DP2.5. Horii et al. (1993) discussed the occurrence of alternative splicing not only within the APC gene but also between the APC gene and the neighboring SRP19 gene.

Wild et al. (2001) reported the 1.8-angstrom resolution crystal structure of human SRP19 in complex with its primary binding site on helix 6 of SRP RNA, which consists of a stem-loop structure closed by an unusual GGAG tetraloop. Protein-RNA interactions are mediated by the specific recognition of a widened major groove and the tetraloop without any direct protein-base contacts and include a complex network of highly ordered water molecules. Wild et al. (2001) proposed a model of the assembly of the SRP core comprising SRP19, SRP54, and SRP RNA based on crystallographic and biochemical data.

Another sequence (Lab Designation 14C_24_#6_Lac (SEQ ID NO: 47)) comprises sequence encoding FER-1, C. ELEGANS, HOMOLOG-LIKE 3; FER1L3. This protein is also known as MYOFERLIN or MYOF. This sequence maps to gene map location 10q23.32.

Dysferlin (DYSF; 603009), the gene product of the limb-girdle muscular dystrophy 2B locus (LGMD2B; 253601), encodes a membrane-associated protein with homology to *Caenorhabditis elegans* fer-1. Humans with mutations in dysferlin develop muscle weakness that affects both proximal and distal muscles. Strikingly, the phenotype in LGMD2B patients is highly variable, but the type of mutation in DYSF did not explain this phenotypic variability. Through electronic database searching, Davis et al. (2000) identified a protein highly homologous to dysferlin that they named myoferlin. The open reading frame of myoferlin predicted a 2,061-amino acid protein. By Northern blot analysis, the authors observed a 7.5-kb myoferlin mRNA transcript highly expressed in cardiac muscle and to a lesser degree in skeletal muscle. However, antibodies raised against myoferlin showed abundant expression of myoferlin (molecular weight 230 kD) in both cardiac and skeletal muscle. Within the cell, myoferlin was associated with the plasma membrane but, unlike dysferlin, myoferlin was also associated with the nuclear membrane. Ferlin family members contain C2 domains, and these domains play a role in calcium-mediated membrane fusion events. To investigate this, Davis et al. (2000) studied

the expression of myoferlin in the mdx mouse, which lacks dystrophin and whose muscles undergo repeated rounds of degeneration and regeneration. They found upregulation of myoferlin at the membrane in mdx skeletal muscle. Davis et al. (2000) suggested myoferlin (MYOF) as a candidate gene for muscular dystrophy and cardiomyopathy, or possibly a modifier of the muscular dystrophy phenotype.

Another sequence (Lab Designation 14_7#2E-rE (SEQ ID NO: 5 and SEQ ID NO: 115)) comprises sequence encoding ALPHA-1,3-@MANNOSYL-GLYCOPROTEIN BETA-1,2-N-ACETYLGLUCOSAMINYLTRANSFERASE or MGAT1. This protein is also known as GlcNAc-T I, MGAT, UDP-N-ACETYLGLUCOSAMINE:ALPHA-3-D-MANNOSIDE BETA-1,2-N-ACETYLGLUCOSAMINYLTRANSFERASE I (GLCT1). This sequence maps to gene map locus 5q35.

There are believed to be over 100 different glycosyltransferases involved in the synthesis of protein-bound and lipid-bound oligosaccharides. One of these, UDP-N-acetylglucosamine:alpha-3-D-mannoside beta-1,2-N-acetylglucosaminyltransferase I (GlcNAc-T I; EC 2.4.1.101), is a medial-Golgi enzyme essential for the synthesis of hybrid and complex N-glycans. Kumar and Stanley (1989) identified the human gene encoding N-acetylglucosaminyltransferase I by complementation of the glycosylation defect in the Lec1 Chinese hamster ovary (CHO) cell mutant. Kumar et al. (1990) cloned the gene. The overall features of the cDNA and deduced protein sequence (445 amino acids) were typical of other Golgi transferases that are type II transmembrane proteins. Hull et al. (1991) isolated 2 overlapping genomic DNA clones which span 18 kb containing the single 2.5-kb exon for GlcNAc-T I. The exon includes most of the 5-prime untranslated region, the complete coding sequence (1,335 bases, 445 amino acids), and the complete 3-prime untranslated region. Southern blot analysis indicated that the gene (symbolized GLCT1) exists in single copy in the human genome, and study of human-hamster somatic cell hybrids indicated that the gene is located on chromosome 5. Pownall et al. (1992) demonstrated that the sequence of the mouse gene *Mgat1* is highly conserved with respect to the human and rabbit homologs and exists as a single protein-encoding exon. They mapped the gene to mouse chromosome 11, closely linked to the gene encoding IL3 (147740), by the analysis of multilocus interspecies backcrosses. Thus, the human gene may be in the same area as IL3, i.e., 5q23-q31. Kumar et al. (1992) mapped the gene to 5q31.2-q31.3 by in situ hybridization. Tan et al. (1995) reported that the MGAT1 gene maps to 5q35 by fluorescence in situ hybridization. They considered the

discrepancy with the findings of Kumar et al. (1992) to be due to greater precision of fluorescence analysis compared with radioactive in situ hybridization. Shows (1999) stated that by use of more sensitive FISH technology than that used in their 1992 report (Kumar et al., 1992), he and his colleagues confirmed the assignment of the MGAT1 gene to 5q35.

5 Another sequence (Lab Designation 19_9BE_rE (SEQ ID NO: 123)) comprises sequence encoding CLEAVAGE STIMULATION FACTOR, 3-PRIME PRE-RNA, SUBUNIT 2, 64-KD (CSTF2). This sequence maps to human chromosome Xq21.33.

Polyadenylation of mRNA is a complex process that requires multiple protein factors, including 3 cleavage stimulation factors (CSTF1, 600369; CSFT2, and CSTF3, 10 600367). CstF2, a 64-kD protein, contains a ribonucleoprotein (RNP)-type RNA binding domain in the N-terminal region (Takagaki et al., 1992). The CstF2 protein expressed in *E. coli* can be cross-linked to RNAs containing polyadenylation signal sequences (AAUAAA).

The concentration of one CSTF subunit (CSTF-64) increases during activation of B 15 cells, and this is sufficient to switch IgM heavy chain mRNA expression from membrane-bound form to secreted form (Takagaki et al., 1996). To extend this observation, Takagaki and Manley (1998) disrupted the endogenous CstF-64 gene in the chicken B-cell line DT40 and replaced it with a regulatable transgene. Strikingly, a 10-fold decrease in CstF-64 concentration did not markedly affect cell growth but specifically and dramatically 20 reduced accumulation of IgM heavy chain mRNA. Further reduction caused reversible cell cycle arrest in G0/G1 phase, while depletion resulted in apoptotic cell death.

Another sequence (Lab Designation 1A_A549_6-rE SEQ ID NO: 310)) comprises sequence encoding RET FINGER PROTEIN 2 (RFP2). This protein is also known as LEU5. This sequence maps to gene map locus 13q14.3

25 B-cell chronic lymphocytic leukemia is often associated with the loss of a region on chromosome 13q14 between the retinoblastoma gene (RB1; 180200) and locus D13S25 (Liu et al., 1993; Liu et al., 1995), suggesting that a tumor suppressor gene may be located in this region. By constructing a cosmid contig corresponding to the minimally deleted region and screening a pre-B lymphocyte cDNA library, Kapanadze et al. (1998) isolated 30 several clones, one of which contained an ORF encoding a deduced 407-amino acid protein, RFP2, which they called LEU5. RFP2 contains a zinc finger domain of the RING type and shares significant homology with the RET finger protein (RFP; 602165) and the tumor suppressor gene BRCA1 (113705). Kapanadze et al. (1998) mapped the RFP2 gene

close to D13S272, bordering the minimally deleted region.

Another sequence (Lab Designation 31_3_5_rE (SEQ ID NO: 158)) comprises sequence encoding ZINC FINGER PROTEIN 207 (ZNF207). This sequence maps to gene map locus 6p21.3.

5 Pahl et al. (1998) isolated a human vascular smooth muscle cell cDNA encoding a protein that they designated ZNF207. The predicted 478-amino acid protein is composed of nearly 20% proline residues and contains a potential nuclear localization signal at the N-terminus and 2 C2H2 zinc finger motifs. Northern blot analysis revealed that ZNF207 is expressed ubiquitously.

10 By fluorescence in situ hybridization, Pahl et al. (1998) mapped the ZNF207 gene to 6p21.3. Rasooly (1999) noted that the ZNF207 sequence is contained within a cloned region from chromosome 17 (AC005899).

Another sequence (Lab Designation 21_5_7E_Lac (SEQ ID NO: 137)) comprises sequence encoding INHIBITOR OF DNA BINDING 3 (ID3). This protein is also known
15 as HEIR1 and the sequence maps to gene map locus 1p36.13-p36.12

Ellmeier et al. (1992) isolated a novel human gene encoding a helix-loop-helix (HLH) protein by molecular cloning of chromosome 1p36-specific CpG islands. Initially termed HEIR1, the ID3 gene was localized to the neuroblastoma consensus deletion region, 1p36.2-p36.12. Its predicted protein was 95.8% identical to the mouse HLH462
20 protein and had clear homology to the mouse Id and Drosophila emc proteins. The gene was expressed at high abundance in adult lung, kidney, and adrenal medulla, but not in adult brain. Despite prominent HEIR1 expression in adrenal medulla, which is a prime target for neuroblastomas, 10 of 12 neuroblastoma-derived cell lines showed very low levels of HEIR1 mRNA. Low HEIR1 expression was generally found in tumor cell lines
25 with NMYC (164840) overexpression, whereas the 2 cell lines displaying high HEIR1 levels did not overexpress NMYC. Mutually exclusive expression of the 2 genes was also found by in situ hybridization in developing mouse tissues, particularly in the forebrain neuroectoderm. Ellmeier et al. (1992) concluded that HEIR1 expression is reduced specifically in the majority of neuroblastomas and suggested an inverse correlation
30 between HEIR1 and NMYC expression in these tumors and in embryonic development.

Deed et al. (1994) reported a comparison of the ID3 gene with ID1 (600349) and ID2 (600386) that showed a highly conserved protein-coding gene organization consistent with evolution from a common ancestral gene. By using a YAC clone of ID3 for

fluorescence in situ hybridization, they mapped the ID3 gene to 1p36.1. White et al. (1995) could exclude ID3 as a candidate for the neuroblastoma suppressor gene because it lies outside the loss of heterozygosity (LOH) region revealed by neuroblastoma studies (see NBS; 256700).

5 Id proteins may control cell differentiation by interfering with DNA binding of transcription factors. Lyden et al. (1999) demonstrated that the targeted disruption of Id1 and Id3 in mice results in premature withdrawal of neuroblasts in the cell cycle and expression of neural-specific differentiation markers. Lyden et al. (1999) crossed Id1 +/- and Id3 +/- mice. Offspring lacking 1 to 3 Id alleles in any combination were
10 indistinguishable from wildtype, but no animals lacking all 4 Id alleles were born. The Id1-Id3 double knockout mice displayed vascular malformations in forebrain and absence of branching and sprouting of blood vessels in the neuroectoderm. As angiogenesis both in the brain and in tumors requires invasion of avascular tissue by endothelial cells, Lyden et al. (1999) examined Id knockout mice for their ability to support the growth of tumor
15 xenografts. Three different tumors failed to grow and/or metastasize in Id1 +/- Id3 -/- mice, and any tumor growth present showed poor vascularization and extensive necrosis. Lyden et al. (1999) concluded that Id genes are required to maintain the timing of neuronal differentiation in the embryo and invasiveness of the vasculature. Because the Id genes are expressed at very low levels in adults, they make attractive targets for antiangiogenic drug
20 design. Lyden et al. (1999) also concluded that the premature neuronal differentiation in Id1-Id3 double knockout mice indicates that ID1 or ID3 is required to block the precisely timed expression and activation of positively acting bHLH proteins during murine development.

Pan et al. (1999) found that Id3-deficient mice had no overt abnormalities but had
25 compromised humoral immunity. After immunization with T cell-dependent or T cell-independent antigens, the responses of Id3-deficient mice were attenuated and severely impaired, respectively. T-cell proliferative responses appeared to be intact, but IFNGamma expression may have been impaired. The defect in B-cell proliferation could be rescued by ectopic expression of Id1.

30

ID3 is an inhibitor of E proteins, such as E2A (147141). By Northern and Western blot analysis, Kee et al. (2001) showed that in mouse transforming growth factor-beta (190180) rapidly induced transient Id3 expression in B-lymphocyte precursors. This

induction involved activation of the SMAD (see 602932) transcription factor pathway.

Another sequence (Lab Designation 31_3_6_2_Lac (SEQ ID NO: 248)) comprises sequence encoding FK506-BINDING PROTEIN 8 (FKBP8). This protein is also known as FK506-BINDING PROTEIN, 38-KD (FKBP38)).

5 FKBP8s are intracellular receptors for the immunosuppressive drug FK506. The FKBP/FK506 complex exerts its immunosuppressive effects by inhibiting calcineurin (e.g., PPP3CA; 114105), a calcium- and calmodulin (e.g., CALM1; 114180)-dependent serine/threonine phosphatase that functions as a critical signaling molecule during T-cell activation. By PCR using Jurkat cell cDNA and degenerate oligonucleotides based on
10 conserved regions of FKBP8s, Lam et al. (1995) identified a cDNA encoding FKBP8. The deduced 355-amino acid FKBP8 protein shares 26 to 28% amino acid sequence identity with other known human FKBP8s. FKBP8 contains an N-terminal domain that is 33% identical to FKBP12 (FKBP1A; 186945), a putative leucine zipper domain, a 3-unit imperfect tetratricopeptide repeat (TPR) domain, and a putative calmodulin-binding
15 domain. Northern blot analysis detected a single, approximately 1.35- to 2.4-kb FKBP8 transcript in all human tissues examined, with the highest expression in brain.

Another sequence (Lab Designation 31_3_9-rE (SEQ ID NO: 135)) comprises sequence encoding MAIL, a nuclear I kappa B protein that potentiates LPS-induced IL-6 production. This sequence maps to gene map locus 3q21.3.

20 Kitamura et al. identified and characterized a novel member of the ankyrin-repeat family named 'molecule possessing ankyrin-repeats induced by lipopolysaccharide' (MAIL). The C-terminal portion of MAIL shared high sequence homology with the I kappa B family. Intraperitoneal injection of lipopolysaccharide (LPS) into mice rapidly (<0.5 h) induced MAIL mRNA in various tissues, particularly in the spleen, lymph node,
25 and lung. Ectopically expressed MAIL was localized in the nucleus, and remarkably potentiated the LPS-induced mRNA expression and secretion of interleukin (IL)-6 in Swiss 3T3 cells. These findings indicated that MAIL is one of the nuclear I kappa B proteins and an activator of IL-6 production.

Another sequence (Lab Designation 34X23_1-rE (SEQ ID NO: 149)) comprises
30 sequence encoding CASPASE RECRUITMENT DOMAIN-CONTAINING PROTEIN 4 (CARD4). This protein is also known as NOD1 PROTEIN (NOD1). This sequence maps to gene map locus 7p15-p14.

APAF1 (602233) in mammals and Ced4 in the worm are members of a family of intracellular proteins composed of an N-terminal caspase recruitment domain (CARD), a centrally located nucleotide-binding domain (NBD), and a C-terminal regulatory domain, which consists of WD40 repeats in the case of APAF1. The APAF1 WD40 repeats act as
5 recognition domains for mitochondrial damage, which leads to APAF1 oligomerization and eventual apoptosis through homophilic CARD-CARD interaction with the prodomain of caspase-9 (CASP9; 602234).

By searching a proprietary EST database for sequences encoding CARD motifs, followed by screening an endothelial cell cDNA library, Bertin et al. (1999) obtained a
10 cDNA encoding CARD4. The deduced 953-amino acid CARD4 protein contains an N-terminal CARD motif, an NBD, and unlike APAF1, 10 tandem leucine-rich repeats in its C terminus. Northern blot analysis revealed abundant expression of a 4.5-kb transcript in adult heart, spleen, and lung, as well as in numerous cancer cell lines and fetal tissues. Yeast 2-hybrid analysis using the CARD domain of CARD4 as bait to screen breast,
15 prostate, and brain cDNA libraries, as well as coimmunoprecipitation analysis, indicated preferential interaction with the CARD of RICK (RIPK2; 603455). Luciferase reporter analysis showed that the CARD domain of CARD4, but not that of APAF1, potentially induces activation of nuclear factor kappa-B (see 164011), but not of JUN N-terminal kinase (see 601158), in a concentration-dependent manner.

20 Using similar methods, Inohara et al. (1999) cloned and characterized CARD4, which they called NOD1. Northern blot analysis detected wide expression of NOD1. In situ hybridization analysis showed relatively restricted expression of Nod1 in day-15.5 mouse embryos. Confocal microscopy demonstrated that NOD1 is a cytosolic protein. Coimmunoprecipitation analysis revealed that NOD1 preferentially interacts with
25 procaspases containing CARDs or death effector domains (DEDs), as well as with itself, RICK, and CLARP (CFLAR; 603599), but not with RAIDD (CRADD; 603454), APAF1, NIK (604655), or other CARD- or DED-containing proteins. Functional analysis indicated that the CARD and NBD of NOD1, but not the LRR, enhance apoptosis induced by CASP9, but not by other caspases or CLARP. The CARD was found to be essential for
30 NOD1 to bind and activate CASP9, as well as to promote apoptosis. Inohara et al. (1999) also observed that NOD1 interacts with RICK in NFkB activation.

By genomic sequence analysis, Inohara et al. (1999) determined that the NOD1 gene contains 7 coding and 7 noncoding exons and maps to 7p15-p14.

Another sequence (Lab Designation 34X23_3-rE (SEQ ID NO: 152)) comprises sequence encoding mdr1b or mdr1. This protein is also known as Abcb1b. This sequence maps to human chromosomal location 7q21.1.

Song et al. "Identification and characterization of a hepatoma cell-specific
5 enhancer in the mouse multidrug resistance mdr1b promoter" *J Biol Chem.*,
270(43):25468-74) (Oct. 27, 1995) demonstrate that the expression of multidrug
resistance/P-glycoprotein genes mdr1b(mdr1) and mdr1a(mdr3) is elevated during
hepatocarcinogenesis. To investigate the regulation of mdr1b gene expression, they used
transient transfection expression assays of reporter constructs containing various 5'-mdr1b
10 flanking sequences in hepatoma and non-hepatoma cells. They found that nucleotides -233
to -116 preferentially enhanced the expression of reporter gene in mouse hepatoma cell
lines in an orientation- and promoter context-independent manner. DNase I footprinting
using nuclear extracts prepared from hepatoma and non-hepatoma cells identified four
protein binding sites at nucleotides -205 to -186 (site A), -181 to -164 (site B), -153 to -
15 135 (site C), and -128 to -120 (site D). Further analyses revealed that, while site B alone
played a major part for the enhancer function, sites A and B combined conferred full
enhancer activity. Site-directed mutagenesis results also supported these results. Gel
retardation experiments using oligonucleotide competitors revealed that the site B contains
a dominant binding protein. This was the first report demonstrating a cell type-specific
20 enhancer in the mdr locus. The role of this enhancer in the activation of mdr1b gene during
hepatocarcinogenesis is discussed by the authors.

Hsu et al. "Differential overexpression of three mdr gene family members in
multidrug-resistant J774.2 mouse cells. Evidence that distinct P-glycoprotein precursors
are encoded by unique mdr genes" *J Biol Chem*, 15;264(20):12053-62, (Jul 1989) show
25 that a hallmark of the multidrug-resistant phenotype is the overproduction of a family of
130-180-kDa integral membrane phosphoglycoproteins collectively called P-glycoprotein.
Gene-specific hybridization probes were derived from three classes of mouse P-
glycoprotein cDNAs. These probes revealed the differential amplification and/or
transcriptional activation of three distinct but closely related mdr genes (mdr1a, mdr1b,
30 and mdr2) in independently selected multidrug-resistant J774.2 mouse cell lines.
Overexpression of mdr1a and mdr1b was found to correlate, in general, with the
differential overproduction of either a 120- or 125-kDa P-glycoprotein precursor,
respectively. This same correlation was observed in a single cell line during the course of

stepwise selection for resistance to vinblastine in which a switch in gene expression from *mdr1b* to *mdr1a* resulted in a switch from the 125- to 120-kDa P-glycoprotein precursor. These findings suggest that differential overexpression of distinct *mdr* genes which encode unique P-glycoprotein isoforms is a possible mechanism for generating diversity in the
5 multidrug-resistant phenotype.

Another sequence (Lab Designation 34X24_126-rE (SEQ ID NO: 148)) comprises sequence encoding MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 7-INTERACTING PROTEIN 1 (MAP3K7IP1). This protein is also known as TAK1-BINDING PROTEIN 1 or TAB1. This sequence maps to Gene map locus Chr.22.

10 Shibuya et al. (1996) used the yeast 2-hybrid system to identify brain cDNAs encoding proteins that interacted with TAK1 (602614). They recovered a gene encoding a predicted 504-amino acid protein that they named TAB1 (TAK1-binding protein-1). On Northern blots, TAB1 was expressed as a 3.5-kb mRNA in all tissues tested.

Shibuya et al. (1996) found that in both yeast and mammalian cells, TAB1
15 activated the kinase activity of TAK1 by direct interaction. They showed that the C-terminal 68 amino acids of TAB1 are sufficient for binding and activation of TAK1 in mammalian cells, while the N-terminal 418 amino acids act as a dominant-negative inhibitor of transforming growth factor-beta (TGFB; 190180)-induced gene expression. Since TAK1 functions as a MAPKKK in the TGFB signaling pathway, Shibuya et al.
20 (1996) suggested that TAB1 may be an important signaling intermediate between TGFB receptors and TAK1.

Using a yeast 2-hybrid screen of gastrointestinal tract tissue with p38-alpha (MAPK14; 600289) as the bait, Ge et al. (2002) isolated multiple clones encoding TAB1. Immunoprecipitation and GST pull-down analyses indicated that TAB1 interacts with p38-
25 alpha, but not with other MAPKs, with or without treatment with TNF (191160). Immunoblot analysis showed that coexpression of TAB1 and p38-alpha enhanced autophosphorylation of p38-alpha even in the presence of dominant-negative forms of MAP2Ks (e.g., MAP2K3; 602315) and TAK1. The amino acids between positions 373 and 418 of TAB1 were found to be required for phosphorylation of p38-alpha. Expression
30 of TLR2 (603028) caused p38-alpha phosphorylation in the presence or absence of inhibitors, whereas p38-alpha phosphorylation after stimulation of TLR4 (603030) could be inhibited by mutant TAB1, suggesting that activation of p38-alpha can be TAB1 dependent or independent. Immunoblot analysis detected the formation of TRAF6

(602355)-TAB1-p38-alpha complexes. Formation of these complexes could be enhanced by stimulation with lipopolysaccharide. Ge et al. (2002) concluded that activation of p38-alpha by a nonenzymatic adaptor protein such as TAB1 may be an important alternative activation pathway operating in parallel with kinase cascades in regulating intracellular signaling.

The International Radiation Hybrid Mapping Consortium mapped the TAB1 gene to chromosome 22 (WI-18691).

Another sequence (Lab Designation 36_5_2_6-rE (SEQ ID NO: 150)) comprises sequence encoding BROMODOMAIN-CONTAINING PROTEIN 2 (BRD2). This protein is also known as FEMALE STERILE HOMEOTIC-RELATED GENE 1, MOUSE HOMOLOG OF FSRG1 (RING3). This sequence maps to gene map locus 6p21.3.

In a search for novel genes in the human major histocompatibility complex (MHC) class II region on chromosome 6p21.3, Okamoto et al. (1991) and Beck et al. (1992) identified a gene that they termed RING3 ('RING' is an acronym for 'really interesting new gene.'). Based on mapping and genomic sequencing, RING3 was located in the middle of the class II region between the genes HLA-DNA (142930) and HLA-DMA (142855). In contrast to all the other genes encoded in the class II region, RING3 appeared to have no obvious function associated with the immune system based on sequence comparisons. The striking sequence similarity to the female sterile homeotic (fsh) gene in *Drosophila*, however, suggested a conserved biologic function for RING3. Denis and Green (1996) discovered that the RING3 product is, in fact, a mitogen-activated nuclear kinase involved in signal transduction and that it is upregulated in certain types of leukemia. With the aim of learning more about the phylogeny of RING3, Thorpe et al. (1996) identified further homologs in different species and determined their gene structures. The functional analysis of RING3 had been further complicated by the finding of a second, non-MHC-linked copy of RING3 in humans by Nomura et al. (1994). This was referred to by them as ORFX (601541). Using a PCR probe derived from the ORFX cDNA sequence, Thorpe et al. (1996) mapped ORFX to 9q34 by fluorescence in situ hybridization analysis. Several other MHC-related genes had been reported to map to the same region of 9q.

Another sequence (Lab Designation 3_2_13-rE (SEQ ID NO:192)) comprises sequence encoding S100 CALCIUM-BINDING PROTEIN A6 (S100A6). This protein is also known as calcyclin. This sequence maps to gene map locus 1q21.

Calcyclin was originally defined as a cDNA clone (2A9) whose cognate RNA was

found to be growth-regulated and whose sequence showed strong similarities to that of the S-100 protein, a calcium-binding protein, as well as to a subunit of the major cellular substrate for tyrosine kinase. Using a full-length cDNA, Ferrari et al. (1987) isolated the entire calcyclin gene plus extensive flanking sequences. They found that the calcyclin gene
5 is present in single copy and has 3 exons. By in situ hybridization, they determined that the CACY gene is located in the 1q21-q25 segment. By linkage studies of interspecific backcrosses of *Mus spretus* and *Mus musculus domesticus*, Seldin (1989) demonstrated that the Cacy gene is located on mouse chromosome 3. Using cDNA probes for CACY, van Heyningen et al. (1989) and Dorin et al. (1990) showed that the gene cosegregates
10 with CAGA (S100A8; 123885) and CAGB (S100A9; 123886), which are located on 1q12-q21.

In the course of constructing a physical map of human 1q21-q23, Oakey et al. (1992) determined that the CACY gene is located at the centromeric end of that segment, proximal to SPTA1 (182860).

15 Schafer et al. (1995) isolated a YAC from 1q21 on which 9 different genes coding for S100 calcium-binding proteins could be localized. The clustered organization of S100 genes allowed introduction of a new logical nomenclature based on their physical arrangement on the chromosome with S100A1 (176940) being closest to the telomere and S100A9 being closest to the centromere. In the new nomenclature, CACY became
20 S100A6.

RhoGEFs play an important role in various signaling cascades and are implicated in human conditions like cancer and mental retardation (Thiesen et al. "Isolation of two novel human RhoGEFs, ARHGEF3 and ARHGEF4, in 3p13-21 and 2q22" *Biochem Biophys Res Commun*, 273(1):364-9, June 24, 2000). A database search combined with
25 screening of a human neuronal teratocarcinoma library identified two novel RhoGEFs, ARHGEF3 and ARHGEF4 (HGMW-approved symbols). The widely expressed ARHGEF3 transcript of 3561 nucleotides encodes a polypeptide of 526 amino acids with homology to NET1. The ARHGEF4 gene generates two transcripts of 3665 and 4000 nucleotides that translate into 720 amino acid residues. Expression of ARHGEF4 is
30 restricted to brain and the encoded protein shows homology to collybistin. FISH analysis of genomic clones mapped ARHGEF3 to 3p13-21 and ARHGEF4 to 2q22. Copyright 2000 Academic Press.

Another sequence (Lab Designation 49_RA2_A-rE (SEQ ID NO: 311)) comprises

sequence encoding HETEROGENEOUS NUCLEAR RIBOPROTEIN L; HNRPL

Heterogeneous nuclear ribonucleoprotein (hnRNP) complexes are the structures that contain hnRNAs and their associated proteins. The hnRNPs are directly involved in mRNA synthesis and maturation. Their protein content consists of 2 principal categories: a family of 3 related major species with common structural features, the so-called A1-A2, B1-B2, C1-C2 core proteins, and a more heterogeneous population of polypeptides designated D to U. There are over 20 different major polypeptides in the molecular mass range of 34,000 to 120,000 Da that are associated with the hnRNA in HeLa cells. Among these is a set of 2 distinct, approximately 68-kD proteins, designated L (HNRPL) and M. By UV crosslinking proteins to RNA and by sedimentation analysis before and after RNase digestion, Pinol-Roma et al. (1989) demonstrated with a monoclonal antibody against HNRPL that HNRPL is stably associated with hnRNP complexes. They also showed that HNRPL is present in the nucleoplasm, in 1 to 3 unidentified discrete nonnucleolar structures, and outside hnRNP complexes. The authors detected HNRPL in various vertebrates and found that HNRPL is associated with most nascent transcripts on the lampbrush chromosomes of the newt *N. viridescens*. Pinol-Roma et al. (1989) screened a HeLa cell cDNA expression library with serum containing antibodies against hnRNPs and isolated a cDNA encoding HNRPL. Northern blot analysis detected an approximately 2.3-kb HNRPL transcript in HeLa cells. The predicted 558-amino acid protein is glycine- and proline-rich and has a calculated molecular weight of 60,187 Da. HNRPL contains 2 segments of approximately 80 amino acids each that are weakly related to each other and to the ribonucleoprotein consensus sequence-type RNA-binding domains of other hnRNP and snRNP proteins.

Another sequence (Lab Designation 6B37H_T7 (SEQ ID NO:65)) comprises sequence encoding ANNEXIN A1 (ANXA1). This protein is also known as ANNEXIN I (ANX1), LIPOCORTIN I (LPC1) and CALPACTIN II. This sequence maps to Gene map locus 9q11-q22.

The antiinflammatory action of glucocorticoids has been attributed to the induction of a group of proteins, collectively called lipocortin, that inhibit phospholipase A2. These proteins are thought to control the biosynthesis of potent mediators of inflammation, prostaglandins and leukotrienes, by inhibiting release of their common precursor, arachidonic acid, a process that requires hydrolysis of phospholipids by phospholipase A2. Lipocortin-like proteins have been isolated from monocytes, neutrophils, renal medullary

cells, and other cell types. The predominant active form has an apparent relative molecular mass of 40,000. Partially purified lipocortin mimics the effect of steroids and mediates antiinflammatory activity in various in vivo model systems. Using amino acid sequence information from purified rat lipocortin, Wallner et al. (1986) cloned cDNA for human lipocortin and expressed the gene in *E. coli*. They confirmed that LPC is a potent inhibitor of phospholipase A2. Lipocortin I belongs to the family of annexins, which are structurally related proteins that have a molecular mass of approximately 35,000 to 40,000. They undergo Ca^{2+} -dependent binding to phospholipids that are preferentially located on the cytosolic face of the plasma membrane. The individual proteins in this family have been discovered by investigators with various goals in mind and have been given a variety of names (Kaplan et al., 1988).

Crompton et al. (1988) reviewed the lipocortin/calpactin family of proteins. Pepinsky et al. (1988) described the characteristics of 3 proteins they called lipocortin III, lipocortin V, and lipocortin VI. Lipocortins III and IV are apparently identical. Shohat et al. (1989) advanced the hypothesis that familial Mediterranean fever (FMF; 249100) patients are homozygous for a mutant allele for one of the lipocortin genes.

Walther et al. (2000) showed that ANXA1 acts through the formyl peptide receptor (FPR; 136537) on human neutrophils. Peptides derived from the unique N-terminal domain of ANXA1 serve as FPR ligands and trigger different signaling pathways in a dose-dependent manner. Lower peptide concentrations possibly found in inflammatory situations elicit Ca^{2+} transients without fully activating the mitogen-activated protein kinase pathway. This causes a specific inhibition of the transendothelial migration of neutrophils and a desensitization of neutrophils toward a chemoattractant challenge. These findings identified ANXA1 peptides as novel, endogenous FPR ligands and established a mechanistic basis of ANXA1-mediated antiinflammatory effects.

Huebner et al. (1987, 1988) mapped the ANXA1 gene to 9q11-q22 by chromosomal in situ hybridization and segregation analysis in somatic cell hybrids using a cDNA clone.

Horlick et al. (1991) isolated overlapping mouse genomic clones for Lipo1. The gene in the mouse spans about 17 kb and is divided into 13 exons encoding a protein of 346 amino acid residues. By analysis of recombinant inbred strains, they showed that Lipo1 is located on chromosome 19. Horlick et al. (1991) pointed out a similarity in gene structure between mouse Lipo1 and Lipo2, suggesting that they have a recent evolutionary

ancestor.

Another sequence (Lab Designation 6B60_Lac (SEQ ID NO:237)) comprises sequence encoding TROPOMYOSIN 1 (TPM1). This protein is also known as TROPOMYOSIN, SKELETAL MUSCLE ALPHA (TMSA). This sequence maps to gene
5 map locus 15q22.1.

Tropomyosins are ubiquitous proteins of 35 to 45 kD associated with the actin filaments of myofibrils and stress fibers. In vertebrates, 4 known tropomyosin genes code for diverse isoforms that are expressed in a tissue-specific manner and regulated by an alternative splicing mechanism (Lees-Miller and Helfman, 1991). The vertebrate alpha-
10 tropomyosin gene consists of 15 exons; 5 exons are found in all transcripts, while 10 exons are alternatively used in different alpha-tropomyosin RNAs (Lees-Miller and Helfman, 1991). The striated muscle isoform is expressed in both cardiac and skeletal muscle tissues.

MacLeod and Gooding (1988) isolated a cDNA clone from a human skeletal
15 muscle library which contains the complete protein-coding sequence of a skeletal muscle alpha-tropomyosin. In cultured human fibroblasts, the TMSA gene was found to encode both skeletal muscle and smooth muscle type of alpha-tropomyosins by using an alternative mRNA-splicing mechanism.

Eyre et al. (1995) developed a sequence tagged site (STS) for the TPM1 gene and
20 used it to isolate a genomic clone containing part of the gene. Using this clone, they localized TPM1 to 15q22 by fluorescence in situ hybridization. By PCR of radiation hybrids, Tiso et al. (1997) mapped the TPM1 gene more precisely to 15q22.1. Schleef et al. (1993) mapped the mouse homolog, Tpm-1, to the d-se region of chromosome 9, using interspecies backcrosses.

25 Brown et al. (2001) described the crystal structure of the tropomyosin molecule. Their results revealed the effects of clusters of core alanines on the axial register, symmetry, and conformational variability of 2-stranded coiled coils that appear to be important for tropomyosin's role in the regulation of muscle contraction.

To assess linkage between the human TPM1 gene and type 3 familial hypertrophic
30 cardiomyopathy (CMH3; 115196), which had previously been mapped to 15q2, Thierfelder et al. (1994) identified a short tandem repeat polymorphism (STR). A combined maximum 2-point lod score of 6.94 at $\theta = 0.0$ was obtained for linkage of the TPM1 marker to CMH3 in 2 families. A point mutation was identified in each of the 2

families used in the linkage study: asp175-to-asn (191010.0002) in one, and glu180-to-gly (191010.0001) in the other. Watkins et al. (1995) concluded that mutations in the TPM1 gene are a rare cause of CMH, accounting for approximately 3% of cases. These mutations, like those in the cardiac troponin T gene (TNNT2; 191045), are characterized
 5 by relatively mild and sometimes subclinical hypertrophy but a high incidence of sudden death. Genetic testing may therefore be especially important in this group.

Blanchard et al. (1997) used gene targeting in embryonic stem cells and blastocyst-mediated transgenesis to create functional mouse alpha-tropomyosin knockouts. Homozygous mice died in utero between embryonic days 9.5 and 13.5 and lacked alpha-tropomyosin mRNA. Heterozygotes had an approximately 50% reduction in alpha-tropomyosin mRNA levels but no reduction in alpha-tropomyosin protein. No differences
 10 in myofibrillar ultrastructure or contractile function were found. The authors postulated that mice have a regulatory mechanism that maintains the level of myofibrillar tropomyosin despite a reduction in mRNA. Furthermore, they concluded that, assuming human and mouse cardiac muscle are similar, simple haploinsufficiency for alpha-tropomyosin would not cause the pathologic changes seen in human type 3 hypertrophic cardiomyopathy (115196) and that alterations in protein stoichiometry may produce a
 15 poison polypeptide that disrupts myofibrillar organization on incorporation into the sarcomere.

Muthuchamy et al. (1999) constructed a transgenic mouse model of CMH3 by introducing the missense mutation asp175 to asn (191010.0002) by site-directed mutagenesis. This mutation occurs in a cardiac troponin T-binding region. The transgenic CMH3 mice exhibited significant in vivo and in vitro evidence of myocardial functional impairment. Histologic analysis of transgenic myocardium showed variable myocyte
 20 disarray and hypertrophy, as reported in the human form of the disease.

ALLELIC VARIANTS

.0001 CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 3 [TPM1, GLU180GLY] In members of family MZ afflicted with a form of familial hypertrophic cardiomyopathy linked to 15q (115196), Thierfelder et al. (1994) identified an A-to-G transition at nucleotide 595 in exon 5 of the TPM1 gene in heterozygous state. The substitution changed codon 180 from GAG to GGG and predicted that a negatively
 30

charged glutamic acid residue is replaced by a neutral glycine residue.

.0002 CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 3 [TPM1, ASP175ASN] In members of family MI afflicted with a form of familial hypertrophic cardiomyopathy linked to 15q (115196), Thierfelder et al. (1994) found heterozygosity for
 5 a G-to-A transition at nucleotide 579 that altered codon 175 from GAC to AAC. The substitution predicted that the mutated allele present in affected individuals would encode a neutral asparagine residue instead of the negatively charged aspartic acid residue found in unaffected individuals.

Watkins et al. (1995) investigated whether the D175N mutation was really
 10 responsible for hypertrophic cardiomyopathy or was only a polymorphism, because some features of the 2 identified mutations in the alpha-tropomyosin gene contrasted with those of mutations in other disease genes for CMH. Unlike the beta-cardiac myosin heavy chain gene (MYH7; 160760) and the cardiac troponin-T gene, the alpha-tropomyosin gene is expressed ubiquitously, yet the disease phenotype is limited to cardiac muscle. Watkins et
 15 al. (1995) found that the asp175-to-asn missense mutation was present in the proband and 2 affected offspring, but in none of the proband's 3 sibs. Although both parents were deceased, the haplotypes of the 4 parental chromosomes could be reconstructed. (The haplotypes made use of an intragenic polymorphism in 10 flanking polymorphisms spanning a region of 35 cM.) One parental chromosome was transmitted to 2 offspring: 1
 20 bearing the asp175-to-asn mutation (the affected proband) and 1 clinically unaffected sib who lacked the TPM1 mutation. Thus the asp175-to-asn mutation must have arisen de novo.

.0003 CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 3 [TPM1, VAL95ALA] Karibe et al. (2001) described a large Spanish-American family with
 25 multiple members affected with hypertrophic cardiomyopathy (115196). They found a novel val95-to-ala (V95A) mutation in TPM1 to segregate with the disease phenotype. This mutation was associated with the same mild degree of left ventricular hypertrophy as seen in some CMH1 families harboring specific mutations in MYH7 (160760.0010, 160760.0012, 160760.0001). Penetrance was estimated at 53% on the basis of an abnormal
 30 echocardiogram; however, 2 mutation carriers with normal echocardiograms and normal ECGs were only in their mid-30s at the time of the study. Penetrance could not be accurately assessed by ECG, since 6 older mutation-negative family members had minor T-wave changes. Cumulative survival rates in this family were 73% +/- 10% at 40 years

and 32% +/- 13% at 60 years. Expression of mutant and control tropomyosin in a bacterial system allowed a functional assessment of this mutation. An increase in calcium binding and abnormal myosin cycling were observed; both were felt to be important contributors to disease pathogenesis.

5 Another sequence (Lab Designation 6b3_rE (SEQ ID NO: 1) comprises sequence encoding ATPase, H⁺ TRANSPORTING, LYSOSOMAL (ATP6L)
This protein is also known as ATPase, H⁺ TRANSPORTING, LYSOSOMAL, 16-KD
This sequence maps to gene map locus 16p13.3.

10 In an attempt to isolate candidate genes for autosomal dominant polycystic kidney disease (173900), Gillespie et al. (1991) identified a number of CpG-rich islands from 16p13.3, the region defined genetically as containing the site of PKD1 (601313) mutations. Genomic fragments adjacent to one of these islands were used to isolate cDNAs from both HeLa cells and cultured cystic epithelium that encode a 155-amino acid peptide having 4 putative transmembrane domains. The corresponding transcript was found in all
15 tissues tested but was most abundant in brain and kidney. The deduced amino acid sequence had 93% similarity to the 16-kD proteolipid component that is believed to be part of the proton channel of the vacuolar H⁽⁺⁾-ATPase. A mutated proton channel might be implicated in the pathogenesis of cystic disease. However, sequencing of cDNAs corresponding to both alleles of an affected person revealed no differences in the deduced
20 amino acid sequence. Moreover, transcript size and abundance were not altered in cystic kidney.

Note: ABCR is a rearranged gene that is not expressed in our cell line- in the mouse, this gene sits next to Char4: P. chabaudi malaria resistance QTL 4- as well as several genes of unknown function. Murine chromosome 3 60.81-61.19 cM is the closest
25 rodent markers. Human genes that reside next door are PARG1; LOC163462; and loc163463.

Another sequence (Lab Designation 6BE72_rE (SEQ ID NO: 2)) comprises sequence encoding CCCTC-BINDING FACTOR (CTCF). This protein is also known as TRANSCRIPTIONAL REPRESSOR CTCF.

30 Filippova et al. (1996) isolated and analyzed human CTCF (CCCTC-binding factor) cDNA clones. They showed that the human CTCF protein contains 11 zinc finger domains and is exceptionally highly conserved, sharing 93% identity with the avian CTCF amino acid sequence. It binds specifically to regulatory sequences in the promoter-

proximal regions of chicken, mouse, and human MYC (190080) oncogenes. CTCF contains 2 transcription repressor domains transferable to a heterologous DNA-binding domain. One CTCF-binding site, conserved in mouse and human MYC genes, is found immediately downstream of the major P2 promoter. Gel shift assays of nuclear extracts from mouse and human cells showed that CTCF is the predominant factor binding to this sequence. Mutational analysis of the P2-proximal CTCF-binding site and transient cotransfection experiments demonstrated that CTCF is a transcriptional repressor of the human MYC gene. Although there is 100% sequence identity in the DNA-binding domains of the avian and human CTCF proteins, the regulatory sequences recognized by CTCF in chicken and human MYC promoters are clearly diverged. Mutating the contact nucleotides confirmed that CTCF binding to the P2 promoter of the human MYC gene requires a number of unique contact DNA bases that are absent in the CTCF-binding site of the chicken MYC gene. Moreover, proteolytic protection assays indicated that several more CTCF zinc fingers are involved in contacting the human CTCF-binding site than the chicken site. Gel shift assays utilizing successively deleted zinc finger domains indicated that CTCF zinc fingers 2 to 7 are involved in binding to the chicken MYC promoter, while fingers 3 to 11 mediate CTCF binding to the human promoter. This flexibility in zinc finger usage reveals CTCF to be a 'multivalent' transcription factor. Northern blot analysis revealed that the human CTCF gene is ubiquitously expressed as an approximately 4-kb transcript.

Bell et al. (1999) identified a 42-bp DNA fragment of the chicken beta-globin insulator that is both necessary and sufficient for enhancer-blocking activity in human cells. They showed that this sequence, FII, is the binding site for CTCF, and these CTCF-binding sites were present in all of the vertebrate enhancer-blocking elements examined. Bell et al. (1999) suggested that directional enhancer blocking by CTCF is a conserved component of gene regulation in vertebrates.

Bell and Felsenfeld (2000) and Hark et al. (2000) independently showed that CTCF binds to several sites within the unmethylated imprinted-control region (ICR) between H19 (103280) and IGF2 (147470) that are essential for enhancer blocking. Hark et al. (2000) demonstrated that CTCF binding is abolished by DNA methylation of the ICR. Methylation of the CpGs within the CTCF binding sites eliminates binding of CTCF in vitro, and deletion of these sites results in loss of enhancer-blocking activity in vivo, thereby allowing gene expression. This CTCF-dependent enhancer-blocking element acts

as an insulator. Bell and Felsenfeld (2000) suggested that it controls imprinting of IGF2 and that activity of this insulator is restricted to the maternal allele by specific DNA methylation of the paternal allele. Bell and Felsenfeld (2000) concluded that DNA methylation can control gene expression by modulating enhancer access to the gene promoter through regulation of an enhancer boundary.

An expansion of a CTG repeat at the DM1 locus causes myotonic dystrophy by altering the expression of 2 adjacent genes, DMPK (605377) and SIX5 (600963) and through a toxic effect of the repeat-containing RNA. Filippova et al. (2001) identified 2 CTCF binding sites that flank the CTG repeat and form an insulator element between DMPK and SIX5. Methylation of these sites prevents binding of CTCF, indicating that the DM1 locus methylation in congenital myotonic dystrophy would disrupt insulator function. Furthermore, CTCF binding sites are associated with CTG/CAG repeats at several other loci. Filippova et al. (2001) suggested a general role for CTG/CAG repeats as components of insulator elements at multiple sites in the human genome.

Chao et al. (2002) identified the insulator and transcription factor CTCF as a candidate trans-acting factor for X chromosome selection in mouse. The choice/imprinting center contains tandem CTCF binding sites that function in an enhancer-blocking assay. In vitro binding is reduced by CpG methylation and abolished by including non-CpG methylation. Chao et al. (2002) postulated that Tsix (300181) and CTCF together establish a regulatable epigenetic switch for X inactivation. Murine Tsix contains greater than 40 CTCF motifs and the human sequence has greater than 10. Dot-plot analysis indicated a contiguous head-to-tail arrangement of highly homologous DXPas34 repeats.

Another sequence (Lab Designation 7A10_1-rE (SEQ ID NO: 41)) comprises sequence encoding DELETED IN AZOOSPERMIA-LIKE (DAZL). This protein is also known as DAZLA or DELETED IN AZOOSPERMIA HOMOLOG or DAZH or SPGYLA. This sequence maps to gene map locus 3p24. This gene was disrupted off the negative strand utilizing the methods of the present invention.

It is widely believed that most or all Y-chromosomal genes were once shared with the X chromosome. The DAZ gene (400003), so named for 'deleted in azoospermia,' is a candidate for AZF, the human Y-chromosomal azoospermia factor (415000). Saxena et al. (1996) reported multiple copies of DAZ (more than 99% identical in DNA sequence) clustered in the AZF region and a functional DAZ homolog (symbolized DAZH by them) on human chromosome 3. The entire gene family appeared to be expressed in germ cells.

Sequence analysis indicated that the Y-chromosomal DAZ cluster arose during primate evolution by (1) transposition of the autosomal gene to the Y; (2) amplification and pruning of exons within the transposed gene; and (3) amplification of the modified gene. Saxena et al. (1996) stated that these results challenged prevailing views of sex chromosome evolution, suggesting that acquisition of autosomal fertility genes was an important process in Y chromosome evolution. By fluorescence in situ hybridization (FISH) and positioning on the radiation hybrid map of the human genome, Saxena et al. (1996) mapped the DAZH gene to 3p24. Saxena et al. (1996) suggested that DAZH is the founding member of the DAZ gene family.

Shan et al. (1996) cloned a human autosomal gene homologous to the DAZ gene by screening different testis libraries with the cDNA probe SPGY1. The gene, designated SPGYLA by them, was mapped to chromosome 3 by FISH. Shan et al. (1996) reported that comparison of the SPGYLA cDNA sequence with the cDNA sequences of DAZ and SPGY1 revealed 2 prominent differences. The tandem repetitive structure of 72-bp sequence units (DAZ repeats) is absent in SPGYLA, as SPGYLA contains only 1 72-bp sequence subunit. Downstream of this subunit a specific 130-bp sequence domain is present which is also present in the mouse Dazla gene (encoded on mouse chromosome 17) and in the Drosophila gene 'boule' but absent from DAZ. Shan et al. (1996) demonstrated that SPGYLA encodes an RNA-binding protein that is expressed only in the male gonad.

Yen et al. (1996) reported the isolation of a human gene homolog of the mouse Dazla gene by screening of a testis-specific library with a DAZ cDNA clone. The gene they isolated contained only 1 of 7 repeats found in DAZ, showed a high degree of homology to the mouse Dazla gene, and mapped to chromosome 3p24.

RBM and DAZ/SPGY are 2 families of genes located on the Y chromosome that encode proteins containing RNA-binding motifs, and both have been described as candidate human spermatogenesis genes. Neither gene family had been shown to be essential for spermatogenesis in human males, but a Dazla homolog in Drosophila is essential for spermatogenesis (Eberhart et al., 1996). With a polyclonal antibody raised in rabbits against Dazla and with knockout technology in mice, Rugglu et al. (1997) demonstrated that the Dazla protein is cytoplasmic in male and female germ cells, unlike the nuclear RBM protein. Disruption of the Dazla gene led to loss of germ cells and complete absence of gamete production, demonstrating that Dazla is essential for the

differentiation of germ cells.

By a comparison of autosomal DAZLA and Y-linked DAZ intron sequences, Agulnik et al. (1998) derived a new figure for the ratio of male-to-male mutation rates; they found that $\alpha(m) = 4$.

5 The single-copy gene DAZL1 on chromosome 3 encodes a testis-specific protein with RNA-binding potential. Y-chromosomal DAZ homologs are confined to humans and higher primates. To investigate the function unique to higher primate spermatogenesis that DAZ may serve and to assess the functional status of the gene by determining the extent of functional conservation, Slee et al. (1999) tested the capacity of the human DAZ gene
10 contained in a 225-kb YAC to complement the sterile phenotype of the Dazl null mouse, which is characterized by severe germ cell depletion and meiotic failure. Although Dazl -/- mice remained infertile when the DAZ transgene was introduced, histologic examination revealed a partial and variable rescue of the mutant phenotype, manifest as a pronounced increase in the germ cell population of the seminiferous tubules and survival to the
15 pachytene stage of meiosis. As well as constituting definitive proof of the spermatogenic role of the DAZ gene product, these findings confirmed the high degree of functional conservation between the DAZ and DAZL1 genes, suggesting they may constitute a single target for contraceptive intervention and raising the possibility of therapeutic upregulation of the DAZL1 gene in infertile men.

20 Another sequence (Lab Designation 7A10_1-rE (SEQ ID NO: 41)) comprises sequence encoding ANNEXIN A2 (ANXA2). This protein is also known ANNEXIN II (ANX2), LIPOCORTIN II; LPC2; LIP2, ANNEXIN II PSEUDOGENE 1, INCLUDED, ANX2P1, INCLUDED ANX2P2, INCLUDED ANX2P3, INCLUDED. This sequence maps to gene map locus 15q21-q22.

25 Annexin II, a major cellular substrate of the tyrosine kinase encoded by the SRC oncogene (190090), belongs to the annexin family of Ca(2+)-dependent phospholipid- and membrane-binding proteins. By screening a cDNA expression library generated from highly purified human osteoclast-like multinuclear cells (MNC) formed in long-term bone marrow cultures, Takahashi et al. (1994) identified a candidate clone that stimulated MNC
30 formation. Sequence analysis showed that this cDNA encoded annexin II. Further studies yielded results suggesting that ANX2 is an autocrine factor that enhances osteoclast formation and bone resorption, a previously unknown function for this molecule.

Spano et al. (1990) isolated and characterized human genomic clones of the gene

encoding lipocortin II (LIP2) and of 3 pseudogenes. The LIP2 gene is at least 40 kb long and consists of 13 exons. The 3 pseudogenes show typical features of retroposons. Spano et al. (1990) reported experiments which, together with the data published by Huebner et al. (1988), led them to conclude that the LIP2 gene is located on chromosome 15. The 3 pseudogenes were assigned to chromosomes 4, 9 and 10. The coexistence on chromosome 9 of the LIP1 gene (151690) and a LIP pseudogene was considered fortuitous. Richard et al. (1994) presented an integration of the physical, expression, and genetic maps of human chromosome 15. They placed the ANXA2 gene in their region IV, i.e., 15q21-q22, thus confirming the previous localization.

10 *PSEUDOGENES* By use of cDNAs in somatic cell hybrid analysis and in situ hybridization, Huebner et al. (1987, 1988) mapped the LPC2A (LIP2P1) locus to 4q21-q31. Spano et al. (1990) presented evidence that the lipocortin II-like gene that maps to chromosome 4 is a pseudogene (ANX2P1) with typical features of a retroposon.

15 By means of a lipocortin cDNA in somatic cell hybrid analysis and in situ chromosome hybridization, Huebner et al. (1987, 1988) mapped LPC2B to chromosome 9. Thus, LPC1 and LPC2B are syntenic. LPC2B is located proximal to ABL (189980). Calpactin I is a synonym for lipocortin II. Spano et al. (1990) presented evidence that the lipocortin II-like gene that maps to chromosome 9 is a pseudogene (ANX2P2) with features typical of a retroposon. The Genome Database (GDB) gave the regional location
20 as 9p13.

Huebner et al. (1987, 1988) mapped the lipocortin IIC (LPC2C) gene to 10q21-q22. According to Spano et al. (1990), the lipocortin II-like gene that maps to chromosome 10 is a pseudogene (ANX2P3) with the structure of a retroposon which is related to the functional lipocortin II gene located on chromosome 15.

25 Another sequence (Lab Designation 10_46_4-Lac (SEQ ID NO: 214)) comprises sequence encoding DNAJ, E. COLI, HOMOLOG OF, SUBFAMILY A, MEMBER 1; DNAJA1. This protein is also known as HEAT-SHOCK PROTEIN, DNAJ-LIKE 2; HSJ2 HEAT-SHOCK 40-KD PROTEIN 4; HSPF4, HDJ2 and HSDJ. Dnaja1 overlaps two other genes: LOC158188 and LOC158187. The gene dnaj1 is also disrupted in present
30 invention. Dnaja1 is off the negative strand.

The E. coli heat-shock protein DNAJ has been implicated in protein folding, proteolysis, phosphorylation, and replication of phage. By screening a human umbilical

vein endothelial cell cDNA expression library with a monoclonal antibody that reacts specifically with human endothelial cells and monocytes, Chellaiah et al. (1993) isolated cDNAs encoding HSJ2, which they named HDJ2. The predicted 397-amino acid HSJ2 protein is 32% identical to DNAJ, with the highest identity in the N-terminal region.

- 5 Among the known DNAJ homologs in *S. cerevisiae*, HSJ2 is most identical to YDJ1, which may be involved in the transport of certain proteins into the mitochondria and endoplasmic reticulum.

Another sequence (Lab Designation 12_3B#2_Lac (SEQ ID NO: 218)) comprises JWA which, on the negative strand is next to:UBE1C: ubiquitin-activating enzyme E1C
 10 (UBA3 homolog, yeast). Subunit of E1 (ubiquitin-activating enzyme)-like complex; activates NEDD8 and targets Hs-cullin-4A (Cul4A) for degradation ecursor protein-binding protein-1) can bind to NEDD8 in rabbit reticulocyte lysates. However, since APP-BP1 shows similarity to only the N-terminal domain of an E1 enzyme, the authors reasoned that it must interact with a protein showing similarity to the C-terminal region of
 15 E1s. By searching sequence databases, Osaka et al. (1998) identified cDNAs encoding UBA3, the human homolog of yeast Uba3. The predicted 442-amino acid UBA3 protein shares 43% sequence identity with yeast Uba3. In vitro, UBA3 formed a complex with APP-BP1 and a thioester linkage with NEDD8. Osaka et al. (1998) suggested that the APP-BP1/UBA3 complex functions as an E1-like enzyme for the activation of NEDD8.

20 Another sequence (Lab Designation 12_3B#8-rE (SEQ ID NO: 107)) comprises sequence encoding APRATAXIN (APTX). This protein is also known as FLJ20157 This sequence maps to gene map locus 9p13.3.

The APTX gene encodes a member of the histidine triad (HIT) superfamily, to which have been attributed nucleotide-binding and diadenosine polyphosphate hydrolase
 25 activities. The APTX gene is mutant in ataxia-ocular apraxia (208920).

Early-onset ataxia with oculomotor apraxia, the ataxia-oculomotor apraxia syndrome (208920), maps to 9p13. Date et al. (2001) identified a group of Japanese patients whose clinical presentation was characterized by autosomal recessive inheritance, early age of onset, Friedreich ataxia (FRDA; 229300)-like clinical presentations, and
 30 hypoalbuminemia. Linkage to the FRDA locus was excluded. They confirmed that the disorder in these patients linked to the same locus, 9p13, as the ataxia-oculomotor apraxia syndrome. They narrowed the candidate region and identified a novel gene encoding a member of the histidine triad superfamily as the causative gene. They called its product

aprataxin, with the gene symbol APTX. Although many HIT proteins had been identified (e.g., FHIT, 601153; HINT, 601314), aprataxin was the first to be linked to a distinct phenotype.

By homozygosity mapping and study of Portuguese and Japanese founder
 5 haplotypes, Moreira et al. (2001) localized the gene mutant in ataxia-oculomotor apraxia syndrome to a 2-cM interval on 9p13.3. They reduced the critical interval to a 300-kb region and identified mutations in the APRX gene, which had been identified as FLJ20157 (GenBank AK000164).

10 *Expression of Alternative Transcripts*

Moreira et al. (2001) identified 2 major mRNA species of APTX resulting from alternative splicing of exon 3: a short form of 168 amino acids and the first ATG codon in exon 3, and a long form with an additional 115 nucleotides of the 5-prime portion of exon 3, resulting in the addition of another 174 amino acids and the first codon ATG codon in
 15 exon 1. Moreira et al. (2001) and Date et al. (2001) numbered mutations according to both the long and short forms of the transcript.

Moreira et al. (2001) demonstrated by RT-PCR that the APTX gene is ubiquitously expressed. The long transcript is the major form found in human cell lines, with the shorter frame-shifted form present in lower amounts; liver tissue has equal amounts of the 2
 20 transcripts. By Northern blot analysis, Date et al. (2001) demonstrated ubiquitous expression of the 2.2-kb long form and limited expression of the 1.35-kb short form.

Date et al. (2001) showed by homology search that both forms of aprataxin have a highly conserved HIT motif (His-X-His-X-His-X-X, where X is a hydrophobic amino acid), an essential motif for HIT proteins. HIT proteins have been classified into 2
 25 branches: the fragile HIT protein family found only in animals and fungi, and the ancient HIT nucleotide-binding protein (HINT) family that has representatives in all cellular life. Phylogenetic tree analysis showed that aprataxin is the third member of the HIT protein superfamily. The mutations found in patients with early-onset ataxia with oculomotor apraxia and hypoalbuminemia involved highly conserved amino acids.

30 Date et al. (2001) and Moreira et al. (2001) identified mutations in the APRX gene as the cause of ataxia-oculomotor apraxia. Date et al. (2001) observed that an insertion or deletion mutation resulted in a severe phenotype with childhood onset, whereas missense mutations resulted in a mild phenotype with relatively late age of onset; in their pedigree

2637 with compound heterozygosity for val89-to-gly (606350.0004) and pro32-to-leu (606350.0002), the age of onset was 25 years.

.0001 ATAXIA, EARLY-ONSET, WITH OCULOMOTOR APRAXIA AND HYPOALBUMINEMIA [APTX, 1-BP INS, 167T] Date et al. (2001) found that

5 affected individuals in 3 pedigrees with EAOH (208920) carried a homozygous insertion of a T after nucleotide 167 (167delT; nucleotide number starting at the first ATG codon of the short form), which results in a frameshift with a premature stop. Affected individuals in these 3 families were homozygous; in 3 other pedigrees affected members had this mutation in heterozygous state in combination with a different mutation. Among their
10 patients, Moreira et al. (2001) found that the Japanese founding haplotypes were associated with the same mutation, which they called 689insT according to the gene's long transcript.

.0002 ATAXIA, EARLY-ONSET, WITH OCULOMOTOR APRAXIA AND HYPOALBUMINEMIA [APTX, PRO32LEU] The second most common mutation

15 found by Date et al. (2001) in families with EAOH (208920) was a C-to-T transition resulting in a pro32-to-leu amino acid change. This mutation removes a proline residue that is highly conserved among all the subfamilies of HIT proteins. Moreira et al. (2001) designated this mutation PRO206LEU according to the APTX gene's long transcript.

.0003 ATAXIA, EARLY-ONSET, WITH OCULOMOTOR APRAXIA AND

20 **HYPOALBUMINEMIA [APTX, 1-BP DEL, 318T]** In one pedigree, Date et al. (2001) observed that members with EAOH (208920) were homozygous for a 318delT single-nucleotide deletion resulting in a frameshift with a premature stop. In 3 pedigrees, the 167insT (606350.0001), P32L (606350.0002), and 318delT mutations were present in compound heterozygous state.

25 **.0004 ATAXIA, EARLY-ONSET, WITH OCULOMOTOR APRAXIA AND HYPOALBUMINEMIA [APTX, VAL89GLY]** In a family with EAOH (208920), Date

et al. (2001) observed that affected members had a val89-to-gly (V89G) missense mutation involving one of the highly conserved hydrophobic amino acids of the histidine triad. As the HIT motif forms part of the phosphate binding loop, the V89G mutation probably
30 affects the phosphate-binding activity.

Another sequence (Lab Designation L195B1E_rE (SEQ ID NO: 138) comprises sequence encoding GENERAL TRANSCRIPTION FACTOR IIE, POLYPEPTIDE 1 (GTF2E1).

Initiation of transcription from eukaryotic protein-coding genes is a complex process requiring RNA polymerase II (PolII; see 180660) and a cadre of transcription factors. These factors can be divided into 2 classes on the basis of their function: the general factors that are required for transcription of all PolII genes, and sequence-specific factors that are required for regulating expression. The general transcription factors and PolII form a specific multiprotein complex near the transcription start site by interacting with core promoter elements. The most common core element is the TATA box, typically located 25-30 bp upstream of the transcriptional start site or initiator element. Sequence-specific transcription factors that bind to DNA-sequence elements located proximal and distal to the core promoter elements can dramatically enhance or repress transcription. The general transcription factors that have been identified are TFIIA, TFIIB (189963), TFIID (313650), TFIIIE (see also 189964), TFIIF (189968, 189969), TFIIG/J, and TFIIH (189972). Human TFIIIE consists of 2 subunits of relative molecular masses 56,000 and 34,000. The structure of TFIIIE appears to be a heterotetramer of 2 alpha and 2 beta subunits, both subunits being required for optimal reconstituted basal-level transcription. Peterson et al. (1991) isolated human cDNA clones for both subunits of the general transcription factor IIE. Using purified recombinant proteins they found that both subunits are essential to form a stable preinitiation complex and to reconstitute basal-level and Sp1-activated (189906) transcription in vitro. Ohkuma et al. (1991) also cloned the TF2E1 gene and pointed to sequence similarities to bacterial sigma factors, suggesting a direct involvement in the regulation of transcription initiation.

High levels of gene transcription by RNA polymerase II depend on high rates of transcription initiation and reinitiation. Initiation requires recruitment of the complete transcription machinery to a promoter, a process facilitated by activators and chromatin remodeling factors. Reinitiation is thought to occur through a different pathway. After initiation, a subset of the transcription machinery remains at the promoter, forming a platform for assembly of a second transcription complex. Yudkovsky et al. (2000) described the isolation of a reinitiation intermediate in yeast that includes transcription factors TFIID, TFIIA (see 600520), TFIIH, TFIIIE, and Mediator (see 602984). This intermediate can act as a scaffold for formation of a functional reinitiation complex. Formation of this scaffold is dependent on ATP and TFIIH. In yeast, the scaffold is stabilized in the presence of the activator Gal4-VP16, but not Gal4-AH, suggesting a new role for some activators and Mediator in promoting high levels of transcription.

Another sequence Lab Designation est_L24_5_3BE_rEa (SEQ ID NO: 359)) comprises sequence encoding TUSP. This sequence maps to gene map locus 6q25-q26.

The mutated gene responsible for the tubby obesity phenotype has been identified by positional cloning (Kleyn et al. "Identification and characterization of the mouse obesity gene tubby: a member of a novel gene family" *Cell* 85(2):281-90 April 19, 1996). A single base change within a splice donor site results in the incorrect retention of a single intron in the mature tub mRNA transcript. The consequence of this mutation is the substitution of the carboxy-terminal 44 amino acids with 24 intron-encoded amino acids. The normal transcript appears to be abundantly expressed in the hypothalamus, a region of the brain involved in body weight regulation. Variation in the relative abundance of alternative splice products is observed between inbred mouse strains and appears to correlate with an intron length polymorphism. This allele of tub is a candidate for a previously reported diet-induced obesity quantitative trait locus on mouse chromosome 7.

Another sequence (Lab Designation L191B2E#1 (SEQ ID NO: 85)) comprises sequence encoding REPLICATION PROTEIN A3, 14-KD (RPA3). This protein is also known as RPA14 or REPA3. This sequence maps to gene map locus 7p22.

Umbricht et al. (1993) cloned the 14-kD subunit of human RPA from a HeLa cell cDNA library. The RPA3 gene was found to have a 692-basepair sequence with an open reading frame encoding a protein of 121 amino acids. The deduced amino acid sequence showed only limited similarity to the small subunit of yeast RPA. Using PCR amplification of genomic DNA from rodent-human hybrid cell lines, Umbricht et al. (1993) mapped the human REPA3 gene to chromosome 7. By Southern analysis and PCR amplification of somatic cell hybrids of chromosome 7, as well as by fluorescence in situ hybridization, Umbricht et al. (1994) mapped RPA3 to 7p22. See also RPA1 (179835) and RPA2 (179836).

Another sequence comprises sequence encoding REPLICATION PROTEIN A1, 70-KD (RPA1). This protein is also known as RPA70 or REPA1. This sequence maps to gene map locus 17p13.3.

Replication protein A (RPA) is a 3-subunit single-stranded DNA-binding protein that has been isolated from human cells and found to be essential for in vitro replication of the papovavirus SV40. Erdile et al. (1991) reported the sequence of a cDNA encoding the 70-kD subunit. The human cDNA directed production in *E. coli* of a 70-kD protein that reacted with a monoclonal antibody directed against the 70-kD subunit of the human

protein. The recombinant subunit, purified from bacteria, exhibited single-stranded DNA-binding activity comparable to that of the complete RPA complex. It could substitute for the complete complex in stimulating the activity of DNA polymerase alpha-primase, but could not substitute for the complete complex in SV40 DNA replication in vitro,

5 suggesting an important functional role for the other subunits. Using PCR amplification of genomic DNA from rodent-human cell lines, Umbricht et al. (1993) mapped the gene for the 70-kD subunit to chromosome 17. By the same method, they mapped the genes for the 32-kD (179836) and the 14-kD (179837) subunits to chromosomes 1 and 7, respectively. Using a combination of PCR amplification of somatic cell hybrids and radiation hybrids

10 containing chromosome 17 fragments, Umbricht et al. (1994) mapped RPA1 to 17p13.3.

Gomes and Wold (1996) constructed a series of N-terminal deletions of RPA70 to explore the function of the protein. Their data indicated that RPA70 is composed of 3 functional domains: an N-terminal domain that is not required for single-stranded DNA binding or SV40 replication, a central DNA-binding domain, and a C-terminal domain that

15 is essential for subunit interactions.

A growing body of evidence shows that the folding of mRNA influences a diverse range of biologic events such as mRNA splicing and processing, and translational control and regulation. Because the structure of mRNA is determined by its nucleotide sequence and its environment, Shen et al. (1999) examined whether the folding of mRNA could be

20 influenced by the presence of single-nucleotide polymorphisms (SNPs). They reported marked differences in mRNA secondary structure associated with SNPs in the coding region of 2 human mRNAs: alanyl-tRNA synthetase (601065) and replication protein A, 70-kD subunit. Enzymatic probing of SNP-containing fragments of the mRNAs revealed pronounced allelic differences in cleavage pattern at sites 14 or 18 nucleotides away from

25 the SNP, suggesting that a single-nucleotide variation can give rise to different mRNA folds. By using oligodeoxyribonucleotides complementary to the region of different allelic structures in the RPA70 mRNA, but not extending to the SNP itself, they found that the SNP exerted an allele-specific effect on the accessibility of its flanking site in the endogenous human RPA70 mRNA. The results demonstrated the contribution of common

30 genetic variation through structural diversity of mRNA and suggested a broader role than previously thought for the effects of SNPs on mRNA structure and, ultimately, biologic function.

Nakayama et al. (1999) reported that a -786T-C mutation (163729.0002), in the

promoter region of the endothelial nitric oxide synthase (eNOS) gene reduced transcription of the gene and was strongly associated with coronary spastic angina and myocardial infarction. Miyamoto et al. (2000) determined that RPA1 specifically binds to the mutant allele in nuclear extracts from HeLa cells. In human umbilical vein endothelial cells, inhibition of RPA1 expression using antisense oligonucleotides restored transcription driven by the mutated promoter sequence, whereas overexpression of RPA1 further reduced it. Serum nitrite-nitrate levels among individuals carrying the -786T-C mutation were significantly lower than among those without the mutation. The authors concluded that RPA1 apparently functions as a repressor protein in the -786T-C mutation-related reduction of eNOS gene transcription associated with the development of coronary artery disease.

Another sequence (Lab Designation L192B3E#13_rE (SEQ ID NO: 143) comprises sequence encoding INSULIN-LIKE GROWTH FACTOR 2 RECEPTOR (IGF2R). This protein is also known as INSULIN-LIKE GROWTH FACTOR II, RECEPTOR FOR MANNOSE 6-PHOSPHATE RECEPTOR, CATION-INDEPENDENT, MIPR or CIMPR. This sequence maps to gene map locus 6q26.

Insulin-like growth factor II (147470) is a polypeptide hormone with structural homologies to insulin and IGF I. Although IGF II can stimulate a broad range of biologic responses in isolated cells, these responses appear to be mediated by the insulin and IGF I receptors (147670, 147370). The receptor for IGF II was found also to be the receptor for mannose 6-phosphate, which is implicated in targeting of lysosomal enzymes (MacDonald et al., 1988; Roth, 1988; Tong et al., 1988). Purified human and rat IGF2 receptors interact with antibodies to the mannose 6-phosphate receptor and with mannose 6-phosphate. Oshima et al. (1988) cloned and sequenced the full-length cDNA for MPRI; 7,473 nucleotides were found to encode a protein of 2,491 amino acids. The amino acid sequence included a putative signal sequence of 40 amino acids and an extra cytoplasmic domain consisting of 15 homologous repeat sequences of 134 to 167 amino acids, a transmembrane region of 23 amino acids, and a cytoplasmic domain of 164 amino acids. The predicted molecular size was greater than 270 kD. On comparison to the reported structure of IGF2R (Morgan et al., 1987), MPRI was found to show 99.8% identity at the nucleotide level and 99.4% identity at the amino acid level. By cDNA sequencing, Laureys et al. (1988) showed that the cation-independent mannose 6-phosphate receptor and IGF2 receptor are identical.

Szebeny and Rotwein (1994) cloned and characterized the mouse *Igf2r* gene. They found that it is 93 kb long, with 48 exons, and encodes a predicted protein of 2,482 amino acids.

Laureys et al. (1988) mapped the human IGF2R gene to 6q25-q27, using cloned
5 cDNAs to probe Southern blots of somatic cell hybrid DNA and for in situ chromosomal hybridization. The corresponding mouse gene mapped to chromosome 17. The cation-dependent mannose 6-phosphate receptor (MPRD; 154540) is coded by chromosome 12. By fluorescence in situ hybridization, Rao et al. (1994) narrowed the assignment of the IGF2R gene to 6q26.

10 Acquati et al. (1994) described a 2-Mb YAC from the telomeric region of 6q containing the plasminogen-apolipoprotein(a) gene family at its centromeric end and IGF2R at the telomeric end. About 350 kb separated IGF2R from the nearest member of the PLG/LPA cluster of genes.

Mutation in either MPRD or MPRI might result in a clinical disorder resembling a
15 mucopolysaccharidosis (252500, 252600). Waheed et al. (1988) showed that the M6P and IGF2 binding sites are located on different segments of the receptor. Kiess et al. (1988) presented biochemical evidence that the IGF2 receptor and the cation-independent mannose 6-phosphate receptor are the same protein but that the binding sites for the 2 ligands are distinct. In its guise as a mannose 6-phosphate receptor, the IGF2 receptor
20 binds mannose 6-phosphate residues on lysosomal enzymes and transports them into lysosomes (Kornfeld and Mellman, 1989).

Mouse embryos produce transcripts of the type II receptor from the maternal chromosome but not from the paternal. This could explain why mice that are heterozygous for deletions of the locus develop normally if their paternal allele is missing but die during
25 early development if the maternal allele is missing. Studies in transgenic mice (Barlow et al., 1991) show parental imprinting, i.e., monoallelic expression, of the *Igf2r* gene. The *Igf2r* gene maps to the T-associated maternal effect locus (Tme) on mouse chromosome 17. It is probably no coincidence that the IGF2 gene and the gene for its type 2 receptor are oppositely imprinted (DeChiara et al., 1991). Haig and Graham (1991) proposed that the
30 oppositely imprinted genes function to control the ultimately adverse effects of excessive production of IGF2 from the maternal allele. The suggestion is based on the model of Haig and Westoby (1989) which proposes that the evolution of genomic imprinting is expected in organisms that have both a breeding system in which females carry offspring by more

than one male during their life span and a system of parental care in which offspring receive most of their postfertilization nutrients from 1 parent (usually the mother) and thus compete with offspring fathered by other males. Strictly, imprinting is possible whenever an individual's interactions are asymmetric with respect to maternal- and paternal-side relatives.

Although in mice the M6P/IGF2R gene is maternally imprinted (Barlow et al., 1991), in humans imprinting appears to be a polymorphic trait (Xu et al., 1993; Kalscheuer et al., 1993; Ogawa et al., 1993). Thus, mice and any humans who are imprinted may have an increased susceptibility to hepatocellular carcinoma since only 1 mutation would be required to render the gene inactive. De Souza et al. (1995) noted that, since the M6P/IGF2R protein is normally present in the circulation, mutant receptors in the plasma might be helpful in liver tumor detection. Furthermore, they stated that mutated receptors on the plasma membrane of liver tumor cells might provide a surface antigen for the targeting of both therapeutic and diagnostic agents to liver tumors.

The serine proteinase granzyme B (GZMB; 123910) is crucial for the rapid induction of target cell apoptosis by cytotoxic T cells. GZMB enters cells in a perforin-independent manner, predicting the existence of a cell surface receptor(s). Motyka et al. (2000) presented evidence that this receptor is IGF2R. Inhibition of the GZMB-IGF2R interaction prevented GZMB cell surface binding, uptake, and the induction of apoptosis. Significantly, expression of IGF2R was essential for cytotoxic T cell-mediated apoptosis of target cells in vitro and for the rejection of allogeneic cells in vivo.

The cytosolic tails of both the cation-independent and the cation-dependent (154540) mannose 6-phosphate receptors contain acidic cluster-dileucine signals that direct sorting from the trans-Golgi network to the endosomal-lysosomal system. Puertollano et al. (2001) found that these signals bind to the VHS domain of the Golgi-localized, gamma-ear-containing, ARF-binding proteins (GGA1, 606004; GGA2, 606005; GGA3, 606006). The receptors and the GGAs left the trans-Golgi network on the same tubulovesicular carriers. A dominant-negative GGA mutant blocked exit of the receptors from the trans-Golgi network. Puertollano et al. (2001) concluded that the GGAs appear to mediate sorting of the mannose 6-phosphate receptors to the trans-Golgi network.

Zhu et al. (2001) found that the VHS domain of GGA2 binds the acidic cluster-dileucine motif in the cytoplasmic tail of the cation-independent mannose 6-phosphate receptor. Receptors with mutations in this motif were defective in lysosomal enzyme

sorting. The hinge domain of GGA2 bound clathrin, suggesting that GGA2 could be a link between cargo molecules and clathrin-coated vesicle assembly. Thus, Zhu et al. (2001) concluded that GGA2 binding to the cation-independent mannose 6-phosphate receptor is important for lysosomal enzyme targeting.

5 Livestock cloning and in vitro embryo culture have been adversely affected by the exceptional size of some resulting lambs and calves. Multiple abnormalities associated with 'large offspring syndrome' (LOS) limit application of these technologies. Similar fetal overgrowth in humans and mice can result from altered expression of several imprinted genes that are expressed only from 1 parental allele, including IGF2R. Cloning or
10 nonphysiologic embryo culture environments may result in inappropriate epigenetic modification of imprinted genes during early embryogenesis, when many allele-specific imprints are established or maintained. Young et al. (2001) demonstrated reduced fetal methylation and expression of sheep IGF2R, suggesting that preimplantation embryo procedures may be vulnerable to epigenetic alterations in imprinted genes. This
15 highlighted the potential benefits of epigenetic diagnostic screening in developing embryo procedures.

A bidirectional silencer for a 400-kb region that contains 3 imprinted, maternally expressed protein-coding genes (IGF2R; SLC22A2, 602608; SLC22A3, 604842) has been shown by targeted deletion to be located in a sequence of 3.7 kb, which also contains the
20 promoter for the imprinted, paternally expressed noncoding Air RNA (604893). Expression of Air is correlated with repression of all 3 genes on the paternal allele; however, Air RNA overlaps just 1 of these genes in an antisense orientation. By inserting a polyadenylation signal that truncates 96% of the RNA transcript, Sleutels et al. (2002) demonstrated that Air RNA is required for silencing. The truncated Air allele maintains
25 imprinted expression and methylation of the Air promoter, but shows complete loss of silencing of the IGF2R/SLC22A2/SLC22A3 gene cluster on the paternal chromosome. Sleutels et al. (2002) concluded that noncoding RNAs have an active role in genomic imprinting.

The mannose 6-phosphate/insulin-like growth factor II receptor functions in the
30 intracellular trafficking of lysosomal enzymes, the activation of the potent growth inhibitor, transforming growth factor beta, and the degradation of IGF2, a mitogen often overproduced in tumors. De Souza et al. (1995) demonstrated that 70% of human hepatocellular tumors have loss of heterozygosity (LOH) at the M6P/IGF2R locus at 6q26.

In a separate report, De Souza et al. (1995) described a mutation screen that identified point mutations in the remaining allele of 25% of human hepatocellular carcinomas with LOH. One mutation created an alternative splice site within an intron (corresponding to intron 40 in mouse) and resulted in a truncated receptor; 2 others (147280.0001,
5 147280.0002) gave rise to significant amino acid substitutions. These mutations provided evidence to the authors that the M6P/IGF2R gene functions as a tumor suppressor in human liver carcinogenesis.

Souza et al. (1996) reported that the IGF2R gene contains a number of microsatellite repeats within its coding sequence. They demonstrated microsatellite
10 instability in this gene in 12 of 92 gastrointestinal tumors studied which were replication/repair error-positive. Mutations occurred in 6 of the poorly differentiated tumors. They noted an anticorrespondence of IGF2R and TGFBR2 (190182) mutations. Of 31 gastrointestinal lesions studied with IGF2R or TGFBR2 mutations, 90% (28) contained mutations in one or the other, but not both, of these genes. Souza et al. (1996)
15 demonstrated that all but 1 of the mutations occurred within an 8-polydeoxyguanine tract spanning nucleotides 4089-4096 of the IGF2R coding sequence. In 1 case of gastric adenocarcinoma, mutation occurred in a polyCT tract spanning nucleotides 6169-6180. These mutations all comprised 1- or 2-bp deletions or insertions within the microsatellite region, causing frameshifts and premature stop codons downstream. Souza et al. (1996)
20 noted that the TGFBR2 gene is also subject to microsatellite instability within its coding region. They noted further that IGF2R and TGFBR2 genes comprise serial points in the same tumorigenesis pathway, since mutation of either gene alone occurred in 90% of the gastrointestinal tumors that they analyzed.

To facilitate genetic analyses of the imprint status of human M6P/IGF2R and loss
25 of heterozygosity at this locus in cancer, Killian et al. (2001) screened American and Japanese populations for M6P/IGF2R single nucleotide polymorphisms (SNPs). They identified 9 novel intragenic SNPs and 3 amino acid variants in the ligand-binding domains of M6P/IGF2R that may be under selection in humans.

To determine whether paternal expression of the Igf2r gene is necessary for early
30 development in the mouse, Lau et al. (1994) derived mice in which the gene had been disrupted by targeted mutagenesis in embryonic stem (ES) cells with the subsequent introduction of the mutation into the germline of mice. Lau et al. (1994) found that murine embryos that inherit a nonfunctional Igf2r gene from their father are viable and develop

normally into adults; however, most mice inheriting the same mutated allele from their mothers die around the time of birth as a consequence of major cardiac abnormalities. The mice that inherit the mutant allele from their mothers do not express Igf2r in their tissues, are 25 to 30% larger than their normal sibs, have elevated levels of circulating IGF2 and IGF-binding proteins, and exhibit a slight kink in the tail. The findings of overgrowth may support the suggestion that relaxation of maternal imprinting of IGF2 plays a role in the features of Beckwith-Wiedemann syndrome (130650) (Feinberg, 1993).

ALLELIC VARIANTS

(selected examples)

.0001 HEPATOCELLULAR CARCINOMA, SOMATIC [IGF2R, GLY1449VAL]

De Souza et al. (1995) found a C-to-A transversion in 1 allele of the IGF2R gene creating a gly1449-to-val amino acid substitution in the gene product. This mutation was found in a tumor which showed deletion of the other allele as judged by loss of heterozygosity (LOH).

.0002 HEPATOCELLULAR CARCINOMA, SOMATIC [IGF2R, GLY1464GLU]

De Souza et al. (1995) found a G-to-A transition in 1 allele of the IGF2R gene creating a gly1464-to-glu amino acid substitution in the gene product. This mutation was found in a tumor which showed deletion of the other allele as judged by loss of heterozygosity (LOH).

Another sequence (Lab Designation L24_4_2BE_rE (SEQ ID NO: 200)) comprises sequence encoding **DISTAL-LESS HOMEO BOX 2 (DLX2)**. This protein is also known as TES 1 and the sequence maps to gene map locus 2q32

To isolate genes involved in forebrain development, Porteus et al. (1992) used subtractive hybridization of cDNA libraries to enrich for cDNAs that are encoded by genes preferentially expressed in mouse gestational day 15 telencephalon. In an attempt to find genes that are candidates for the regulation of forebrain development, the subtracted cDNA library was screened with probes homologous to the homeo box, a conserved motif found in transcriptional regulators that often control development. A novel cDNA, named

Tes1, that encodes a homeodomain was identified. Its sequence showed that Tes1 was a member of the 'Distal-less' family of homeodomain-encoding genes. Related by amino acid homology within their homeodomains, the known members of the family are Tes1, Dlx1 (a mouse gene), and Dll (a *Drosophila melanogaster* gene). Ozcelik et al. (1992) determined the chromosomal location of the Tes1 gene in mouse and human. Because Tes1 is a member of the Dlx gene family, the gene symbol for this locus was established as DLX2 (human) and Dlx2 (mouse). By Southern analysis of somatic cell hybrid lines, they assigned the human locus to chromosome 2cen-q33 and the mouse locus to chromosome 2. An EcoRI dimorphism was used for recombinant inbred strain mapping in the mouse. The results placed the Dlx2 gene near the Hox4 cluster on mouse chromosome 2.

Qiu et al. (1995) utilized information about the genomic structure of the murine Dlx2 gene to carry out gene targeting experiments and made deletions in the Dlx2 gene in mouse embryonic stem cells for use in transgenic mice. They reported that heterozygous mice appeared normal and homozygous mice died on the day of birth. The mutant mice had altered differentiation of interneurons in the olfactory bulb and abnormal morphogenesis of the cranial neural crest-derived skeletal structures formed from the proximal first and second branchial arches, causing cleft palate.

McGuinness et al. (1996) reported the DNA sequence of the human DLX2 gene and compared this to the murine gene. Analysis of the sequence indicated that the human DLX2 gene has 3 exons and 2 introns. The deduced sequence of the human DLX2 protein shows that the human and mouse DLX2 proteins are 92% identical. The human DLX2 protein is 330 amino acids in length, while the mouse DLX2 protein contains 332 amino acids. The introns have 63 to 71% identity. Domains identified in the human and mouse DLX2 gene include a homeodomain and short stretches of homology to several transcription factors. McGuinness et al. (1996) noted that availability of the sequence of the human DLX2 gene will facilitate the use of PCR analysis for screening for human mutations in DLX2 in abnormal development.

Another sequence (Lab Designation seq1b_lac (SEQ ID NO: 267) comprises sequence encoding ZINC FINGER PROTEIN 7 (ZNF7). This protein is also known as KOX4. This sequence maps to gene map locus 8q24

On the basis of sequence similarity in the repeated zinc finger domain, Lania et al. (1990) identified and characterized 2 human cDNA clones, designated ZNF7 and ZNF8,

both of which encoded proteins containing potential finger-like nucleic acid binding motifs. The predicted 686-amino acid ZNF7 protein contains 15 zinc finger domains that comprise nearly 70% of the protein. Northern blot analysis revealed that ZNF7 is expressed as 2.8- and 3.3-kb mRNAs in a variety of human cell lines.

5 By in situ hybridization, Lania et al. (1990) localized ZNF7 to 8q24 and ZNF8 to 20q13. Bray et al. (1991) likewise mapped ZNF7 to 8qter by chromosomal in situ suppression hybridization with fluorescent probe detection. Bray et al. (1991) determined that the genomic locus designated ZNF7 corresponds to KOX4 in the set of 30 zinc finger protein-encoding cDNAs (KOX1-KOX30) previously isolated from a T-cell library
10 (Thiesen, 1990). They concluded that the human genome contains many, probably several hundred, zinc finger genes with consensus his/cys (H/C) link regions. Huebner et al. (1993) confirmed the assignment of ZNF7 to 8q24 by analysis of rodent/human somatic cell hybrids and by in situ hybridization. They showed that ZNF7 is telomeric to the MYC locus (190080).

15 Another sequence (Lab Designation L197B3E-rE (SEQ ID NO: 135))comprises sequence encoding BCL2-LIKE 1 (BCL2L1).

Boise et al. (1993) isolated a BCL2-related gene, which they designated BCLX, and showed that it can function as a BCL2-independent regulator of programmed cell death (apoptosis). Alternative splicing resulted in 2 distinct BCLX mRNAs. The protein
20 product of the larger mRNA (BCLXL) was similar in size and predicted structure to BCL2. When stably transfected into an IL3-dependent cell line, it inhibited cell death upon growth factor withdrawal at least as well as BCL2. Unexpectedly, the smaller mRNA species (BCLXS) encodes a protein that inhibits the ability of BCL2 to enhance the survival of growth factor-deprived cells. In vivo, the smaller BCLX mRNA was expressed
25 at high levels in cells that undergo a high rate of turnover, such as developing lymphocytes. In contrast, the large form of BCLX was found in tissues containing long-lived postmitotic cells, such as adult brain. Together these data suggested that BCLX plays an important role in both positive and negative regulation of programmed cell death. Boise et al. (1993) found that BCLX is highly conserved in vertebrate evolution. Vander Heiden et al. (1997) observed in Jurkat cells that a wide variety of apoptotic and necrotic stimuli induce progressive mitochondrial swelling and outer mitochondrial membrane rupture. Discontinuity of the outer mitochondrial membrane results in cytochrome c redistribution from the intermembrane space to the cytosol, followed by subsequent inner mitochondrial
30

membrane depolarization. The mitochondrial membrane protein BCLX could inhibit these changes in cells treated with apoptotic stimuli. In addition, BCLX-expressing cells adapt to growth factor withdrawal or staurosporine treatment by maintaining a decreased mitochondrial membrane potential. BCLX expression also prevents mitochondrial swelling in response to agents that inhibit oxidative phosphorylation. These data suggested to Vander Heiden et al. (1997) that BCLX promotes cell survival by regulating the electrical and osmotic homeostasis of mitochondria.

Silva et al. (1998) found that erythroid cells from patients with polycythemia vera (263300) survived in vitro without erythropoietin. This finding correlated with the expression of BCLX protein, even in mature erythroblasts that normally do not express BCLX. The large BCLX mRNA was the predominant form detected in the erythropoietin-independent erythroid cells. They concluded that deregulated expression of BCLX may contribute to the erythropoietin-independent survival of erythroid-lineage cells in polycythemia vera and thereby contribute to the pathogenesis of this disorder. Moliterno et al. (1998) simultaneously reported impaired expression of the thrombopoietin receptor (MPL; 159530) by platelets from patients with polycythemia vera.

During transduction of an apoptotic signal into the cell, there is an alteration in the permeability of the membranes of the cell's mitochondria, which causes the translocation of the apoptogenic protein cytochrome c into the cytoplasm, which in turn activates death-driving proteolytic proteins known as caspases (see 147678). The BCL2 family of proteins, whose members may be antiapoptotic or proapoptotic, regulates cell death by controlling this mitochondrial membrane permeability during apoptosis. Shimizu et al. (1999) created liposomes that carried the mitochondrial porin channel VDAC (604492) to show that the recombinant proapoptotic proteins Bax (600040) and Bak (600516) accelerate the opening of VDAC, whereas the antiapoptotic protein BCLXL closes VDAC by binding to it directly. Bax and Bak allow cytochrome c to pass through VDAC out of liposomes, but passage is prevented by BCLXL. In agreement with this, VDAC1-deficient mitochondria from a mutant yeast did not exhibit a Bax/Bak-induced loss in membrane potential and cytochrome c release, both of which were inhibited by BCLXL. Shimizu et al. (1999) concluded that the BCL2 family of proteins bind to the VDAC in order to regulate the mitochondrial membrane potential and the release of cytochrome c during

apoptosis.

FUS- associated proteins and TLS appear to be the same;

Uranishi et al. ("Involvement of the pro-oncoprotein TLS (translocated in liposarcoma) in nuclear factor-kappa B p65-mediated transcription as a coactivator" *J Biol Chem* 20;276(16):13395-401, Apr. 2001) demonstrate that translocated in liposarcoma (TLS), also termed FUS, is an interacting molecule of the p65 (RelA) subunit of the transcription factor nuclear factor kappaB (NF-kappaB) using a yeast two-hybrid screen. We confirmed the interaction between TLS and p65 by the pull-down assay in vitro and by a coimmunoprecipitation experiment followed by Western blot of the cultured cell in vivo. TLS was originally identified as part of a fusion protein with CHOP arising from chromosomal translocation in human myxoid liposarcomas. TLS has been shown to be involved in TFIID complex formation and associated with RNA polymerase II. However, the role of TLS in transcriptional regulation has not yet been clearly elucidated. We found that TLS enhanced the NF-kappaB-mediated transactivation induced by physiological stimuli such as tumor necrosis factor alpha, interleukin-1beta, and overexpression of NF-kappaB-inducing kinase. TLS augmented NF-kappaB-dependent promoter activity of the intercellular adhesion molecule-1 gene and interferon-beta gene. These results suggest that TLS acts as a coactivator of NF-kappaB and plays a pivotal role in the NF-kappaB-mediated transactivation.

A group of evolutionarily conserved pleiotropic COP/DET/FUS proteins was initially defined by their ability to repress photomorphogenesis in Arabidopsis (Suzuki et al. "Arabidopsis COP10 is a ubiquitin-conjugating enzyme variant that acts together with COP1 and the COP9 signalosome in repressing photomorphogenesis" *Genes Dev* 16(5):554-9, March 1, 2002). It was proposed that this regulation be mediated by targeting degradation of key cellular regulators that promote photomorphogenesis. Among them, COP1 and the COP9 signalosome have been hypothesized to fulfill the roles as an ubiquitin ligase (E3) and an essential E3 modulator. Here we report that COP10 encodes a protein similar to ubiquitin-conjugating enzyme (E2) variant proteins (UEV). COP10 is part of a nuclear protein complex and capable of directly interacting with both COP1 and the COP9 signalosome. Our data indicates that COP10 defines a possible E2 activity, thus validating the working hypothesis that the pleiotropic COP/DET/FUS group of proteins defined a protein ubiquitination pathway.

Another sequence (Lab Designation 8C5_6_rE (SEQ ID NO: 46)) comprises

sequence encoding AMINOPEPTIDASE, PUROMYCIN-SENSITIVE (NPEPPS). This protein is also known as PSA and METALLOPROTEASE MP100(MP 100). This sequence maps to gene map locus 17q21

Aminopeptidases are a group of exopeptidases that hydrolyze amino acids from the N terminus of a peptide substrate. Puromycin-sensitive aminopeptidase (EC 3.4.11.14) contains the zinc-binding domain characteristic of the gluzincin group of zinc metalloproteases (see 605896).

Tobler et al. (1997) cloned PSA from a human fetal brain cDNA library using the mouse PSA cDNA as probe. They established that translation is initiated at the second of 2 possible start codons, resulting in a deduced 875-amino acid protein with a molecular mass of 99 kD by SDS-PAGE. PSA contains a zinc-binding motif conserved among gluzincin aminopeptidases and shares 98% sequence identity with the mouse protein. Northern blot analysis detected ubiquitous expression of a 4.8-kb transcript, with highest expression in brain. By in situ hybridization of adult human brain sections, expression was localized to the perikaryon of neurons of the cortex and cerebellum. Using immunofluorescence localization of transfected HeLa cells, Tobler et al. (1997) found that PSA localizes to the perinuclear cytoplasm and shows a filamentous staining pattern. Bauer et al. (2001) cloned PSA cDNA from a human skeletal muscle library. Northern blot analysis detected major and minor transcripts of 4.8 and 4.2 kb, respectively. Huber et al. (1999) determined that PSA is identical to the metalloprotease MP100 that was originally isolated as a beta-secretase candidate from human brain by Schonlein et al. (1994).

Huber et al. (1999) were able to colocalize and coimmunoprecipitate PSA with beta-amyloid precursor protein (104760); however, PSA did not increase production of the amyloid-beta peptide in cotransfected cells. By RT-PCR, but not by Northern blot analysis, Bauer et al. (2001) found that PSA was upregulated in human leukemic cells following vitamin D stimulation.

Thompson et al. (1999) determined that the PSA gene contains 23 exons spanning approximately 40 kb. They found that the active site motif is split between exons 9 and 10. Analysis of the 5-prime flanking region indicated that the gene lacks a TATA box, is GC rich, and contains 5 putative SP1 (189906)-binding sites.

By FISH, Bauer et al. (2001) mapped the PSA gene to chromosome 17q21. Osada et al. (1999) mapped the mouse Psa gene to a region of syntenic homology on

chromosome 11.

Another sequence (Lab Designation 70A_rE (SEQ ID NO: 188)) comprises sequence encoding ANNEXIN A3 (ANXA3). This protein is also known as ANNEXIN III (ANX3) and as LIPOCORTIN III. This sequence maps to gene map locus 4q21.

5 The annexins are a family of calcium-dependent phospholipid-binding proteins. The family consists of at least 10 distinct members, each of which contains 4 or 8 copies of an 80-amino acid repeating unit first identified in lipocortin/annexin I. Annexin III was previously identified as inositol 1,2-cyclic phosphate 2-phosphohydrolase (EC 3.1.4.36), an enzyme of inositol phosphate metabolism, and also as placental anticoagulant protein
10 III, lipocortin III, calcimedlin 35-alpha, and an abundant neutrophil cytoplasmic protein. The mature annexin III protein contains 322 amino acids and, like other annexins, consists primarily of 4 copies of a 70- to 80-amino acid repeat unit. Characterizing the gene from directly amplified genomic DNA and from 6 genomic clones in phage lambda, Tait et al. (1993) determined that the transcribed region spans 58 kb and contains 12 introns ranging
15 from 0.3 to 19.1 kb and 13 exons ranging from 53 to 374 bases. Northern blot showed a single mRNA species with approximately 1.7 kb in all tissues examined.

Tait et al. (1991) localized the ANXA3 gene to 4q21 (q13-q22) by PCR analysis of a human-rodent hybrid cell panel, confirmed by genomic Southern blot analysis of the same panel with a cDNA probe, and by in situ hybridization with a cDNA probe.

20 Another sequence (Lab Designation 6BSA#12-rE (SEQ ID NO: 39)) comprises sequence encoding ADAM 10. This sequence maps to human chromosomal location 15q21.3-q2.

Lunn et al. ("Purification of ADAM 10 from bovine spleen as a TNFalpha convertase" FEBS Lett 400(3):333-5, Jan 6, 1997) purified a protease with characteristics
25 of TNFalpha convertase from bovine spleen membranes. Peptide sequencing of the purified protein identified it as ADAM 10 (Genbank accession no. Z21961). This metalloprotease cleaves a recombinant proTNFalpha substrate to mature TNFalpha, and can cleave a synthetic peptide substrate to yield the mature TNFalpha amino terminus in vitro. The enzyme is sensitive to a hydroxamate inhibitor of MMPs, but insensitive to
30 phosphoramidon. In addition, cloned ADAM 10 mediates proTNFalpha processing in a processing-incompetent cell line.

Lab Designation 6b65 is a rearranged vector- the tag site may be in ptpl1, sequence is in abcr (abca4- which is not expressed in the parent cell or mutant) and maps to

chromosomal location 1p22.1-p21. We have disrupted other rho related genes.

PTPL1-associated RhoGAP 1, a GTPase activating protein; activates members of the Rho subfamily of ras-related GTP binding proteins; has a cysteine rich domain

Another sequence (Lab Designation 4AE5_rE (SEQ ID NO: 64)) comprises
 5 sequence encoding MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, MEMBER 8B (MS4A8B). This sequence maps to gene map locus 11q12-q13.

MS4A family proteins share structural similarity, amino acid sequence homology, and chromosomal location. They contain 4 highly conserved transmembrane domains, flanked by N- and C-terminal cytoplasmic regions.

10 By database searching for homologs of CD20 (MS4A1; 112210), Liang and Tedder (2001) obtained a cDNA encoding MS4A8B. The predicted 250-amino acid protein is 63% identical to its mouse homolog. PCR analysis detected weak expression of MS4A8B in cDNA from 3 B-cell lines.

By genomic sequence analysis, Liang and Tedder (2001) mapped the MS4A8B
 15 gene to chromosome 11q12-q13, in the same region as MS4A2 (147138) and MS4A3 (606498).

Rho GTPases play a fundamental role in numerous cellular processes that are initiated by extracellular stimuli that work through G protein coupled receptors. The encoded protein may form complex with G proteins and stimulate Rho-dependent signals.
 20 This protein is similar to the NET1A protein.

Rho guanine nucleotide exchange factor 3 (RhoGEF); may function in signaling cascades

Another sequence (Lab Designation 42_8#3_rE (SEQ ID NO: 324)) comprises sequence encoding ARHGEF3. This sequence maps to gene map locus 3p21-p13.

25 RhoGEFs play an important role in various signaling cascades and are implicated in human conditions like cancer and mental retardation (Thiesen et al." Isolation of two novel human RhoGEFs, ARHGEF3 and ARHGEF4, in 3p13-21 and 2q22" *Biochem Biophys Res Commun* ;273(1):364-9, Jun 24, 2000). A database search combined with screening of a human neuronal teratocarcinoma library identified two novel RhoGEFs,
 30 ARHGEF3 and ARHGEF4 (HGMW-approved symbols). The widely expressed ARHGEF3 transcript of 3561 nucleotides encodes a polypeptide of 526 amino acids with homology to NET1. The ARHGEF4 gene generates two transcripts of 3665 and 4000 nucleotides that translate into 720 amino acid residues. Expression of ARHGEF4 is

restricted to brain and the encoded protein shows homology to collybistin. FISH analysis of genomic clones mapped ARHGEF3 to 3p13-21 and ARHGEF4 to 2q22. Copyright 2000 Academic Press.

Another sequence (Lab Designation 34X25_23_rE (SEQ ID NO: 153)) comprises
5 sequence encoding PHOSPHODIESTERASE 4B, cAMP-SPECIFIC (PDE4B); murine chr
4 2377737..2727820. This protein is also known as DUNCE-LIKE
PHOSPHODIESTERASE E4, FORMERLY; DPDE4. This sequence maps to gene map
locus 1p31.

Using RNA from a human lymphocytic B-cell line and a rat PDE IV member B
10 probe, Oberholte et al. (1993) isolated a 3.8-kb cDNA. A single large open reading frame
predicted a 564-amino acid protein with 92.9% identity to rat Pde4b; at the nucleotide
level, the identity was 86.3%. They determined that a related cDNA clone isolated from
human monocytes by Livi et al. (1990) was the human homolog of rat Pde4a (600126).
Southern blot analysis indicated that distinct genes encode these 2 PDE IV family
15 members.

Huston et al. (1997) cloned a novel human (plus its cognate rat) PDE4B splice
variant and compared its activities to the 2 other splice variants from this locus.
Alternative splicing of mRNA generated from both the human and rat PDE4B genes
produced long and short splice variants that had unique N-terminal regions. It was
20 suggested that these alternatively spliced regions determined changes in the maximal
catalytic activity of the isoforms, their susceptibility to inhibition by rolipram, and mode of
interaction with particulate fractions.

Milatovich et al. (1994) mapped the PDE4B gene to human 1p31 by a combination
of Southern analysis of somatic cell hybrid lines and fluorescence in situ hybridization
25 (FISH); they assigned the mouse homolog to chromosome 4 by Southern analysis of
recombinant inbred (RI) mouse strains. Through the use of somatic cell hybrids
segregating either human or rat chromosomes, Szpirer et al. (1995) mapped the PDE4B
gene to human chromosome 1 and rat chromosome 5.

Xu et al. (2000) determined the 3-dimensional structure of the catalytic domain of
30 phosphodiesterase 4B2B to 1.77-angstrom resolution. The active site was identified and
contains a cluster of 2 metal atoms. Xu et al. (2000) concluded that the structure suggests
the mechanism of action and basis for specificity, and will provide a framework for
structure-assisted drug design for members of the phosphodiesterase family.

Gale et al. describe the pharmacokinetic and pharmacodynamic profile following oral administration of the phosphodiesterase (PDE)4 inhibitor V11294A in healthy volunteers (Br J Clin Pharmacol 2002 Nov;54(5):478-84). Their aim was to assess the pharmacokinetic and pharmacodynamic profile of the novel PDE4 inhibitor V11294A (3-(3-cyclopentyloxy-4-methoxybenzyl)-6-ethylamino-8-isopropyl-3H purine hydrochloride) in healthy male volunteers. METHODS: This was a double-blind, single dose, randomized crossover study in eight healthy volunteers who received a single oral, fasting dose of V11294A (300 mg) or placebo. Blood samples were taken before and 0.5, 1, 2, 2.5, 3, 4, 6, 9, 12, 18 and 24 h after oral dosing for determination of plasma concentrations of V11294A. Blood samples were also taken before and 3 and 24 h after dosing for the assessment of the effect of V11294A on mononuclear cell proliferation and tumour necrosis factor (TNF) release in whole blood. RESULTS: Following a single oral dose of 300 mg V11294A, plasma concentrations of V11294A and its active metabolite V10332 reached C_{max} (ng ml⁻¹; mean +/- s.d.; 1398 +/- 298, 1000 +/- 400, respectively) after 2.63 +/- 0.79 and 5.9 +/- 2.3 h, respectively. For V11294A and V10332, t_{1/2} were 9.7 +/- 3.9 and 9.5 +/- 1.7 h, and AUC(0, infinity) were 18100 +/- 6100 and 18600 +/- 8500 ng ml⁻¹ h, respectively. At 3 h dosing, plasma concentrations of V11294A and V10332 (3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-isopropyl-3H-purin-6-ylamine) were 1300 +/- 330 and 860 +/- 300 ng ml⁻¹, 7 and 3 times their in vitro IC₅₀s for inhibition of TNF release and proliferation, respectively. Treatment with V11294A resulted in a significant reduction of lipopolysaccharide (LPS)-induced TNF release at 3 h (P << 0.001) and at 24 h (P << 0.05) post ingestion. The amount of TNF released (pmol ml⁻¹) in response to a submaximal concentration of LPS (4 ng ml⁻¹) was not significantly altered following placebo treatment (before 681 +/- 68 vs 3 h postdose 773 +/- 109, P = 0.27). In contrast, there was a significant reduction in the amount of TNF released following treatment with V11294A (before 778 +/- 87 vs 3 h postdose 566 +/- 72, P = 0.02). Phytohaemagglutinin (PHA) stimulated the incorporation of [3H]-thymidine in whole blood prior to drug administration. V11294A inhibited the PHA-induced proliferation at 3 h (P << 0.05). No adverse reactions were noted following single oral administration of V11294A. CONCLUSIONS: A single oral 300 mg dose of V11294A administered to healthy volunteers results in plasma concentrations adequate to inhibit activation of inflammatory cells ex vivo, which persists for at least 24 h without any adverse reactions.

Another sequence comprises sequence encoding GLUCOCORTICOID

RECEPTOR (GCCR). This sequence maps to gene map locus 5q31

Vingerhoeds et al. (1976) reported a case of cortisol resistance. High levels of cortisol (without stigmata of Cushing syndrome), resistance of the hypothalamic-pituitary-adrenal axis to dexamethasone, and an affinity defect of the glucocorticoid receptor
5 characterized the disorder. Chrousos et al. (1982) restudied the family reported by Vingerhoeds et al. (1976). A man who was presumably homozygous had mineralocorticoid excess resulting in hypertension, hypokalemia, and metabolic alkalosis. One of his brothers, who had severe hypertension and died of a cerebrovascular accident at age 54, may also have been homozygous. Another brother and his son were apparently
10 heterozygous; they showed slightly elevated 24-hour mean plasma cortisol levels and increased urinary free cortisol. Lipsett et al. (1986) provided further follow-up on the 4-generation family originally reported by Vingerhoeds et al. (1976). Autosomal dominant inheritance of glucocorticoid resistance was clearly demonstrated. Lipsett et al. (1986) believed that a mutation in the glucocorticoid receptor was responsible, although other
15 explanations could be invoked. The single homozygote in the family was the proband; the other persons with elevated plasma cortisol levels and increased urinary free cortisol represented heterozygotes. The parents of the proband descended from families with consanguinity that occurred before the 16th century. The 2 parental families had lived in close proximity for many generations. This cortisol resistance is probably the rarest cause
20 of treatable hypertension yet described. Affected mother and son with decreased glucocorticoid receptors were reported by Iida et al. (1985).

Bronnegard et al. (1986) described a woman with receptor-mediated resistance to cortisol as indicated by elevated 24-hour mean plasma cortisol levels and increased free urinary cortisol. Plasma ACTH concentrations were normal but she was resistant to
25 adrenal suppression by dexamethasone. No stigmata of Cushing syndrome were present. The patient had symptoms of pronounced fatigue. Menopause had occurred at age 43. The patient's only child, a son, aged 29 years, had periods of inexplicable fatigue that had made him stay home from school and work. Because of the extreme fatigue that led to the mother's working only half-time, Addison's disease was suspected, but rather than
30 hypocortisolism, elevation of urinary cortisol values was found. Bronnegard et al. (1986) found that the end-organ insensitivity to cortisol was not due to decreased concentration or ligand affinity of the receptor. Rather the woman and her son showed an increased thermolability of the cortisol receptor, a phenomenon also observed with the androgen

receptor in patients with the testicular feminization syndrome (300068).

Lamberts et al. (1986) described cortisol resistance in a 26-year-old woman with hirsutism, mild virilization, and menstrual difficulties. They thought that the abnormality was autosomal dominant because her father and 2 brothers had increased plasma cortisol concentrations that did not suppress normally in response to dexamethasone. No hypertension or hypokalemic alkalosis was present. The proband had male-pattern scalp baldness. Nawata et al. (1987) studied a 27-year-old woman with the syndrome of glucocorticoid resistance. She was initially thought to have Cushing disease, based on high plasma ACTH and serum cortisol levels, increased urinary cortisol secretion, resistance to adrenal suppression with dexamethasone, and bilateral adrenal hyperplasia by computed tomography and scintigraphy; however, she had no clinical signs or symptoms of Cushing syndrome. Laboratory studies indicated that the patient's glucocorticoid resistance was due to a decrease in the affinity of the receptor for glucocorticoids and a decrease in the binding of the GCCR complex to DNA.

Corticotrophinomas

As cortisol resistance can be caused by genetic abnormalities in the GRL gene, Huizenga et al. (1998) investigated whether the insensitivity of corticotrophinomas to cortisol is also caused by de novo GRL mutations. Except for 1 silent point mutation, they did not identify mutations in the GRL gene in leukocytes or corticotrophinomas from 22 patients with Cushing disease. Of the 22 patients, 18 were heterozygous for at least 1 polymorphism, and 6 of the 18 had loss of heterozygosity (LOH) in the tumor DNA. They concluded that LOH at the GRL locus is a relatively frequent phenomenon in pituitary adenomas of patients with Cushing disease and that this may explain the relative resistance of the adenoma cells to the inhibitory feedback action of cortisol on ACTH secretion.

Examples of resistance to cortisol are known; the guinea pig is a 'corticoresistant' species (Vingerhoeds et al., 1976).

Two New World primates, the squirrel monkey and the marmoset, have markedly elevated plasma cortisol levels without physiologic evidence of glucocorticoid hormone excess. Chrousos et al. (1982) showed that their hypothalamic-pituitary-adrenal axis is resistant to suppression by dexamethasone. They studied glucocorticoid receptors in circulating monocytes and cultured skin fibroblasts of New and Old World monkeys and found that, although the receptor content was the same in all species, the 2 New World

species had markedly decreased binding affinity for dexamethasone. The presumed mutation must have occurred after bifurcation of the Old and New World primates (about 60 Myr ago) and before diversion of the 2 New World species (about 15 Myr ago). A difference between the disorder in man with an affinity defect of the glucocorticoid receptor and the state in New World monkeys is that in the severe form of the human disease, sodium-retaining corticoids (corticosterone and deoxycorticosterone) are elevated many-fold, producing hypertension and hypokalemic alkalosis. The mineralocorticoid overproduction, which does not occur in the New World monkeys, is probably due to corticotropin hyperstimulation of the adrenal cortex.

Glucocorticoid hormones, like other classes of steroid hormones, exert their cellular action by complexing with a specific cytoplasmic receptor which in turn translocates to the nucleus and binds to specific sites on chromatin. The glucocorticoid receptor was the first transcription factor to be isolated and studied in detail (Muller and Renkawitz, 1991). The glucocorticoid receptor (GCCR) is crucial to gene expression. It is a 94-kD polypeptide and according to one model is thought to have distinct steroid-binding and DNA-binding domains. Weinberger et al. (1985) used expression cloning techniques to select human glucocorticoid receptor cDNA.

Hollenberg et al. (1985) identified cDNAs encoding the human glucocorticoid receptor (symbolized hGR by them). These DNAs predicted 2 protein forms of 777 (alpha) and 742 (beta) amino acids, which differ in their carboxy termini. The proteins contain a cysteine/lysine/arginine-rich region which may define the DNA-binding domain.

Weinberger et al. (1985, 1987) pointed out that the glucocorticoid receptor that they cloned is related to the erb-A family of oncogenes (see 190120 and 190160). Cloned members of the erb oncogene family showed a strong relatedness to the DNA-binding domain of the glucocorticoid receptor. A short region of GRL was homologous to certain homeotic proteins of *Drosophila*. Carlstedt-Duke et al. (1987) analyzed the domain structure of the rat liver GCR protein. The steroid-binding domain, defined by a unique tryptic cleavage, corresponded to the COOH-terminal protein with the domain border in the region of residue 518. The DNA-binding domain, defined by a region with chymotryptic cleavage sites, was immediately adjacent to the steroid-binding domain with its border in the region of residues 410-414.

Of the 2 isoforms of the glucocorticoid receptor generated by alternative splicing, GR-alpha is a ligand-activated transcription factor that, in the hormone-bound state,

modulates the expression of glucocorticoid-responsive genes by binding to a specific glucocorticoid response element (GRE) DNA sequence. In contrast, GR-beta does not bind glucocorticoids and is transcriptionally inactive. Bamberger et al. (1995) demonstrated that GR-beta is able to inhibit the effects of hormone-activated GR-alpha on a glucocorticoid-responsive reporter gene in a concentration-dependent manner. The inhibitory effect appeared to be due to competition for GRE target sites. Since RT-PCR analysis showed expression of GR-beta mRNA in multiple human tissues, GR-beta may be a physiologically and pathophysiologically relevant endogenous inhibitor of glucocorticoid action and may participate in defining the sensitivity of tissues to glucocorticoids.

10 Roux et al. (1996) found that mutation of isoleucine-747 to threonine in the C-terminal portion of the ligand-binding domain of NR3C1 alters the specificity of the ligand for transactivation. Whereas natural glucocorticoids such as cortisol or corticosterone were completely inactive, synthetic steroids like dexamethasone efficiently stimulated I747T mutant NR3C1-mediated transactivation. The basis for the inability of cortisol to activate
15 I747T was predicted from the canonical 3-dimensional structure of nuclear receptor ligand-binding domains because isoleucine-747 is in the direct vicinity of residues that contribute to the ligand-binding pocket.

Using oligonucleotide-directed mutagenesis, Lind et al. (1996), found functional substitutions of residue 736 with serine (cys736 to ser) and threonine (cys736 to thr). The
20 cys736-to-ser protein showed reduced sensitivity to all hormones tested in transactivation assays and a reduced hormone binding affinity. A correspondence between sensitivity to hormone in transactivation assays and hormone-binding affinity was also observed for the cys736-to-thr protein. The authors concluded that very conservative substitutions of cys736, including serine and threonine, cause variable effects on hormone binding that
25 distinguish between different glucocorticoid steroid hormones.

Diamond et al. (2000) showed, in diverse cell types, that glucocorticoids can up- or down-modulate aggregation and nuclear localization of expanded polyglutamine polypeptides derived from the androgen receptor (AR; 313700) or huntingtin (HD; 143100) through specific regulation of gene expression. Wildtype glucocorticoid receptor,
30 as well as C-terminal deletion derivatives, suppressed the aggregation and nuclear localization of these polypeptides, whereas mutations within the DNA-binding domain and the N terminus of GCR abolished this activity. Surprisingly, deletion of a transcriptional regulatory domain within the GCR N terminus markedly increased aggregation and

nuclear localization of the expanded polyglutamine proteins. Thus, aggregation and nuclear localization of expanded polyglutamine proteins are regulated cellular processes that can be modulated by a well-characterized transcriptional regulator, the GCR. The findings suggested approaches to study the molecular pathogenesis and selective neuronal
5 degeneration of polyglutamine expansion diseases.

Glucocorticoid Receptor-Beta

Oakley et al. (1996) examined the expression, biochemical properties, and physiologic function of GR-beta. They found that the GR-beta message has a widespread
10 tissue distribution. Although the GRL gene had previously been reported to consist of 10 exons (Encio and Detera-Wadleigh, 1991), Oakley et al. (1996) suggested that the GRL sequences formerly identified as exon 9-alpha, intron J, and exon 9-beta comprise 1 large terminal exon (exon 9) of approximately 4.1 kb and that the GRL gene is organized into 9 rather than 10 exons. They demonstrated that GR-beta resides primarily in the nucleus of
15 transfected cells independent of hormone treatment. Oakley et al. (1996) showed that dominant-negative activity occurs in cells that have endogenous GR-alpha receptors. In addition, they demonstrated that the repression of GR-alpha activity occurs with the simple promoter pGRE2CAT, indicating that the repression is a general phenomenon of glucocorticoid-responsive promoters and that GRE-mediated transcription is actually
20 inhibited.

Corticosteroids have specific effects on cardiac structure and function mediated by mineralocorticoid and glucocorticoid receptors (MR and GR, respectively). Aldosterone and corticosterone are synthesized in rat heart. To see whether they might also be
25 synthesized in the human cardiovascular system, Kayes-Wandover and White (2000) examined the expression of genes for steroidogenic enzymes as well as genes for GR, MR, and 11-hydroxysteroid dehydrogenase (HSD11B2; 218030), which maintains the specificity of MR. Human samples were from left and right atria, left and right ventricles, aorta, apex, intraventricular septum, and atrioventricular node, as well as whole adult and
30 fetal heart. Using RT-PCR, mRNAs encoding CYP11A (118485), CYP21 (201910), CYP11B1 (202010), GR, MR, and HSD11B2 were detected in all samples except ventricles, which did not express CYP11B1. CYP11B2 (124080) mRNA was detected in the aorta and fetal heart, but not in any region of the adult heart, and CYP17 (202110) was

not detected in any cardiac sample. Levels of steroidogenic enzyme gene expression were typically 0.1% those in the adrenal gland. The authors concluded that these findings are consistent with autocrine or paracrine roles for corticosterone and deoxycorticosterone, but not cortisol or aldosterone, in the normal adult human heart.

5

Neutrophils are markedly less sensitive to glucocorticoids than are T lymphocytes. Using immunofluorescence, Western blot, and RNA dot blot analyses, Strickland et al. (2001) showed that GR-alpha and GR-beta are both expressed on mononuclear cells and neutrophils, with GR-beta expression somewhat greater than GR-alpha on neutrophils. IL8
10 (146930) stimulation of neutrophils resulted in a significant increase in GR-beta but not GR-alpha expression in neutrophils. Unlike human neutrophils, mouse neutrophils do not express GR-beta. Transfection of GR-beta into mouse neutrophils led to a significant reduction in the cell death rate when exposed to dexamethasone. Strickland et al. (2001) concluded that the high constitutive and proinflammatory cytokine-inducible upregulation
15 of GR-beta in neutrophils enhances their survival during glucocorticoid treatment of inflammation. They proposed that this knowledge may help in the development of novel antiinflammatory strategies.

Glucocorticoid Receptor-Gamma

20

Rivers et al. (1999) described GR-gamma, a novel variant of GCCR in which, as a result of alternative splicing, 3 bases are retained from the intron separating exons 3 and 4. These 3 bases code for an additional amino acid (arginine) in the DNA-binding domain of the receptor. Insertion of arginine at this site had previously been shown to decrease
25 transcriptional activation by the GR to 48% that of GR-alpha (Ray et al., 1996). Analysis of cDNA from different tissues showed that GR-gamma is widely expressed at a relatively high level (between 3.8% and 8.7% of total GR).

Gehring et al. (1984, 1985) achieved mapping of GRL to chromosome 5 by study
30 of hybrids of a human lymphoblastic cell line (that is glucocorticoid-sensitive and contains glucocorticoid receptors of wildtype characteristics) and a mouse lymphoma cell line (that is resistant to lysis by glucocorticoids because of a mutant receptor that exhibits abnormal DNA binding).

Weinberger et al. (1985) used a cDNA clone in connection with a panel of somatic hybrid cells with various rearrangements involving chromosome 5 to assign GCCR to 5q11-q13. However, Francke and Foellmer (1989) demonstrated by in situ hybridization that the GRL gene is located on 5q31-q32. The new assignment is consistent with linkage to a DNA marker that maps to the same region (Giuffra et al., 1988) and also with human/mouse comparative mapping data. From family linkage studies, Giuffra et al. (1988) likewise concluded that the GRL locus is located toward the end of the long arm of chromosome 5.

Hollenberg et al. (1985) confirmed the assignment of a glucocorticoid receptor gene to chromosome 5 by Southern analysis of a hybrid cell line containing only chromosome 5. In addition, 2 fragments (formed with EcoRI and Hind III) were found in total human DNA and not in the hybrid line. To map these, Hollenberg et al. (1985) used a dual-laser fluorescence-activated cell sorter and spot-blotting. This confirmed the assignment to chromosome 5 and in addition showed hGR sequences on chromosome 16. The assignment to chromosome 16 was confirmed by Southern analysis of DNA from a mouse erythroleukemia cell line containing human chromosome 16. They concluded that both the alpha and beta receptor proteins are probably encoded by a single gene on chromosome 5 and generated by alternative splicing. In addition they concluded that a gene on chromosome 16 contains homology to the glucocorticoid receptor gene, at least between nucleotides 570 and 1,640. This could be the receptor gene for a related steroid, a processed gene or pseudogene, or a gene with other function that shares a domain with the GRL gene. See 138060.

Theriault et al. (1989) used in situ hybridization with a biotinylated cDNA probe to localize the human GRL gene to human chromosome 5q31. The assignment was confirmed by hybridization to chromosomes from an individual with a balanced reciprocal translocation (5;8)(q31;q13). Using chromosome-5-linked DNA probes to study somatic cell hybrids retaining partial chromosome 5 and clinical samples from patients with acquired deletions of 5q, Huebner et al. (1990) concluded that the GRL gene is telomeric to CSF2 (138960) and centromeric to CSF1R (164770)/PDGFRB (173410), near ECGF (131220).

Huizenga et al. (2000) described 5 patients with biochemical and clinical cortisol resistance. They found alterations in receptor number or ligand affinity and/or the ability of dexamethasone to inhibit mitogen-induced cell proliferation. To investigate the molecular defects leading to the clinical and biochemical pictures in these patients, they screened the GCCR gene using PCR-SSCP sequence analysis. No GCCR gene alterations were found in these patients. The authors concluded that alterations somewhere in the cascade of events starting with ligand binding to the GCCR protein, and finally resulting in the regulation of the expression of glucocorticoid-responsive genes, or postreceptor defects or interactions with other nuclear factors, form the pathophysiologic basis of cortisol resistance in these patients.

Inflammatory responses in many cell types are coordinately regulated by the opposing actions of NF-kappa-B (164011) and the glucocorticoid receptor. Webster et al. (2001) reported the identification of a tumor necrosis factor (TNF)-responsive NF-kappa-B DNA-binding site 5-prime to the GCCR promoter that leads to a 1.5-fold increase in GR-alpha mRNA and a 2.0-fold increase in GR-beta mRNA in HeLaS3 cells, which endogenously express both glucocorticoid receptor isoforms. However, TNF-alpha (191160) treatment disproportionately increased the steady-state levels of the GR-beta protein isoform over GR-alpha, making GR-beta the predominant endogenous receptor isoform. Similar results were observed following treatment of human lymphoid cells with TNF-alpha or interleukin-1 (IL1; see 147760). The increase in GR-beta protein expression correlated with the development of glucocorticoid resistance.

25 ANIMAL MODEL

Pepin et al. (1992) developed transgenic mice in which antisense RNA complementary to the 3-prime noncoding region of the glucocorticoid receptor mRNA led to reduced glucocorticoid receptor capacity and function, predominantly in neuronal tissue. Montkowski et al. (1995) demonstrated that the transgenic mice have profound behavioral changes and elevated plasma corticotropin concentrations in response to stress. Treatment with moclobemide, an inhibitor of monoamine oxidase type A (309850), reversed the behavioral deficits in this mouse model.

Since the glucocorticoid receptor can influence transcription both through DNA-binding-dependent and -independent mechanisms, Reichardt et al. (1998) attempted to separate these modes of action by introducing the arg458-to-thr point mutation into the glucocorticoid receptor by gene targeting using the Cre/loxP system. This mutation
5 impairs dimerization and therefore GRE-dependent transactivation, while functions that require cross-talk with other transcription factors, such as transrepression of AP-1-driven genes, remain intact. In contrast to GR^{-/-} mice, these mutants, termed GR-dim, are viable, revealing the in vivo relevance of DNA-binding-independent activities of the glucocorticoid receptor. The GR-dim/dim mice lose the ability to transactivate gene
10 transcription by cooperative DNA binding but retain the repressing function of the corticosteroid receptor. Furthermore, the development and function of the adrenal medulla are not impaired in these mice.

The glucocorticoid receptor controls transcription of target genes both directly by
15 interaction with DNA regulatory elements and indirectly by cross-talk with other transcription factors. In response to various stimuli, including stress, glucocorticoids coordinate metabolic, endocrine, immune, and nervous system responses and ensure an adequate profile of transcription. In the brain, glucocorticoid receptor has been thought to modulate emotional behavior, cognitive functions, and addictive states. These aspects
20 could not be studied in the absence of functional glucocorticoid receptor because inactivation of the *Gr11* gene in mice causes lethality at birth. Therefore, Tronche et al. (1999) generated tissue-specific mutations of this gene using the Cre/loxP-recombination system. This allowed them to generate viable adult mice with loss of glucocorticoid receptor function in selected tissues. Loss of glucocorticoid receptor function in the
25 nervous system impaired regulation of the hypothalamus-pituitary-adrenal axis, resulting in increased glucocorticoid levels that lead to symptoms reminiscent of those observed in Cushing syndrome. Conditional mutagenesis of glucocorticoid receptor in the nervous system provided genetic evidence for the importance of glucocorticoid receptor signaling in emotional behavior because mutant animals showed an impaired behavioral response to
30 stress and displayed reduced anxiety.

Using a tandem array of mouse mammary tumor virus reporter elements and a form of glucocorticoid receptor labeled with green fluorescent protein, McNally et al. (2000) observed targeting of the receptor to response elements in live mouse cells.

Photobleaching experiments provided direct evidence that the hormone-occupied receptor undergoes rapid exchange between chromatin and the nucleoplasmic compartment. Thus, McNally et al. (2000) concluded that the interaction of regulatory proteins with target sites in chromatin is a more dynamic process than had been believed.

5

.0001 GLUCOCORTICOID RESISTANCE, FAMILIAL [NR3C1, ASP641VAL]

In the kindred originally reported by Vingerhoeds et al. (1976) and studied by Chrousos et al. (1982, 1983) and Lipsett et al. (1985), Hurley et al. (1991) sequenced the glucocorticoid receptor from 3 affected members. A change at nucleotide 2054 predicted substitution of valine for aspartic acid at amino acid residue 641. The proband was homozygous while the other relatives were heterozygous for the mutation. The point mutation was in the steroid-binding domain of the receptor.

15 .0002 GLUCOCORTICOID RESISTANCE, FAMILIAL [NR3C1, IVS6DS, 4-BP DEL]

In all 3 affected members of a Dutch kindred, Karl et al. (1993) found that 1 NR3C1 allele had a 4-bp deletion that removed the donor splice site affecting the last 2 bases of the exon and the first 2 nucleotides of intron 6. The father and 3 of 5 children were affected. Affected members had hypercortisolism and approximately half of normal glucocorticoid receptors. The proband was a daughter with manifestations of hyperandrogenism. Furthermore, in the proband, in 1 of her affected brothers, and in her unaffected sister, Karl et al. (1993) found a single nucleotide substitution, asparagine to serine at codon 363 in exon 2 (G1220). Transfection studies indicated that the amino acid substitution did not alter the function of the glucocorticoid receptor. The presence of the null allele in this family was apparently compensated for by increased cortisol production at the expense of concurrent hyperandrogenism.

30 .0003 GLUCOCORTICOID RESISTANCE, CELLULAR [NR3C1, LEU753PHE]

Ashraf and Thompson (1993) showed that 2 glucocorticoid-resistant cell lines were hemizygous for a leu753-to-phe mutation. Both were derived from a wildtype cell line

heterozygous for this mutation; the resistant cell lines had suffered the loss of the normal allele.

.0007 GLUCOCORTICOID RECEPTOR POLYMORPHISM [NR3C1, ASN363SER

5 Koper et al. (1997) identified a polymorphism, located at nucleotide position 1220 (AAT to AGT), that results in an asparagine-to-serine change in codon 363 of the NR3C1 protein. Huizenga et al. (1998) investigated whether this polymorphism is associated with altered sensitivity to glucocorticoids. In a group of 216 elderly persons, they identified 13 heterozygotes for the asn363-to-ser polymorphism by PCR/SSCP analysis. Thus, they
10 found the polymorphism in 6.0% of the studied population. Huizenga et al. (1998) concluded that individuals carrying this polymorphism were clinically healthy, but had a higher sensitivity to exogenously administered glucocorticoids, with respect to both cortisol suppression and insulin response. Huizenga et al. (1998) speculated that life-long exposure to the mutated allele may be accompanied by an increased body mass index and
15 a lowered bone mineral density in the lumbar spine with no effect on blood pressure.

Dobson et al. (2001) investigated the association between the 363S allele and risk factors for coronary heart disease and diabetes mellitus in a population of European origin living in the northeast of the United Kingdom. Blood samples from 135 males and 240
20 females were characterized for 363 allele status. The overall frequency of the 363S allele was 3.0%; 23 heterozygotes (7 males and 16 females) but no 363S homozygotes were identified. These data showed a significant association of the 363S allele with increased waist-to-hip ratio in males but not in females. This allele was not associated with blood pressure, body mass index, serum cholesterol, triglycerides, low-density lipoprotein and
25 high-density lipoprotein cholesterol levels, or glucose tolerance status. The authors concluded that this GR polymorphism may contribute to central obesity in men.

 Another sequence comprises sequence encoding **Metap11**LOC165470 which is similar to methionine aminopeptidase-like 1.

30

 Another sequence comprises sequence encoding TCF4: transcription factor 4. TCF4 encodes transcription factor 4, a basic helix-turn-helix transcription factor.

The protein recognizes an Ephrussi-box ('E-box') binding site ('CANNTG') - a motif first identified in immunoglobulin enhancers. TCF4 is expressed predominantly in pre-B-cells, although it is found in other tissues as well. TCF4 is known to produce multiple transcripts; however as the complete structure is only known for the transcript that encodes the b isoform, that is the variant presented here.

Another sequence comprises sequence encoding IMMUNOGLOBULIN TRANSCRIPTION FACTOR 2 (ITF2). This sequence maps to gene map locus 18q21.1 Corneliussen et al. (1991) identified a family of nuclear proteins that bind to a motif of the glucocorticoid response element (GRE) in the enhancer of the murine leukemia virus SL3-3. This motif resembled those found in Ephrussi, or E, boxes (see 147141). Corneliussen et al. (1991) termed this family SEF2 for 'SL3-3 enhancer factors 2.' They cloned the gene encoding one of these proteins, SEF2-1B, from human thymocytes. Corneliussen et al. (1991) found that the SEF2-1B gene encodes a 667-amino acid polypeptide with homology to other basic helix-loop-helix (bHLH) transcription factors. Corneliussen et al. (1991) found multiple related mRNA species, presumed to be the result of differential splicing.

Henthorn et al. (1990) identified a helix-loop-helix transcription factor that bound to the mu-E5 motif of the immunoglobulin heavy chain enhancer and to the kappa-E2 motif found in the light chain enhancer, and designated it ITF2 for 'immunoglobulin transcription factor 2.' ITF2 encodes a predicted 623-amino acid protein (Henthorn et al., 1990).

Pscherer et al. (1996) isolated the promoter region of human somatostatin receptor 2 (SSTR2; 182452) and identified a novel initiator element. By screening a mouse brain cDNA expression library, Pscherer et al. (1996) isolated a transcription factor, which they termed SEF2, that bound to the E box of the SSTR2 initiator element. Sequencing revealed that this factor was the murine homolog of human SEF2-1B. DNA binding studies demonstrated that the basal transcription factor TFIIB (189963) can be tethered to the SSTR2 initiator element through physical interaction with SEF2. Northern blotting revealed that SEF2-1B is expressed in human adult and embryonic tissues including heart, brain, placenta, skeletal muscle, and lung.

In a search for polymorphic CTG repeats as candidate genes for bipolar disorder, Breschel et al. (1997) screened a genomic human chromosome 18-specific library and identified a 1.6-kb clone with a CTG(24) repeat that mapped to 18q21.1. The expansion

was located in an intron of SEF2-1. The repeat was highly polymorphic in both bipolar and control subjects with an observed heterozygosity of 84%. Expansions of up to CTG(2100) were possible but were not associated with an obvious abnormal phenotype. The location of the repeat was determined by radiation hybrid mapping and by linkage analysis.

- 5 Analysis of a mouse Sef2-1 gene showed that it contains 22 exons and that many of the introns are more than 10 kb long.

Another sequence comprises sequence encoding CRYZ: crystallin, zeta (quinone reductase); LOC348462. This sequence maps to gene map locus 1p31-p22. There are two sequences associated with CRYZ; Lab designation RA5A-re (SEQ ID NO: 317) - 1q21.2
10 synaptotagmin XI; and Lab designation RA5B-re (SEQ ID NO: 316) - 1p31.1
There are two genes: CRYZ and LOC348462 - and cryz sits at the start of both.

Crystallins are separated into two classes: taxon-specific, or enzyme, and ubiquitous. The latter class constitutes the major proteins of vertebrate eye lens and maintains the transparency and refractive index of the lens. The former class is also called
15 phylogenetically-restricted crystallins. This gene encodes a taxon-specific crystallin protein which has NADPH-dependent quinone reductase activity distinct from other known quinone reductases. It lacks alcohol dehydrogenase activity although by similarity it is considered a member of the zinc-containing alcohol dehydrogenase family. Unlike other mammalian species, in humans, lens expression is low. One pseudogene is known to
20 exist.

In addition to the alpha, beta, and gamma crystallin families, which are present in the ocular lenses of all vertebrates, a number of other crystallins have been found to be present in high amounts in lenses from phylogenetically restricted groups. Most of these 'taxon-specific' crystallins are pyridine nucleotide-dependent oxidoreductases that are also
25 present at enzymatic levels in nonlenticular tissues. The acquisition of this new function as a lens crystallin generally occurs without gene duplication and apparently without affecting the catalytic role of the enzyme. Zeta-crystallin/quinone reductase was initially described as a major protein in the lens of the guinea pig (Huang et al., 1987), in which a mutation in the gene is associated with hereditary cataracts (Rodriguez et al., 1992). It was
30 later found to be also present in high amounts in the lens of camels (Garland et al., 1991) and at enzymatic levels in a number of nonlenticular tissues of various species. In the lens of guinea pigs and camels, it comprises about 10% of the total soluble protein. Gonzalez et al. (1994) isolated and characterized the human zeta-crystallin gene and its processed

pseudogene. The functional gene is composed of 9 exons and spans about 20 kb. The 5-prime flanking region of the gene is rich in G and C (58%) and lacks TATA and CAAT boxes. Previous analysis of the guinea pig gene revealed the presence of 2 different promoters, one responsible for the high lens-specific expression and the other for expression at the enzymatic level in numerous tissues. A comparative analysis with the guinea pig gene showed that a region of approximately 2.5 kb that includes the promoter responsible for the high expression in the lens in the guinea pig is not present in the human gene.

By Southern analysis of human/mouse somatic cell hybrids, Heinzmann et al. (1994) assigned the CRYZ gene to human chromosome 1 and regionalized the assignment to 1p31-p22 by fluorescence in situ hybridization. They also identified 5 RFLPs.

Another sequence (Lab designation RA3_A_rE.txt (SEQ ID NO: 317)) comprises sequence encoding HM13; histocompatibility (minor) 13. This sequence maps to gene map locus 20q11.21.

Signal peptide peptidase, or SPP, catalyzes intramembrane proteolysis of some signal peptides after they have been cleaved from a preprotein. In humans, SPP activity is required to generate signal sequence-derived human lymphocyte antigen-E epitopes that are recognized by the immune system, and to process hepatitis C virus core protein. Weihofen et al. (2002) [PubMed 12077416] identified human SPP as a polytopic membrane protein with sequence motifs characteristic of the presenilin-type aspartic proteases.[supplied by OMIM]

Throughout this application, various publications are referenced. The disclosures of these publications in their entireties, as well as the references cited in these publications, are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains. References containing the sequences of the proteins described herein are also cited throughout this application. These references and the sequence contained within these references are also hereby incorporated by reference for the purposes of describing the gene sequence, chromosomal location, structural properties and functional properties of the genes and gene products described herein.

REFERENCES

- Hicks, G. G. et al. "Functional genomics in mice by tagged sequence mutagenesis." *Nat Genet* **16**, 338-44. (1997).
- Blay, J. & Brown, K. D. "Functional receptors for epidermal growth factor in an epithelial-cell line derived from the rat small intestine." *Biochem J* **225**, 85-94 (1985).
- Blay, J. & Brown, K. D. "Epidermal growth factor promotes the chemotactic migration of cultured rat intestinal epithelial cells." *J Cell Physiol* **124**, 107-12 (1985).
- Bell, A. C. & Felsenfeld, G. "Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene." *Nature* **405**, 482-5. (2000).
- Ohlsson, R., Renkawitz, R. & Lobanenko, V. "CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease." *Trends Genet* **17**, 520-7 (2001).
- Oldham, S. M., Clark, G. J., Gangarosa, L. M., Coffey, R. J., Jr. & Der, C. J. "Activation of the Raf-1/MAP kinase cascade is not sufficient for Ras transformation of RIE-1 epithelial cells." *Proc Natl Acad Sci U S A* **93**, 6924-8 (1996).
- von Melchner, H., Reddy, S. & Ruley, H. E. "Isolation of cellular promoters by using a retrovirus promoter trap." *Proc Natl Acad Sci USA* **87**, 3733-7 (1990).
- Ahmed, R. & Graham, A. F. "Persistent infections in L cells with temperaturesensitive mutants of reovirus." *J Virol* **23**, 250-62 (1977).
- Ahmed, R. et al. "Role of the host cell in persistent viral infection: coevolution of L cells and reovirus during persistent infection." *Cell* **25**, 325-32 (1981).
- Morgan, D. O. et al. "Insulin-like growth factor II receptor as a multifunctional binding protein." *Nature* **329**, 301-7 (1987).
- Tong, P. Y., Tollefsen, S. E. & Kornfeld, S. "The cation-independent mannose 6-phosphate receptor binds insulin-like growth factor II." *J Biol Chem* **263**, 2585-8 (1988).
- Bakay, M., Zhao, P., Chen, J. & Hoffman, E. P. "A web-accessible complete transcriptome of normal human and DMD muscle." *Neuromuscul Disord* **12** Suppl 1, S125-41 (2002).
- Hark, A. T. et al. "CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus." *Nature* **405**, 486-9 (2000).
- Bell, A. C. & Felsenfeld, G. "Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene." *Nature* **405**, 482-5 (2000).
- McFall, A. et al. "Oncogenic Ras blocks anoikis by activation of a novel effector pathway independent of phosphatidylinositol 3-kinase." *Mol Cell Biol* **21**, 5488-99

(2001).

Wright, J. F., Kurosky, A. & Wasi, S. "An endothelial cell-surface form of annexin II binds human cytomegalovirus." *Biochem Biophys Res Commun* **198**, 983-9 (1994).

Zhao, W. Q. et al. "Secretion of Annexin II via activation of insulin receptor and insulin-like growth factor receptor." *J Biol Chem* **278**, 4205-15 (2003).

Nakagawa, H. et al. "Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer." *Proc Natl Acad Sci USA* **98**, 591-6 (2001).

Rainier, S. et al. "Relaxation of imprinted genes in human cancer." *Nature* **362**, 747-9 (1993).

Arceci, R. J.; King, A. A.; Simon, M. C.; Orkin, S. H.; Wilson, D. B. "Mouse GATA-4: a retinoic acid-inducible GATA-binding transcription factor expressed in endodermally derived tissues and heart." *Molec. Cell. Biol.* **13**: 2235-2246, 1993.

Das, A. K.; Helps, N. R.; Cohen, P. T. W.; Barford, D. "Crystal structure of the protein serine/threonine phosphatase 2C at 2.0 angstrom resolution." *EMBO J.* **15**: 6798-6809, 1996.

Mann, D. J.; Campbell, D. G.; McGowan, C. H.; Cohen, P. T. W.: "Mammalian protein serine/threonine phosphatase 2C: cDNA cloning and comparative analysis of amino acid sequences." *Biochim. Biophys. Acta* **1130**: 100-104, 1992.

Takekawa, M.; Maeda, T.; Saito, H.: "Protein phosphatase 2C- α inhibits the human stress-responsive p38 and JNK MAPK pathways." *EMBO J.* **17**: 4744-4752, 1998.

Gradi, A.; Imataka, H.; Svitkin, Y. V.; Rom, E.; Raught, B.; Morino, S.; Sonenberg, N. : "A novel functional human eukaryotic translation initiation factor 4G." *Molec. Cell. Biol.* **18**: 334-342, 1998.

Imataka, H.; Gradi, A.; Sonenberg, N.: "A newly identified N-terminal amino acid sequence of human eIF4G binds poly(A)-binding protein and functions in poly(A)-dependent translation." *EMBO J.* **17**: 7480-7489, 1998.

Irurzun A, Sanchez-Palomino S, Novoa I, Carrasco L. "Monensin and nigericin prevent the inhibition of host translation by poliovirus, without affecting p220 cleavage." *J Virol* 1995 Dec;69 (12):7453-60

Raho G, Barone V, Rossi D, Philipson L, Sorrentino V. "The gas 5 gene shows four alternative splicing patterns without coding for a protein." DIBIT, Istituto Scientifico San Raffaele, Milan, Italy. *Gene* **256** (1-2):13-7 Oct. 3, 2000.

Lai WS, Thompson MJ, Blackshear PJ. "Characteristics of the intron involvement in the mitogen-induced expression of Zfp-36." *J Biol Chem* **273**(1):506-17 1998 Jan 2;

Hu, S.-I.; Carozza, M.; Klein, M.; Nantermet, P.; Luk, D.; Crowl, R. M. :

“Human HtrA, an evolutionarily conserved serine protease identified as a differentially expressed gene product in osteoarthritic cartilage.” *J. Biol. Chem.* 273: 34406-34412, 1998.

Zumbrunn, J.; Trueb, B. “Localization of the gene for a serine protease with IGF-binding domain (PRSS11) to human chromosome” 10q25.3-q26.2. *Genomics* 45: 461-462, 1997.

Zumbrunn, J.; Trueb, B. “Primary structure of a putative serine protease specific for IGF-binding proteins.” *FEBS Lett.* 398: 187-192, 1996.

Johnson, K. R.; Merrick, W. C.; Zoll, W. L.; Zhu, Y. “Identification of cDNA clones for the large subunit of eukaryotic translation initiation factor 3: comparison of homologues from human, *Nicotiana tabacum*, *Caenorhabditis elegans*, and *Saccharomyces cerevisiae*.” *J. Biol. Chem.* 272: 7106-7113, 1997.

Osaka, F.; Kawasaki, H.; Aida, N.; Saeki, M.; Chiba, T.; Kawashima, S.; Tanaka, K.; Kato, S. “A new NEDD8-ligating system for cullin-4A.” *Genes Dev.* 12: 2263-2268, 1998.

Ye XY, Ng TB “Isolation of a new cyclophilin-like protein from chickpeas with mitogenic, antifungal and anti-HIV-1 reverse transcriptase activities.” *Life Sci* 2002 Jan 25;70(10):1129-38

Wang P, Cardenas ME, Cox GM, Perfect JR, Heitman J. “Two cyclophilin A homologs with shared and distinct functions important for growth and virulence of *Cryptococcus neoformans*.” *EMBO Rep* 2001 Jun;2(6):511-8

Quintrell, N.; Lebo, R.; Varmus, H.; Bishop, J. M.; Pettenati, M. J.; Le Beau, M. M.; Diaz, M. O.; Rowley, J. D. “Identification of a human gene (HCK) that encodes a protein-tyrosine kinase and is expressed in hemopoietic cells.” *Molec. Cell. Biol.* 7: 2267-2275, 1987.

Ziegler, S. F.; Marth, J. D.; Lewis, D. B.; Perlmutter, R. M. “Novel protein-tyrosine kinase gene (hck) preferentially expressed in cells of hematopoietic origin.” *Molec. Cell. Biol.* 7: 2276-2285, 1987.

Deleuze, J. F.; Dhorne, S.; Hazan, J.; Borghi, E.; Raynaud, N.; Pollet, N.; Meunier-Rotival, M.; Deschatrette, J.; Alagille, D.; Hadchouel, M. “Deleted chromosome 20 from a patient with Alagille syndrome isolated in a cell hybrid through leucine transport selection: study of three candidate genes.” *Mammalian Genome* 5: 663-669, 1994.

Kaestner, K. H.; Hiemisch, H.; Luckow, B.; Schutz, G. “The HNF-3 gene family of transcription factors in mice: gene structure, cDNA sequence, and mRNA distribution.” *Genomics* 20: 377-385, 1994.

Mincheva, A.; Lichter, P.; Schutz, G.; Kaestner, K. H. “Assignment of the human genes for hepatocyte nuclear factor 3-alpha, -beta, and -gamma (HNF3A, HNF3B, HNF3G) to 14q12-q13, 20p11, and 19q13.2-q13.4.” *Genomics* 39: 417-419, 1997.

Nagase, T.; Ishikawa, K.; Miyajima, N.; Tanaka, A.; Kotani, H.; Nomura, N.; Ohara, O. "Prediction of the coding sequences of unidentified human genes. IX. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro." *DNA Res.* **5**: 31-39, 1998.

Nakamura, H.; Sudo, T.; Tsuiki, H.; Miyake, H.; Morisaki, T.; Sasaki, J.; Masuko, N.; Kochi, M.; Ushio, Y.; Saya, H. "Identification of a novel human homolog of the *Drosophila* dlg, P-dlg, specifically expressed in the gland tissues and interacting with p55." *FEBS Lett.* **433**: 63-67, 1998.

Aso, T.; Haque, D.; Fukudome, K.; Brower, C. S.; Conaway, J. W.; Conaway, R. C. "A human cDNA encoding the 110-kDa A subunit of RNA polymerase II transcription factor elongin." *Gene* **168**: 277-278, 1996.

Aso, T.; Lane, W. S.; Conaway, J. W.; Conaway, R. C. "Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II." *Science* **269**: 1439-1443, 1995.

Aso, T.; Mokady, N.; Haque, D.; Conaway, R. C.; Conaway, J. W. "Assignment of a human gene encoding the 110-kDa subunit of general transcription factor elongin (SIII) to chromosome 1p36.1." *Genomics* **30**: 393-394, 1995.

Duan, D. R.; Pause, A.; Burgess, W. H.; Aso, T.; Chen, D. Y. T.; Garrett, K. P.; Conaway, R. C.; Conaway, J. W.; Linehan, W. M.; Klausner, R. D. "Inhibition of transcription elongation by the VHL tumor suppressor protein." *Science* **269**: 1402-1406, 1995.

Kibel, A.; Iliopoulos, O.; DeCaprio, J. A.; Kaelin, W. G., Jr. "Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C." *Science* **269**: 1444-1446, 1995.

Kavsak, P.; Rasmussen, R. K.; Causing, C. G.; Bonni, S.; Zhu, H.; Thomsen, G. H.; Wrana, J. L. "Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF-beta receptor for degradation." *Molec. Cell* **6**: 1365-1375, 2000.

Lallemant, F.; Mazars, A.; Prunier, C.; Bertrand, F.; Kornprost, M.; Gallea, S.; Roman-Roman, S.; Cherqui, G.; Atfi, A. "Smad7 inhibits the survival nuclear factor kappa-B and potentiates apoptosis in epithelial cells." *Oncogene* **20**: 879-884, 2001.

Roijer, E.; Moren, A.; ten Dijke, P.; Stenman, G. "Assignment of the Smad7 gene (MADH7) to human chromosome 18q21.1 by fluorescence in situ hybridization." *Cytogenet. Cell Genet.* **81**: 189-190, 1998.

Topper, J. N.; Cai, J.; Qiu, Y.; Anderson, K. R.; Xu, Y.-Y.; Deeds, J. D.; Feeley, R.; Gimeno, C. J.; Woolf, E. A.; Tayber, O.; Mays, G. G.; Sampson, B. A.; Schoen, F. J.; Gimbrone, M. A., Jr.; Falb, D. "Vascular MADs: two novel MAD-related genes selectively inducible by flow in human vascular endothelium. Proc. Nat. Acad." *Sci.* **94**: 9314-9319, 1997.

Groden, J.; Thliveris, A.; Samowitz, W.; Carlson, M.; Gelbert, L.; Albertsen, H.; Joslyn, G.; Stevens, J.; Spirio, L.; Robertson, M.; Sargeant, L.; Krapcho, K.; Wolff, E.; Burt, R.; Hughes, J. P.; Warrington, J.; McPherson, J.; Wasmuth, J.; Le Paslier, D.; Abderrahim, H.;

- Cohen, D.; Leppert, M.; White, R. "Identification and characterization of the familial adenomatous polyposis coli gene." *Cell* **66**: 589-600, 1991.
- Horii, A.; Nakatsuru, S.; Ichii, S.; Nagase, H.; Nakamura, Y. "Multiple forms of the APC gene transcripts and their tissue-specific expression." *Hum. Molec. Genet.* **2**: 283-287, 1993.
- Joslyn, G.; Carlson, M.; Thliveris, A.; Albertsen, H.; Gelbert, L.; Samowitz, W.; Groden, J.; Stevens, J.; Spirio, L.; Robertson, M.; Sargeant, L.; Krapcho, K.; Wolff, E.; Burt, R.; Hughes, J. P.; Warrington, J.; McPherson, J.; Wasmuth, J.; Le Paslier, D.; Abderrahim, H.; Cohen, D.; Leppert, M.; White, R. "Identification of deletion mutations and three new genes at the familial polyposis locus." *Cell* **66**: 601-613, 1991.
- Larsen, N.; Samuelsson, T.; Swieb, C. "The Signal Recognition Particle Database (SRPDB)." *Nucleic Acids Res.* **26**: 177-178, 1998.
- Lingelbach, K.; Zweib, C.; Webb, J.; Marshallsay, C.; Hoben, P.; Walter, P.; Dobberstein, B. "Isolation and characterization of a cDNA clone encoding the 19 kDa protein of signal recognition particle (SRP): expression and binding to 7SL RNA." *Nucleic Acids Res.* **16**: 9431-9442, 1988.
- Wild, K.; Sinning, I.; Cusack, S. "Crystal structure of an early protein-RNA assembly complex of the signal recognition particle." *Science* **294**: 598-601, 2001.
- Davis, D. B.; Delmonte, A. J.; Ly, C. T.; McNally, E. M. "Myoferlin, a candidate gene and potential modifier of muscular dystrophy." *Hum. Molec. Genet.* **9**: 217-226, 2000.
- Hull, E.; Sarkar, M.; Spruijt, M. P. N.; Hoppener, J. W. M.; Dunn, R.; Schachter, H. "Organization and localization to chromosome 5 of the human UDP-N acetylglucosamine:alpha-3-D-mannoside beta-1,2-N-acetylglucosaminyltransferase 1 gene." *Biochem. Biophys. Res. Commun.* **176**: 608-615, 1991.
- Ioffe, E.; Stanley, P. "Mice lacking N-acetylglucosaminyltransferase I activity die at mid-gestation, revealing an essential role for complex or hybrid N-linked carbohydrates." *Proc. Nat. Acad. Sci.* **91**: 728-732, 1994.
- Kumar, R.; Stanley, P. "Transfection of a human gene that corrects the Lec1 glycosylation defect: evidence for transfer of the structural gene for N-acetylglucosaminyltransferase I." *Molec. Cell. Biol.* **9**: 5713-5717, 1989. Note: Erratum: *Molec. Cell. Biol.* **10**: 3857 only, 1990.
- Kumar, R.; Yang, J.; Eddy, R. L.; Byers, M. G.; Shows, T. B.; Stanley, P. "Cloning and expression of the murine gene and chromosomal location of the human gene encoding N-acetylglucosaminyltransferase I." *Glycobiology* **2**: 383-393, 1992.
- Kumar, R.; Yang, J.; Larsen, R. D.; Stanley, P. "Cloning and expression of N-acetylglucosaminyltransferase I, the medial Golgi transferase that initiates complex N-linked carbohydrate formation." *Proc. Nat. Acad. Sci.* **87**: 9948-9952, 1990.
- Metzler, M.; Gertz, A.; Sarkar, M.; Schachter, H.; Schrader, J. W.; Marth, J. D. "Complex

asparagine-linked oligosaccharides are required for morphogenic events during post-implantation development." *EMBO J.* **13**: 2056-2065, 1994.

Pownall, S.; Kozak, C. A.; Schappert, K.; Sarkar, M.; Hull, E.; Schachter, H.; Marth, J. D. "Molecular cloning and characterization of the mouse UDP-N-acetylglucosamine:alpha-3-D-mannoside beta-1,2-N-acetylglucosaminyltransferase I gene." *Genomics* **12**: 699-704, 1992.

Puthalakath, H.; Burke, J.; Gleeson, P. A. "Glycosylation defect in lec1 Chinese hamster ovary mutant is due to a point mutation in N-acetylglucosaminyltransferase 1 gene." *J. Biol. Chem.* **271**: 27818-27822, 1996.

Tan, J.; D'Agostaro, G. A. F.; Bendiak, B.; Reck, F.; Sarkar, M.; Squire, J. A.; Leong, P.; Schachter, H. "The human UDP-N-acetylglucosamine:alpha-6-D-mannoside-beta-1,2-N-acetylglucosaminyltransferase II gene (MGAT2): cloning of genomic DNA, localization to chromosome 14q21, expression in insect cells and purification of the recombinant protein." *Europ. J. Biochem.* **231**: 317-328, 1995.

Yip, B.; Chen, S.-H.; Mulder, H.; Hoppener, J. W. M.; Schachter, H. "Organization of the human beta-1,2-N-acetylglucosaminyltransferase I gene (MGAT1), which controls complex and hybrid N-glycan synthesis." *Biochem. J.* **321**: 465-474, 1997.

Takagaki, Y.; MacDonald, C. C.; Shenk, T.; Manley, J. L. "The human 64-kDa polyadenylation (sic) factor contains a ribonucleoprotein-type RNA binding domain and unusual auxiliary motifs." *Proc. Nat. Acad. Sci.* **89**: 1403-1407, 1992.

Takagaki, Y.; Manley, J. L. "Levels of polyadenylation factor CstF-64 control IgM heavy chain mRNA accumulation and other events associated with B cell differentiation." *Molec. Cell* **2**: 761-771, 1998.

Takagaki, Y.; Seipelt, R. L.; Peterson, M. L.; Manley, J. L. "The polyadenylation factor CstF-64 regulates alternative processing of IgM heavy chain pre-mRNA during B cell differentiation." *Cell* **87**: 941-952, 1996.

Kapanadze, B.; Kashuba, V.; Baranova, A.; Rasool, O.; van Everdink, W.; Liu, Y.; Syomova, A.; Corcoran, M.; Poltarau, A.; Brodyansky, V.; Syomova, N.; Kazakov, A.; Ibbotson, R.; van den Berg, A.; Gizatullin, R.; Fedorova, L.; Sulimova, G.; Zelenin, A.; Deaven, L.; Lehrach, H.; Grander, D.; Buys, C.; Oscier, D.; Zabarovsky, E. R.; Einhorn, S.; Yankovsky, N. "A cosmid and cDNA fine physical map of a human chromosome 13q14 region frequently lost in B-cell chronic lymphocytic leukemia and identification of a new putative tumor suppressor gene, Leu5." *FEBS Lett.* **426**: 266-270, 1998.

Liu, Y.; Hermanson, M.; Grander, D.; Merup, M.; Wu, X.; Heyman, M.; Rasool, O.; Juliusson, G.; Gahrton, G.; Detlofsson, R. "13q deletions in lymphoid malignancies." *Blood* **86**: 1911-1915, 1995.

Liu, Y.; Szekely, L.; Grander, D.; Soderhall, S.; Juliusson, G.; Gahrton, G.; Linder, S.; Einhorn, S. "Chronic lymphocytic leukemia cells with allelic deletions at 13q14 commonly have one intact RB1 gene: evidence for a role of an adjacent locus." *Proc. Nat. Acad. Sci.* **90**: 8697-8701, 1993.

Pahl, P. M. B.; Hodges, Y. K.; Meltesen, L.; Perryman, M. B.; Horwitz, K. B.; Horwitz, L. D. "ZNF207, a ubiquitously expressed zinc finger gene on chromosome 6p21.3." *Genomics* **53**: 410-412, 1998.

Deed, R. W.; Hirose, T.; Mitchell, E. L. D.; Santibanez-Koref, M. F.; Norton, J. D. "Structural organisation and chromosomal mapping of the human Id-3 gene." *Gene* **151**: 309-314, 1994.

Ellmeier, W.; Aguzzi, A.; Kleiner, E.; Kurzbauer, R.; Weith, A. "Mutually exclusive expression of a helix-loop-helix gene and N-myc in human neuroblastomas and in normal development." *EMBO J.* **11**: 2563-2571, 1992.

Kee, B. L.; Rivera, R. R.; Murre, C. "Id3 inhibits B lymphocyte progenitor growth and survival in response to TGF-beta." *Nature Immun.* **2**: 242-247, 2001.

Lyden, D.; Young, A. Z.; Zagzag, D.; Yan, W.; Gerald, W.; O'Reilly, R.; Bader, B. L.; Hynes, R. O.; Zhuang, Y.; Manova, K.; Benezra, R. "Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts." *Nature* **401**: 670-677, 1999.

Pan, L.; Sato, S.; Frederick, J. P.; Sun, X.-H.; Zhuang, Y. "Impaired immune responses and B-cell proliferation in mice lacking the Id3 gene." *Molec. Cell. Biol.* **19**: 5969-5980, 1999.

White, P. S.; Maris, J. M.; Beltinger, C.; Sulman, E.; Marshall, H. N.; Fujimori, M.; Kaufman, B. A.; Biegel, J. A.; Allen, C.; Hilliard, C.; Valentine, M. B.; Look, A. T.; Enomoto, H.; Sakiyama, S.; Brodeur, G. M. "A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3." *Proc. Nat. Acad. Sci.* **92**: 5520-5524, 1995.

Lam, E.; Martin, M.; Wiederrecht, G. "Isolation of a cDNA encoding a novel human FK506-binding protein homolog containing leucine zipper and tetratricopeptide repeat motifs." *Gene* **160**: 297-302, 1995.

Kitamura H, Kanehira K, Okita K, Morimatsu M, Saito M. "A novel nuclear I kappa B protein that potentiates LPS-induced IL-6 production." *FEBS Lett* **17**;485(1):53-6 2000 Nov

Bertin, J.; Nir, W.-J.; Fischer, C. M.; Tayber, O. V.; Errada, P. R.; Grant, J. R.; Keilty, J. J.; Gosselin, M. L.; Robison, K. E.; Wong, G. H. W.; Glucksmann, M. A.; DiStefano, P. S. "Human CARD4 protein is a novel CED-4/Apaf-1 cell death family member that activates NF-kappa-B." *J. Biol. Chem.* **274**: 12955-12958, 1999.

Inohara, N.; Koseki, T.; del Peso, L.; Hu, Y.; Yee, C.; Chen, S.; Carrio, R.; Merino, J.; Liu, D.; Ni, J.; Nunez, G. "Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-kappa-B." *J. Biol. Chem.* **274**: 14560-14567, 1999.

Ge, B.; Gram, H.; Di Padova, F.; Huang, B.; New, L.; Ulevitch, R. J.; Luo, Y.; Han, J. 'MAPKK-independent activation of p38-alpha mediated by TAB1-dependent

autophosphorylation of p38-alpha." *Science* **295**: 1291-1294, 2002.

Shibuya, H.; Yamaguchi, K.; Shirakabe, K.; Tonegawa, A.; Gotoh, Y.; Ueno, N.; Irie, K.; Nishida, E.; Matsumoto, K. TAB1: an activator of the TAK1 MAPKKK in TGF-beta signal transduction. *Science* **272**: 1179-1182, 1996.

Ge B, Gram H, Di Padova F, Huang B, New L, Ulevitch RJ, Luo Y, Han J. "MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha." *Science*; **295**(5558):1291-4 2002 Feb 15

Beck, S.; Hanson, I.; Kelly, A.; Pappin, D. J.; Trowsdale, J. "A homologue of the *Drosophila* female sterile homeotic (fsh) gene in the class II region of the human MHC." *DNA Sequence* **2**: 203-210, 1992.

Denis, G. V.; Green, M. R. "A novel, mitogen-activated nuclear kinase is related to a *Drosophila* developmental regulator." *Genes Dev.* **10**: 261-271, 1996.

Nomura, N.; Nagase, T.; Miyajima, N.; Sazuka, T.; Tanaka, A.; Sato, S.; Seki, N.; Kawarabayasi, Y.; Ishikawa, K.; Tabata, S. "Prediction of the coding sequences of unidentified human genes. II. The coding sequences of 40 new genes (KIAA0041-KIAA0080) deduced by analysis of cDNA clones from human cell line KG-1." *DNA Res.* **1**: 223-229, 1994.

Okamoto, N.; Ando, A.; Kawai, J.; Yoshiwara, T.; Tsuji, K.; Inoko, H. "Orientation of HLA-DNA gene and identification of a CpG island-associated gene adjacent to DNA in human major histocompatibility complex class II region." *Hum. Immun.* **32**: 221-228, 1991.

Thorpe, K. L.; Abdulla, S.; Kaufman, J.; Trowsdale, J.; Beck, S. "Phylogeny and structure of the RING3 gene." *Immunogenetics* **44**: 391-396, 1996.

Dorin, J. R.; Emslie, E.; van Heyningen, V. "Related calcium-binding proteins map to the same subregion of chromosome 1q and to an extended region of synteny on mouse chromosome 3." *Genomics* **8**: 420-426, 1990.

Ferrari, S.; Calabretta, B.; deRiel, J. K.; Battini, R.; Ghezzi, F.; Lauret, E.; Griffin, C.; Emanuel, B. S.; Gurrieri, F.; Baserga, R. "Structural and functional analysis of a growth-regulated gene, the human calcyclin." *J. Biol. Chem.* **262**: 8325-8332, 1987.

Oakey, R. J.; Watson, M. L.; Seldin, M. F. "Construction of a physical map on mouse and human chromosome 1: comparison of 13 Mb of mouse and 11 Mb of human DNA." *Hum. Molec. Genet.* **1**: 613-620, 1992.

Schafer, B. W.; Wicki, R.; Engelkamp, D.; Mattei, M.-G.; Heizmann, C. W. "Isolation of a YAC clone covering a cluster of nine S100 genes on human chromosome 1q21: rationale for a new nomenclature of the S100 calcium-binding protein family." *Genomics* **25**: 638-643, 1995.

Seldin, M. F. van Heyningen, V.; Emslie, E.; Dorin, J. R. "Related calcium binding proteins map to the same sub-region of chromosome 1q and to an extended region of

synteny on mouse chromosome 3." *Cytogenet. Cell Genet.* **51**: 1095 only, 1989.

Pinol-Roma, S.; Swanson, M. S.; Gall, J. G.; Dreyfuss, G. :

"A novel heterogeneous nuclear RNP protein with a unique distribution on nascent transcripts." *J. Cell Biol.* **109**: 2575-2587, 1989.

Crompton, M. R.; Moss, S. E.; Crumpton, M. J. "Diversity in the lipocortin/calpactin family." *Cell* **55**: 1-3, 1988.

Horlick, K. R.; Cheng, I. C.; Wong, W. T.; Wakeland, E. K.; Nick, H. S. "Mouse lipocortin I gene structure and chromosomal assignment: gene duplication and the origins of a gene family." *Genomics* **10**: 365-374, 1991.

Huebner, K.; Cannizzaro, L. A.; Croce, C. M.; Frey, A. Z.; Wallner, B. P.; Hecht, B. K.; Hecht, F. "Chromosome localization of the human genes for lipocortin I and the lipocortin II family. (Abstract) *Cytogenet. Cell Genet.* **46**: 631 only, 1987.

Huebner, K.; Cannizzaro, L. A.; Frey, A. Z.; Hecht, B. K.; Hecht, F.; Croce, C. M.; Wallner, B. P. "Chromosomal localization of the human genes for lipocortin I and lipocortin II." *Oncogene Res.* **2**: 299-310, 1988.

Kaplan, R.; Jaye, M.; Burgess, W. H.; Schlaepfer, D. D.; Haigler, H. T. "Cloning and expression of cDNA for human endonexin II, a Ca(2+) and phospholipid binding protein." *J. Biol. Chem.* **263**: 8037-8043, 1988.

Pepinsky, R. B.; Tizard, R.; Mattaliano, R. J.; Sinclair, L. K.; Miller, G. T.; Browning, J. L.; Chow, E. P.; Burne, C.; Huang, K.-S.; Pratt, D.; Wachter, L.; Hession, C.; Frey, A. Z.; Wallner, B. P. "Five distinct calcium and phospholipid binding proteins share homology with lipocortin I." *J. Biol. Chem.* **263**: 10799-10811, 1988.

Shohat, M.; Korenberg, J. R.; Schwabe, A. D.; Rotter, J. I. "Hypothesis: familial Mediterranean fever--a genetic disorder of the lipocortin family?" *Am. J. Med. Genet.* **34**: 163-167, 1989.

Wallner, B. P.; Mattaliano, R. J.; Hession, C.; Cate, R. L.; Tizard, R.; Sinclair, L. K.; Foeller, C.; Chow, E. P.; Browning, J. L.; Ramachandran, K. L.; Pepinsky, R. B. "Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity." *Nature* **320**: 77-81, 1986.

Walther, A.; Riehemann, K.; Gerke, V. "A novel ligand of the formyl peptide receptor: annexin I regulates neutrophil extravasation by interacting with the FPR." *Molec. Cell* **5**: 831-840, 2000.

Blanchard, E. M.; Iizuka, K.; Christe, M.; Conner, D. A.; Geisterfer-Lowrance, A.; Schoen, F. J.; Maughan, D. W.; Seidman, C. E.; Seidman, J. G. "Targeted ablation of the murine alpha-tropomyosin gene." *Circulation Res.* **81**: 1005-1010, 1997.

Brown, J. H.; Kim, K.-H.; Jun, G.; Greenfield, N. J.; Dominguez, R.; Volkmann, N.; Hitchcock-DeGregori, S. E.; Cohen, C. "Deciphering the design of the tropomyosin molecule." *Proc. Nat. Acad. Sci.* **98**: 8496-8501, 2001.

Eyre, H.; Akkari, P. A.; Wilton, S. D.; Callen, D. C.; Baker, E.; Laing, N. G. "Assignment of the human skeletal muscle alpha-tropomyosin gene (TPM1) to band 15q22 by fluorescence in situ hybridization." *Cytogenet. Cell Genet.* 69: 15-17, 1995.

"Karibe, A.; Tobacman, L. S.; Strand, J.; Butters, C.; Back, N.; Bachinski, L. L.; Arai, A. E.; Ortiz, A.; Roberts, R.; Homsher, E.; Fananapazir, L. "Hypertrophic cardiomyopathy caused by a novel alpha-tropomyosin mutation (V95A) is associated with mild cardiac phenotype, abnormal calcium binding to troponin, abnormal myosin cycling, and poor prognosis." *Circulation* 103: 65-71, 2001.

Lees-Miller, J. P.; Helfman, D. M. "The molecular basis for tropomyosin isoform diversity." *BioEssays* 13: 429-437, 1991.

MacLeod, A. R.; Gooding, C. "Human hTM-alpha gene: expression in muscle and nonmuscle tissue." *Molec. Cell. Biol.* 8: 433-440, 1988.

Muthuchamy, M.; Pieples, K.; Rethinasamy, P.; Hoit, B.; Grupp, I. L.; Boivin, G. P.; Wolska, B.; Evans, C.; Solaro, R. J.; Wieczorek, D. F. "Mouse model of a familial hypertrophic cardiomyopathy mutation in alpha-tropomyosin manifests cardiac dysfunction." *Circ. Res.* 85: 47-56, 1999.

Schleef, M.; Werner, K.; Satzger, U.; Kaupmann, K.; Jockusch, H. "Chromosomal localization and genomic cloning of the mouse alpha-tropomyosin gene Tpm-1." *Genomics* 17: 519-521, 1993.

Thierfelder, L.; Watkins, H.; MacRae, C.; Lamas, R.; McKenna, W.; Vosberg, H.-P.; Seidman, J. G.; Seidman, C. E. "Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere." *Cell* 77: 701-712, 1994.

Tiso, N.; Rampoldi, L.; Pallavicini, A.; Zimbello, R.; Pandolfo, D.; Valle, G.; Lanfranchi, G.; Danieli, G. A. "Fine mapping of five human skeletal muscle genes: alpha-tropomyosin, beta-tropomyosin, troponin-I slow-twitch, troponin-I fast-twitch, and troponin-C fast." *Biochem. Biophys. Res. Commun.* 230: 347-350, 1997.

Watkins, H.; Anan, R.; Coviello, D. A.; Spirito, P.; Seidman, J. G.; Seidman, C. E. : "A de novo mutation in alpha-tropomyosin that causes hypertrophic cardiomyopathy." *Circulation* 91: 2302-2305, 1995.

Watkins, H.; McKenna, W. J.; Thierfelder, L.; Suk, H. J.; Anan, R.; O'Donoghue, A.; Spirito, P.; Matsumori, A.; Moravec, C. S.; Seidman, J. G.; Seidman, C. E. "Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy." *New Eng. J. Med.* 332: 1058-1064, 1995.

Gillespie, G. A. J.; Somlo, S.; Germino, G. G.; Weinstat-Saslow, D.; Reenders, S. T. : CpG island in the region of an autosomal dominant polycystic kidney disease locus defines the 5-prime end of a gene encoding a putative proton channel. *Proc. Nat. Acad. Sci.* 88: 4289-4293, 1991.

Bell, A. C.; Felsenfeld, G. :

Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. *Nature* 405: 482-485, 2000.

Bell, A. C.; West, A. G.; Felsenfeld, G. : "The protein CTCF is required for the enhancer blocking activity of vertebrate insulators." *Cell* 98: 387-396, 1999.

Chao, W.; Huynh, K. D.; Spencer, R. J.; Davidow, L. S.; Lee, J. T. :

"CTCF, a candidate trans-acting factor for X-inactivation choice." *Science* 295: 345-347, 2002.

Filippova, G. N.; Fagerlie, S.; Klenova, E. M.; Myers, C.; Dehner, Y.; Goodwin, G.; Neiman, P. E.; Collins, S. J.; Lobanenko, V. V. : "An exceptionally conserved transcriptional repressor, CTCF, employs different combinations of zinc fingers to bind diverged promoter sequences of avian and mammalian c-myc oncogenes." *Molec. Cell. Biol.* 16: 2802-2813, 1996.

Filippova, G. N.; Thienes, C. P.; Penn, B. H.; Cho, D. H.; Hu, Y. J.; Moore, J. M.; Klesert, T. R.; Lobanenko, V. V.; Tapscott, S. J. :

CTCF-binding sites flank CTG/CAG repeats and form a methylation-sensitive insulator at the DM1 locus. *Nature Genet.* 28: 335-343, 2001.

Hark, A. T.; Schoenherr, C. J.; Katz, D. J.; Ingram, R. S.; Levrose, J. M.; Tilghman, S. M. :

CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. *Nature* 405: 486-489, 2000.

Agulnik, A. I.; Zharkikh, A.; Boettger-Tong, H.; Bourgeron, T.; McElreavey, K.; Bishop, C. E. :

Evolution of the DAZ gene family suggests that Y-linked DAZ plays little, or a limited, role in spermatogenesis but underlines a recent African origin for human populations. *Hum. Molec. Genet.* 7: 1371-1377, 1998.

Eberhart, C. G.; Maines, J. Z.; Wasserman, S. A. : Meiotic cell cycle requirement for a fly homologue of human Deleted in Azoospermia. *Nature* 381: 783-785, 1996.

Rugglu, M.; Speed, R.; Taggart, M.; McKay, S. J.; Kilanowski, F.; Saunders, P.; Derin, J.; Cooke, H. J. : The mouse Dazla gene encodes a cytoplasmic protein essential for gametogenesis. *Nature* 389: 73-77, 1997.

Saxena, R.; Brown, L. G.; Hawkins, T.; Alagappan, R. K.; Skaletsky, H.; Reeve, M. P.; Reijo, R.; Rozen, S.; Dinulos, M. B.; Disteche, C. M.; Page, D. C. : The DAZ gene cluster on the human Y chromosome arose from an autosomal gene that was transposed, repeatedly amplified and pruned. *Nature Genet.* 14: 292-299, 1996.

Shan, Z.; Hirschmann, P.; Seebacher, T.; Edelmann, A.; Jauch, A.; Morell, J.; Urbitsch, P.; Vogt, P. H. : A SPGY copy homologous to the mouse gene Dazla and the Drosophila gene boule is autosomal and expressed only in the human male gonad. *Hum. Molec. Genet.* 5: 2005-2011, 1996.

Slee, R.; Grimes, B.; Speed, R. M.; Taggart, M.; Maguire, S. M.; Ross, A.; McGill, N. I.; Saunders, P. T. K.; Cooke, H. J. : A human DAZ transgene confers partial rescue of the mouse *Dazl* null phenotype. *Proc. Nat. Acad. Sci.* 96: 8040-8045, 1999.

Yen, P. H.; Chai, N. N.; Salido, E. C. : The human autosomal gene *DAZLA*: testis specificity and a candidate for male infertility. *Hum. Molec. Genet.* 5: 2013-2017, 1996.

Huebner, K.; Cannizzaro, L. A.; Croce, C. M.; Frey, A. Z.; Wallner, B. P.; Hecht, B. K.; Hecht, F. : Chromosome localization of the human genes for lipocortin I and the lipocortin II family. (Abstract) *Cytogenet. Cell Genet.* 46: 631 only, 1987.

Huebner, K.; Cannizzaro, L. A.; Frey, A. Z.; Hecht, B. K.; Hecht, F.; Croce, C. M.; Wallner, B. P. : Chromosomal localization of the human genes for lipocortin I and lipocortin II. *Oncogene Res.* 2: 299-310, 1988.

Richard, I.; Broux, O.; Chiannikulchai, N.; Fougereuse, F.; Allamand, V.; Bourg, N.; Brenguier, L.; Devaud, C.; Pasturaud, P.; Roudaut, C.; Lorenzo, F.; Sebastiani-Kabatchis, C.; Schultz, R. A.; Polymeropoulos, M. H.; Gyapay, G.; Auffray, C.; Beckmann, J. S. : Regional localization of human chromosome 15 loci. *Genomics* 23: 619-627, 1994.

Spano, F.; Raugei, G.; Palla, E.; Colella, C.; Melli, M. : Characterization of the human lipocortin-2-encoding multigene family: its structure suggests the existence of a short amino acid unit undergoing duplication. *Gene* 95: 243-251, 1990.

Takahashi, S.; Reddy, S. V.; Chirgwin, J. M.; Devlin, R.; Haipek, C.; Anderson, J.; Roodman, G. D. : Cloning and identification of annexin II as an autocrine/paracrine factor that increases osteoclast formation and bone resorption. *J. Biol. Chem.* 269: 28696-28701, 1994.

Chellaiah, A.; Davis, A.; Mohanakumar, T. : Cloning of a unique human homologue of the *Escherichia coli* DNAJ heat shock protein. *Biochim. Biophys. Acta* 1174: 111-113, 1993.

Osaka, F.; Kawasaki, H.; Aida, N.; Saeki, M.; Chiba, T.; Kawashima, S.; Tanaka, K.; Kato, S. : A new NEDD8-ligating system for cullin-4A. *Genes Dev.* 12: 2263-2268, 1998.

Date, H.; Onodera, O.; Tanaka, H.; Iwabuchi, K.; Uekawa, K.; Igarashi, S.; Koike, R.; Hiroi, T.; Yuasa, T.; Awaya, Y.; Sakai, T.; and 9 others : Early-onset ataxia with ocular motor apraxia and hypoalbuminemia is caused by mutations in a new HIT superfamily gene. *Nature Genet.* 29: 184-188, 2001.

Moreira, M.-C.; Barbot, C.; Tachi, N.; Kozuka, N.; Uchida, E.; Gibson, T.; Mendonca, P.; Costa, M.; Barros, J.; Yanagisawa, T.; Watanabe, M.; Ikeda, Y.; Aoki, M.; Nagata, T.; Coutinho, P.; Sequeiros, J.; Koenig, M. : The gene mutated in ataxia-oculomotor apraxia 1 encodes the new HIT/Zn-finger protein aprataxin. *Nature Genet.* 29: 189-193, 2001.

Ohkuma, Y.; Sumimoto, H.; Hoffmann, A.; Shimasaki, S.; Horikoshi, M.; Roeder, R. G. : Structural motifs and potential sigma homologies in the large subunit of human general transcription factor TFIIE. *Nature* 354: 398-401, 1991.

Peterson, M. G.; Inostroza, J.; Maxon, M. E.; Flores, O.; Admon, A.; Reinberg, D.; Tjian, R. : Structure and functional properties of human general transcription factor IIE. *Nature* 354: 369-373, 1991.

Yudkovsky, N.; Ranish, J. A.; Hahn, S. :
A transcription reinitiation intermediate that is stabilized by activator. *Nature* 408: 225-229, 2000.

Umbricht, C. B.; Erdile, L. F.; Jabs, E. W.; Kelly, T. J. : Cloning, overexpression, and genomic mapping of the 14-kDa subunit of human replication protein A. *J. Biol. Chem.* 268: 6131-6138, 1993.

Umbricht, C. B.; Griffin, C. A.; Hawkins, A. L.; Grzeschik, K. H.; O'Connell, P.; Leach, R.; Green, E. D.; Kelly, T. J. : High-resolution genomic mapping of the three human replication protein A genes (RPA1, RPA2, and RPA3). *Genomics* 20: 249-257, 1994.

Erdile, L. F.; Heyer, W.-D.; Kolodner, R.; Kelly, T. J. : Characterization of a cDNA encoding the 70-kDa single-stranded DNA-binding subunit of human replication protein A and the role of the protein in DNA replication. *J. Biol. Chem.* 266: 12090-12098, 1991.

Gomes, X. V.; Wold, M. S. : Functional domains of the 70-kilodalton subunit of human replication protein A. *Biochemistry* 35: 10558-10568, 1996.

Miyamoto, Y.; Saito, Y.; Nakayama, M.; Shimasaki, Y.; Yoshimura, T.; Yoshimura, M.; Harada, M.; Kajiyama, N.; Kishimoto, I.; Kuwahara, K.; Hino, J.; Ogawa, E.; Hamanaka, I.; Kamitani, S.; Takahashi, N.; Kawakami, R.; Kangawa, K.; Yasue, H.; Nakao, K. :
Replication protein A1 reduces transcription of the endothelial nitric oxide synthase gene containing a -786T-C mutation associated with coronary spastic angina. *Hum. Molec. Genet.* 9: 2629-2637, 2000.

Nakayama, M.; Yasue, H.; Yoshimura, M.; Shimasaki, Y.; Kugiyama, K.; Ogawa, H.; Motoyama, T.; Saito, Y.; Ogawa, Y.; Miyamoto, Y.; Nakao, K. :
T(-786)-C mutation in the 5-prime-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. *Circulation* 99: 2864-2870, 1999.

Shen, L. X.; Basilion, J. P.; Stanton, V. P., Jr. : Single-nucleotide polymorphisms can cause different structural folds of mRNA. *Proc. Nat. Acad. Sci.* 96: 7871-7876, 1999.

Umbricht, C. B.; Erdile, L. F.; Jabs, E. W.; Kelly, T. J. : Cloning, overexpression, and genomic mapping of the 14-kDa subunit of human replication protein A. *J. Biol. Chem.* 268: 6131-6138, 1993.

Umbricht, C. B.; Griffin, C. A.; Hawkins, A. L.; Grzeschik, K. H.; O'Connell, P.; Leach, R.; Green, E. D.; Kelly, T. J. :
High-resolution genomic mapping of the three human replication protein A genes (RPA1, RPA2, and RPA3). *Genomics* 20: 249-257, 1994.

Acquati, F.; Malgaretti, N.; Hauptschein, R.; Rao, P.; Gaidano, G.; Taramelli, R. :
A 2-Mb YAC contig linking the plasminogen-apoprotein(a) gene family to the insulin-like

growth factor 2 receptor (IGF2R) gene on the telomeric region of chromosome 6 (6q26-q27). *Genomics* 22: 664-666, 1994.

Barlow, D. P.; Stoger, R.; Herrmann, B. G.; Saito, K.; Schweifer, N. :
The mouse insulin-like growth factor type-2 receptor is imprinted and closely linked to the Tme locus. *Nature* 349: 84-87, 1991.

DeChiara, T. M.; Robertson, E. J.; Efstratiadis, A. :
Parental imprinting of the mouse insulin-like growth factor II gene. *Cell* 64: 849-859, 1991.

De Souza, A. T.; Hankins, G. R.; Washington, M. K.; Fine, R. L.; Orton, T. C.; Jirtle, R. L. :
Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. *Oncogene* 10: 1725-1729, 1995.

De Souza, A. T.; Hankins, G. R.; Washington, M. K.; Orton, T. C.; Jirtle, R. L. :
M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. *Nature Genet.* 11: 447-449, 1995.

Feinberg, A. P. :
Genomic imprinting and gene activation in cancer. *Nature Genet.* 4: 110-113, 1993.

Haig, D.; Graham, C. :
Genomic imprinting and the strange case of the insulin-like growth factor II receptor. *Cell* 64: 1045-1046, 1991.

Haig, D.; Westoby, M. :
Parent-specific gene expression and the triploid endosperm. *Am. Nat.* 134: 147-155, 1989.

Kalscheuer, V. M.; Mariman, E. C.; Schepens, M. T.; Rehder, H.; Ropers, H.-H. :
The insulin-like-growth factor type-2 receptor gene is imprinted in the mouse but not in humans. *Nature Genet.* 5: 74-78, 1993.

Kiess, W.; Blickenstaff, G. D.; Sklar, M. M.; Thomas, C. L.; Nissley, S. P.; Sahagian, G. G. :
Biochemical evidence that the type II insulin-like growth factor receptor is identical to the cation-independent mannose 6-phosphate receptor. *J. Biol. Chem.* 263: 9339-9344, 1988.

Killian, J. K.; Oka, Y.; Jang, H.-S.; Fu, X.; Waterland, R. A.; Sohda, T.; Sakaguchi, S.; Jirtle, R. L. :
Mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) variants in American and Japanese populations. *Hum. Mutat.* 18: 25-31, 2001.

Kornfeld, S.; Mellman, I. :
The biogenesis of lysosomes. *Annu. Rev. Cell Biol.* 5: 483-525, 1989.

Lau, M. M. H.; Stewart, C. E. H.; Liu, Z.; Bhatt, H.; Rotwein, P.; Stewart, C. L. :
Loss of the imprinted IGF2/cation-independent mannose 6-phosphate receptor results in fetal overgrowth and perinatal lethality. *Genes Dev.* 8: 2953-2963, 1994.

- Laureys, G.; Barton, D. E.; Ullrich, A.; Francke, U. :
Chromosomal mapping of the gene for the type II insulin-like growth factor receptor/cation-independent mannose 6-phosphate receptor in man and mouse. *Genomics* 3: 224-229, 1988.
- MacDonald, R. G.; Pfeffer, S. R.; Coussens, L.; Teppner, M. A.; Brocklebank, C. M.; Mole, J. E.; Anderson, J. K. :
A single receptor binds both insulin-like growth factor II and mannose-6-phosphate. *Science* 239: 1134-1137, 1988.
- Morgan, D. O.; Edman, J. D.; Standring, D. N.; Fried, V. A.; Smith, M. C.; Roth, R. A.; Rutter, W. J. :
Insulin-like growth factor II receptor as a multifunctional binding protein. *Nature* 329: 301-307, 1987.
- Motyka, B.; Korbitt, G.; Pinkoski, M. J.; Heibin, J. A.; Caputo, A.; Hobman, M.; Barry, M.; Shostak, I.; Sawchuk, T.; Holmes, C. F. B.; Gaudie, J.; Bleackley, R. C. :
Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis. *Cell* 103: 491-500, 2000.
- Ogawa, O.; McNoe, L. A.; Eccles, M. R.; Morison, I. M.; Reeve, A. E. :
Human insulin-like growth factor type I and type II receptors are not imprinted. *Hum. Molec. Genet.* 2: 2163-2165, 1993.
- Oshima, A.; Nolan, C. M.; Kyle, J. W.; Grubb, J. H.; Sly, W. S. :
The human cation-independent mannose 6-phosphate receptor: cloning and sequence of the full-length cDNA and expression of functional receptor in COS cells. *J. Biol. Chem.* 263: 2553-2562, 1988.
- Puertollano, R.; Aguilar, R. C.; Gorshkova, I.; Crouch, R. J.; Bonifacino, J. S. :
Sorting of mannose 6-phosphate receptors mediated by the GGAs. *Science* 292: 1712-1716, 2001.
- Rao, P. H.; Murty, V. V. V. S.; Gaidano, G.; Hauptschein, R.; Dalla-Favera, R.; Chaganti, R. S. K. :
Subregional mapping of 8 single copy loci to chromosome 6 by fluorescence in situ hybridization. *Cytogenet. Cell Genet.* 66: 272-273, 1994.
- Roth, R. A. :
Structure of the receptor for insulin-like growth factor II: the puzzle amplified. *Science* 239: 1269-1271, 1988.
- Sleutels, F.; Zwart, R.; Barlow, D. P. :
The non-coding Air RNA is required for silencing autosomal imprinted genes. *Nature* 415: 810-813, 2002.
- Souza, R. F.; Appel, R.; Yin, J.; Wang, S.; Smolinski, K. N.; Abraham, J. M.; Zou, T.-T.; Shi, Y.-Q.; Lei, J.; Cottrell, J.; Cymes, K.; Biden, K.; Simms, L.; Leggett, B.; Lynch, P. M.; Frazier, M.; Powell, S. M.; Harpaz, N.; Sugimura, H.; Young, J.; Meltzer, S. J. :

Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours. (Letter) *Nature Genet.* 14: 255-257, 1996.

Szebeny, G.; Rotwein, P. :

The mouse insulin-like growth factor II/cation-independent mannose 6-phosphate (IGF-II/MPR) receptor gene: molecular cloning and genomic organization. *Genomics* 19: 120-129, 1994.

Tong, P. Y.; Tollefsen, S. E.; Kornfeld, S. :

The cation-independent mannose 6-phosphate receptor binds insulin-like growth factor II. *J. Biol. Chem.* 263: 2585-2588, 1988.

Waheed, A.; Braulke, T.; Junghans, U.; von Figura, K. :

Mannose 6-phosphate/insulin like growth factor II receptor: the two types of ligands bind simultaneously to one receptor at different sites. *Biochem. Biophys. Res. Commun.* 152: 1248-1254, 1988.

Xu, Y.; Goodyer, C. G.; Deal, C.; Polychronakos, C. :

Functional polymorphism in the parental imprinting of the human IGF2R gene. *Biochem. Biophys. Res. Commun.* 197: 747-754, 1993.

Young, L. E.; Fernandes, K.; McEvoy, T. G.; Butterwith, S. C.; Gutierrez, C. G.; Carolan, C.; Broadbent, P. J.; Robinson, J. J.; Wilmut, I.; Sinclair, K. D. :

Epigenetic change in IGF2R is associated with fetal overgrowth after sheep embryo culture. *Nature Genet.* 27: 153-154, 2001.

Zhu, Y.; Doray, B.; Poussu, A.; Lehto, V.-P.; Kornfeld, S. "Binding of GGA2 to the lysosomal enzyme sorting motif of the mannose 6-phosphate receptor." *Science* 292: 1716-1718, 2001.

McGuinness, T.; Porteus, M. H.; Smiga, S.; Bulfone, A.; Kingsley, C.; Qiu, M.; Liu, J. K.; Long, J. E.; Xu, D.; Rubenstein, J. L. R. "Sequence, organization, and transcription of the *Dlx-1* and the *Dlx-2* locus. *Genomics* 35: 473-485, 1996.

Ozcelik, T.; Porteus, M. H.; Rubenstein, J. L. R.; Francke, U. "DLX2 (TES1), a homeobox gene of the Distal-less family, assigned to conserved regions on human and mouse chromosomes 2." *Genomics* 13: 1157-1161, 1992.

Porteus, M. H.; Brice, A. E. J.; Bulfone, A.; Usdin, T. B.; Ciaranello, R. D.; Rubenstein, J. L. R. "Isolation and characterization of a library of cDNA clones that are preferentially expressed in the embryonic telencephalon." *Molec. Brain Res.* 12: 7-22, 1992.

Qiu, M.; Bulfone, A.; Martinez, S.; Meneses, J. J.; Shimamura, K.; Pedersen, R. A.; Rubenstein, J. L. "Null mutation of *Dlx-2* results in abnormal morphogenesis of proximal first and second branchial arch derivatives and abnormal differentiation in the forebrain." *Genes Dev.* 9: 2523-2538, 1995.

Bray, P.; Lichter, P.; Thiesen, H.-J.; Ward, D. C.; Dawid, I. B. "Characterization and mapping of human genes encoding zinc finger proteins." *Proc. Nat. Acad. Sci.* 88: 9563-9567, 1991.

Huebner, K.; Druck, T.; LaForgia, S.; Lasota, J.; Croce, C. M.; Lanfranccone, L.; Donti, E.; Pengue, G.; La Mantia, G.; Pelicci, P.-G.; Lania, L. "Chromosomal localization of four human zinc finger cDNAs." *Hum. Genet.* 91: 217-222, 1993.

Lania, L.; Donti, E.; Pannuti, A.; Pascucci, A.; Pengue, G.; Feliciello, I.; La Mantia, G.; Lanfranccone, L.; Pelicci, P.-G. "cDNA isolation, expression analysis, and chromosomal localization of two human zinc finger genes." *Genomics* 6: 333-340, 1990.

Thiesen, H.-J. "Multiple genes encoding zinc finger domains are expressed in human T cells." *New Biologist* 2: 363-374, 1990.

Boise, L. H.; Gonzalez-Garcia, M.; Postema, C. E.; Ding, L.; Lindsten, T.; Turka, L. A.; Mao, X.; Nunez, G.; Thompson, C. B. "Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death." *Cell* 74: 597-608, 1993.

Moliterno, A. R.; Hankins, W. D.; Spivak, J. L. "Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera." *New Eng. J. Med.* 338: 572-580, 1998.

Shimizu, S.; Narita, M.; Tsujimoto, Y. "Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC." *Nature* 399: 483-487, 1999.

Silva, M.; Richard, C.; Benito, A.; Sanz, C.; Olalla, I.; Fernandez-Luna, J. L. "Expression of Bcl-x in erythroid precursors from patients with polycythemia vera." *New Eng. J. Med.* 338: 564-571, 1998.

Vander Heiden, M. G.; Chandel, N. S.; Williamson, E. K.; Schumacker, P. T.; Thompson, C. B. "Bcl-X(L) regulates the membrane potential and volume homeostasis of mitochondria." *Cell* 91: 627-637, 1997.

Bauer, W. O.; Nanda, I.; Beck, G.; Schmid, M.; Jakob, F. "Human puromycin-sensitive aminopeptidase: cloning of 3-prime UTR, evidence for a polymorphism at aa 140 and refined chromosomal localization to 17q21." *Cytogenet. Cell Genet.* 92: 221-224, 2001.

Huber, G.; Thompson, A.; Gruninger, F.; Mechler, H.; Hochstrasser, R.; Hauri, H.-P.; Malherbe, P. "cDNA cloning and molecular characterization of human brain metalloprotease MP100: a beta-secretase candidate?" *J. Neurochem.* 72: 1215-1223, 1999.

Osada, T.; Sakaki, Y.; Takeuchi, T. "Puromycin-sensitive aminopeptidase gene (Psa) maps to mouse chromosome 11." *Genomics* 56: 361-362, 1999.

Schonlein, C.; Loffler, J.; Huber, G. "Purification and characterization of a novel metalloprotease from human brain with the ability to cleave substrates derived from the N-terminus of beta-amyloid protein." *Biochem. Biophys. Res. Commun.* 201: 45-53, 1994.

Thompson, M. W.; Tobler, A.; Fontana, A.; Hersh, L. B. "Cloning and analysis of the gene for the human puromycin-sensitive aminopeptidase." *Biochem. Biophys. Res. Commun.* 258: 234-240, 1999.

Tobler, A. R.; Constam, D. B.; Schmitt-Graff, A.; Malipiero, U.; Schlapbach, R.; Fontana, A. "Cloning of the human puromycin-sensitive aminopeptidase and evidence for expression in neurons." *J. Neurochem.* 68: 889-897, 1997.

Tait, J. F.; Frankenberry, D. A.; Miao, C. H.; Killary, A. M.; Adler, D. A.; Disteche, C. M. "Chromosomal localization of the human annexin III (ANX3) gene." *Genomics* 10: 441-448, 1991.

Tait, J. F.; Smith, C.; Xu, L.; Cookson, B. T. "Structure and polymorphisms of the human annexin III (ANX3) gene." *Genomics* 18: 79-86, 1993.

Liang, Y.; Tedder, T. F. "Identification of a CD20-, Fc-epsilon-RI-beta-related gene family: sixteen new MS4A family members expressed in human and mouse." *Genomics* 72: 119-127, 2001.

Huston, E.; Lumb, S.; Russell, A.; Catterall, C.; Ross, A. H.; Steele, M. R.; Bolger, G. B.; Perry, M. J.; Owens, R. J.; Houslay, M. D. "Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3." *Biochem. J.* 328: 549-558, 1997.

Livi, G. P.; Kmetz, P.; McHale, M. M.; Cieslinski, L. B.; Sathe, G. M.; Taylor, D. P.; Davis, R. L.; Torphy, T. J.; Balcarek, J. M. "Cloning and expression of cDNA for a human low-K(m), rolipram-sensitive cyclic AMP phosphodiesterase." *Molec. Cell. Biol.* 10: 2678-2686, 1990.

Milatovich, A.; Bolger, G.; Michaeli, T.; Francke, U. "Chromosome localizations of genes for five cAMP-specific phosphodiesterases in man and mouse." *Somat. Cell Molec. Genet.* 20: 75-86, 1994.

Oberholte, R.; Bhakta, S.; Alvarez, R.; Bach, C.; Zuppan, P.; Mulkins, M.; Jarnagin, K.; Shelton, E. R. "The cDNA of a human lymphocyte cyclic-AMP phosphodiesterase (PDE IV) reveals a multigene family." *Gene* 129: 239-247, 1993.

Szpirer, C.; Szpirer, J.; Riviere, M.; Swinnen, J.; Vicini, E.; Conti, M. "Chromosomal localization of the human and rat genes (PDE4D and PDE4B) encoding the cAMP-specific phosphodiesterases 3 and 4." *Cytogenet. Cell Genet.* 69: 11-14, 1995.

Xu, R. X.; Hassell, A. M.; Vanderwall, D.; Lambert, M. H.; Holmes, W. D.; Luther, M. A.; Rocque, W. J.; Milburn, M. V.; Zhao, Y.; Ke, H.; Nolte, R. T. "Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity." *Science* 288: 1822-1825, 2000.

Ashraf, J.; Thompson, E. B. "Identification of the activation-labile gene: a single point mutation in the human glucocorticoid receptor presents as two distinct receptor phenotypes." *Molec. Endocr.* 7: 631-642, 1993.

Bamberger, C. M.; Bamberger, A.-M.; de Castro, M.; Chrousos, G. P. "Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans." *J. Clin. Invest.* 95: 2435-2441, 1995.

Bronnegard, M.; Werner, S.; Gustafsson, J.-A. "Primary cortisol resistance associated with a thermolabile glucocorticoid receptor in a patient with fatigue as the only symptom." *J. Clin. Invest.* 78: 1270-1278, 1986.

Carlstedt-Duke, J.; Stromstedt, P.-E.; Wrange, O.; Bergman, T.; Gustafsson, J.-A.; Jornvall, H. "Domain structure of the glucocorticoid receptor protein." *Proc. Nat. Acad. Sci.* 84: 4437-4440, 1987.

Chrousos, G. P.; Renquist, D.; Brandon, D.; Eil, C.; Pugeat, M.; Vigersky, R.; Cutler, G. B., Jr.; Loriaux, D. L.; Lipsett, M. B. "Glucocorticoid hormone resistance during primate evolution: receptor-mediated mechanisms." *Proc. Nat. Acad. Sci.* 79: 2036-2040, 1982.

Chrousos, G. P.; Vingerhoeds, A.; Brandon, D.; Eil, C.; Pugeat, M.; DeVroede, M.; Loriaux, D. L.; Lipsett, M. B. "Primary cortisol resistance in man: a glucocorticoid receptor-mediated disease." *J. Clin. Invest.* 69: 1261-1269, 1982.

Chrousos, G. P.; Vingerhoeds, A. C. M.; Loriaux, D. L.; Lipsett, M. B. "Primary cortisol resistance: a family study." *J. Clin. Endocr. Metab.* 56: 1243-1245, 1983.

Diamond, M. I.; Robinson, M. R.; Yamamoto, K. R. "Regulation of expanded polyglutamine protein aggregation and nuclear localization by the glucocorticoid receptor." *Proc. Nat. Acad. Sci.* 97: 657-661, 2000.

Dobson, M. G.; Redfern, C. P. F.; Unwin, N.; Weaver, J. U. "The N363S polymorphism of the glucocorticoid receptor: potential contribution to central obesity in men and lack of association with other risk factors for coronary heart disease and diabetes mellitus." *J. Clin. Endocr. Metab.* 86: 2270-2274, 2001.

Encio, I. J.; Detera-Wadleigh, S. D. "The genomic structure of the human glucocorticoid receptor." *J. Biol. Chem.* 266: 7182-7188, 1991.

Francke, U.; Foellmer, B. E. "The glucocorticoid receptor gene is in 5q31-q32." *Genomics* 4: 610-612, 1989.

Gehring, U.; Segnitz, B.; Foellmer, B.; Francke, U. "Chromosome assignment of the human gene for the glucocorticoid receptor (GRL)." (Abstract) *Cytogenet. Cell Genet.* 37: 476, 1984.

Gehring, U.; Segnitz, B.; Foellmer, B.; Francke, U. "Assignment of the human gene for the glucocorticoid receptor to chromosome 5." *Proc. Nat. Acad. Sci.* 82: 3751-3755, 1985.

Giuffra, L. A.; Kennedy, J. L.; Castiglione, C. M.; Evans, R. M.; Wasmuth, J. J.; Kidd, K. K. "Glucocorticoid receptor maps to the distal long arm of chromosome 5." *Cytogenet. Cell Genet.* 49: 313-314, 1988.

Hollenberg, S. M.; Weinberger, C.; Ong, E. S.; Cerelli, G.; Oro, A.; Lebo, R.; Thompson, E. B.; Rosenfeld, M. G.; Evans, R. M. "Primary structure and expression of a functional human glucocorticoid receptor cDNA." *Nature* 318: 635-641, 1985.

Huebner, K.; Nagarajan, L.; Besa, E.; Angert, E.; Lange, B. J.; Cannizzaro, L. A.; van den Berghe, H.; Santoli, D.; Finan, J.; Croce, C. M.; Nowell, P. C. "Order of genes on human chromosome 5q with respect to 5q interstitial deletions." *Am. J. Hum. Genet.* 46: 26-36, 1990.

Huizenga, N. A. T. M.; de Lange, P.; Koper, J. W.; Clayton, R. N.; Farrell, W. E.; van der Lely, A. J.; Brinkmann, A. O.; de Jong, F. H.; Lamberts, S. W. J. "Human adrenocorticotropin-secreting pituitary adenomas show frequent loss of heterozygosity at the glucocorticoid receptor gene locus." *J. Clin. Endocr. Metab.* 83: 917-921, 1998.

Huizenga, N. A. T. M.; De Lange, P.; Koper, J. W.; De Herder, W. W.; Abs, R.; Kasteren, J. H. L. M. V.; De Jong, F. H.; Lamberts, S. W. J. "Five patients with biochemical and/or clinical generalized glucocorticoid resistance without alterations in the glucocorticoid receptor gene." *J. Clin. Endocr. Metab.* 85: 2076-2081, 2000.

Huizenga, N. A. T. M.; Koper, J. W.; de Lange, P.; Pols, H. A. P.; Stolk, R. P.; Burger, H.; Grobbee, D. E.; Brinkmann, A. O.; de Jong, F. H.; Lamberts, S. W. J. "A polymorphism in the glucocorticoid receptor gene may be associated with an increased sensitivity to glucocorticoids in vivo." *J. Clin. Endocr. Metab.* 83: 144-151, 1998.

Hurley, D. M.; Accili, D.; Stratakis, C. A.; Karl, M.; Vamvakopoulos, N.; Rorer, E.; Constantine, K.; Taylor, S. I.; Chrousos, G. P. "Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance." *J. Clin. Invest.* 87: 680-686, 1991.

Iida, S.; Gomi, M.; Moriwaki, K.; Itoh, Y.; Hirobe, K.; Matsuzawa, Y.; Katagiri, S.; Yonezawa, T.; Tarui, S. "Primary cortisol resistance accompanied by a reduction in glucocorticoid receptors in two members of the same family." *J. Clin. Endocr. Metab.* 60: 967-971, 1985.

Karl, M.; Lamberts, S. W. J.; Detera-Wadleigh, S. D.; Encio, I. J.; Stratakis, C. A.; Hurley, D. M.; Accili, D.; Chrousos, G. P. "Familial glucocorticoid resistance caused by a splice site deletion in the human glucocorticoid receptor gene." *J. Clin. Endocr. Metab.* 76: 683-689, 1993.

Kayes-Wandover, K.; White, P. C. "Steroidogenic enzyme gene expression in the human heart." *J. Clin. Endocr. Metab.* 85: 2519-2525, 2000.

Kontula, K.; Pelkonen, R.; Andersson, L.; Sivula, A. "Glucocorticoid receptors in adrenocortical disorders." *J. Clin. Endocr. Metab.* 51: 654-657, 1980.

Koper, J. W.; Stolk, R. P.; de Lange, P.; Huizenga, N. A.; Molijn, G. J.; Pols, H. A.; Grobbee, D. E.; Karl, M.; de Jong, F. H.; Brinkmann, A. O.; Lamberts, S. W. "Lack of association between five polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance." *Hum. Genet.* 99: 663-668, 1997.

Lamberts, S. W. J.; Poldermans, D.; Zweens, M.; de Jong, F. H. "Familial cortisol resistance: differential diagnostic and therapeutic aspects." *J. Clin. Endocr. Metab.* 63:

1328-1333, 1986.

Lind, U.; Carlstedt-Duke, J.; Gustafsson, J.-A.; Wright, A. P. H. "Identification of single amino acid substitutions of cys-736 that affect the steroid-binding affinity and specificity of the glucocorticoid receptor using phenotypic screening in yeast." *Molec. Endocr.* 10: 1358-1370, 1996.

Lipsett, M. B.; Chrousos, G. P.; Tomita, M.; Brandon, D. D.; Loriaux, D. L. "The defective glucocorticoid receptor in man and nonhuman primates." *Recent Prog. Horm. Res.* 41: 199-247, 1985.

Lipsett, M. B.; Tomita, M.; Brandon, D. D.; De Vroede, M. M.; Loriaux, D. L.; Chrousos, G. P. "Cortisol resistance in man. In: Chrousos, G. P.; Loriaux, D. L.; Lipsett, M. B. : Steroid Hormone Resistance: Mechanisms and Clinical Aspects." *New York: Plenum Press* (pub.) 1986. Pp. 97-109.

McNally, J. G.; Muller, W. G.; Walker, D.; Wolford, R.; Hager, G. L. "The glucocorticoid receptor: rapid exchange with regulatory sites in living cells." *Science* 287: 1262-1265, 2000.

Montkowski, A.; Barden, N.; Wotjak, C.; Stec, I.; Ganster, J.; Meaney, M.; Engelmann, M.; Reul, J. M. H. M.; Landgraf, R.; Holsboer, F. "Long-term antidepressant treatment reduces behavioural deficits in transgenic mice with impaired glucocorticoid receptor function." *J. Neuroendocrinology* 7: 841-845, 1995.

Muller, M.; Renkawitz, R. "Review: the glucocorticoid receptor." *Biochim. Biophys. Acta* 1088: 171-182, 1991.

Nawata, H.; Sekiya, K.; Higuchi, K.; Kato, K.-I.; Ibayashi, H. "Decreased deoxyribonucleic acid binding of glucocorticoid-receptor complex in cultured skin fibroblasts from a patient with the glucocorticoid resistance syndrome." *J. Clin. Endocr. Metab.* 65: 219-226, 1987.

Oakley, R. H.; Sar, M.; Cidlowski, J. A. "The human glucocorticoid receptor isoform: expression, biochemical properties, and putative function." *J. Biol. Chem.* 271: 9550-9559, 1996.

Pepin, M.-C.; Pothier, F.; Barden, N. "Impaired type II glucocorticoid-receptor function in mice bearing antisense RNA transgene." *Nature* 355: 725-728, 1992.

Ray, D. W.; Davis, J. R. E.; White, A.; Clark, A. J. L. "Glucocorticoid receptor structure and function in glucocorticoid-resistant small cell lung carcinoma cells." *Cancer Res.* 56: 3276-3280, 1996.

Reichardt, H. M.; Kaestner, K. H.; Tuckermann, J.; Kretz, O.; Wessely, O.; Bock, R.; Gass, P.; Schmid, W.; Herrlich, P.; Angel, P.; Schutz, G. "DNA binding of the glucocorticoid receptor is not essential for survival." *Cell* 93: 531-541, 1998.

Rivers, C.; Levy, A.; Hancock, J.; Lightman, S.; Norman, M. "Insertion of an amino acid

in the DNA-binding domain of the glucocorticoid receptor as a result of alternative splicing." *J. Clin. Endocr. Metab.* 84: 4283-4286, 1999.

Roux, S.; Terouanne, B.; Balaguer, P.; Jausons-Loffreda, N.; Pons, M.; Chambon, P.; Gronemeyer, H.; Nicolas, J.-C. "Mutation of isoleucine 747 by a threonine alters the ligand responsiveness of the human glucocorticoid receptor." *Molec. Endocr.* 10: 1214-1226, 1996.

Strickland, I.; Kisich, K.; Hauk, P. J.; Vottero, A.; Chrousos, G. P.; Klemm, D. J.; Leung, D. Y. M. "High constitutive glucocorticoid receptor beta in human neutrophils enables them to reduce their spontaneous rate of cell death in response to corticosteroids." *J. Exp. Med.* 193: 585-593, 2001.

Theriault, A.; Boyd, E.; Harrap, S. B.; Hollenberg, S. M.; Connor, J. M. "Regional chromosomal assignment of the human glucocorticoid receptor gene to 5q31." *Hum. Genet.* 83: 289-291, 1989.

Theriault, A.; Harrap, S. B.; Hollenberg, S. M.; Boyd, E.; Connor, J. M. "Regional chromosomal assignment of the glucocorticoid receptor gene to 5q31." (Abstract) *Cytogenet. Cell Genet.* 51: 1089, 1989.

Tronche, F.; Kellendonk, C.; Kretz, O.; Gass, P.; Anlag, K.; Orban, P. C.; Bock, R.; Klein, R.; Schutz, G. "Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety." *Nature Genet.* 23: 99-103, 1999.

Vingerhoeds, A. C. M.; Thijssen, J. H. H.; Schwarz, F. "Spontaneous hypercortisolism without Cushing's syndrome." *J. Clin. Endocr. Metab.* 43: 1128-1133, 1976.

Webster, J. C.; Oakley, R. H.; Jewell, C. M.; Cidlowski, J. A. "Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta-isoform: a mechanism for the generation of glucocorticoid resistance." *Proc. Nat. Acad. Sci.* 98: 6865-6870, 2001.

Weinberger, C.; Evans, R.; Rosenfeld, M. G.; Hollenberg, S. M.; Skarecky, D.; Wasmuth, J. J. "Assignment of the human gene encoding the glucocorticoid receptor to the q11-q13 region on chromosome 5." (Abstract) *Cytogenet. Cell Genet.* 40: 776, 1985.

Weinberger, C.; Giguere, V.; Hollenberg, S. M.; Thompson, C.; Arriza, J.; Evans, R. M. "Human steroid receptors and erb-A gene products form a superfamily of enhancer-binding proteins." *Clin. Physiol. Biochem.* 5: 179-189, 1987.

Weinberger, C.; Hollenberg, S. M.; Ong, E. S.; Harmon, J. M.; Brower, S. T.; Cidlowski, J.; Thompson, E. B.; Rosenfeld, M. G.; Evans, R. M. "Identification of human glucocorticoid receptor complementary DNA clones by epitope selection." *Science* 228: 740-742, 1985.

Weinberger, C.; Hollenberg, S. M.; Rosenfeld, M. G.; Evans, R. M. "Domain structure of human glucocorticoid receptor and its relationship to the v-erb-A oncogene product." *Nature* 318: 670-672, 1985.

Breschel, T. S.; McInnis, M. G.; Margolis, R. L.; Sirugo, G.; Corneliussen, B.; Simpson, S. G.; McMahon, F. J.; MacKinnon, D. F.; Xu, J. F.; Pleasant, N.; Huo, Y.; Ashworth, R. G.; Grundstrom, C.; Grundstrom, T.; Kidd, K. K.; DePaulo, J. R.; Ross, C. A. "A novel, heritable, expanding CTG repeat in an intron of the SEF2-1 gene on chromosome 18q21.1." *Hum. Molec. Genet.* 6: 1855-1863, 1997.

Corneliussen, B.; Thornell, A.; Hallberg, B.; Grundstrom, T. "Helix-loop-helix transcriptional activators bind to a sequence in glucocorticoid response elements of retrovirus enhancers." *J. Virol.* 65: 6084-6093, 1991.

Henthorn, P.; Kiledjian, M.; Kadesch, T. "Two distinct transcription factors that bind the immunoglobulin enhancer mu-E5/kappa-E2 motif." *Science* 247: 467-470, 1990.

Henthorn, P.; McCarrick-Walmsley, R.; Kadesch, T. "Sequence of the cDNA encoding ITF-2, a positive-acting transcription factor." *Nucleic Acids Res.* 18: 678, 1990.

Pscherer, A.; Dorflinger, U.; Kirfel, J.; Gawlas, K.; Ruschoff, J.; Buettner, R.; Schule, R. "The helix-loop-helix transcription factor SEF-2 regulates the activity of a novel initiator element in the promoter of the human somatostatin receptor II gene." *EMBO J.* 15: 6680-6690, 1996.

Garland, D.; Rao, P. V.; Del Corso, A.; Mura, U.; Zigler, J. S., Jr. "Zeta-crystallin is a major protein in the lens of *Camelus dromedarius*." *Arch. Biochem. Biophys.* 285: 134-136, 1991.

Gonzalez, P.; Rao, P. V.; Zigler, J. S., Jr. "Organization of the human zeta-crystallin/quinone reductase gene (CRYZ)." *Genomics* 21: 317-324, 1994.

Heinzmann, C.; Kojis, T. L.; Gonzalez, P.; Rao, P. V.; Zigler, J. S., Jr.; Polymeropoulos, M. H.; Klisak, I.; Sparkes, R. S.; Mohandas, T.; Bateman, J. B. "Assignment of the zeta-crystallin gene (CRYZ) to human chromosome 1p22-p31 and identification of restriction fragment length polymorphisms." *Genomics* 23: 403-407, 1994.

Huang, Q.-L.; Russell, P.; Stone, S. H.; Zigler, J. S., Jr. "Zeta-crystallin, a novel lens protein from the guinea pig." *Curr. Eye Res.* 6: 725-732, 1987.

Rodriguez, I. R.; Gonzalez, P.; Zigler, J. S., Jr.; Borrás, T. "A guinea-pig hereditary cataract contains a splice site deletion in a crystallin gene." *Biochim. Biophys. Acta* 1180: 44-52, 1992.

Sawamura, T.; Kume, N.; Aoyama, T.; Moriwaki, H.; Hoshikawa, H.; Aiba, Y.; Tanaka, T.; Miwa, S.; Katsura, Y.; Kita, T.; Masaki, T. "An endothelial receptor for oxidized low-density lipoprotein." *Nature* 386:73-77, 1997.

Yamanaka, S.; Zhang, X.-Y.; Miura, K.; Kim, S.; Iwao, H. "The human gene encoding the lectin-type oxidized LDL receptor (OLR1) is a novel member of the natural killer gene complex with a unique expression profile." *Genomics* 54: 191-199, 1998.

SEQUENCE LISTING

<110> Rubin, Donald H.

<120> Mammalian Genes Involved in Viral
Infection and Tumor Suppression

<130> 01123.0005P1

<150> 60/062,021

<151> 1997-10-10

<160> 430

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 828

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic
construct

<400> 1

AAAAAAAAAAT	TACCATTTTT	GGGNGAACCT	TTNATANTTN	G TTCCTAGAG	GGNGAGTCAG	60
GGGTAAAAAA	AACGATNAAG	GGAGTTGNGG	CGATTGGAGA	AGCTATTATG	AAGGGATAAA	120
ANACTTAGGT	TGAGCCGGCG	GGTGGGGTGT	ATTCTTGGGG	TGGNGAAAAG	NNAGATCAAC	180
ATGAGATTTT	TTTGTTT TAG	GTTTGTGCATG	TTGTAATGCA	ATANTTTAAC	CTGATTTTAT	240
GTGCAGGATG	CCTGAGGTTT	GTGAGCAGGA	ACACAGGAAA	AGGAACACCG	GTANTCGAAC	300
ACCGGTGAGT	CCGCGCAGCC	GCAGAGAAGG	CGGGTATCAT	TCGNTCCACC	CTGTATGNTA	360
ATATGGAGCG	CTACGGCCCC	GCCCCTGGGG	CCGATGGGCC	CAAAAAGGTA	GGGTTCGAGA	420
AGACGTCTGC	ATGGAGCAGT	GGACCAGTGA	AGACCCAGGC	AAGGCCGAAC	GTTGGGCCCC	480
GGGCCCCGGG	GGCGGGTAGC	AGGGCCCATA	CATTGTCCAA	GGGCTGCTGG	AGAGCCTGGA	540
GCCTCGCTCC	CCCACCGGCG	CAAAGTGGTA	CAGCCCATGG	GGGCGTGGCC	CATATCATGG	600
ACGCGAGCGC	GGCCGCCATC	TTGNTCTGCG	GTGCTGGTAT	TTAGAGCGCA	GCGCCTGACT	660
GGCGGGGTCG	CCTTCGCATC	CGCCGCTTCG	AGAATCTTCT	TTCGTCTGCT	CGCTCTCTCT	720
CCCGTCGTCC	TAGCCCGCCG	CCGCCTGCTG	AGCTTGCCCT	CTTCCCCGCT	TGCAGACATG	780
GNGGACATTG	AAAGACCCTA	CCTNAAGGGC	CNGCANGCNA	GAAAAAGT		828

<210> 2

<211> 845

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic
construct

<400> 2

TCNCCTAAGA	NANGAGANAG	GTTAGATGGN	AATGGAGANT	ANATACCGGG	CTTAGCTTCG	60
CCNNGGACCC	ACCNAGGGGA	AAAGAGCCNT	CNNGCAACAA	ACNAAAGGAN	CGGAAAGAGG	120
AAGGGNANGN	GGNNAAACAN	ATTGGGCGAA	TTTAAANACT	NNGNCCNGTT	TGAAATAGNG	180
CNCGGCCGNT	CCNTGGGCCN	GATCCANCCT	TCCNTNACTT	TTCNTCCCCN	GCNTTAAATT	240
GCGNCGNCGG	CCCCCCCCAAC	CATNTNTTCC	GTTTNNANCA	CCNGNGGCC	CGGCAGTGCN	300
GATGNNGGGG	AATTGNNAAT	GCCCCCANC	CATTTTGNNT	CNGNNCCTGG	GGAGAGANTN	360
AAACGGTGNG	NGNAGNNGTT	AATATGGCGG	CAGCGGNGAC	ANCAGTAGCC	AGNGCAGGCA	420
CGCGNAGTTG	GCNGGGGACG	CCANGTGNCN	GGAGANNTGG	AGCGGCGGCG	GAGCGGGCNC	480
CNAAAAAAA	AAANAANNGN	TGGTAAGGGG	GCCCCGGGTG	GANGANATT	CNNGGGCNGC	540
TTCTAGGNGT	CANGNTGNGG	CCGCTNCGTT	CGGCCCTGGA	TGNAGCCCNG	NGCCNGTGCC	600
NCCNCCGGGG	GGAGTTTGTT	TCCNTCTACC	GTNCCCTGCT	GNGGAGCGAC	GANCTGCANT	660

NCCNCCGGGG	GGAGTTTGTT	TCCNTCTACC	GTNCCCTGCT	GNGGAGCGAC	GANCTGCANT	660
CCCCNGGAGC	GTCTANNAGG	CCGTGGCNAA	CCCCATCNAN	GCNCNCCAGT	NAGCTTCCTT	720
CNTCCCGACA	TAGTAGGCGT	CNGGNGGCGT	TGNCGACAGN	GGCCNNCGTC	GATGGGANNN	780
TCTATTTNNG	NTTCATGGGC	CGTATGTTAG	ACCTNTCGAA	GGACGCGNNA	AATAGATAGG	840
GGGGG						845

<210> 3
 <211> 818
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note: = synthetic construct

<400> 3						
TACACCTTTG	NGNGTGTTGA	AAATTACGGG	GGANANGAAN	AAAAANGTAT	CCTTTTGGAN	60
GCCCCGNCCT	CTTGTGGAAT	TTGTGATTTA	CGGCGGNANT	CATATGATTT	CGGAAANAAG	120
ATAAAGCCNN	NCNNNNNGGG	GTAGGGAAGA	AGGATTTTGN	AAACAAANTN	TGGGTNTATA	180
TAANNGTGCG	GGGGGGAGNT	CATTGAGGNG	GGNGGAATA	TNNAATNTTT	TTTTTTTNNT	240
TNNNNGGCAA	GAGGGATGAA	GGTAAGGTTA	GTATGAAATG	GCCNNNCCAG	AGAAGTTNGA	300
TGAAAAAGAT	AGTGCCACCA	AGAGANATNA	TTTGTTATTT	TTAACAGTGG	GGGGAGGTAG	360
TTNTAGACCA	CCATTTATTA	NAACTGAGGC	ACAAAGAAGA	TGATTGGGGG	GCACTTACAG	420
AGTAAGCAGT	ATTTACATAA	AGATTTNTTC	CCCAGGAATN	ANGAGGAAGN	TGGATAACTG	480
AACAAAGCCA	TGTAAGCAGG	CTTTTGGTGA	TGCATGTGGT	CCCATTACAA	GGAATACCCA	540
ATAAATAGCA	AATGCACACT	GCCATTCACA	AGCAATTGCA	GAGAATGGGT	GGGGGATGTG	600
AAACTAAAGA	GCTTTGTAGC	TGCCTGAGGA	GGTGGGTTCCT	CTATATCCGT	GGGAGCTAGT	660
GATCCCCCAC	AGGTCTTAGC	TGGTGCCATG	ATTGTGATCT	TAGGCCAGAT	TTGATGTCCC	720
CCACATGGCC	GAGTCCGCCA	TGGATGCAAC	AGGGCAGCTT	TATTTGCTGT	GGGCNGGTAN	780
TGAAGGATNT	CACAAATGAA	CTTGGCAAGT	AGAGAGGT			818

<210> 4
 <211> 857
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note: = synthetic construct

<400> 4						
TGGAAAGANT	GNGNTAAAGT	TNAGTTNNNA	GATATTGANN	AANNTNGGGN	AAAANAAGGT	60
GNNNNACAAT	CTCNCAANNA	TTTNAANGAA	GGGGGAATAA	ATGNAAANTG	GGANTTAAAA	120
AAANAGGGGN	NANANGNTTN	NGGTTNAANA	NAAGGGGGGT	NTNCCCGTTT	TTTTTTTAGG	180
ATCCTGGGAG	TAACCNACAG	GAACCNAAAA	TTNGNANAAG	GNGNNTCCTT	CCCTTCCNGT	240
CAGTAAGGGA	TGGGGCCCTA	TTTTTANCAA	CGAACACCAT	TGACAGGANA	CCGGTCAGNA	300
TTCCGTTAAG	TATTTTGACC	TTTCCAGGGG	ATGTNTCCGC	ACAGCCGTTG	NGACCTTAAA	360
CGCGNCCAGA	TTNTGCGAAN	GTCATTTTGG	GAATGACTGT	TGTAGACACT	GCTTTTTTAG	420
TCGCAGATNT	GACCGCAGAT	TTTCNTTTCC	CACCTTATGT	CCGNTGGAGC	AGTGGTGGCC	480
GGAGAAAATT	TCTTGGGGTT	CCNTCCCGNG	ACCCAAAGAA	CACAACTGTT	CTCGCTGCCC	540
GGCACCCATC	GCCACGTCAG	CTCACGCTCG	CGACGCCAGC	ACGCNTGCGC	GCAGAGAAAG	600
GCGGAGCATG	CGCAAAGGCC	TGCNTNTAAC	ATCCGGGGCT	CGGGCGGCGG	CGCTGCCGCC	660
GCGAGGGATT	AANGGGGTCT	TTCNTTTTCNG	TCTCTGGCCG	GCTGGGCGCG	GGCGACTGCT	720
GGCGAGGCGC	GTGGAAGCTC	GCGATAGTTC	CCCTCCGCCT	CCTCTTCCCG	GTCCAGGCCA	780
CTAGGGAGTT	CGCTGACGCC	GGGTGAACTG	AGCGTACCGC	CTGAAAGACC	CCACAAGTAG	840
GTTTGGCAAG	TAGAAAG					857

<210> 5
 <211> 896
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 5

GGGAGAAAGG	GGCGACNTTT	ATTGGTCCNG	GAGNNGGGGG	NCAAATGGGT	TTTTATCCAN	60
TTTAACGGGG	GGAGGCCCCG	GNNGAGGAAT	TCCCGGGGGA	GGAANAAAAA	CAAGATCCGC	120
NTAAGAGGGN	GGGGGTNTCC	GNNNTTNTTN	GAATNGTGGN	GCACCGGGGG	GGCAAGGAAG	180
AGGGTTCCCG	GAGAATGGGG	NGGATAAAAN	GATTGGCAAC	TCACCCCGGN	TAGTTGTACC	240
AGGTGTTTTT	TTTTTTTTTT	TTTGTTTANA	AANAGGAAAA	TGATTCAAGT	TAAAAAAGTA	300
ATTGGCAAGG	AAATTTTTTT	CCTANCTTCC	TTGAAAAATA	GTGGGAACAG	GGGTTCCCAA	360
GGGGAAAGGT	CCCCNATTNA	ACAAAATGNG	TTTCAGNNGA	GTGTGGCCCA	CCCATTGTGT	420
NTCCATGGAA	GAGTGGCTTT	TNTGGNGAAG	TTCATTTTCC	TTAACCTTNA	NNACTGTAAN	480
GGNTCTTGTG	CTTGAGAATA	TTGTTGGCCA	GCTTTATNGT	CTTCATTTNT	AANACTATTT	540
AGACTAGAGT	GTTNTAGATT	NTAGGTCTTC	ANGTTTCCAG	TCACCAGTCC	TTGGCTTTTT	600
AGTATGGAAG	TCACCAGTAA	TGGCAATATA	ACATCCCTGC	TTCTGTTTCT	TAGAAGGCTN	660
NATTACAGTG	TGTTCAAAC	CCGTGTCATT	GCAACAGGTT	AAACTAACTT	TNTACGTAGG	720
ACATCAGGGT	ATTGACATTC	TCATCCTAAA	GTCAGTTTGT	CTGTTTCCAG	AGGAGGAACT	780
GAAGCAGTGG	TTCTTTAAGT	AACTGACTCA	GGGCTTTCCT	GCCTGGCGCG	CCTGCCAGGC	840
ATNGTGTAGC	ATTGTACTGC	ATCTTCTTTG	ACCAGTTTCC	CCAGGTGAAG	AGCCTG	896

<210> 6

<211> 937

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 6

GGGCCCCCCC	CCCCCNANTT	AATTTTNGGG	AAGAAAAAAG	GGAAAAAANT	TTGGGGTCAG	60
GAAAAANGAA	GTTGGNAANC	GNNGGGGNGN	CAGNATTNGA	ANAGTGGGGG	ANNTTAATTT	120
NAGAGGTCCC	TTNNTTCCNN	GGAAAAGTTT	AAAAGGGGTT	CAATTAACTT	NGGATCNCCA	180
TTTATCAGAT	TACCCGNGNG	TCACCTGGGG	ACCCTTTACN	GGTGGCGGGA	CATTNGAAAN	240
ACATATTAGT	CAGATTATAC	ATAGCAAANA	TAGTTAGGAG	CACAANGAAT	CATTTATGGT	300
GGNGGTCACC	ACACAGGAGA	TGTATTATCC	GCAGTATTAG	AGAGTTGAGA	ACCATATNTT	360
AGAGATGCGG	TAGACTGACT	GTTCCCTTTT	CGNTTGGAGT	GACCTTGCCA	TTAGAGGCAA	420
CAGCATCAGT	ATTGTTCCCA	GTCCCNCTCA	CACFTGATTCG	AACTTTAAGG	ACACTGATCT	480
NTGGCTGGTA	GAGGTTTCAGC	ACACATACCA	GAGTTACGAG	TCACGTGCCA	GAAGGGCAAA	540
CTGAACACGG	AATTAGAGGG	AACTCGATGT	CTCCGGCTTG	CACTGGTCTT	CTCTTGCAAT	600
AGAATCCTTC	ATCCTGCTCC	CAGTCCGGAC	GTCCAGGCAA	CAAGGGCGTG	GAAAGTGAGG	660
GGGCTGGGAG	GTGTGTTTGC	CTTGCCTCAG	GCGNTGGGTG	GGGTGGGGGC	GTGCCAGCAC	720
TCCCTGGGCG	GGGCNTCACC	GATGCTGGCC	ACTATAAGGC	CAGCCAGACT	GCGACACAGT	780
CCATCCCCCTC	GACCACTCTT	TTGGCGCTTC	ATTGTCGACG	TGTGGTGAGC	TCTCACTGGG	840
GCGTCCCTCT	AAGATCTGTC	CACTNCCTGG	TCTAGGGGTT	AAGCNTTTTC	CTGCCCTGAA	900
AGACCCCA	ATGTAGNTTT	GGCAAGCTAG	CAAAGGT			937

<210> 7

<211> 888

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 7

AAAAGGGGGC	CCCAGCGGNG	GGGGGTTGTC	CAAGGAATCA	AAANGTGGGG	NGGGGGGGAA	60
AAAANTACTT	TTAAAAAAGG	CNGCCNNANA	ATANANGACG	TTCNNGGGNG	TTTGAAAAAA	120

GGCCGGAAGC	CTCGGACNGG	TTTCNNTGTT	AGGACAAGGA	AAAAGGGNAC	GCACNGGGAT	180
TTCTTTTCCT	TATNTTAGCA	AATNGCCGGC	CAGGAAACCA	NCGAGTTGGG	NGGGNTTNGG	240
TTTTCNGTNA	AAGGAAAGCA	GGGGGGGGAN	AAACACGGAN	AAAAAGGGAA	GAANNNGGTT	300
NATTNNGGTT	AGNAATTGGN	TCCCAGAGAG	NGCCAAGAAA	ATNGGCCTGT	CCAAAATTCT	360
TTTTCCCNGC	TTTTAAGACA	GGCANGATAN	TATNNGGCAG	CAGGTNATTA	CCANAGGTAA	420
GTAAATTACA	ATGGGTAAGG	GCTTGGCACA	GGCCAGGGTA	AGTAGGGCAN	GTATGGATGT	480
TAAACATTAC	CCTTCATCCN	GAGGNAGTTA	ACACAAGCAT	TCNTGGCGGG	TCTCACATAT	540
CCCAAANAAA	AATNTTCAAA	AGNAGCCCCN	TGGGGAACGT	TAAGCCAAGC	NTANGACTCA	600
CAAGGGANGA	CATGGGCAGG	NTAGGGNACA	GAATCAGTGN	TCAGAGACTC	CAGGGGCACC	660
CCTGATTCCN	TTTGNTGTCA	CACAGACANT	GCTCCAGGGA	CAACCTTCCC	GGANGTGAGT	720
ATANGACTTT	CCTGATGGNG	ACGCTGCCGT	GANGGGACAC	TNCCTCGTGG	TAGCACACAT	780
TCCTCAGTCA	GCTTCTGAGC	CTCAGGGTCC	CAGCAGGCAC	AGTGGCAANG	ACCTCATTTCT	840
TCTCGTCTGT	CCCACTGAAA	GACNNTCACN	AAGGAGCTGG	CTAGTAGA		888

<210> 8

<211> 980

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 8

AGAAATGAAA	AAGAAGGAAA	GCTAAAAATA	GATTATAAGT	GTTCTATTTG	AAAAAAGAAA	60
GAAAAAAAAG	AAAAAGAACA	CAGAGAAGAA	TAAAGGAGAA	GAAAAAGGAA	GAGAAAAAAA	120
AGAAAGAAAA	AACGGAAAAAG	AAACCTAGAA	AATAAAAAAA	CAAAGTATCC	GATAAGGAAG	180
AGAAAGGAGA	AAGACTTACC	TAGAGCCCAAG	AAATAGAGAA	ACTAGAACAA	AAAATGGAGA	240
AGAAGAGGAG	AGAAAAAGGA	TTAGAGAGGG	TGAGGTAAGAA	GGAAGAAAAG	ACAAGAAAGC	300
AGAAAAAAAC	TAACAAAGAT	GCATATAAAC	AGAGAGAAGA	TGATTAAGAT	TAGAGAAAAA	360
GACCAAAGAG	AGAAGGTAGA	CAGGACAAAT	AAAACAAAAA	CAGGAGGGGA	GAAGGGGAAA	420
GAAGAAAGAG	GGCAAAAGCA	AAGGAATAAG	ATAATAGCAC	CAATAGCAGG	ACAGTAAAGG	480
GTAGAGAAGG	GACCATTCCC	TACCCCATAG	GGGGGAACGA	CCCCGGAATC	AAAATACAAG	540
GCACCGAGCT	GAACCTGGTT	ATCACACAGG	CAGGAGTGGT	ATAGCACGGC	GTTCCGGGCA	600
AAAAAAAATA	TGAAAAATAA	ATTCTTTCGG	GCGGAGAACT	AGAAGAGGAT	GGGAACCTCT	660
TGACAGAAGT	AGCAGGCAGG	AAGCCAGCCA	GCACCCAGC	CCAAACAGAA	GCAGCCGCAA	720
TGAAACGGGC	GGCAGATCCA	CATCCGCAAA	GTCCTCAAGG	GAGCATCGGC	GAGGCCCGGA	780
GCCAATGAGG	AAGGGCAGGA	AACCATATCA	AGCCGAGCGT	CGGGACGGCT	GCCATGAGAC	840
ACCCGGAGAG	GTAATTTTTT	TTTTACGGGA	AGCGTCCAGC	CAAGTTAGTG	GGCCGGAAGC	900
GACGGTACTT	TAGTATACAT	CGTTTTGCCC	GAGTGGTCAG	ATTCTTTTGT	TATCCCCAAC	960
AGAACCGTAA	GCTAGAAATA					980

<210> 9

<211> 845

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 9

TCNCCTAAGA	NANGAGANAG	GTTAGATGGN	AATGGAGANT	ANATACCGGG	CTTAGCTTCG	60
CCNNGGACCC	ACCNAGGGGA	AAAGAGCCNT	CNNGCAACAA	ACNAAAGGAN	CGGAAAGAGG	120
AAGGGNANGN	GGNNAAACAN	ATTGGGCGAA	TTTAAANCT	NNGNCCNGTT	TGAAATAGNG	180
CNCGGCCGNT	CCNTGGGCCN	GATCCANCCT	TCCNTNACTT	TTCNTCCCCN	GCNTTAAATT	240
GCGNCGNCGG	CCCCCCCAAC	CATNTNTTCC	GTTTTNANCA	CCNGNNGGCC	CGGCAGTGCN	300
GATGNNGGGG	AATTGNNAAT	GCCCCCANC	CATTTTGNNT	CNGNNCCTGG	GGAGAGANTN	360
AAACGGTGNG	NGNAGNNGTT	AATATGGCGG	CAGCGGNGAC	ANCAGTAGCC	AGNGCAGGCA	420
CGCGNAGTTG	GCNNGGGGACG	CCANGTGNCN	GGAGANNITGG	AGCGGCGGCG	GAGCGGGCNC	480
CNAAAAAAA	AAANAANNNGN	TGGTAAGGGG	GCCCGGGGTG	GANGANATTT	CNNGGGCNGC	540

TTCTAGGNGT	CANGNTGNNG	CCGCTNCGTT	CGGCCCTGGA	TGNAGCCCNG	NGCCNGTGCC	600
NCCNCCGGGG	GGAGTTTGTT	TCCNTCTACC	GTNCCCTGCT	GNGGAGCGAC	GANCTGCANT	660
CCCCNNGGAGC	GTCTANNAGG	CCGTGGCNAA	CCCCATCNAN	GCNCNCCAGT	NAGCTTCCTT	720
CNTCCCGACA	TAGTAGGCGT	CNGGNGGCGT	TGNCGACAGN	GGCCNNCGTC	GATGGGANNN	780
TCTATTTNNG	NTTCATGGGC	CGTATGTTAG	ACCTNTCGAA	GGACGCGNNA	AATAGATAGG	840
GGGGG						845

<210> 10
 <211> 528
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note: = synthetic construct

<400> 10						
GGATTTNNTA	ACCTTTCNNG	GAAGGGNGNG	GAAAAGGNGC	CAAACAAAAA	GACCCCNNTG	60
CCCGGAAATN	CTTGGGGGNN	ATTGNGGAGC	GTTTTTTANN	GGGGATTGGG	GGGNTNGGGN	120
TGCNCCCNNA	TATTCGCCGC	TNAGGGGCAA	CCCGAGGGGT	NNTNTCCGAC	CATGTAACTT	180
GTTTCGGAAT	GAGGGGGAAT	GCNNATTNTG	ANTATTGAAN	NGNGACCCGG	NGGGGNCNTG	240
TTNNAATTAA	CCTNNTACCC	GGAATTTTCNG	CGAGANCGNG	ANGATNNCTG	GCACTTNTTC	300
CGTATTACGN	GTGGCGTTCN	NGANTGCAGG	GGNTGCCCTT	GTTTGNNNTT	CTGAGGGTTT	360
CTTATANGCA	GATTGTGGGG	TTGGAAACGA	GANATCCCTN	ANGTAATGCC	ANNTCACACG	420
GGATGGAGCA	GGAACNCCCT	ACGNATAGTT	NACCTTCANT	CAGGGTGGGG	AANCGATNGA	480
CCNGAGGTAT	ATGGGCNGAA	CNGGACATGT	NGGGNNANCC	GTTCAATC		528

<210> 11
 <211> 927
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note: = synthetic construct

<400> 11						
AANACGGTTT	AATAAGGGGG	ATGTTCAAAA	CNCCACTCCG	GGGGAANAAA	ANAAAAAATT	60
AGGGGGGGAG	AANGGATTGG	NGTATAGTTT	CCCACCACAA	ACCTNGTTCC	ATTTTTTCGG	120
GGGGGNAACG	GAGGNCATGA	TTATGGGGTG	AAGGCAGCAC	CCACCCATTT	TTCGGGGGNA	180
AGTCAGTTTT	TTTTGGTANA	ATCAAAGTTC	CTTCGAACAT	NTCGTTTTAT	CCAAGGAGTT	240
TTGGTGTTAA	ATTAGCANTT	TNTGNGAGTT	TCAAAGTTNT	GGTTCCNGAG	NAGNTTTGTA	300
ATTGGTTCAC	CGGTTNTTTT	GNGCCAGGAA	AGCAGACCCN	TGTTNGGAGG	GGAGATTCCN	360
ATTTTTAGTT	CCCATTTGGT	GTTTCCNTAG	GTAATGGAGT	CTGCAGACAG	TTTGAGTNTA	420
NTGAGTTGAG	TCCCTTNTCC	TATCAGCCGG	GGTGGCATTC	TGTCCAAAGG	AGGAATCCAG	480
CAGCCAGATT	AGATTTTCAGT	NTCNTTTNTA	ACAGGGAAGT	TAGACACACC	CGGCCAGNTT	540
GCAGCCTTTC	CACCCCCAAN	GAGTGAACCC	TGCCNTTTCA	GCTTTTACCC	AATTTACTTT	600
CGTTGGCTTA	GCATGCAGAT	TNTTTGGCTC	CATGCCCGGA	GCAGCTGACA	TGGGAGGCTT	660
TGAAACTTCC	ATTATCATAG	AATGGCAGGC	AGGTCCTTTG	CGGTTAAAC	CAGGAGCCTG	720
GGCCNAATGA	GATGGNTCAN	TGAGCAAAGG	CGNTTACTGC	CAACCCTGAT	GCCTTCAGTT	780
TAGTNTTGGA	ATTCACAGGG	TAGAAGTTGA	ANACNTTTGA	CTCTTCAAAA	GTTGTCCCTG	840
TAGCAGGGCA	GNNGTGGTGC	ATNCCTTTAA	TTTGGGCTAC	TTTGTGAAAG	ATATCCACAA	900
NGAACCTTGG	CAAGTAGAGG	ANGTCGT				927

<210> 12
 <211> 911
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note: = synthetic

construct

<400> 12

GGGAGTTTGC	TCCTCAGAGNG	CCNATTACGC	NACAGGGGGN	GTCTCACANT	ATAANCTCAT	60
ATANNATACT	CTACNNTNCC	CCCCCTNANG	TNTCAAGGGC	AAGAGAATAT	NNTCTCTCTC	120
NTATCGTCTN	GGGGNNTCTN	AAATGTTTGN	GCTCCCCGGG	NAAAATANNT	CTCTNTCNCG	180
NCTCTATNTT	CTCNCCTCAC	ATATNTGCGN	ACTCTTTCTC	NNCCACANNA	AAAGCGCCCA	240
GTGNGGGGAN	CTCNNAGAGT	GTATNGNGAA	GAAGTGNAG	TGTNTNTGGG	GCGCGTTCTC	300
GGGGAGANNA	TACNCTTCTC	TCNTCTCTCT	NTAGAGTGNG	ATGTANAAAA	CCNCANNGTG	360
TGCANAGANA	AATGGGGCTC	NGAGNCTCTT	ATATTTCCCC	NCCCCTCTCN	CCATATATNA	420
CCTNCGGGGG	CTTNTNTNTA	AATCNCCTNT	CNCCATTNTT	NNNANNNGCG	TGTNTNTATT	480
GTNNGTNTCC	NCNTGNTCCA	AAAATCTCAA	ATTTGTGTCT	CTTNTCCCAA	ACNCTATNTC	540
TCCCNATANCC	CTGGGGGNGT	NTATTATNTN	TNTNTATATN	CNTATNTTAT	ATACNTATAN	600
TNTATNTNNT	ATATATTTGG	GGTCNTTACC	AAAACCCCN	TTTTNTCTCA	CTTTTCNTCN	660
ACTCCCTTCC	CGGGGCCTNG	AAANTTTAT	NCCNNCCNTT	NNGNTCCTTT	TCTNTTAAAT	720
TCNTTNCNTN	NGGAAAACCC	TTTTCNAAAC	NGGNTTTCCC	CTTTTNNCNT	CCCNCTCAAA	780
CCCCCCAAAT	TNGGGCATTT	TTTCTTTTCC	CCTCACCNAA	CCCCNTTTNC	CTCCCCCCNC	840
CCCCCCCCAA	NTGNGAATAC	CCTGNTTTTC	AGNGGNNNG	AAAAATCCCT	CCCCGANGGN	900
CCCCCCTCC	T					911

<210> 13

<211> 880

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 13

GGGCACCAAC	GGNGGAAGAG	TTTTCCANGG	TANAAGAAAG	NAGGANTGGG	NCGANAANAA	60
TTANTTTTNA	AAAAGGNCAC	CAGATANAAA	AAACTTTTNA	GGGGNGTTAA	NAAAAANGCN	120
GAAACCCTCN	GACGGTTTTC	NNGANTNTTA	AANAGATTCA	GGGGAAGCAC	GAGATTATCT	180
TTTCNTTTTT	GAGCAAATTG	CCAGCAGGGA	ACNGACNAGA	GGNTNGGTTT	TTGNATNCNN	240
TTAAACGTAA	CGCAGNTTTG	GANAAACACA	GNTNACATGG	AAAGACCTGG	GNNATTAGGG	300
TAANGNAAGN	GGTTCAAGAG	AGAGCCGATG	AAATNGCCNG	GTCCAAAATC	TTTTTCCTTG	360
NCTTTAANAC	AGGTNNNAAA	AATNNGGCTG	CTGTTTATAA	CNATAGNTAA	GTGAANNACA	420
ANGGGTAAGT	GNTTGGCACA	GNCCAGGGTA	AGTAGGCATN	NAAGGAATGT	TAAACATNAC	480
CNTTGATCGN	GNGGTTGTTT	ACACCGCNTT	AAAGAAANGT	TTAAAAATAT	CCCTGGGCTG	540
TTTCTTCCTN	GGTGCCNCAN	GGNGAACGAC	AAGCCAAGCG	NATGANTCAC	AGGAGACGAC	600
ATGGGCAGGT	TGGGTACAGA	ATCAGTGTTT	AGAGACTCCA	GGGGCACCCA	GATTCCNTCA	660
GNCTGTCACA	CAGACACTGC	TCCCAGGGAC	AACCCTCCGG	GATGTGAGGN	NANGACTTCC	720
GNGNNGGAGA	CGCTNCAGNG	ANGGGACACT	CCTGGTGGTA	GCACACATTC	TTTCTCNGA	780
TTNTGAGCNT	CTGGTCCCNG	CAGAGNACAG	TGGNAATGAC	TTTTTTCTTA	CTTGNGNCTC	840
CAAGGGCGTC	TCCACAAGAC	AGCGTGNCNA	GATAGATAAGT			880

<210> 14

<211> 923

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 14

GGGAGGAGTA	CNGGANGGGT	CCGACGTAAN	TNTNTCACAG	GNAAGNCGAN	ANGAGGAGGG	60
GTNGCGTAGG	NNACAAAGAG	ATAGGAACGG	GGNCGNNAAC	NTNNCNTNTN	GAAAAGGCCG	120
CCANNGTNAA	NCAACTNTGG	CGGGGGTGGG	ACNNAAGGCG	NGNGGCNNNA	GAAGGTTTNN	180
TTNNTTGNA	CCNAGATTGG	AGGGACGGAC	NGGANTATCN	TATCCNTNTT	NGTTNCGANT	240
GCCNGCGNGN	ATCNGGCNAG	GGAGGGTNGG	TTNNNNGGTT	TCNGGNGACN	NCCCCAGTTT	300

NTGGNNNATA	CCCNGCTCTC	ACANGNNGGA	CGNGGGTNTT	TNNGGTGAGG	AAGNNGCNTC	360
CCCGCGAGAG	CCCGNGGNAA	GGGCGNGTCC	AAAANTCTTN	TTCCCTGCTT	NTNCNACAGG	420
CTNNGANANN	ATNNGGCTGN	TGTTNATCNC	NATAGGTAGN	TCAACCNNCA	NGGGGANGTG	480
CTNNCACACC	CCAGGTTAGT	GTCCCNNTCA	NGGTATGTTA	ANACGTTACC	NNTGATCGGG	540
GGTTNTTTAC	NNAAAANNAA	AAAAAAANTC	ACCNTCCCGG	GCNTGNTGNT	TCCTNGGGGC	600
CCCANGGTGA	ACGACNANCC	AANCTNTTGA	NTNACAAGGG	ACGACGTGNG	CAGGTTGNCG	660
TNCNGAGTCA	GTGTTTCAGAG	ANTTCNNGGG	CACCCCTGAT	TCCCNCGGNN	GTNACACAGA	720
NACTGNTCCA	GGNNCNCCCC	TCCGGTTGNG	AGTCNAAGAC	TTCNNGNNGG	TGACNCTACN	780
GTGANNGGAC	ACTTCGTGGN	GGTGNCNCAC	ATTCGTCGGT	CGGCTTANGA	NCNTCTNNGT	840
CCCNGCAGAG	CACTNTNGCA	ATGNCTTTNT	TTGTTCTGGG	GCTTCCNAAT	GGGTCCCTCCC	900
AAAAGNCNGC	TTTAGCTGTA	ATA				923

<210> 15
 <211> 880
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note: = synthetic construct

<400> 15						
ANANAGAGTA	ANTAANANAA	GAGGAAGAGA	NAAGAAAGNA	GAAGGNAAGG	ANANAAANGG	60
GNNGGCGAGG	AAAAAAGGAA	AGGAGAANAA	TAAAAGAAAA	AGTGAGGAAG	GAAGGAGTAN	120
NAGAAAAAAG	NAAAGNNGGAG	ATAGNAGAAA	GGNCCGGNGG	ANAAAAGANT	AGATTAANGA	180
NAGNTGAAAG	AATAAAGANN	ANGGCGANAA	GGAAAGAAGA	NCGAGNATTA	GAAANAAGAG	240
AGGAAAGANN	NGGGGGGAGG	GAANGAGGCG	AANTCNNGAG	ANCAGTNNAN	AAGGCAAGAG	300
AATNAGGAGN	AGANANGAAG	NNNANGANGA	AGGAGGGGAA	AGAGGGNACA	GAAAAACAA	360
GTANAGTAAC	CNACNNCNGC	GAGNGNGCCA	AATAGGTNGC	GCCAGCNACA	NGGCCCAGGC	420
CCNNGGGGAG	GGGGCATCAN	GAGCCAAGGG	GAGCGGGTCC	AGNCNTAGTT	NTGAAAGGAA	480
AGGGGAGGNG	GGNAGATATT	ATATGGTCGN	GCCCCCCCCN	GTGTCTCGGT	GAAAAAATAA	540
AGGNGTGANN	AGCAGGGCCN	TNTTGGNTGN	GGGATCGNGC	ATGATCAGAG	ACCNGAGGCC	600
GGACNTTCCG	CNGNGCCTTC	CGTAGGCCCA	NTGTCAAATG	TATTCAAGCC	GGTTNGAAGG	660
ATGCCCGNGN	TAGNGANTGA	TGCGGGGGCC	NGCCCCCCCC	GNTTTCGCC	CCCGCAGCCN	720
CNGTGGCCGC	CATNACGGAG	TTCCCAGTGG	TGAGNGTGCG	GAGNTGAGGC	CCCGCGGGTC	780
GCCGCCGGTC	CCCGCAGACA	GGAACGCGGA	GCGNNCCCTG	CGCTNGAACG	TANGGGNCCA	840
CTTGAAAGAC	TNNACNAAAN	GACGCNGATT	TGTAGAAAAG			880

<210> 16
 <211> 166
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note: = synthetic construct

<400> 16						
ATTCTTCAGC	TTTTGCNTAG	AGGAAAAAGA	ATGGATTGTT	TCTAGGACAA	CCTGCTGAGG	60
TGCTCACCNA	GNGTTCTCTC	TCTCTCTCTC	TCTCTCTCTC	TCTCTCTCTC	TCTCTCTCTC	120
TNTGNTCTCT	TCCTGAANNT	CCCCANAGGN	NCTTNGCAGN	AAAANG		166

<210> 17
 <211> 162
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note: = synthetic construct

<400> 17

CNTTTTNCTG	CNAAGNNCCT	NTGGGGANNT	TCAGGAGAGA	GNCANAGAGA	GAGAGAGAGA	60
GAGAGAGAGA	GAGAGAGAGA	GAGAGAGAGA	GAACNCTNGG	TGAGCACCTC	AGCAGGTTGT	120
CCTAGAAACA	ATCCATTCTT	TTTCCTCTAN	GCAAAAGCTG	AA		162

<210> 18

<211> 871

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 18

GAATAAAACC	CCAGAAAGGT	TTTAAAACAT	TCCGTATAGA	AGTTGATNAA	TTNAAATAAT	60
TGGAGGTGAA	ATACACAGAG	GGTTTTTCAA	TTAATCAATA	AAAAAATAAA	TTACNTACNT	120
NTTTTGGGGG	GTTTTATGNA	NAAANGAATT	GGAGGGATCA	ATTTGCAAGA	AATTTATTTT	180
TTNGTATTAT	TTAAAAACCG	TTANGGATTC	NGTTGATTTT	AAATCAAGCA	GTAAATATAT	240
TAAAAGGTAG	GAGAAATGGTA	TCAATAGGCC	AAGATAACAG	AGTGTAAGAG	TTAAAAGTAT	300
TGGACAGAAA	TATTAAGAGT	TATTGTAAAG	ATCCNGGACT	TTGGAAAATT	TAAAACCAAG	360
CGATTTAGGC	CAAGTTATTT	CCACAGTATG	GTATCAGAAG	GAGTAAAGAG	ACAGCACAGG	420
TGCAGATNTG	ACGGCTTGGT	TCCTTAGGTT	ATTGCCACAG	CAACGGTCTT	GGCCGCAAGG	480
CAGGCTTGGG	CCCAGCATGA	GAAGAGAGGG	GGAACCAAGT	TCTTCAGGGA	CCNGACGGGC	540
GGCGCCGGTG	AGAAAGGACT	TCATCTTGCC	ATGNTCANTC	AGCGAAACTG	CAAACGCTTN	600
TGGCAGAGAC	AACGCCAGAT	CTGCAGAGGC	ATTCCGGCCT	TTAACCGCTT	TCCCACAGTC	660
GGCCCACAGG	CCTTACCGCA	GCAGAAAGCG	CGCGACCCGG	AGGTCCCGCC	AGTCAAAAGA	720
AAAAGGGGGG	CGCAAAACCA	TATAAGGCNT	GGAGCAGGCG	GCCCGGCCCC	GCCCCCAGGA	780
CATGGGCCCC	GCCCCAATCA	TGCCCCGCCC	CCAGGATTCG	GTCCCGCCTC	CTCCCGCTCC	840
CGGGATGGGC	CGTTATGCTC	CCGATACGCA	T			871

<210> 19

<211> 936

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 19

TGGGATTCAA	AAATTGGAAG	TTANTTTTTN	AGGAAATTTN	TTTTTAAAAT	TNTAATTGGG	60
GGGNNTNGCC	ACCAATTAAA	ANGNGTTTGA	ATTNAAAANG	ATTGCCGGGG	GAAAAANCCA	120
TTTNCTGCAN	GGAATTAACC	AAGTAATTTG	GNTTGGNAGC	ACTNGTTTGT	GGCCTNTAAA	180
AGGCATTTTA	AANACAAATT	AACAGGGCNG	GCATNTTCAA	CGGGNGNTAG	NTTGTTTNA	240
TGAAACNGAG	GNTTTTGGGG	GCGGGCCTTT	CCNATTNGTT	TCCTTTTTTA	GGATTAACAG	300
ATGNGAAAAA	AAATNATGGT	TTTATATCAT	CGTTNTTGGC	ATCAGCAGAT	TGGCNATTCA	360
ATTAAAACAG	ATCATTCATG	ATNGGCCTTT	TGGCCATTAC	CATGNAAACA	CAAAGAGCCA	420
GGGTTTGATT	GCCCTGACCC	GCCNACCTTC	GGTTGCTTAG	GTGAGGTGCA	GCACTGCGTT	480
TTTCCTTTTC	GGACTGAAAA	CAGGCGAATG	AATCATTTCN	GTCGTGTCTT	GAGGGTGCAT	540
TTTTNACATT	TTTGTGCCNT	GCTGTGCGCC	GGTGTGTGAT	TTCCCTGTTT	TAAGTGGCCC	600
CTGAGGATAA	CAGTGAAGTG	CTGTCTAGCA	TTCTTCTGCG	CAGGAAGGCG	GAGATCTGCC	660
CTGCGGAGAA	AGTATGCGTG	CTGGATAAGC	ATTACTGAGC	ATGACACAGA	GCACCGTTGA	720
CCCCGAGTGC	AGCGTTAGTG	AACCGGCCAA	TGTGCTGGGG	GATTTTAAAT	GGAATCACAC	780
AGAAGCTGAG	GCTGAGGATT	GATCTGTGAG	TAACAAGTTG	TGAATGAGGC	TGGCAGGAGC	840
TAGCCTGGGA	GTAAGATTCA	GTGTTTGNTA	ACAGCGTGCA	GGCATTAAGC	CAGGGAAGTG	900
AAAGTNCCCA	CANNGNCTTT	GGCAAGTAAG	AAGTCG			936

<210> 20

<211> 888

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 20

AGGNNGGGGG	GGGAAACTTN	TTTATNTGGA	AAANTTTTGT	TTNGGCGGGN	AAGGAGTTTT	60
TAANAANGTT	AANGGAAAAA	GCTTTTANTT	AANATGACCT	TTTTGGGGGA	AANACAAANT	120
TGGTNNGTGT	ATTNGNGAAA	AAGATTTATT	ATAAGATTTT	TTATAANATT	TTNGGGGGGG	180
AAATATTTCA	AANAAAATTC	TGTAACAAAA	GGNTTTTGT	TTTTTGTNT	CCAAGNAGTT	240
NTCCAGGTAG	TTNTCAACAA	CNNANGCCNT	AGGGAAGGAC	ATCATATGGA	TATTTTCANA	300
GATTTGTTTT	TAGGAAACAT	TNTAAAGTCA	AGGTTAAGAT	GACAGTCAAN	TCCCANGAGN	360
GNGGTAAC TG	TNTGCTTCTT	TATTTAAAAT	TCAATATTCA	GGATTTTATT	TATACTAACA	420
AGANTAATTA	CCATCTTAAT	GAAACATAAT	TTGAATAATT	TGCAAACAAT	NTGATTTTTC	480
TTGAATATAC	ATGTTACTAA	AATATTANGG	ATGCAAATAG	NTAATAAACA	AATAGATANG	540
NAACCATGGN	ACACCCCTTC	TGTGATTGGN	GGGACNTGGG	CATAAGGCTT	GTTTGTATAA	600
TAATGTTTAT	ATTTTACATT	CTTCCTNNGA	GGANGGTCCT	CCCTGTTAAG	AAAANGACTC	660
CAGGATAAGG	AGACAGCACC	AGTNTAGGAA	GTGAGGNTCT	GTTTAATGTC	TTAGCAAAGT	720
AGTAAATGNT	GGGACCATCA	GAATAGCCCN	TAAGGNTGTG	GANAGAACTC	TAAAAGCNTG	780
ATATATATAT	ATATATATAT	ATATATATAT	ATATATATAT	ATATATNTAT	ATAAAGAGGC	840
AGTATTGAAA	GACNTNCACC	AATNGAGCTG	GCNAGCTAGA	AGAGGTCG		888

<210> 21

<211> 903

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 21

CTTGGAAGGT	TTTTTTNNCA	AAANCCNGGG	NGGGTTTTTT	TTAANAANA	GGNGAAAAGA	60
TTTGGAAACT	TTTTTTTTTG	GTTGAAGTTA	NTTGGGGATT	GGGGGAAAAA	TTAAAAGGAT	120
TCAAAGTTCC	CATGGNTTGG	AAGTANAACT	TTTATTCAGA	AGNGAAAGTT	TTAATAATGA	180
AANATGTTTT	TTTGGAATTNA	CGGNGGNGGA	ATTGGGGAGN	GGAGAGAGAA	GAGAGAGAGA	240
GAGGGAGAGA	GAGCCGGATC	CGCANTCGGG	GGTTTCTACC	GGCAGAGCCA	GGACGGAGAG	300
GGTTTTCGGC	AGCCGCNGCG	GGTTCGGAGN	TTTTTAAGGTT	TNTTAATCTT	GGAAGGTGTC	360
TGANATNACC	CCGTTTCTTG	TCGGTGATGT	TTNGTACAAG	CTTTCATTTT	TTCAGGATTT	420
CGGAGCGCCA	ATTACTGCCC	CGATNTGGTG	TTTATGTTTG	CCCGTTCNTG	CGCNTGGCCC	480
CGCGCCCGCC	CGNGAGCTGC	GTTTTCCCTG	GCCGCGCGGC	CCGAGGGGGT	GGGTGGGGGG	540
CCTTGCCCCG	CGCACCCAG	CGCAAGGGAG	GGGTCCCCTT	CATTTTTTTT	CATTGACTTC	600
AGCACCATGT	GATCAGGAAG	TCTGGCTCCN	TCCATTTCCC	NTCCCGACTG	AAGGGAAACA	660
TTGTGTAGCA	GCCCGCCGCG	GCCACTGGTG	GGATGGCNTT	CGCTGGCCTG	ANGTAGGGGG	720
ATAAAAATAA	CCGGCATATT	TAAGGCCGGA	GCAGGAATCC	CGGCGCTCAC	ACGCGGCCTG	780
GTCAGTTCCC	GAAGCCGCCA	GCAGCGCTCT	GCGCAGCGAG	CTGCTGCTGC	GCCAGCCAGN	840
TCGGGAGTGC	GGACACCGTG	AAAGACCTTC	ACCTATAGNG	CNTGGCAAGC	TAGAAGAGGT	900
CGT						903

<210> 22

<211> 918

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 22

TCGGGGGCAG	GAAAANTTTG	GGGTTTTTCGN	AAAAAAAAAA	ANGGGCANAA	ACCCGGTNAA	60
CNTATTNGTT	TTNGGCCCN	AAAGTAAANA	ATTTTTTTTT	NAAAANATGG	AAAAATTGAA	120
AAGGGANANG	CAGGGAAGGG	NGGNATTTTA	TNTCCAANTT	TCNGGTCCT	ACTTTTTTCC	180
NGATTCTGTC	AGTTTCGCTT	TAAGCAAAGG	NGANGAAGGG	NNAGTTTCAG	AAGTTAGGCT	240
TGCCTGAGAA	AATTTCAATG	GGTGGCAATT	CTTAGGACTC	AGGACAGGAT	TCAGNGNGGA	300
CTAATNTGCA	TTTNGGGATN	TGTCCCTGGG	GTCCNTAAGN	TCCGGACCGG	GANAGATGTT	360
CNAGGGGGGAG	ACCCAANTAA	CCCAAAGGAC	TGAAATTATC	ATGGCAGCNA	CNNACCAGTA	420
GTTGNTCTGG	TAATAGAGCA	GATTGCTCAN	AAACACGGTT	GTTCCATTTG	GATATATCCN	480
TGAAGTCCGG	CCGTGCGAAA	CGATCAGAGC	CCGGGAAGAA	ATCATCCCAG	GCACGGAGCG	540
GGGCAAGGTT	TAACGTCCAT	GTTCTTTTGC	TTGGCGAGCT	TCGCCTTCGG	AATCCGGAGG	600
CGGCGGCGGT	AGCAACCAGC	TGAATGAAAG	ATGACAGCGG	CTCNTTCGGA	TTGGCTCTGC	660
GGTTAGAGCA	CCGCAGGGCC	CAGAAAATTG	GCCGCGGGCG	GGTGTGTTGG	TCTTTCTGTG	720
ATTGGCTGGA	AGTGGTTAGT	GACGGAAAAC	TGTGGGCTTT	ACCAAATGTA	AAACGGAGTA	780
CTAACAAAAA	GTAACCAGCG	GAAATGCCCC	CCTAAACTAA	AGGTGGTGTC	AGTAGTCTCT	840
CTGGCAGTTT	AAATACAAAC	NATCTCTTTT	TAGGCATTGT	TTTGAAAGTC	CCCACAAGGN	900
TTTGCAAGTA	ANAAGTCG					918

<210> 23

<211> 309

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 23

AGAGAGGGTT	TAGCACAGGC	AGCNTATTCC	CAGTTTGTGC	TGTAGAACTG	GAACCTCAGG	60
CCTCATTTCTG	AAATNTGCAG	CCNTCCCCAG	CATCCTTCNT	GGCACAGCNT	GGCACAGACN	120
TGNTAAGTGT	CTATTAGTGA	CTAATACAAA	GGAGTATTTT	AGAACGTTGG	CACATCTCAG	180
CACGTTGCAA	CTGGCTGGAG	CTGGTTGAGC	TCTTGCTGCT	TCCATATCCC	TTTGTAGCTG	240
CTCTCCACTT	TTCTGAACCC	CGGGTCCATG	TGAAAGTCCC	CACAAGGNNC	TTTGCAAGTA	300
GAGAAGNCG						309

<210> 24

<211> 904

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 24

TTTCATTTAA	AACNCGGGGG	NTGAACCCAA	TCTTNANGGT	GGCAGTGNGG	NNGATCTTAA	60
CGGTTTTTNA	GAAAAAAAAN	TNCTTCGCTC	NCACCCCCAA	GCCTCCCNNT	CTTANCAGCT	120
TTTTTATANG	AAAAAAGATG	ATAACGAAAT	TTTAAAAACC	GTCGTTAGAG	GAAATGAAGG	180
TTCAGCCGAC	CATTACCTGA	NAGTAATGAA	GGTNTTCCGG	AGGGTTGCCT	TCCAATCCCA	240
GATGGATTTG	AGTTTCAGGA	TCAATTCAGT	TACCGNTGAC	CATCCACCNN	CCTCCNGTAT	300
AATCATTTNGA	TGAGGATGAA	TGGTGAGTGA	GTGATGATGA	TGATGATGAT	GATGAAGGGA	360
TGAGAAGNAC	ACTATGATAA	CAAGTGTCTC	AGTCCACATT	AAGGTTTGCC	TGNAAATTAG	420
TGCATAAGCC	ATGGGAGACA	AATTCTTTTC	NNACACAATT	AATAGTNTCT	TANTCCTTCC	480
CATCTTCTCT	GCCCCATTCT	GTTTTCCACC	ACAGGTCTGC	AGCGGGCTAC	AGCTTCCAGT	540
CTCCAAGCAA	ATACCAGAAC	TGGAGGAGAA	AATTCAGTCT	CAGTGAGTCA	TGGGCAGGGG	600
GAGGGGTGGG	GTAAGGGCAG	TGGCGCTCAT	TCCTNACATG	GTGTCTTCTC	TTGCCTAGCC	660
TGGGATCTGA	GGGCAAGAGA	ACCTGTAAGC	TTGATTTGAT	TTCCACTGCT	GACTGGAGTC	720
ACTGCCAAGG	GATTTGGGAC	TTCTCCATCT	CTCTCTCTAA	CCTGAAATCC	TTAGGATTCT	780

ATTATTTTCAC	CGGACCAGAG	CTGTAGCAGA	GATGAGCTCC	AAGTTTGAAA	TGAGAAAGGG	840
GAAATTGAGA	GCTATGAGCT	AGGNGCGAAA	GNCCCCACAA	AGNNTTTGGC	AAGTAGAAAA	900
GNCG						904

<210> 25
 <211> 883
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note: = synthetic construct

<400> 25

GGGGGGGGAA	ACTTNTTTAT	NTGGAAAANT	TTTGTTTNNG	CGGGNAAGGA	GTTTTTAANA	60
ANGTTAANGG	AAAAAGCTTT	TANTTAANAT	GACCTTTTTG	GGGGAAANAC	AAANTTGGTN	120
NGTGTATTNG	NGAAAAAGAT	TTATTATAAG	ATTTTTTTATA	ANATTTTNNG	GGGGGAAATA	180
TTTCAAANAA	AATTCTGTAA	CAAAAGGNTT	TTTGTTTTTT	GTTNTCCAAG	NAGTTNTCCA	240
GGTAGTTNTC	AACAACNNAN	GCCNTAGGGA	AGGACATCAT	ATGGATATTT	TCANAGATTT	300
GTTTTTAGGA	AACATTTNTAA	AGTCAAGGTT	AAGATGACAG	TCAANTCCCA	NGAGNGNGGT	360
AACTGTNTGC	TTCTTTATTT	AAAATTCAAT	ATTCAGGATT	TCATTTATAC	TAACAAGANT	420
AATTACCATC	TTAATGAAAC	ATAATTTGAA	TAATTTGCAA	ACAATNTGAT	TTTTCTTGAA	480
TATACATGTT	ACTAAAATAT	TANGGATGCA	AATAGNTAAT	AAACAAATAG	ATANGNAACC	540
ATGGNACACC	CCTTCTGTGA	TTGGNGGGAC	NTGGGCATAA	GGCTTGTTTG	TATAATAATG	600
TTCATATTTT	ACATTCTTCC	TNNGAGGANG	GTCTCCCTG	TTAAGAAAAN	GACTCCAGGA	660
TAAGGAGACA	GCACCAGTNT	AGGAAGTGAG	GNTCTGTTTA	ATGTCTTAGC	AAAGTAGTAA	720
ATGNTGGGAC	CATCAGAATA	GCCCNTAAGG	NTGTGGANAG	AACTCTAAAA	GCNTGATATA	780
TATATATATA	TATATATATA	TATATATATA	TATATATATA	TNTATATAAA	GAGGCAGTAT	840
TGAAAGACNT	NCACCAATNG	AGCTGGCNAG	CTAGAAGAGG	TCG		883

<210> 26
 <211> 924
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note: = synthetic construct

<400> 26

TTTGGAAGGN	TTTTNAGGAA	AGAAANTGTN	TTTNAGGGNA	GGGAACCCTA	TTCCGACGGG	60
TTGGGGGAAA	ATTTTGGGTT	GACCTTTCGT	TAAAAAGGGT	TNCGGTAAAA	GGGGGCNANG	120
TNTTNNAANA	AAAATAATAG	TAATAGTAGT	AGTAATAGTA	TTAATAATAA	TAATAATTGC	180
AGGAATCCTG	TNACCNTCAG	GAATTGGGGA	AGTAGTTTCT	TATTTTAGGA	CCAGGTGTTT	240
TGTTTCAGGG	GAGTTATTTT	TTGTTTGTG	GATGGGATGA	GTGGTNTCAA	TTGCTTTNAA	300
AAACCTGTAT	TAGTTTGTGC	ACAGTTAGTG	TGTNTCNGNT	TCGTTNGAGG	AGTTTGAAC	360
GGATGGTAGG	CAATGGNTGC	ACAGATTCAT	AGTGGCCAGA	GTTAGAGTAA	ATGCTTGCGG	420
AGCAGTCAGA	ATAGATGAGA	NTCAGGGACC	CGGCAGATGA	TGCAGGGAGA	ATGTAAGAGC	480
AGAAGGTGGT	GGGTAGCATG	TGGAATGCAC	ATTTCCAGGC	GTGACATGAN	TCGGAACAGC	540
TGTGACTGCT	TAGACCAAAG	TGATCCCATC	AACACGGCCA	TTCAGTAAGG	AAGGGTCATG	600
GGNTCCCCC	NTCCCTTAGG	ATTNACATAC	AGATAATGAT	TGATTGGTGG	ACCAGGGGAA	660
TGGGGAAAAA	TGTCNTTTTC	GTTGGTATAG	TCACTGGTAG	CTGCCCATGT	TTNTATAAAC	720
AAATTNTAAA	GAAANTCATT	GGTTCATACA	CGTAAGAAGA	CATCAAAACA	GAACTGAGGC	780
AAGTTGGGAA	GAGAAATGGG	ATTAGTAGGA	GAGGGTCAAG	AAAAGGCAAA	GGTATGTGCA	840
CATGCATGAA	TACATTGTAT	ACATGTATGA	AAGNGCCACA	ATGATGANTT	ACCCCANATG	900
GNNGTTTGGC	AAGTAAAAGA	GTCG				924

<210> 27
 <211> 482

<212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 27

TCTCTCCTGA	GGGGGGTTTT	NTGGANGAAT	AGAAGAANAN	ACCNCTCTT	TGTTTCNTCC	60
TGTGGNGNMC	CCTGCTGNTA	AAGNNGATTT	NCNCGGTGNT	ATACANNATA	GAAGGAGGAT	120
CTCTCCCCC	ATTGTNANAG	AACCCCGTGT	GTGGGGAGGG	GGTGTNGCCA	CNANCCAGAN	180
NTGGCCCNNG	GGTCNTCTCC	CCACTCNTNT	GNATAACNTC	TNNCTCCAC	AAANACCCCA	240
NANAAAANCA	CCCCNCNTGT	GAGNNCNGCA	GANGCGCCCT	NTNACAAGAN	AAGAGNNCAT	300
GTGNTGTGGC	CCTGTGCTNN	GACANTNTAN	ACTCTTCTNT	NGNGGGGNGN	GGNCTGTGGT	360
TTTATAAGAG	NGTGTNNCCG	TGGGGGGGAG	AGTANTCNTT	TTATATAGAG	AGANAGNGNC	420
CTGTGNAAAC	TNCCTCTGAG	AAGAGCACCN	TGGTGTCTC	TCCCATCTNC	TAGNAGGGGA	480
GG						482

<210> 28
 <211> 460
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 28

TAGCTTCTCT	GTGAGGGGTA	GAAGTCAAGC	TCCCCCATGA	ACAGGCTTTG	GGGTTCCTGC	60
CATCCCCTGG	GGCTGTTTAT	TAGGTGCCCA	CACAGACTTC	TCATGCCATG	ACTCACACTT	120
GACGTCACAG	AGCACACAAA	GAGCACAAAA	GCAGGCTGAC	CACATCCGGC	CATGCACACC	180
CCTTTAACAG	TCCCAAGCTT	TCTCTCTCTC	TTCTAAGTCA	CTGCCCTGGG	AAGACGGTTT	240
CATACCCAAG	CTGATGTGCA	CTTATTTCTT	TGTGTTATTG	CTCTGACAGT	CTCACAGTGC	300
TCTGCAAACA	CTCTGCATTC	GCCTTTACCA	CACCAGAAGA	AATTCCTCTT	TGTGCAGGGA	360
AAAATACATT	CGTCTTAGTA	GCTTCTACTT	TCCAGCTTGT	CCCTAGTCTG	TCTGATATGT	420
GGTTACGTAN	TGTTAGGGGC	CACGGAAGGG	GGGGGGGGGG			460

<210> 29
 <211> 465
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 29

TCCCAAGACA	AGAGGGGCTG	AAGAACGGGG	GGGGGAAGAA	TCAGGAGTGT	GTCGCTGCTT	60
CCCACATAAA	GACGGCACCT	ANATCTGTCT	CTCTCGGTGT	CTCCTCCCCA	CCTGGGGCAG	120
GGTGAGCTCT	CTAGACAAGA	GAGAGACTGT	CACAGAGAGA	GAGAGATGTG	TCACCCCTGT	180
GGAGATCAGA	GNCNCCGACA	CCTAGGGGAC	AAATGGGGAT	CTCTTTTTTT	TTTCTCTCTC	240
GAGACAGGGG	GTCTCTGTGC	AACACTTGCT	GTTCTGGAGA	TGTTCTGTAG	ACCAGGGTGT	300
CCCCCAACTC	AGAGAGCCTC	CTCCTTTNCA	CAACTGTGTC	GCCGCCGCCG	CCGCCGCCGC	360
CATCACCAGG	CTATATTTAC	TATTATCTCT	ATTACTATTG	TTGTGTGTTG	TGTTGAGACA	420
GGATGCTCAC	GCATAACCCT	ANCTATCCTA	GTGATAGACC	CCACC		465

<210> 30
 <211> 568
 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 30

TNNCNNTTNC	CTGNGGCCGN	GTANCTCTGA	GNGANAGTNT	CCCCGAGAGG	GGGGGTCTCA	60
CNNTAGNTNT	ANANAGTATN	GNGTGCTCGA	GTTTNNAGAG	AGCTCTCTCT	NNNTCTCTCT	120
CCCCNGAGCT	ATNGNNTTAG	GGNTATGGCA	CNNCNCGTCT	CTCNNCNCN	TATNGAGNGG	180
TGNGNTATNG	GGGNGAGAGT	NTCTGCCCCG	GACCCACATT	CTCNGAGTNN	GGNAGAGTNT	240
GGGAGACACA	CANCTCCGGG	NANATCTNTC	TCCNCCCCC	CAGGGGCGGT	GGTNCANATN	300
GNCNACAGAG	CCNCNGNNTT	NTATGTGGAG	AGGGGATATC	NCANCNCACN	CCCNGAGCAC	360
AGGNTCCACA	CNCAGAGANG	TGTCTCTCCC	CANCACACAA	GCACNTCTGG	TGAGNTCTAN	420
GTTTTGNGAG	AGACNNTGCC	CTGTCTCCCT	TTTCCCCGCT	CTNACACACA	TGAGAGGGTG	480
TGCACATCTT	CCCCATGTCC	CTCTCTAAAA	CCNCCCCAGA	NTTTTGNGGT	TNTGTGCAAN	540
ACCCTTTTCA	CNCTCANGGG	AGATNTTTT				568

<210> 31

<211> 920

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 31

GAGGGTTANT	TGGCCCAANT	CGGCAATCAT	CCNGGGAAGA	AGANGNCAGG	GTTTNGGCAA	60
ATCGGAAGAT	CAAGGACGCA	ATTCGNGGGG	GGGGATGGAT	AGNNGCNAAA	GGGNACNGAA	120
AGNNGGATTG	GNAGGNAAAA	TTAAACGGGA	GTTGTAATCC	AAAAGGACGA	CAAGGC AAAA	180
ACAAATCCGG	NAGTAAGCAG	GAAGCACAGT	GAANTTGGGG	GAGGCAGNGT	GGNGNAANTA	240
AAAAATNGTT	TTTTTAATCC	CAATANGGTC	AACANGTAGG	CAANTGGATN	TATTAGATAT	300
TATATCTTAG	CGCAAGNTTN	TCACCCATTG	GTCCAACCCA	TATAACATGG	CGGTGGTNAA	360
TNTNTGAGCN	TGGCACAATT	TTTNACCCAT	TAGTTCCCAA	GGCAGATCGC	CACCATGCCA	420
GAANAAAATC	CCAATTCCAT	GGTGGCCCAG	TGTGTCCAGC	CACCAATANT	TTCTTGAATT	480
CAATTAAATC	ACCACATGAA	GGAATACATA	ACACAATAAC	ATCTGATCCA	ATTGATAAGA	540
TATAATTTGC	TCACNTAGAC	ATACAAAATC	CTGTACATTC	CATCTCTTAA	GAATATTCAT	600
AACAAACTAT	AAATGTGTAG	AGAGGAATTT	TAATATCCAC	TTCCATGTTC	TCTTGGCTGC	660
TCCTCTCTCC	CAGTCTCCTC	CTCCTCCTTT	AAAAC TTTT	TCTCCCACCC	ATCATTT TTT	720
TTTGTCCNAA	GGACGGGCCT	TGTTNTATCC	TGNACCTGCN	TTCGTCTGCA	TAAGGCCATC	780
ATCCCACAGG	CAGGACTGGA	GCAATGGCTC	ATTGGTTAAG	AGCACTTGCT	GATCTTGAAG	840
AAGACCAGGG	TGCAATTCTC	AGAGCACTNC	ACTGCTNCAC	ACTGAAAGAC	CCCACNNGTA	900
GGTTTGGCAA	GTAAGAAGAGA					920

<210> 32

<211> 176

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 32

TTGACCATAT	TATTTTTATT	CACGTTGGGA	CAAAAGAGCA	AACGCAAAGG	ATAGGAAACG	60
AAAGGAATTA	ATTTCTTTTC	AATAGAGATA	TCGGTTTTTT	TTAGAGGGAA	AAAATTGAGT	120
ATTAGAAAAT	AAAAATAGGT	TTCGGAATTT	CCGGAAAGAC	CACTAAATTG	TAGGTT	176

<210> 33
 <211> 336
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note: = synthetic construct

<400> 33

AAAAGGGNTN	CCGAANAAAA	ANAATTNGGA	TCTTNTGGGG	GCCCNGAGGN	AAAAAAAANA	60
NTAANCNGGG	GGNGACCCAG	NGAANAGACA	AATTNTTTTN	CCNGGAGTCC	TTGGGGTGNN	120
ANGCCAAACN	GNCGTTTANN	GNAANNNGNC	GNGNTACCNC	TTCGGAGNGG	GGGCGCTGNA	180
AAAGAATNGT	GAGAATNCNG	TTACNNGTGT	TGNTTNATCN	GAGATAGTNG	TNTGTAACAA	240
CCCCGATTCA	GCCNGAAAGT	TACGCATATG	CGNANCGTTG	TGTGAATCGA	ACCTGGNNAA	300
AACAGACCCA	TNGNCAAGNG	GCAGACCNA	CGGAAC			336

<210> 34
 <211> 92
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note: = synthetic construct

<400> 34

TGAATAAGGG	TACAAAGATT	GTGTTTCAGA	GGAGAGAGGT	AACAAGAAAA	GACTCCTAAC	60
GCAATGGCCA	GAGGGCCAAG	AAAAAGGGAA	AA			92

<210> 35
 <211> 838
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note: = synthetic construct

<400> 35

GGNGTNATTT	TCTTCTNGTG	AANTCTTTNC	CAAATCCGNG	GGTNTGNCCC	ANNGCCCCNN	60
TTTATACACN	NNATTACNCN	TNNNCCAAAA	CNCTATATGT	NTCGANATGT	CCCATNTTAA	120
ANATATGNGA	CTCAGTTTGA	GTNTCCCCAN	NTTGGNGTTG	GGGTATNTGG	GTAAANACAN	180
NGACCTCTCN	NGGNGNTTTA	TTTATATATN	NGNCCCNATA	TAACNCAGAG	ATCTGTGTAA	240
AAAATATNNC	NNTTCGCGGG	GNGGGAGATT	TCTCTCTGNN	GTAGNGCNCT	CNNCTGAGAN	300
GCACAGNGCC	CTGTGTTNTN	TCCCCCTCNC	CGAAAANAAT	TTTNTNCAAA	AANANANAAT	360
ATNNACANAC	CCCNANAAAT	ATNCCCCTTN	TCTACCNCCC	CTCAAANACA	CCNCNNTTTT	420
TTTTTNCCCC	TCAGAAATNT	TTNTAATNTG	GGNNAAAAAA	ATCTNNGNTG	GNNTTNTCCC	480
CCCNNTTNNA	GNCGCCCCCT	NNAAACCCCC	NCTNTTNANA	GANAAATATG	TANACTCNTA	540
TTTAAAAAAN	AACANTTTTT	GTTNGGGCTN	GGGTNTNCCA	NCCCTTCACT	CTCTTTGTGG	600
GTNTNCCTTN	CCATATNCCC	CCTNTTTGAG	ACNTTTAAAN	AACCCTCTCC	CTAATTCCTC	660
CNCCCNCTGT	TTCCCCCTTT	TNNAAAAACN	TCNGGCCCTT	TNGCCCCCCT	TTTCTNACTC	720
CCTCTTNTCC	NGAGATTTTT	TCCTCNTNNT	NNCTAATTCC	NTTNTTCNAN	TCTANATNNC	780
NNTGTTNCNA	NCGCANGNTN	NCCCCNCCTT	NNCTNAATT	NTNGGGNAGG	TTCCAACC	838

<210> 36
 <211> 314

<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 36

CAAACCAGAA	ATGGCCCAAG	GGTCATCTCC	CCACTCAGTA	TGAATAACAT	CTAACCTCCA	60
CAAAAACCCC	AAAAAAAAAAC	ACCCAGATG	TGAGAACAGC	AGAAGCGCCC	TATAACAAGA	120
AAAGAGAACA	TGTGATGTGG	CCCTGTGCTA	AGACAATATA	AACTCCTCTA	TAGAGGGGAG	180
AGGACTGTGG	TTTTATAAGA	GAGTGTAACC	GTGGGGGGGA	GAGTAATCAT	TTTTATATAG	240
AGAGAAAGAG	ACCTGTGAAA	ACTACCTCTG	AGAAGAGCAC	CATGGTGTTT	TCTCCCATCT	300
ACTAGAAGGG	GAGG					314

<210> 37
<211> 226
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 37

AGGGGGGGGAA	ACCCCTTCGC	CNCGGGCCTA	TCGNAANTTT	TNNTCCACCG	TAAAAANATTT	60
NCCANGNGCN	CCATGTANGG	ATTGNGGGNG	TAGTGGGGGG	AACGATTNTG	GAGGGGCCTA	120
AAAGGNANAT	AGAGGACGTA	TTGTATTTGG	TTTTGCNGAG	CCAGTACCTT	NGAAAAAGGT	180
TGGTATTTTT	GATCCGGCAA	CAACCACNGT	GGTAGNGTGT	TTTTTT		226

<210> 38
<211> 843
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 38

GAATTAAAAC	GGGAAAGATT	GGAATTCAAT	TTCTTACAGC	CAAAAGCTAG	ACCGGGCATA	60
TAGGAGATTA	TTTCGATTTA	GCACCTTCCA	AAGCCTGCCC	CAGATTTAAA	GTTTAGGGGT	120
ATTATTTAAA	AGCAGGTTCC	GGGAAGTTCC	AAGATAGGCC	TAGAGGTAAT	GGTATGCAAG	180
CAGTCCTAGG	TTTCAGAAGA	GTTCAAACAC	GGGTCTTCAG	GAAAAGACGG	AAAGTGTAAG	240
TTGATCAGGC	CAGCAATCAT	ACAACAGTGT	TTGTTGTAGT	ATTACCTTTT	CTAATGGTTG	300
TCACTGAAAG	GAGATTATTC	TAGGTTTGGA	GATACAAAAT	TAAAAGAATA	AACCCCAAAA	360
GGCCACAGAC	CCAGGGTAAG	CCCTGTAGCC	AGGACTAGCA	GGCCATAAAG	AAAAAGGAGC	420
ACAGGAAACA	CTGTCCAGGC	AGGACTGGCA	AGCCATAAAG	ATAAGGAAAA	GGAATGCAGG	480
AACCAGCCTG	AGTTAATGAG	AAAAATTAAT	GGGACGTCTG	GCAGGAAGAC	ATCTCCCCCT	540
AGCACACTCC	GGGCCATATC	TCAACTAGGT	GTCTCCAGC	CCCTGACTTA	TAGCACGTAC	600
TCTATCTGCT	TTGTTATCAC	AGATATGTTT	GAATGAGCCA	ATTGTATGTA	ACCACGCCAA	660
AACCCCTAG	CTTTGTCTAT	ATAACCGTCT	GACTTTTGAG	TTTCGTGTTT	AACTCCTCTG	720
TATCTTGGGT	GAGACACGTG	TTGGCCCGGA	GCTTCGTTAT	TATTAAACGA	CCTCTTGCTA	780
TTACATCATG	ACCAGTCTGG	TCCTGTTGTA	AGACATTGGC	AAAAGAGCCT	GAAAAC TAGA	840
AAA						843

<210> 39
<211> 943
<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 39

TTTTTTTTTT	GGAAAAACGG	GTTTAATAAG	GGGNANGNAT	CCGAACCCCC	ACTCGGGNGA	60
AAGGAAANAA	AANAATANGG	GGGGAANAAN	GANTTGGNGG	TAATGCTTTA	CCACGACAAA	120
CTAGTCCCAT	TNTTCGGGGG	GGGAAAGGGA	NGGCATGAAT	AATGGGGTGA	AGGCNGGCAC	180
CCACCCCAT	TTTTTCGGGG	TAAGTCNGTT	TTTTTTTGGT	ANATCAAAGT	TCCTTTCGGA	240
ANATGTCCGT	TTNATCCAAG	GNGTTTGGG	TGTTNNAATT	AGNATTTNNG	NGAGTTTCAA	300
AAGTTTGTGT	TCNNGAGNAG	TTTGTAATTG	G TTCAGCNGG	TTTTTTTGTG	NCAGGAAAGC	360
AGACCCNTGT	TTGGGAGGGA	GATCCAATTT	TNTAGTTCCC	ATTTGGCTGT	TTCTTTAGTA	420
ATGGGTCTGC	AGACAGTNTG	AAGTNTATGA	GTTGGTCCCT	TCTCNTATCA	GCCCGGGGTG	480
GCATTNTGTC	CAAAGGAGGA	AATCCAGCAG	CCAGACTAGA	TTTCAGTNTC	CTTTNTAACA	540
GGGAAGTTAG	ACACACCCGG	CCAGTTGCAG	CCTTTCCACC	CCCAANGAGT	GAACCCTGCC	600
NTTTCAGNTT	TNACCCAATT	TACTTTCGTT	GGCTTAGCAT	GCAGANTCTT	TGGCTCCATG	660
CCCGGAGCAG	CTGACATGGG	AGGCTTTGAA	ACTTCCATTA	TCATAGAATG	GCAGGCAGGT	720
CNTTTGCGGT	TAAAACCAGG	AGCNTGGGCC	AATGAGATGG	NTCANTGAGC	AAAGGCGCTT	780
ACTGCCAACC	CTGATGCCNT	CAGTTTAGTN	TTGGAATTCA	CAGGGTAGAA	GTTGAAAACC	840
TTTGACTCTT	CAAAAGTTGT	CCTGTAGCAG	GGCAGTGGTG	GTGCANACNT	TTAATTGNNG	900
TACTTGTGAT	AGTCCCACAA	GGANCTTNGC	AAGTAAGAAG	TCG		943

<210> 40

<211> 904

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 40

ACTTCTCTAC	TTGCCATGGT	CCTTGTGGAA	TCTTTCAATC	TGTGTCCTTA	GAACGCTAAG	60
CTAAGACTTG	ACCTTGGCTC	CCAGGGCGGG	CTGGGACTTG	GCCACCCCGT	GAAAAGGGCT	120
CTTTCCTCAGG	CAGGTGTTTT	CGTTTAAGAA	AATAAACCAT	CCAAGTCCGG	GCAGACTGAG	180
AGCTACACAC	CCCTCCAAGC	CAATCTGGAG	TGGCTCTGCC	CAACCCCCAC	TGCTGGGAAA	240
ACATGGCTGC	CTCAGCACCT	CCCTAAATGA	AGGGAACAGA	GTGTCTCCTG	TGGCCTTGAA	300
AATATTAATA	AATGAGACTT	AACCTGATGG	CTCAAGGCTC	TCAGGGGGCT	TTTTTTTGTT	360
TTTACACACT	CTGTGGAGCT	GTTACAAGGT	CAGTCAGTCA	TTTGCATGGG	ACAGACAATC	420
TGTTTTTAATA	TTTTATATGT	TTGTCTTTTA	AAAAACCTAA	GATCTATATC	TTTTTACATT	480
TTATTGTTTT	GTTCAAAAAA	AAAAGTTTTA	CACAATGATC	AAAAAGTTCA	AATGAAGTCT	540
TTTTTAAACC	TCTCTCCTGC	CAAAGGAAAC	CAAGCAAAC	TTTTCCAGAA	ACCTGATAAG	600
AATATCTCCC	TTTTACCCTG	GAAACATTAA	AAATAAGGAT	CCCTGAATTA	AAAATTCTAT	660
TCCAGAATCC	TAATTTTATT	TTTTATTTAA	AAAAAATAAA	ACCCCTTAA	CTGACGGGCG	720
GTTTTTAAAT	CACCTGCCTT	CAAACCCCC	CTGGAAATTT	TTAAAATTTT	TTTTTTGTTC	780
CCCAACATTC	CTCCCCCCT	AATAACACCT	GATTGATACC	CACCAATTTT	CCACTGTGGG	840
TGATTGAGGT	GGTCCCCCCT	CTTTTTTGCC	GTTTGATTTT	CCCCGTAAA	AAATTTAGAA	900
AAAG						904

<210> 41

<211> 917

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic

construct

<400> 41

AAGGGGGGNG	AAATTTAGNG	GACNAAAATT	ATTCCTTAAG	GGCCNCCTTT	CTTCAGGGAA	60
NANGGGGGAA	GGAGATANTN	CGGCCCTTGT	CCGCCTTTTN	GGANACGATA	GGGNCGGTTC	120
GGNTTGGAAA	TTTTTCCTCC	AAAATTNCCA	ACAAAAATNG	TTTTTCCCCT	TCCTTCAAAA	180
AGAAAATTGG	TTTTTTTGNN	GGCTTNGGGG	NGTCNGGAAG	TCANAACCCN	GNGTATTATT	240
GCNTTCCAGC	CCCACCCGTN	AGTTCATTGG	TAATTCCTAT	TCGTTCGGNT	CAANATAATT	300
CGNACTTCC	GCTTCCNAAT	GGATCCCTTC	AANGATTNGG	TTTTTCCGGA	TTATCGCAAG	360
TCCCCNGGTT	NTCCAATCCG	GAGCGCNTCG	GATATTTCCG	GNTNTCCGTG	CNTTTCCTAGC	420
CCCACCCCCA	NGACCACCNT	TGGTTNTTTA	GGTGGGTCTT	TGATCCGCTT	CACGTTGCTT	480
CAGTGACNTA	GATCCTTNTT	CGGTCTTTCC	GGCTCATTTT	AGTCTCGAGT	TATTCTCAGC	540
TGTGTTANAA	AAAAACANNA	NAANAANCTC	CGCCTCGCCC	TTCCGNTTCG	GTTCTTTCCG	600
CNNGCNTTCG	GGCGGGCNGT	NTCTGCCTTC	TCCACGTGAC	GNTTNTTCGG	CNTCCCAGTN	660
ACCCCTCCCN	TCCACGCCTT	CNTCCAGNTT	CAGCTTNTGT	GCTCGTCCCG	GNTGTGCCGC	720
CANNNTNGTGT	CAATTCCNGA	CCGCGGCGGG	GGCCGGGCAG	NTGGGGNATN	TAGGGCGGGC	780
AGACAGTCGG	CCNATCTCCA	TAGGCCGTTT	CCTATNCTNC	CCTGATTTTT	TTAAACCATT	840
TCCAAAAGCT	CGCTGTCCTC	TTTCCGGGNC	TTCCATTNNG	GNGTNTCCAN	AAGGAAGNAA	900
GNCNAGTAAA	GGANCTC					917

<210> 42

<211> 835

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 42

GGNCCCCTAN	NGATTGGCCN	TTGATCAAGA	NGGGACCATC	CTGNACCTGG	NGGTNGNTGT	60
TTCCGCTTGG	GACGGAGATG	GTTGTTTTTG	CGGAGTAGTT	TCNGNGGGTT	TGAGGCGCGG	120
NTANTTTTTT	TGTTNTGGTC	CAGACCGTTT	TGATTTAGCC	GCNGCNGACA	GTAATGGGGC	180
GATACCTCAG	NTCCTTGTGA	ACCCAGGGTG	CAGNTGGTTC	AGCAGGATAG	ATGTACAGCC	240
TCCGAACCTT	TCAATTCCCN	GACTAACCAT	TGATGTCAAG	TTGAGTGTTT	AAATGCTTGC	300
TACCAAGCTG	GTTGGTAACC	TGAGTTCAGT	CCCTGGAACC	CACATGGGGA	GAGAGAACAT	360
GCTTCTGTAA	CTTGTCCTCT	AACTACCCCC	AATACACGCA	TGCGCGCGCG	CGCGCACACA	420
CACACACACA	CACACACACA	CACACAGAGA	GAGAGAGAGA	GAGAGAGAGA	GAGAGAAGCA	480
CAAACAATAA	AAGAAAAAAA	TAAAATCTCA	TTTAATTTTC	ATTAGTATAA	TACCTTGATT	540
CTTTGAATGA	CAGCAAGATA	AAGTAAACCA	AAGCACACTG	TAGAAGGGAT	TACGCAACTG	600
AAAAGTGACA	ATCCTTACTC	CAGCCCTTCC	TGCTATGTTG	GCAGTCTTGC	TGGGAGCCAT	660
TGATCTAATC	AGTTTTATTT	GAGGCAGGGG	CTCATGTAGC	CCAGGAGGAT	GGTCAAATCC	720
ATAGCTCATC	TGAGGATGAG	TTTGAACCTC	TGACCCTCCT	CATTCTCCAG	TTCTCCATAT	780
CCTGAGTGCT	GGCACTGAAA	GACNCCACNA	GTAGCCTTGG	CAGGCTAGAA	ANGNT	835

<210> 43

<211> 924

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 43

GTNTTTTNGC	CGNNGGAATT	TAAGGGNGAT	TTGGAGACTT	TNGAATTTTC	GAANGTTCCA	60
AAATAGANNT	TNAGGNCAAT	GGGNTTGGGG	CAGNGGNGCT	TTTTTAAATC	ANANAAGTAT	120
TAGATTTNTA	TGGAAACCCT	GGGGGTTCCT	GTTTAAATCCC	TTTCATCATCT	TGAAATATNA	180

CTTGTTTATG	GGAANGGTGN	GATAGCAGCC	NGAAACAGAG	GTTTTTATTA	TTACTGTTAG	240
AGANGAGGAT	TGGGGAATAG	AACAATGAGA	GTCTTGGTAA	TATTNTTCNG	GAAACAACNG	300
ACATAATTGG	AACATTAAGG	AAATATATCC	ATGCATTCTG	TACTTGCAAA	TTGCTCCAAG	360
GAAGATGGAG	AGTATTGTAT	TTCAGATAGA	GATANGACTA	TACCTGTTAT	TTTTTTCATT	420
ATAGCAACAT	TAAAAAAGAT	AGTAATCTAA	TTTCACATAA	CCATTACTAC	TAAAGTATAT	480
ATGTANTCTT	TGTTTATCAG	GTTTTACTTC	TCAGAAATTG	CAGCATCTCC	TACAGAGCCT	540
GTCAAATGAG	ACNGCATAGA	TCCCCAGAGA	ACAGAGAGAC	TGGGAAATCA	TTGAAATTAC	600
ACAATCCTAT	CCCAAATGTT	TGCGTAGACT	CAAGCTCGTA	TCAGCTCATA	AGATCAGTGT	660
GTGTGTGTGT	TTGTGTGTGT	GTGTGTCCCG	CACATGCTTG	AGTATGCATG	TGTGCATGCA	720
TGTGTGTATG	TCTATTGCAT	TAGTAGAGAT	GTTAAGGTTG	AATGTATTTT	CTGCTCATGG	780
TCATTGTAAG	ATATTGTGCT	GTATGTGATA	AGAATCAATG	TAACAAGGCT	GGAGAGATGA	840
CTTCAGCTGT	TAAAGGCTAG	ACTCACTACC	AAAAATAGNG	CNATCAGTGT	GAANTTCCCC	900
ACAGGAGCTT	AGCAAGNTAA	TAGG				924

<210> 44
 <211> 435
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note: = synthetic construct

<400> 44

GATTCCAGAG	AGAGGAGTGA	ACTGGCAGAT	AAGGCAGTCA	GCATAATGGC	TTAGATACCA	60
TGTGCTTTCG	CTCACTATGC	ACCCATGACA	CAAGATCACA	GGGTACAGGC	CTGGACCATG	120
GCAGAGTATA	CACTGGTTGG	GTAAATGAAG	AGGAGAGACA	GAGTGGGAAG	TCGGCTTAGT	180
GGATATGGAC	TTCAAATTTG	ATGAACAAGC	AATTCAAATG	AGTATCGTGG	GCTTGANTGG	240
TATGAAGACC	CGTTTGCAAA	GCAGTGGTCA	TAAGAGAGAA	AAGAGAGAGA	GAGAGAGAGA	300
GAGAGAGAGA	GAGAGAGNAA	GAGAGAGAGN	GTGTGTTGTT	GTTGTTGTTG	TTGTTGTTTA	360
TTGGTTNATA	ACAANATNTA	CCTTTGGGCN	CTTTNGAAAG	ACTNTNCACA	AAGGAGCTTG	420
NCAAGCTAGA	AAGGT					435

<210> 45
 <211> 919
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note: = synthetic construct

<400> 45

CCCCNGTTAC	CCNGANGTTT	ACNNGTTGGA	TTAAANGGGN	NNNAAAACGG	GTGGGGNNAA	60
ACGAATTTTT	TGTNCNCGAC	CCNTCCCCGG	TTGGGGNTGG	NGAAATAAGT	TTTAAGGTGG	120
GAAANGGAAA	GGAAATAAAA	ANATTTTTTT	TNAAGGAAGT	TCCTTNCCAC	AAAAAANTNG	180
NTTNGTTCAG	TAGGGTTCGG	GCCCCGGAGG	NAAGGCAANN	TTGAANTNCA	NTTAAAAATT	240
NCCNGGAANG	TACCTTGGGN	AGGGATTACC	NTGNAATTTN	TTTAAGAAAA	NNTGGGTNTT	300
TTGGGGNGAT	TTTNNGCCCC	ACCTGGACCA	NTTTNGGGAA	ANGCAGAAAC	GTTCCAGNGN	360
GTTTTTCCTT	CAGAGAGAGG	GTTAGGTTCC	TTCAGGGGNT	TCCAAGGACG	GGGACCAGAA	420
NGTGAAACAA	ACCAGGNTNT	GAAGAGACCA	GNCGGGGGGG	GGGGAGGGGG	CCGTNTNTAG	480
TAGATTGAAC	CTGCAGAGTT	GCCTGTTACC	TGAAGTTGTC	ACCNTTTNAC	CNACANACTT	540
NATAAANNTN	TGNTGACCAT	NTCAGCAAGT	GTACCTTCG	TTGCCAGGAC	ACAAGTTTCT	600
TAAAGCTTAT	TTCAGTNTCA	CCCGCTGGGG	AGANACATTC	AGGGCATGGG	CGTCCCCCAG	660
CCNTCGGGGA	GAATGTGGGA	GGTGGCGATG	TGGGAGGGAT	TCGAGAGAAG	AGAATGCTTA	720
AGAACCATCC	AGGGAACCTG	TGCGTTTGAA	GGTNTGAGTT	ACACACAGGC	TGCTCAGGAA	780
GGAGCTAGAG	CTCCAAATAG	GAGCTGTGAT	CAGGCTGTGT	GTGTGTGCTG	GAAGGGCCAG	840
TTAGCAGAGG	TTGTNTTGAC	CACCCAGNCT	ATTGAATTGN	GNNTNNTCCC	AAANGGANNT	900
TTGGCAAGTT	AATGAAGTC					919

<210> 46
 <211> 915
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note: = synthetic construct

<400> 46

TTTTTTGGAA	TNTTGGAACC	NCGNTTTGGA	AGAAGACCTT	TNNNNTNCAA	TTGGGGAANA	60
ATAACCGGGG	CCAAACCTTG	GGAAGGGGGG	AAAANATTCC	NGGGGGGAGG	TAATTTNTTG	120
GNNGGNAGGG	GNGGAGGTTA	NTATNNCGGT	TGNGGAAGTT	TGGAATTGTC	CNAANGGATT	180
TTGTTTAAAA	AGAGGNTTGC	NGGGCNTGNT	CCCTTCAACC	ANGAGGTGGG	GCCNTTGCAT	240
TTATTTTCCT	TTTAACNTTT	GAAGGTGAAG	CCGGGTATT	TNNTTGTCCT	TCGTACATTT	300
ATCACCACGG	NGTTTAAAN	GTNTTTTAT	TTCGNTTNA	TGGAGGNGAG	TTAAATNTCN	360
ATTTCCAATT	AAACCTCNGT	GAAACCTTCT	TTGATCCTGC	CTNGTGTTTC	CTGAGTGNGA	420
CATACCTGCN	TAGTTNTGGC	CTTCCCTTTC	CTTNTCGTCC	TTCTTCCATT	CCCTTCCGAA	480
GATTCCTGAA	GGAGTGAAGG	TTTGGGAAAG	GGGGAGGGAC	AGAGTGTTCA	GGGCTTGCGT	540
GTCAGTAGAC	ANNAAANAGC	CGNAGGGCAG	CCCGGGGTGA	AACCACAAGG	CAGAGGCCCC	600
AGGGTAGACA	GCTGACAGGC	CCGCCCACTT	TGGCTCCTGC	NTTCGCTGTC	TCACCCAGAG	660
ATTTTCCTGG	CAGGAGTGGA	AGAAGTTGGT	ATCGAGTCTT	TGAGCCCTGA	CTCATNTCT	720
GTCCTAGCTG	GGTGCTCCTC	AGTTACATCT	CCAAGTGTCT	CTCAGGGGTT	CAGTGTTAGC	780
CACATGGCTG	CCTCAGNTCA	AACCGGAAAC	CCAAGAGGCG	GAAACATGCT	TCATTTAATT	840
CCCATCTGGG	GACCCNTACA	AATTTANGGN	TTGTACTNAN	GGATTNCCAC	AANGNNAAG	900
GCNAGNTAGA	NAGGT					915

<210> 47
 <211> 849
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note: = synthetic construct

<400> 47

GTTAAANANG	AAAAAGNNGG	GGTGACAGGG	GGNGANACCC	NTTGCGCCGG	GCTATGGATT	60
NTNGGCACCG	ANAAGATTTN	CAGGNGACAN	GGAAGGTGGN	NGGGGANGGG	GGAAAGTTTN	120
GAGGGGCCAA	AAGGANAAGG	AGGANGATTG	ATTGGTTNGG	GAGCAGTACT	TGGAAAGAGT	180
GTGTTNGATC	GGNAAACAAC	CACGNGNAGN	GNGTTTTTGT	TGCAGCAGAG	ANAAGNGAGA	240
AAAAGATNTC	AGGAGATCTT	GATTTTTTTC	GGGTCGAGCT	ANGTTGGGGG	ATGNGAGGGN	300
ACAATTACAC	AGATTTGTTC	ACAGGGAGNT	CNAGGAGGTG	GTCCCANTAG	CCGGTAGGGG	360
GGTTTTCTCA	ANAAATGGGN	TCAGTCAGGT	GNTTGCCTAG	ATCTTTCATT	AGTTCCTCCC	420
TTCAAAGGGA	NTTTGAAGGA	CTGCTTTGTC	CTGTGGAGCA	ATTGACTCAA	TCAATAAACN	480
TAAGTAATCT	CCCGGANTAC	TGNNGANGCG	TTCCCAGAGA	GGTCCCCCGT	AGTNACCAGT	540
GAATCACAA	TTCTTAACCA	TANGANTNTT	GTTAATCTCA	CCACATAAAC	CCACAATTCT	600
CGCGTCCTTN	GTGATGGTTT	CAAAGTCNGG	AATATNTTTT	CCTCCATCCC	TCCTTTCCTT	660
CCTCCTTNTA	TCCCTCCCTT	CCTTTTTTCC	TTTCACAGGA	TCTCANNATG	CAGCCCAGTC	720
AGGCCTTAAA	CTTGTGATCC	TCCTGTCTCA	GCCTCCTAGG	TGTTAAGATG	ACCCAAATGT	780
AAACCATGTC	CAGNNACTTC	CTCCTAATCC	CATCTTCAGA	TATCCTTTAA	GACCAAATTA	840
AATATTAAC						849

<210> 48
 <211> 925
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 48

AAAAAANAA	ATNTTGGNGG	ACCNAANACC	ACCAATGGGT	TTTGGGGTCC	GANCGNNCAA	60
ACNTGNTTTC	ANTGTTNTTC	TGGNTTTNTT	TGNNTAAACT	TGGGGTTTTA	AGGGTTNAAG	120
GTTCCAAACC	CNATGTTTTC	GCNCAATTTA	GGCGGGGNGG	GGAATCCNTT	TGGGGANGTT	180
TNAGTATCTA	GTTAAGAGGG	GCCATTTNGA	GATTGACACC	TGAGTTAAAC	TTCNGAACNN	240
AGNTGTNTAA	TNAACCCGTG	AAGGGGCTGA	GGGGNGTTGG	TTANGATNCT	CAATNNTAGG	300
GNAAAAANNA	ATGTGGTANG	GAGACAGTAG	NNTANTCGGA	NCAANTNCGC	ATCGGCCNTT	360
NNATTAATAA	GCAGNCAATT	GAGGAGGTTA	TCCACGACAG	NGANAGGTGC	AGACCCACAG	420
CACACTGTGA	CAGTGGTTTA	TGTNACANNA	TNTCGGGAGN	GATGGNGCCA	CACCNACTGA	480
GTTCCGTTTT	GTTCCGNTGA	AGGTAGGNCA	ANACTGGCAN	AGGTGTTNGG	GGGCNAGACG	540
NGAGATGNGG	NTTGAGCNTT	CAGACCNAGN	TNCANGGNNN	NGGACNANGG	TCCCCNGNGC	600
CNTTCTAGCC	TNGAGCAGNT	TCNAGAGAAN	TATTCGNCGG	GTATAGGTCC	CCCCNANGAC	660
GCNAAACGAC	CGNGAGCGAG	GGCGGAACAG	CCAATCAGTT	CGANTTATCG	TGTNTGTTNG	720
CGGGGTTTGA	TCCCNGAGTT	AGNTCAATGA	GCCCANAAACC	CTGAGTGGAG	GNACCGTCAT	780
GGGAGGAGAG	GNGAGTCACC	NGGTACCTGG	CATACNGATG	GACCATCCAG	TANTTGGATN	840
GGAGGGCGAT	ATNGTNANTC	TTAGGGGNTC	TCCTGAGGAG	GGNATAACCCG	TGAGTTCCGT	900
AAGGGCGTTN	GCAAGTAANA	AGTCG				925

<210> 49

<211> 827

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 49

GCCAGTTGCC	CTCAGATGNC	CNATACCCCA	CNGGGGGNGT	CTCNCCCCTC	TCTCAANTGT	60
ACACACACTT	CCCCATAGAC	ACNGGGGACC	ATAGCTCTAG	GGGGAAAACA	AAATNTTATN	120
TGTGTGTGCA	CNTGTGNGTG	TGTGTGNTGC	CCCAAACACA	GGGGTNTCTC	TTCCCCAGNG	180
GCCCTAAAAT	GTTNTNTGTT	CNCCACTNGG	NCCTCATNTN	NACATACCCC	CCNNGNCTCN	240
GNCCCNATA	CCCNAGACANN	GAATGTGTGN	NTNCCCATNN	GCGCTNTCAC	CACCACAGNT	300
TTNTNTAANAC	ATCTCTCCCC	NNNATATCTN	TTNTTTNNTN	NGGGTCTCAA	TGGAGACNAC	360
ATATACACNA	GTGTGTNAGA	CACACCCCCA	CACCCCAAAT	GNGCGGGGGG	AGGGCTCTTA	420
GCGCAANGAG	AGNGCAGNGT	GCTTACTCCT	CGCCCCCTCT	AGAAAACCTCA	CACTNTTNAG	480
ATCTCGGGAC	TCNNCCTCAG	CNCATTCTCT	ATCTCCCANA	AANACACAGA	GNNACCCTNT	540
TTGNGAAAAC	TCANNTGTGT	ATAGTGCTCT	GNGTGTNACC	CCNAGNCCAC	ACCCCCATAA	600
NANATNTNTC	TCTCAAAACA	TGTGCATGNG	CGTGTAACAC	TCNCCATCTC	TCGGGCNNGC	660
TCTCCCCNTN	ACATCTCTCG	NGNNAANANA	AATATATCCC	CTCNNTTANC	CCCCGTGTCC	720
NGGANAATAT	TNCCCCCCTG	NGACCANTCC	CTCCCCGGAG	ACCNANCCCC	CCCGTGGANA	780
CCCCCCCCNG	GNATCAACCC	CCCCGGGTAN	ACAACCCCCG	GAACCCC		827

<210> 50

<211> 899

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 50

AAAAATTGTA	AGGAGTTGGG	GGNATCCCCC	ATAATTNAAA	NAGGGAACAA	NCCNTAAAGG	60
GAGGGNNGGG	AANGGCCAAN	ATTGGNTTAA	AAANAGTANG	TTTGGTTGAT	CCANACACAA	120
GGAATTTGTT	ANAATTTTNN	TAATGGAAAT	NGGGCACTTC	AATTGGGANG	ATAAAACCCC	180
AGGAAGTGAT	ACCNGGGTTA	TCAAGTNAAA	CNTGATTCTT	GGNGNNGAGG	GAAAGGATAT	240
TGAATTTGAG	TGAGTGCAGG	TGAAGTGAGA	CTTGGGAGNA	CAGGTCATGC	CCACCCAAGG	300
GAGGAGCAAG	GGNTGGGCAG	TGTAGGTGGT	GNGGTGGTCC	TTCTTGGGGT	GGGCGGGGAG	360
ACAGATGAGA	ACGTTATTGG	AGGACAGGCA	CAAGTGTTAC	TGAAATGCAA	ATCCCTGTAG	420
ATNTGGAAAA	GTTCTGGNTT	CAGGCTTGAT	GCTTGGGCCG	GCAACTGTGN	ACTTTCCCTG	480
TACGTTACAG	CCCCCACCC	TTACGGAAGT	TNTCGTCACT	GAGANTAGTG	GCTAATCAGA	540
GTCTTCAATG	GACCTGCCAA	TCAGAAAGGA	AGGCGGGCTT	TTCCGGGTGC	NTAGGTGTAG	600
GATTTCGCTCA	GTAGTTAAGC	AGTCTTAACT	GGTTNTGGCT	GCTGTGCTCT	CTGTCCTGCC	660
GTTGGATTNT	NTGAGGCATG	TTCAGGCAAG	CTCCAAAGTT	GCGACATGGT	GAGCACAGGG	720
GCAGGGGGGG	CGGGCGGACG	GGCAGGGGAC	TGAGCAGTGG	GAGCTGGTGT	GGTGGGTCTT	780
TCCCGGGGCT	GAGTTGGAAT	CCGCGGCTAC	CCGTGAGGTC	TTAGCCACTC	ACTAGACCCA	840
GCGGCAGTTT	CTGAATAACT	TTCTTGTAG	GGGCTGCAAC	TCTTGAAAGA	CCCCACCAG	899

<210> 51

<211> 852

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 51

AAAACATTGG	CNAGACTTGT	AATAATTNCC	NGTTNNGGGA	AAANAGNNGN	NTGNGCTTCG	60
GGGGNNGGGA	NCCGAGGTTC	CCCCCAAAT	TCTTANNAAT	TGAGGGANAT	TNANGGGGGG	120
AACCGANNNG	TCNNNAAGGN	GGGGTTTTTC	CCNTTNGCCC	CCTTGGGGNT	TNACAAANTG	180
ACCNTNAGTT	AACGGGGANA	ACCCGCCNTG	TCCTNNGGGA	GGGGGGTTCC	CTNNGGAGTT	240
NCGTNGTGGG	TTTCAGTTCG	GACCAGGTCG	TTNACTCGAA	AACNGGTCCG	CNGTATNCAC	300
CCGGTNGGCN	GNCTGTTGAN	NGCTAACGNG	GTAAGTATTT	TCATGTGTCC	GAACGTGTTA	360
GACTCCAAGT	ATGGCCATGT	GCANGAACCN	CCGGTTAGCN	AGACGCAGAG	CGTGATCNGN	420
GGAGGNTCTN	CAGGNGTCCA	ACCNGGNANG	NCAAGATNCG	TCGACACTGG	CAGNACCCAN	480
TGGNGACTGG	NNGATCAGAG	GGAGNCAGGT	ACGCNNGGAA	ACAGAGTTGN	TGNATTGGAT	540
CCGGNANACG	GACANNCNAG	NGGGNCNGTN	GTTTGGTATG	TGNGCTAGNA	GGANGCCAGG	600
NACAGTCGGA	AAGGNTGTCG	GGAGGNTCNG	ATCATGTCNT	ACATAACCNC	TCGTGAGTAT	660
GCGGTGGNTG	TGGAGTTGNG	CAGGCGGCAG	NTAACGCACC	AGAGAATTCN	GATNTNTCCG	720
CAGATCGACA	GATNTGTTAG	GTGGGTCTCT	GACGTTNAGG	NCGANAGGAN	NNGGGAGNGG	780
ATAACANTNT	CACACAGAAT	TTCACTGAGG	CTGAAAGACC	CCANTTGTA	NTGNCCAAGC	840
TAGCTGAAAT	CG					852

<210> 52

<211> 967

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 52

AAANCCTTCC	CGGNGGGGTT	AAAANAGATT	ANGGGTTTTT	CGNNGGGAAN	CCCCNNCCNC	60
CGCCTTCGTA	ATTTGTCCCC	AAGAAAAATT	CCCGCGCCCN	CAAAAANNAG	GGGANTNGGG	120
GAAATNTTAG	NGGCCANAAG	NAAAAAAGAN	AATTGTTTNG	TTTTGGAGNC	CACNNCGNAA	180
NAGGGGGTNT	TAAACGCAAN	AACACCGGGG	GGGGGNTTTT	TNTTNCAACG	CGAAAAANGC	240
GGAAAAAGAT	TTCAGGANAC	NTGAATTTTT	TNNGGTTCGAA	GTTCAAGTGGG	GGGATTGGGG	300
NGNNAAAATT	TNANACNGAT	TATTGGTCCN	ACCTTTCCTC	TTCCCNCTCC	TNCCAAAATT	360
TTNTCCAATT	TTCTTCTTTN	TNTCCATTTC	CCCACCAGGA	GGGAGTCACC	CACCTTNTGC	420

NGCAACATTC	TCAGGGTTCT	TCATTCTCAG	TGTAACAGCA	GNTCTTCNGG	TTCTNGGGNA	480
NTCAGAAACT	GGGCTGAATC	ATGTCCAGAG	TTGCNGAGTT	CCCACATAAC	AGATAGTGTT	540
NGNGAGATTC	TCAGTCTAGA	ACCATGTGAG	CCAATCCCCA	TCAAATCTCT	TCTCTCANGN	600
ATAAATNNAA	ACATNCTTAN	GGGAGGCTCT	ATTTCTATGG	AGAAACCAGN	ACCCATATTT	660
NGGGCTGGAT	CACTCTTTAT	TTCCATTATG	GGATGTTTAA	CAGTAATCCT	GGTCTGCATT	720
CCNTAGGTGC	CAGTAGCCAT	CTCCTAGTTG	TGACAATCAT	CATTTTCTGG	GGATGAGGGT	780
GGAGAAGGGG	GCAGATATCA	AAACTATCCT	GNATCTAAGA	AATGTTAGTT	GAAATGAAGT	840
TGTCATGGGT	CATAAAGTCT	AGGATAAAGA	GTGATGAGAT	GTCAC TAACC	CAACTCTTTT	900
GGCCAGAACT	CAATGAGGTN	GTCCCATT TG	ANTTACCCCA	AAGNGCNTT	AGCAAGTAAA	960
AGGGNCG						967

<210> 53

<211> 700

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 53

GGNGTGCTGG	GATTATAGAT	GCACTCCCCC	AAATCCAGCT	TTTTACCTGA	TACCGGAGGA	60
AGGAACGGAA	GTCCNCCGGC	TTGCACCGGA	AGCAGTTTCA	CCCACTGAGC	CATCTCCCTG	120
GTCTGTCTGT	CTCAGCTTCC	TGAGCTGGTG	TTATGGCTGT	GCACCACCAT	AGCTGGCTTC	180
TTTATTATTT	ATGTATGACT	NGGGTCTNTC	TGGGGGTCTG	TTAGNCAGTC	TGTTAACTAC	240
CATCTTTTGN	CTCAGGCAGC	TGCAACAGAA	AACAACNGGC	TGTAAATNGT	TTTGACAAAT	300
GGGTCTGGGG	AGAAGTCTGT	NATGCAGGGA	GATCTNGAGT	TTATNCAGAG	GAAAAGGTGT	360
CTNTCAGNGN	ATCTAGGGNA	GCA TNTCCTN	TCNGCGTCTT	GGTTTGGGNG	AANGANGGAT	420
CAAGAGCCCC	NNAGCNNNNN	AANTTNCNT	CGAGCAGCCC	AGGGATTTTN	GCTTTCAACG	480
NANCTNNAGG	GAACCCCNNA	NCAACCTNGG	CNACAATTGG	GGNNTTTCCC	CCNCCCCCCC	540
CGATTACTTT	TNCAAACNT	TGCCACNCCC	TCGCNCNATG	CCNANCCCCC	AAAACGTCGT	600
NNTTCATAAN	CNCNNCNTC	NCNCTTNNCC	CATGGGGNGC	ACACTCCCTT	CNCCCNCNTN	660
TNTTAACNGG	NGGCGCAAGN	CCTTTCTTNC	CCCCTNCCCC			700

<210> 54

<211> 229

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 54

NCNACGAGAN	GTCAANGTGN	AANCTGNCGA	TGATNAAAAN	AACCGANCTT	AGGGTGNC AA	60
NGGGTTACCC	AGGANGGGGN	CAAAGCAAGN	TCCAGGCCCA	TNANGGACCT	GCTGGTNCAT	120
NGCCNGNAAA	NACCTACTTA	TCCTNGAANA	GCCCGAAANG	TCCGCTNNGA	CCANNTAAGT	180
NCANNNCAAN	ANGNACCACN	CCNTTAACAC	CACCGTATGA	NCCCNAANT		229

<210> 55

<211> 465

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 55

CCCCTTTCGN	NGGCCTCAAT	NANTNATTGN	CTACCCNANA	GTGGCGGTCT	NNCATCATGA	60
CAAATAAANC	AGCCTTCATG	AAATACGATG	GCGGGGGGAT	TAGAGGNNTT	TNTTGAAAGA	120
GCTGAAGGGG	CTTGCAACCC	CATAAGAACA	ACAATGCCAA	CCACCCAGAG	CTTCNAGGGC	180
ATTAAAACAC	TACTGAAAGA	CTATACATGG	ACTGACCCTG	GNCTCCAAC	GCATATGTAG	240
CAGAGCAAGA	GCCTNGTTGG	NGCACCAGTG	GAAGGGGAAG	CCCTTGNTCC	TGCCAAGGTT	300
GGNCTCCCAG	NCCAGGGGTA	ATNTNGGGGG	CGNGGAGCA	GTAAGGGAGG	GTGGATGGCG	360
GGGCTACCCA	TATNGNGTGG	CGGAGGAGAT	CGNNGCTNAT	GGACAGGAAA	CTGGNAAACG	420
GGAATNACAT	TGGANATCTC	NATAAAGNNN	NCATTTCTTA	TTCNA		465

<210> 56
 <211> 564
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note: = synthetic construct

<400> 56

TTGGGGCCGN	TNAACTCTGN	GTNNNAGTAT	NCCCNANAGG	GGGGGTCTCA	CANCGGGTCN	60
CACCNCAATNT	GNGGGNGCCC	NTTCNCNACA	ACACATTTTG	TCNNGNGGTT	ATAGNGAGAG	120
CACANATTTT	GAGAGTCNCC	NGANAGGGGA	GAGAGACNCA	CACNAGTCTC	TTCTCCCCGT	180
GTTCGCGAGN	GNACNCTTCT	CTNCACATCT	ANAGTATANC	CCAGNGTCAC	ATATGTGGCG	240
GGGGGGTNGT	GTCAGNNACA	GNGTTTCCCC	CNCCNGTNTT	TCCCCCTNCC	CCCCCCNCAG	300
GGGNAGACAA	NGTNNTAGAG	AGAACAGGGG	TTATCCACAC	ATCNCACTGN	GNGGCACAGG	360
AGGANNANAN	TTGTGCTNAG	AGCCCCTGCN	CTTCTGGTGG	TANCTCTGGG	GCCCATATTC	420
TCTNCTCTGG	GTCCCCCCCC	GGGGGGTGTN	NCCCTCNCCG	GGAGAGAGTN	TTAGAGANAA	480
ATCTCCATCN	CANATGANAA	AATNTGNGGG	NGAGAAANCCC	GGGGGATATC	ACTNPTTTAN	540
AANNAGACCC	ACCCCCCCCC	CCCT				564

<210> 57
 <211> 822
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note: = synthetic construct

<400> 57

GATTTGCNCT	CATATNTCNT	TTACCAAACA	GNGGGNGTCT	GCCCCCTGT	NATANACCTC	60
TTGTTNTCGC	GGGGTGCTNN	TNGGGGCCCC	CCNTGTAGAA	AAAGAACANN	NGNTGTGGGN	120
GGGGGATTTC	TCTCTGNTGT	AGANCTNTNC	NCTGAGACAC	ACAGNGCCCT	GTGTGGGGTC	180
CCCCTCNCCG	AAAAAGANAC	CCCNAAAAAA	AAAAAAAAN	AGACCGCGNG	GGGNNGAAAA	240
ATATCTCTNG	NNATCTTCTC	TCTAANCTCG	CTTTTANTCC	TCAGAAAACC	CCACCCCNCC	300
NCTCTNCCCA	GAAATATNAT	ACANNNNNGN	TTCCCCTNCC	CAAAACCCCA	AAGGGNNTCC	360
CCTCTCNTCT	NCCCCNAATA	CTCTTCCNCC	CCTTNATTCT	CNTATCTCTN	NGGACTCANA	420
CTCTAAAACA	CANGNNNCTT	NTCTGTGCCG	CAATNTNTTN	TGTNACANGG	CNCCCTGAAA	480
AAAACCCCCG	TGTTCTCCAC	ATCNCCTCTN	TNATATCTCT	GCCCCCTTCC	NCTATATCNC	540
TGNGTTTATA	ATTTCCAAGG	AGAAATGTNCN	CAGGGGGGCC	CCAATCTCCC	CCCCTNGTTT	600
CNNCGAGNAG	GGCTCTTTTN	TATATTTTTN	NTCNAACCN	CCNTTGTCTT	TTTAAATNGG	660
CNTTNACNCC	CNGNCCCNCC	CAACNNCCCG	ANCGGGGGAA	ACGTTCCCCA	NTTTTCCNTT	720
TCCCCCGGCC	CNCCCNACC	CCAATNCCCT	TTTTTCGCGT	TCCGGGGGCC	CTGTTTCCCT	780
AANCCCGGAA	TNAANTNCNT	TNTTCAANCC	CCCCCTTTT	TT		822

<210> 58
 <211> 553
 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 58

TTTGGGTGCG	GTCTCCTCTG	TGTTAGTGTA	TCCCCCATAG	GGGGGGTCTC	ACAGGGAGCC	60
CTTCTCTTTT	GGGGGGTTAT	ACACAGGGGA	CACACATGTG	ATATAGAGAG	AACACATGAG	120
AGTGGGAGAG	TGGGGGGGTG	GGTGGAAGTG	AGAAACAGAG	AGAGAGAGAC	TTTATTTTTT	180
GTGGTGTAAG	ATGTGTTGAA	TCTCTGGTTT	GATAAATTTT	ACACATTGGG	GTTTGTGTAG	240
ATCCCTGATC	TCTCTCCTAT	CCCCATTCTC	TTTCAGAGAT	GTGTCTCTGG	ATTCTCAGAG	300
AGATTTTCTG	GTCTCACATG	TTTGGTCCCT	TATGTTCTCA	CTCTCTCTTC	TTTATTCTCT	360
GATACATGTG	CTCTTCCCCC	TTGGGTCTTC	TCTCTGTCTC	TGTCTCCCCC	CCCATGATAC	420
ATAGAGTGTG	TTTTCTCCCC	GGGGTTTCCC	TTGTTCACAA	GAAGAGCTCT	GGGGAATCTC	480
TATCTTCTCA	AGGGTATAGC	CCCCAGTCC	CCAGGCCCTT	TTTCTTGGA	TTTTGGAGGG	540
GGTTCCCCAT	TTT					553

<210> 59

<211> 904

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 59

GGGATTTGCT	CTCAGATGGT	AGTTTACGTA	AACTGTGGGT	GTCTTGCCCTC	TCTCTCAAAA	60
CATGTGCGCG	TTTCTGGGCC	CGTGCGCGTT	TTCTGTGCTC	CTCCTTCTTC	ACTTCTTTGT	120
CGCGGGGGCG	CTCGCCCTG	TGTTTTCTGT	GCTCCTCGGG	GAGATGCTCT	CCCTTGGGGC	180
TGTGGGGCTC	TGTGGCGGTG	GTGGCGGTGT	CCTCGATACC	GTGCTTTTTT	GTTTTCTCGA	240
GATCTTACTT	TTTCCTCTCC	CCCTTGTTGT	TTTCTTGGGT	ATACACGAGA	TTGTGTGTGT	300
CTCTTTTCTT	ACCCCTCTC	TAGTTTATAT	TCACACTTAC	TCTCTCTCTT	TTCTTTTCTT	360
CTTTAGATTC	TATCCTTTGT	GCACTTTTTC	TATTGTGCTC	TAGATTTCTC	CCCTTTTGT	420
TTATTTCTCT	TCTCCCTGTG	TCCAGTGTGG	TGAAAAAGAC	CCTTATTAAA	TTTAGACTTG	480
TGCGCTCTCT	TCTTAAATTT	CATGTGTTCT	ACAGTCTCTC	TGCGCTTTAG	ATATTTTTAG	540
AAGCGCCTAA	ATCTTTTAAA	AACGTGTGAG	ATCTCTTTTT	TTTTTTTACA	CTCCTTTGTT	600
TTTTCTTACT	CCTCAGGGGC	ATATAAACC	CCCTCTCCTT	TAATATTTCT	CACTCTCTTT	660
CTTTTCAAAA	AAATTTTCA	ATCTAAATCC	AAATTTTTTT	TTTTTTTGG	TGGCCCTAA	720
TTTTTTGGGA	CGGCCCCCCC	CCCTCCTCTG	GGCCCTCATT	GGGGGGATTT	TTTAAATTC	780
CGTAAATAAA	AAGGGTCGGG	CCCTTCTCCC	CCCGTGGGGT	AATTAATCAA	GGATTTTAGG	840
GTTGGTAAAA	ATTTTCGGGT	TTGATGGTTT	TGCCCCCCCC	TTAACCCTC	TTTTTTTTTT	900
TTTT						904

<210> 60

<211> 698

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 60

CTCAGCACTG	AAAGAGATAG	ATTAAAAACA	AAACAAAACA	ACAACCAAAA	AAATACAAAC	60
AAACAAACAA	AAAAAAACCC	CAAACAAGTC	GCTCAACTGT	CTTGAGTCAA	TAGATTTTAA	120
AAAATGAGTT	AAGGTAGGG	TTAGGTAGG	GTTAGGGTAT	AGCTCAGGCA	GTAAGGTACT	180

TGCCAAGAAT	GTTTGAGGAC	CTAAGTTTGN	CTTTTTTCTT	TCTTCTTNT	GAAACAGGGT	240
TTCTCTGTGT	AGCCTTTGNT	ATAGACCAAG	GCTGGCTTCG	AACTCAGAGG	ATCCACCTGC	300
CTCTGNCTCC	GAGTGNCAGA	ATTAAAGGCA	TGTGCCATCA	CTGTCCAGCT	CTTAGGTATT	360
CATTTTTCAG	CTTATAGTCT	TTTGGCAAGG	GATGCCAGGG	NAGGAACCAG	AGGCAGGGTT	420
GAAAAACAGG	CCACNGNGGG	GGGAACGCTG	CTTCCCCGGG	TTATTTTCTT	GGGTCANATC	480
NTGTGGCCTT	CCNGGGGGGT	CTTTCCCCTT	TCAAAATNT	TTGGGNTTGG	GGNGGGGTCC	540
AAATNANTTT	TTTNGGCCGG	GTTTNGGGGN	CCCCCNNTT	TGGNTTTTTT	TTTAGAAGGC	600
CCGGNGGGGA	NAAACCCCCC	GGACTAAAAA	AAAAAGGGGG	GGANCCCCCC	NGGGGNGGAA	660
TTTTTCCCGN	CCCTNAAAAG	NAAAAATTTT	TNTTTTCC			698

<210> 61
 <211> 851
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note: = synthetic construct

<400> 61

GAAANAANTC	GGGAGAAAAA	NAAANNNCCN	TTAAGAGCTT	GCCCCCANAG	AAAAANTANN	60
AANTNAAAAA	CTGNTAGACC	ANNNGAAAAG	GAAGCGCAGT	NANAAAATGG	TTCTTACGGG	120
TTAANTAAGA	AGCANGACNG	AAAGANNNGN	TNNATNTAAC	CGGGGNTAGN	AAACGGCCCN	180
CTTGTANNAG	GACCNAATCG	AANTAGTACG	ATCATGNTAC	ANAGGGAAGG	GGACGTTACC	240
CNCGGANGAA	ACCCGGCACA	AGATCTCNNA	AGGGAGAAGA	TTCTGAACGN	NANNAANCCA	300
CAAGGAAATT	ACTGTGGANA	CGGGAGGAAT	CNATNGTNAT	NNAGNNNAGC	TGGNCACTTT	360
GANAAAGGCAT	CGATANAANT	GATGATGGNT	CAGGCGAAAG	AGCATACGTA	AAACCAAGCA	420
AGNGGGAATA	GTCATANAAC	CATGNAAAAA	ACNTTCAATA	AAAGATNNCC	NGAATATTGA	480
TCNGTANNNA	ANAACNCCCG	GTGGCCGTGA	TTCTTTTTTT	AACGGCAAAC	AGCANNTTAG	540
TTTCAGATCA	CCCAGATCAT	CGNTGNAGAT	NCCATNGATG	TTNTTGAAAC	TNANCTNGAG	600
GATTCAAGAA	NNGNTGACAT	GGTGAAATGA	TGTACAAATN	ACAACANAGA	NCGTGAGAT	660
NNTATTCCCC	CNGNATGNAN	GGACNTCTTA	TGATGAANAC	CTTATACCAG	ACTCAAGTAN	720
AACNATATGA	TCCCATGAGG	GNGGNNACCC	AGGNAGTCAN	GAANAAATAC	CNGAGAGTTA	780
AATGCNTTTT	TTTGTNTGNG	AACCCANTGC	CCGACCTNTC	AAANAGAAGC	ANAGCCCNAA	840
AATTAATCCA	A					851

<210> 62
 <211> 936
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note: = synthetic construct

<400> 62

CTAAGGAAAA	GGTTTTAGGA	GGGAAAACCA	ATAGGCCCTT	GAGTTCTTAT	TCTTAAGACA	60
TTGTAAAGGA	AAGGTTTAGG	GGAAAAATTA	CCAGCCCGAT	CCATTAGGGT	TCCAAAAGAA	120
CCGTTCTTCC	ATAAAGGCCA	GAGTTCACCA	TGAGTAACCA	GGATGTTTCT	TCGGACCTTA	180
TAAATATATT	TTGAGGGGTT	CATGGAATTG	GGTTGCCATT	TGGTAGTTGG	TAGCCTACCC	240
TGCTCCTTCC	CAGTGTTGGA	TGCAGATATG	CGCCCTGTTG	GTTTTGAGTA	GTTTTGAGAT	300
CAGTCAATTT	TAGGTTTTAT	GGCAAGCATT	TATTCATCCC	CACATTTTCT	GCCAGGGTGT	360
AGTAAGTGAG	TTCTTACAGA	GCAGAGAGAA	GGAGCAATCT	GTGTTATCAA	ATCAACTAGC	420
ACCAAGCACA	CCAAGCAGCC	AATCCTTAGA	AGGAAGAAGC	AAACACTTGG	GTATCCTTCC	480
ATGGCTAGGA	AATCTTCATG	GCTCACGAAC	CTTGGGATTT	CCCTGTCAGG	GTAGAATACA	540
AGCAGCTGAG	ACCGAACAGG	TATGGGTGGC	ATGTCGAGAC	AGGAAAAGAA	CCTGTGCTCTG	600
GGGAGAGGTG	TGTGCTACAA	AGCCAGAGAG	AGGAACAGAT	AGGGAGGGGT	GTGCTGCACC	660
ATCATGGAGG	GGGACAGACG	ATTTGTCCCC	AAGGAAAAGC	TCCCTTTATG	AGAGTTCTTA	720
CTGAATTTGG	GAATGACATG	GGAGACCAAG	GGCCAAAGTC	CAGATGAGCA	GAGTGGGGAG	780

GAGGGTTGGA	AAGTTCCAAG	GAGAGAGGCG	TGGGGGTAAG	GGAAGCTCGC	AGGGCTCCGC	840
CTCTGCCAGT	GACCTTGGAC	CGCTTTCTCT	GAGGATCAGA	GTTATCTGTA	GGGGAGATGA	900
GGTTGAAAGA	TACCCACAAT	AACTTTGGCA	AGTAGA			936

<210> 63
 <211> 911
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note: = synthetic construct

<400> 63

GGGAATTTAA	GGGNGATTTG	GAGACTTTNG	AATTTTCGAA	NGTTCCAAAA	TAGANNTTNA	60
GGNCAATGGG	NTTGGGGCAG	NGGNGCTTTT	TTAAATCANA	NAAGTATTAG	ATTTNTATGG	120
AAACCCTGGG	GGTTCCAGTT	TAATCCCTTC	ATCATCTTGA	AATATNACTT	GTTTATGGGA	180
ANGGTGNGAT	AGCAGCCNGA	AACAGAGGTT	TTTATTATTA	CTGTTAGAGA	NGAGGATTGG	240
GGAATAGAAC	AATGAGAGTC	TTGGTAATAT	TNTTCNGGAA	ACAACNGACA	TAATTGGAAC	300
ATTAAGGAAA	TATATCCATG	CATTCTGTAC	TTGCAAATTG	CTCCAAGGAA	GATGGAGAGT	360
ATTGTATTTT	AGATAGAGAT	ANGACTATAC	CTGTTATTTT	TTTCATTATA	GCAACATTAA	420
AAAAGATAGT	AATCTAATTT	CACATAACCA	TTACTACTAA	AGTATATATG	TANTCTTTGT	480
TTATCAGGTT	TTACTTCTCA	GAAATTGCAG	CATCTCCTAC	AGAGCCTGTC	AAATGAGACN	540
GCATAGATCC	CCAGAGAACA	GAGAGACTGG	GAAATCATTG	AAATTACACA	ATCCTATCCC	600
AAATGTTTGC	GTAGACTCAA	GCTCGTATCA	GCTCATAAGA	TCAGTGTGTG	TGTGTGTTTG	660
TGTGTGTGTG	TGTCCCGCAC	ATGCTTGAGT	ATGCATGTGT	GCATGCATGT	GTGTATGTCT	720
ATTGCATTAG	TAGAGATGTT	AAGGTTGAAT	GTATTTTCTG	CTCATGGTCA	TTGTAAGATA	780
TTGTGCTGTA	TGTGATAAGA	ATCAATGTAA	CAAGGCTGGA	GAGATGACTT	CAGCTGTTAA	840
AGGCTAGACT	CACTACCAAA	AATAGNGCNA	TCAGTGTGAA	NTTCCCCACA	GGAGCTTAGC	900
AAGNTAATAG	G					911

<210> 64
 <211> 781
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note: = synthetic construct

<400> 64

TTCAGGGGTA	ATCCTAAGGT	AAACGGACAA	AGTAAAGGGG	AGGTTGGACC	AATAAAGGGG	60
AAAAATAAAA	GATTAACCGG	ATGTTCCCTG	GAACGACAAA	TTGCCTTGGA	AGTTTCCTAT	120
ACGGAAAAAA	ATGAACAAGT	TTCTTGTA	GCAGGTAGCC	GGAACGTTTC	TAGGCTATAA	180
ATTTAACTGG	CCTTATATTT	ACAAAGTCTA	AACATTTTAC	TGGGGCATT	CAATTTTATA	240
ACACTAATTA	GATCATGTGT	GTACACCCAC	AGTCTGACAG	ACAGGGTATT	TTTTCCTTCT	300
TATCCCAAGT	GAGTTTAACC	TTCTTCTCTC	ACATTTATTG	CCATGTGCAA	TGCGTAGCTT	360
CTATTAATCT	CTGATTATTG	ATTGAACCTT	ATGAGACATA	AGAATGTACT	TGACAACAGC	420
ATGTGAGAAA	GGGAAAGTTG	AGGGACTGAG	TGTAATAGAG	ACTGATAAGA	AATGAATGGG	480
CTGTGTCTGA	CTCTTATCCA	ACATTCCAAT	TCTTCAAGTC	TAAAGGTGAA	GGGTCATTTT	540
CAATCTACTA	AGTTTGAATA	TGATTGTGTC	TCCTGGTGTC	TACAGAGTAT	TAGGAAATGT	600
TTGGTTTGTT	AGGTCATTAG	GGTAGGGCTC	TTATGATAGA	ATTCTTGTGG	CTTTACATGG	660
AAAGGCAGAG	AGAATACACC	CACCTAAAC	ATTTCTGCCA	TTGTGCAATA	CAGTAAGGTA	720
TATTTCTTTC	TTTTTATTAA	CTATTGGTG	ATAGTGACAA	ACAAC TAGAC	TTCATATGTG	780
A						781

<210> 65
 <211> 389
 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 65

TTGCTCTTAG	GAGTTTCCTA	ATACATCCCA	AACTCAAATA	TATAAAGCAT	TTGACTTGTT	60
CTATGCCCTA	GGGGGCGGGG	GGAAGCTAAG	CCAGCTTTT	TTAACATTTA	AAATGTTAAT	120
TCCATTTTAA	ATGCACAGAT	GTTTTTATTT	CATAAGGGTT	TCAATGTGCA	TGAATGCTGC	180
AATATTCCTG	TTACCAAAGC	TAGTATAAAT	AAAAATAGAT	AAACGTGGAA	ATTACTTAGA	240
GTTTCTGTCA	TTAACGTTTC	CTTCCTCAGT	TGACAACATA	AATGCGCTGC	TGAGAAGCCA	300
GTTTGCATCT	GTCAGGATCA	ATTTCCCATT	ATGCCAGTCA	TATTAATTAC	TAGTCAATTA	360
GTTGATTTTT	ATTTTGTACA	TATACATGT				389

<210> 66

<211> 340

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 66

AAATCGGGNT	TNCGCGATTC	GGTAATGACG	NCNNATCCGT	AAANNCATNC	GCCGNNATNC	60
NATTNGAAAA	TNCCGGGNGC	AANNCGATGT	CTNAT'TGAGG	TNNCAGANCC	ATCCGGCACA	120
GGCAATANGN	AAAAAANGGG	AGTTTCACAA	TGTNTNTGAA	TNTGNANCCA	TTGGGCCCNA	180
AAAANTCCTN	CGNTNNATGA	ACCTTNNCGT	NCAAAANTTT	GGTNCGACNC	AGCNGCTTTG	240
CNAGCNTTNA	ATAAACACCG	GNNTCCANAA	TGNNACCAGN	GNTGT'TTNTN	TCNANTNGCA	300
TNNCNNTTTG	GAANCCCNCT	TTTCCCAAAA	CNTTNAAAAA			340

<210> 67

<211> 557

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 67

AGTCCGGGNA	TGGTGGCANA	TGCTTTTCAT	NCCAGCACTT	GGGAAGGCAA	AAAACAGTTA	60
NACCTNAGGT	TTANCCCAGN	CTTTATTAGN	ACCCCGTGTT	CTNAAACACA	AACNACAAAA	120
NTTTGNGGGN	NTTTAAGTGN	AAACACTGTG	TAAAACCTTG	GCCCTGATGN	AGGGNTCTCC	180
TTTNGAACAG	AAAATGTTTG	AAGANTCCNA	AAACATGTTG	GGATGCCANA	CGNGTTNTTG	240
NGCATCCATC	TCAACGANGT	TTTGNGAATA	AATGGCAGGT	NAAACTAGTA	CATCATCATG	300
TNGNANCCAC	CGGGCNTGCA	GATTTGTGGT	GGGAACCAAG	TCCTCCCATA	AAACAGGCTC	360
CTGTGGTACN	AACAGGGCTG	GANCCACNGA	ATCAGTGCAG	NTCTGGACAC	CTGTCTGGCC	420
GGANGGNCTG	GNCTAAGTNA	ANNCAGGGGG	GGCAAGAGCA	TNGGANCNAA	CGNCAGAAAN	480
CGNCCCNCCC	GGTGAGCTNT	TCCATGCCTN	NCCTCGNTTT	ATTTGGCACT	GGGCATGTCC	540
CAACTNAACT	TAGGATG					557

<210> 68

<211> 302

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 68

GCCTATAAGT	TTTGATTCCA	TTCGTGAAAA	TTTTTCCTAT	ATCCCGAANA	GTCCACTTAT	60
TACTACTGCG	GCCTATTTGG	AAACTAACCG	AAATTCAGTT	AGTTCCCTAG	TAGCCTGCTC	120
TTGTAATATG	TGTACTTTTC	AATATTATAA	AAAATTGGTC	AGCAGATCTG	AGTAAAACAG	180
GTGAAATTCC	GATCGGTAGT	CCAATTTGGT	TAAAGAACAG	GATATCCAGT	GGTCCAAGGC	240
TCCAGTTTTC	AACTCAAACA	ATTATCAACC	AGCTGNAAGC	CCTATAGNAG	TACGNAGCCC	300
AT						302

<210> 69

<211> 820

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 69

GACTGCCTTT	TTTTTCTTCC	CAAGGATACC	CTGCAGCACC	CAACAGTAAA	AGACTTCATA	60
AATAGGCAGC	TTGGAGAAGA	AGGCATTACC	ACTGAAGCCA	TATTAAATTT	CTTCCCTAAC	120
GGTCCCCGAG	AGAACCAAGC	TGATGACATG	ACCAGCTTTG	ACTGGAGGGA	TATATTCAAC	180
ATCACTGACC	GCTTCTGCGC	CTGGCTAATC	AATACCTGGA	GGTAAGAGGC	AGCAATCCAC	240
CCGAGGACCA	TAGTGAACCT	CTTAATGTCA	TGGGTGAGGC	TAGAGACCTG	TTAGCCAGTC	300
AGCTGGCACT	GGATTCAGTC	TTTCATCCTT	CGCACAAAGT	GGTAAGGGTG	CCATGGCCAT	360
CTGACAGACT	TGCGTGCGAC	TGTCCTCACA	TCTCGATAAC	TTCATGACTC	CTCTGGCTCC	420
CCCTCTTTCC	CTTCCAGCAC	ACATCCATTC	CCAGCTATCT	CCGGGCTGCC	ATTGTCTAAT	480
GACTTCTGTT	GGCCGGTGTC	CGCCAAACCT	TTGAGTTGAG	CTCATTGATT	GTGGACACTT	540
TACTCAAAGT	TTAACAGCAT	GTGAAAGACC	CCGCTGACGG	GTAGNAATCA	CTCAGAGGAN	600
CCTCCAAGGA	ACAGCGGGCC	ACAAGNGGTN	AACNTAANAG	GGTTATTGNT	AACGGGNNCC	660
GGGANCNAGT	AATCGGGNCT	GGCCCCAANT	AAGGGTTTGG	GCTTTATTNN	CNGGGACAAA	720
AACCGCAAAA	AAANNAAACG	CCTTNTTGTA	TTAAAANGCA	NGNTTTTAGC	CTTGGCCTGA	780
AATGGNGNTA	AGNTACGGCC	CNCNGTCAAT	TCCTACTATA			820

<210> 70

<211> 955

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 70

AANCCGANAN	TTTNAAAAAA	CAANNANAAN	GGGCCANGAN	NTNAATANTT	TCTNAAAAAA	60
NGANTACANG	NACACGGCAG	GGNNGTTTAG	TCAGAATANA	ATNNAGNGNN	AACCATTTGNC	120
TTTTGAGCAG	GGTTTATNGG	NCTACGTTGA	CCCAAGTCAC	ANTGNTANCA	GAGATNANNG	180
AGGGGGNGGG	AAGGGGTNGG	GNTTTCACCA	GCNTTNAAGT	CAGAANTNGG	AGAGACATTT	240
NGCCNTGATT	CANGNCTTTN	CCTCCTTATT	TCCNANCNTC	NCATTAANAN	NAGAAAAGAG	300
TNTTTTNTTG	TNTTGNGNAC	AGGTGCACAA	GTTTAGNANA	GAGGAGACAN	TGTNTAGAGA	360
TCAGATACGG	ATGAGAGTTT	CCGGGGANAG	TATGNGGGGA	TTTTTCAGTCA	GNNCACTACC	420
CAGAANGGAT	TCAGTCGNGA	GGAGNCAGGG	ANGGGGTGNT	GGAGTTNAGA	CCGANAGAGC	480
GGNTAGCATN	TAATGNNNAG	AGAACACACA	TNTTTTGGAT	TTNAGAGACG	NCCAAANCGC	540
TATACANGAT	NTNTCGNTAN	AGGGTGAAGA	GTGAAGAAAG	TGATGTCTCC	ANCGCANACN	600
GGAACANGCN	GCGANTTTCT	TAGAGACCNA	GGTTTTGATA	NAGGGAAAGT	CTATTCAAGC	660

CTCCCGTANA	CTTGTAGGNC	AAGNAAATAN	TGCNNATTAT	GAGNCCGTTG	TTNTCAAACC	720
ANGTCCCCTA	TAGCAGCAAA	NAGTTGNCAG	AAANTCNCAC	AGAGNTCCCC	CGTGAGATNG	780
NNNTTATNGN	GGACACGATG	TCATCAAGAG	GGAGTNNTGN	ACTGTGACTC	CAGTCCTGTT	840
GAAGNGCATA	GTAGACCATT	CGCCGTGTTC	ACCNACANTC	AGCCNCTACC	AGCNGAAAGA	900
GNAAAGGAGA	GAGTTCGCAT	ATGANAGACC	CCACGGGTAG	TTTGCAAGTA	ATGAG	955

<210> 71

<211> 886

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 71

NTNGAAGNAN	AAATTNGNAA	AAANNCCNAA	AACCTCCAAA	TTTGCTACCA	NTCTTCNACG	60
GTNGACTTTT	AAACAAAAGG	AGGGGGGGGT	TCTTNTTCAA	ATGGGCCCCCT	TCCCAATCCT	120
GTTCCCNAGG	CAATTGTTC	TTNTTTCANC	NTTCAACGGT	TTTTGGGTTC	CATCCAACCT	180
TTATTTNACC	CNTTGAGTTT	CCTGGCCGGN	GCCTAGGGAC	CTCCTTTTTA	CNTGGGCCAG	240
TTCCCGTTCA	AGACNACCCG	GCGGTTAGTG	GNCATGGGGA	GATGGCCCCA	TGANTCCAAG	300
ACAACTGTAT	TCCCGGTTTT	TTAGTATTTT	CAAGCTTCCC	GCCAATTTTT	CTTCCTTCCG	360
CTTCCAGACA	GTTTTGCCAG	TNACGTGATT	CGGTTCGAG	GCCCCAGCAC	CATGGAGANT	420
GCGCGCTGTA	NTCTTAGAAG	GGCATTCTTC	CGCCCCACNT	CCCGGTNTAG	CCNGAAGGCC	480
CACGGAGCAA	CGAGGAGAGC	GACGNTNTCT	CCACAGCCGT	GGCTTTTTTA	TGGTTGGCAC	540
TTAAGGNTTC	GCCGCCATTT	TGTCCGTTCN	TNGAGTTATT	GTGTGAGGG	CAAGATCTTA	600
CGATTGGGTT	TTGAAGGCAT	GGGTAGTGGC	TTGTAGACGC	ATGGCAGGAG	TTGGGATTCG	660
TTTGGGGACA	CTGAGGGGAA	GCCGNTTCTT	GGGTGTGTTC	CCCTNGACGC	TGTTGTGGGT	720
GGGGACCGGA	ACTAGACGTG	CCGGGCTGCG	GCGCCCAGCG	TGGGAGGACT	CGCGCGGGCT	780
GGCAGCCGGG	CTGGGTGTCC	CGGCGCTCA	CTCACATTTT	TTGCCACGAT	TGTCGCCTGG	840
TTTGATTTC	CACCAATCCC	CCAGACCGTG	CACGAGGAGT	AGAAGC		886

<210> 72

<211> 900

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 72

GGGNGTTNGC	TCTCAGATGC	NAGNTACNNN	TCAGGGGGNG	TCTCACGAGA	AAANCTNATG	60
TGTGGGGGNT	ANTNTGTATC	CCCTNNNCTC	NCTCGAGANC	CCNNNTCTCG	ANATTTTGGN	120
GACCNGGGGC	CGGGGCCCAG	ANACTCNCCA	CCCCATATGG	NGACCCTNTA	TAAGTGTCNN	180
CCAGGGNNTG	TTTTGGGNAA	AATATANCNN	ANAGNGGTGT	NTNTNANATC	TCGGGGGGTG	240
ACAGACCCNN	ATTTTTTTTT	ATAAAGACCC	GGGGCATNTT	CTCNGCCCN	TCTCCTCNGC	300
TACANGNNAC	CCACACACAG	TGTGTCTCCT	CTCAGCCCC	TGGCACACTT	TNTNTNGANT	360
CNGNGGGGAT	ATGAGATTCN	CNAGACTGGG	NCCGCNNTAN	TANNCNCCCC	CNTGTCTCCT	420
CTCATAGTGT	NGTGTCCCC	CCTCACCCNN	TNTTGNGGTN	CCCTACACCC	ACACAATNTA	480
GACTCTNCCC	NCCNTCNGCT	NTGNGACNCA	CANCTGNAAA	TCCCGNNNCN	CAAAAAGGGC	540
TGTNCTCCTC	TCTNTTACNG	GGNGGTCNCC	CNCNNNNGAC	TCTNAAANGT	CCCTCNCAAA	600
AGGGACNCTT	TTCTATACAC	NCTTANTTTN	CCTCCTTTGT	NTNGCAAAA	ANNANCCTGT	660
GTTNCCCCC	NCTTTATNAT	NTTTNTTTTN	TTCCCCAAAC	TAANCTTTTA	GGNNTNANCT	720
TCCGGGGCCC	CAACCCCAA	ATCCCANTNT	TCTTTTNTNT	TGGTTGGGGT	GTCAAAATTC	780
CTNCCCCTAA	ANTTTGAAC	CCCCTTTAAT	TCCCCCCCCC	GGNTNAAGGC	CCNACTTCCC	840
TNGGNTNTTT	TCNCTAAAA	ATTTTTTGTN	GCCCTCCCTG	GGAAATCCCC	GGTATTCCTC	900

<210> 73

<211> 1033

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 73

CCTACGTTCA	CCTATGCGTA	ACAGATCTGC	TGTGTCAGGA	GCCTCCTACC	CTCGCGCATC	60
CTGACCCCCA	ACCACGTCCT	CTTATCTGAT	GACTGGTCAT	CTTCCCAAGT	CATACACCTC	120
ACCAGATCAC	TCGTGGGGAT	CTCTAGGCCA	CCTCCTGTGG	TACCCTAGGC	CTTGGATCAC	180
TACTAACTCC	TGCATCGTGG	TAACCTCAAT	GGCTGATCTT	GAGGATGCAG	TCTGGAGTTC	240
GACTCCATCA	GGAAGCCACA	TGGGGAGGTG	GCTGAATGCC	ACAGGCACCT	ACCACATAAT	300
GCTTCATGTC	CCCACAATAG	TGTCATCAAG	CANCGNTATC	TCCCTTTGTA	CCTGNCTATC	360
ACAGTAGGCC	CTATGTGTTG	AAGACAGAAA	CGTTCTNATA	CTCAAAATAG	CTACCTACTT	420
TCATCTTTAG	NAAAGTTATC	ACCAGAGATT	TCATCACATG	NCTNGGCTTA	NGTATTTTAT	480
CCCCTTTCTG	AACTATTTAT	CACGGGCAGA	AAATNTACTG	ATTATCCCTG	TATCATGACA	540
TCGTGCTGNA	GAGAAGACCC	GAGTGGGCAG	CATGGNGATC	CAAGGAGACA	AGGGAAACCA	600
AGCAGCTATA	CATAGGATGT	CAGCAGCAAG	CCCTTCCCTG	CCCACGTCAG	ACTAAACCCT	660
TCAGTCCCTT	CATCTTTTCC	TAGAAGGGTT	TGTAATTTCT	GTTGATTGTG	CACCAGCGCT	720
TCCCAATCGC	TGAACATCTT	TCTTCGAATG	TGACTCAAAG	TGAGTGCACC	GAGTCTGGCT	780
AATGTCCTCT	GCTCCTCTTA	ACCTCTGTGG	CACACTCCTC	CTAACACATG	TGTGTCGTCT	840
TGTTCCACAG	TGGCCCCACG	GTACTGGTTT	CAATATAGCT	TATGTATGAG	CAATAAGGGC	900
TATGTATTTT	TTTTTTTTCAG	ACACTGTTCC	TTTTGTATTC	AACAACCTCC	TCACATACTC	960
AGCCGNACCA	CATTTCTTCC	AGGTCAAAAA	CCATCTCTCC	AATTTGTTAT	GAATTACTCC	1020
TNCAAGTTCA	GGT					1033

<210> 74

<211> 883

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 74

GGGGGGNNAA	NAATTTCCCA	AAAANNNGNNG	GNCCCNTTTT	TTATCCAGTT	TNNGGTTGAA	60
NATCTCNCCC	CGGTTTNAAA	ACCCNCAATG	GGGAAAAAGG	TACANCNGAT	TNTTTATNGG	120
TTTGGGCGGA	GGGGGAAATT	TTTTTTGGTTT	TTTTNTTTNN	GGGATTTTTG	AAAAAAAAAN	180
GAANTTTTTA	GGTTTCCCN	ANGTAATTTA	TTTCAATGGA	CCATTTTTTG	GGTTCTCCCT	240
TTTGTAANAN	GTTAAAAANA	AGGGANTTCC	AANNTTNCTT	TTCAGTTTCC	AGTTTCACCT	300
TCNGTAGCAG	ACCCAGTTTT	CATTTTGAGN	TGGTNCCNAA	AAGGNTTCCC	AACTATGTTT	360
AATACCACAG	GCAGCCTGCA	GGAGGGAGAA	TGGGTATGTA	TTTAACAGCA	TTTGACCAAA	420
TTATAAGAGC	AGAGAGGAGC	TTTACCAGGG	ACAGGAAGGC	AAAAGAGCTG	AATNTTAAAC	480
AAAAGAATAA	GAACAGGATN	TCATCTGTGA	GCTGTCACAG	TGGGTTTGCA	GAGCAGGAGA	540
ACACAGACAG	GATTAGCTAT	AAAGTTGTTA	CATTAGTTAT	TNTATTGGAG	CATACAATAC	600
TTAAATAGTT	CTAGGGCAAG	AGAAATGAAC	AGAAATGACC	TTATAAGAGC	CAGAGCTGTA	660
GCCACAGCTT	TCTTTGTGCT	TAGTTTGNTA	GTTTCANTCTT	TCCAGGGCAG	TCTGGTGGAT	720
NACACCAAAT	TGCTTTAGAA	AATGCTAGNT	CTACTGTCCC	TGTCTATTGT	CAGCTTTGCA	780
ATGTGCATAG	TGACAGGAGT	TGCCTGGGAG	CTTGGGGCTT	ATGTTTTGCA	GATCCATTGT	840
AATTAAAAAA	GAATTGTAAG	GAGATGGAGG	CACGGGGTGA	GGG		883

<210> 75

<211> 892

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 75

GGGCCCCCCT	CGAGGTCGAC	GGTATCGATA	AGCTTGATAT	CGAATTCAGC	TCTTAGCAAT	60
CTGACACCCT	CTTCTGGCCT	CTTCAGGCAC	CTGCATGGTT	CCACAGGACT	GTCACACCCA	120
CGTACATAGA	TAGTCAAAAT	CTAGAGCACT	GTTTCTATAC	CTGTGAGTTG	CAACCCCTTT	180
GGGAGTGCGG	TCAAATGACC	CTATCACAGG	GGTCTCAAAT	GAGATATCCT	GCATATCAAA	240
TATTTACATT	ATGATTCATA	GTAGTACCAG	AATTACAGTT	ATGAAGTTAC	AAAATAATTT	300
TATAGCTGAG	AGTCACCACA	ACATGCATAA	CTGTATTAAA	ATGTTACAGC	ATTAGCAAGG	360
TTGAGAAATA	CTGGTCTAGA	GCCATTCCTT	GTGCTGATAA	AGGTGGCAGT	GAGCATTATC	420
TTTCTGTCTC	CACACCACTA	GCAAATTTTT	TCTCTATATA	TAAACATGTA	ATATGAGACA	480
GTCTGAATCC	ACTGAGGCAC	GGTCTGACTC	CAGAACAAAG	GATCGTATTC	CTGAAAAGCA	540
AAACGTGTGT	TTGGCACTGA	CTGTGTGNCC	CAGGTTNTCT	TTCTGNACTC	CTAGAGGTCT	600
GTANTGGGTC	TTGAAGCACA	GATNCTCTAA	CCTTACCCTG	GNNGCTCAGT	AGNATGCCCC	660
AAAACNCANG	NTGTTCAACA	TNGGGNNCCN	CCCNAAAACA	GNGNTGTNGG	ATTTGGNAGA	720
AAGGTGNAAT	NCTTTGGGCN	NNTCGGTTTA	GGAATTTTAA	ACANNAACTG	GCTTNCNAGG	780
TCCNTTCCGG	AGTCATCCTT	NCACTGGNGC	CCNCTGGACC	CGGNGNANNG	GGCCANTTCG	840
CCAGTTCGTN	CCCCTGGNAC	CCNTCNC CGG	GGGCNAAANG	CCCCTNNNNT	TC	892

<210> 76

<211> 884

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 76

TGGGCCCCCC	TCGAGGTCGA	CGGTATCGAT	AAGCTTGAGG	GACCCACGTG	ATGGAAAGGG	60
AGAAGCAATT	TAGTGTCCTT	TGTCCTCTGA	CCTCCACAAG	TGCTGTGGCA	TGGGGACACA	120
GGACTGTACA	CACACACACA	CACACACACA	CACACACACA	CACACACGCA	CGCACACACA	180
CCCCTCAAGT	AACCGTGGAA	TAAAGGTCCG	ACCAGAAACC	ACGCTGGAAC	GGGAGATGCT	240
GGAGCACATC	AGGGTGGTGC	TAAGCAGCAG	ATCGGCCTGT	AACTGGCAGC	AGAGGGGTGT	300
GGCTCTTTCA	GAACCAGGAG	GGCATCGCCC	CTCCAGCCAG	ACTCTCCAGC	TTTCTTCCCC	360
TCCTTGCCCTC	CTGTTTTCCT	TCTGCCTACC	TTCCTTTGGC	CTCAAACCAT	AATGTGCAAC	420
ACATTCAAAC	TGTAGTAAGT	GTTTTAATTT	TCTACTAAAC	AATAAAACCT	TTAGATTTTC	480
ACTGGGCCAG	TGCTGGTAAC	AGCAGACTGG	GTGGAGTATC	ACAGAGGGTG	TGGAGCAAGC	540
TGGCTACCCA	GGGCTGGGCA	CACTCAACAC	TCTGGCATTG	TGTGGAAGTT	CTGGGCAGTA	600
AAAACAGAAG	CATACGTCAC	GCACAGGTTC	CATAGTGTTA	GGCATCTTAA	TCTATCTAGA	660
ATACCTGGTG	TTTAGTTTGT	TTACAAAATT	GATTGTTGTA	CTTGGACAGT	GGTGTTTTTT	720
TCCCAGGGCT	TCCAGGATTT	AGGGGTATAC	CAGGCCCAT	ACATTGGGTA	AACGTGTGTG	780
TTAATTTTTT	CTTTTAAAC	CTCCTTGGTT	GACTACTTGT	TTTCTTTTTT	AATGGTCCCA	840
GTTCCCTTGT	GGGGGTTTGT	TTTGGAAAAA	GGCTTTCCGG	TTTC		884

<210> 77

<211> 326

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 77

AGCACACCAC	AGAGAGGGGG	TCTCCGTGCC	CGAGAGGCAA	AAGTCTCCCA	CTGTGCTCCT	60
------------	------------	------------	------------	------------	------------	----

CTCCCCCCT	GGTGGGGGTT	AAGAGATGGG	GGCTCTGGGG	GGTGATAGAA	CCCCTGGCGG	120
GACACCCCC	CGCTCTCGTG	GAGAGAGACA	GAGGGGGGTG	CCCCTGATAT	CTCACTAGAG	180
GGGAGAGGTG	AGAGGGCTCC	ACAGTGTGGT	GTGGTGGTGA	GTGCTCTATC	TCCAGGTGTC	240
TCACATATTT	TCACAGCTCT	TGACCACAGA	GAGATCTTGT	TGACTCTGTG	CTCGCGGAAT	300
CTAATGTGCC	CCACATCATA	TACACA				326

<210> 78
 <211> 557
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note: = synthetic construct

<400> 78

GGGGGGGTCT	CACNNTANAN	CACTCNGGNG	TCTCCCATGT	CTAGATCTCC	CCCCNGCNCN	60
NGNGANGAGT	GTGNGGAGAT	CCCTCTCTGN	TCTCTACACT	CTAAAGGGTA	NGCGGGGAGA	120
GAGAGAGAGC	ACANTCTATA	GANACANAG	CACACNCGCT	CNANGTGCCC	NANTNACANG	180
NNAGAGAGAN	CCCCTCTCNC	AGTATATNGG	GGAGAGAGTN	TGAGGGACNC	TCCTCTTTTC	240
TCTCAACNCT	GNGGGGGGAG	NGNGAGTGT	CTCTCTGNGG	GGNGGAGNGG	NACACTCNGN	300
TCTNCGTNTG	NGTGCNCNNG	TNTTCTGGGG	GTCACANAGA	AATCNCCTNT	CTCAACACAA	360
CAACAACAAC	CCCCCGCACG	NGCACACACC	ACAACAACAA	NGGGACANC	CGNGGGGGNT	420
NGNGCACACC	CAGNGGAGAC	ACTGTTTCT	GTTTNACACA	CACACACACA	CACACACACA	480
CNCNCCCCC	ACANAGTTTT	TNGGAAAANC	GCNGGGGGGG	GNGGGNCTTT	TTGCCNCAAG	540
CCTTTTTTNA	NCNCCCA					557

<210> 79
 <211> 376
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note: = synthetic construct

<400> 79

GTCTCCCCCA	AAGGGGGGGT	CTCACCTCC	CGGACACCAC	ACATCTGTCT	GTCTCTCTGA	60
TCTCTGACAC	CCCACAGAGA	TATATATAGG	GACAACGCCG	CTGTCCCCAT	GATATAGAGA	120
GAAGCGAGAC	AAACTCTCAG	GTACACATGA	CACATGATCC	CCATGATCCC	CGGCACACTC	180
TTCTAATATA	GTTGAGAGAG	TTGTGTCTCT	CAAGTGTCTC	TGGTATTTTC	TAACCCCATG	240
TTTTCTCTCA	CAATGTCACA	CGGGGGAGCT	CGGACGCGGT	GCACATGGGG	GAGAGTTCGT	300
GTCTATGACA	CACTAGTCTT	GCCCCGAAC	CACAGAGACC	TCGACTCGGG	TTTAGTCTCC	360
TCTGCCCCC	CAGCTC					376

<210> 80
 <211> 533
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note: = synthetic construct

<400> 80

ATNNCCCAAN	ATCANATGNG	GAANNCCCA	CATTTTNTAT	NTAGAAANGN	GTTTTGTGTG	60
TGTGNGTNNA	ATTTGAGNTT	TCACAGAGNT	NACATTCTCT	GTGTCACAA	CCCTTTCTCT	120
CTACACTCCA	CAGTGTGGTG	NGAGATATAC	TNTGANACAN	ATGNGCTCTC	TCCTCNCCCC	180

CCNNCATGTT	NTNCCCCACA	GTNTACNNCN	NCNATATATN	GNNCNCNGNA	GANNNGGTATG	240
NGNGNTGTNT	TTNTTTAAAA	AGATNTNANA	NAGNNGGTAT	GCGTGNGGGG	TATGTNNANA	300
CATATATGTN	NNAGAGGGTC	TCTCTGNGGC	CCNATGGAGG	CANATCCCCC	CCNCTCNGAG	360
NNATATAGAA	AAGAGTNTTT	NANGGTGTTT	GTGGACACAG	ATAAGGGGAG	AGAGAGAGAG	420
AGAGANAGAG	AGAGANAGAG	AGAGAGAGAG	AGAGAGANAN	GGNGTNTTNG	GNTTCNTCCC	480
CCCCNATATA	CAGAAAAANC	GGGGGGGGGT	TAGGNGGNNG	GGGGTTTNCT	TTA	533

<210> 81

<211> 346

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 81

TTTCACACGA	GATGTCGCGA	CTCTCGCGAG	ACTCTCAGCG	CGGAGATATA	GACCCACAAG	60
GGGAATCCCC	CGGGTTTTTT	GCCACAGGAG	AGCGCGAGGA	GAGAGATATT	CTTATTATGG	120
CTATAGACAC	CCCCGTGGGT	GGGGGACATT	TGTGGTGTTT	CCACAGGGGG	GGGGATGTAC	180
CCCGGATATC	AGAGTATTCT	CTAAAAAAGG	TGAGAAGAGG	TCTTCTCTTT	TGAGAGTATG	240
GGGACACTCG	AGGAGAGCTC	TCTATCTATC	TCTCACAGCG	CCCCTGTGTG	GGCGGATCCT	300
CCACACCAGA	TGTTAGTGTG	NAGATCTCCC	CATCTTCTAT	ATTGAA		346

<210> 82

<211> 461

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 82

GAANACCCAA	AATTGNGCTN	GTGGGCAAAN	NTTTTNCCGT	TTCTTG TGCT	TGNGCGGCNA	60
AGNNAAAAAT	TCAAAACCAA	NACCACANAA	GCGCGTTATC	CTGNCTNTCT	GCCNTTNCCC	120
TGTCACACTG	NGGCTGTACA	GACATCNANC	GCTTTCTAGA	GAGACGNGAG	AGTCAGGGGA	180
CTCTTTCCCC	CANNCGCATT	ATANCCACAT	ATTAGNGTAN	NANATTCAGC	TGTGNTNCAC	240
TGGGNGTGTC	TCCNTAGTGT	GAAGCAACAC	AGGGAAACTN	TTCGCNCACA	TGTCCTCTGG	300
TGTTACACAGA	NATAAGNAGG	CTCCTAGACC	NNTATNACTG	TGGGNAGAGN	ATGTTACCTC	360
CCTATANNTC	GGGGTCTATC	TCTGTGAGAN	AGAGNTTCCT	TTCTCCCATN	CCTACCTCAG	420
TGGGGTGNTA	TNTACATCNC	AGAGAGCAGA	NAACTGTGAG	C		461

<210> 83

<211> 367

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note: = synthetic construct

<400> 83

GGGGTNTCAC	AGAGANAGGG	CACANCTCTC	CCNAGAANGG	GNCNNCCCTC	TTTTTNNGGN	60
GTAACACCTC	TCNCCGTGTC	TCTTTCTTTC	TTTTTTNTTT	TTTGGGGGGC	TCTTTTTCGN	120
GGAGGNGGAG	NNCGNCCGAG	GGTCGGGCNN	NNCNGNGGAN	AGCTCTNTCN	CANNGATATA	180
TCNCCNNANC	CCCCCTGTNT	CTTATAANNN	ACATCTCTTC	NTCNCAGGGT	CACACCNAGA	240
NTCTCNTTTC	TACAACAACC	CCCACACGCN	AAAGCTCCCC	ACNNNGNGNG	GGGGTCTCNC	300

AAGAANATCT CNGCGGAGAG GTGGNGGAGA GAGTGANATC TGNATNTCTG GNTTCCCCNC 360
 ANTGCC 367

<210> 84
 <211> 925
 <212> DNA
 <213> Rattus norvegicus

<400> 84
 ggggggaaaac cnggnaattg ttttttgacg anccaaaaag gggncnagna gcnnttntcc 60
 tanatggggn cgggatcntn tccnaggana gattnatgga gtatnccttt tttgcnchnaa 120
 ggttgattgc tcttgaaagg ntttgagggtg naattcctcc gtnagtttga ccgtagtcgg 180
 atntgaagag ggattgttna gcagncataa tttcattccc tgnacacca gtaacnnttt 240
 accgtcattt gggtgggaat tgatntcggg aggtanacan ggccacagtt atttattgtt 300
 ncggaggatt gcaccaattn ggccggctgc ctctganatc tgtttctcat ccatgccggg 360
 tcaccagac gaaagccgaa agcntcggga gtcctaactn tagtcctga aagtcattcc 420
 cagctgcgta attgggctgt gcagagtcct agctcggtaa atatttgccc cgtgactgag 480
 ctggagagaa tgctcctttc ttggctcctg gcagctcctg gcagctcaca tgcactgttt 540
 acctatcctc ccacattccc ccttgaggaa tcctcgtgcc tcgggtccct taagtcctct 600
 caacagaaaa caaggcagag tggaacgaag gaaagtgcgt ggccgttaga aagcctgtct 660
 cgaatctgtc ccacgtgcct caggtagcgt tccaaacagc aaagattcta gtgaagaaaa 720
 ataccgtccg gtcaattagt caggtggaca gagcaggacc cgggtgcttg gaagcctcgt 780
 ccattcctct ggggaagggtg ggggggggag tgtaatgcag ctctcaagaa gaaggatatt 840
 ttgttttctt ggagaaactg ccattcccagg agctgagagt ggatcagtag gaaggcctgt 900
 gacaggaagc agggagggttc agcng 925

<210> 85
 <211> 554
 <212> DNA
 <213> Rattus norvegicus
 <400> 85

caagatngan ggggaggcgg ttcgnccaga gagcgggtag ggaagggaac gcgcccgatg 60
 agccnggggtg cgganagcca gaccccaggc gtgggaaggg gagagagata gagcggccgg 120
 ttgggaagag gaggaccgtg gttntataat aacagaaagc ccagagggac gtanccatcc 180
 gggatggaga gaggtaggga atccagntgt aagtcccaaa ctgccaccac cttcatnaga 240
 actgcttcgt gtaaggtcac gcaccgggac agctgtccng agtggcgggc ctggcgtgtt 300
 aagttagcta aagtnactgc aactccgncg gtgcagactg ntgcataaatt ctctctgtcc 360
 gccaaattct ccttcctatt aaacttttca cttcctttca cttagtttcc tnaacttctt 420
 caaacggaag ctgtaactga gacctgccacc cnganacntt gtgggttgcca tttttatgct 480
 aaagtaatcg tgttttttat gctgttcaac tcccttttca tntaaagcag ggcntaccct 540
 attataactc tgcc

554

<210> 86
 <211> 891
 <212> DNA
 <213> Rattus norvegicus

<400> 86
 ttngaaanaa tttccgtnaa ggtcngnaat nggccccgga aaaaatgngt tcttccccac 60
 cttcattggn gcggatcctg ccngggaggc caatgggtta acaaataatc tttnggagnt 120
 ntggtngggg ggggagggac ncccacagan tcatngggtg gttngggngg ngggcatcgt 180
 tnngatatta tcacattntg ngaanctatg tnggggcttc ctttcngaca ggtggtggtt 240
 nnacangngg atgtgtgctt cttttttcag cagtgggtga cccggattct aagaccctta 300
 cngtaacaat gccctntttt cctaagccta accagtcctt tangaggant gctcttggn 360
 acccatgctg nntcacctag ccttggnctc catnttnnac acaggaaaag gcagcatgtc 420
 ttntnggagc tcagcttatt ccttccctc ccatccagn atctccctgg gntggatgag 480
 gtggatgacg catcttcaaa gcaccccacg tntcatggga tgtgcacagg agcttcgttg 540
 gaaatgtgtt gcgcgaccag gcttgtgtag gaaacaacag actactcgaa attaaagtcn 600
 taacttgacg ggttctcaga ggcttttacg cattaataaa catttgaatc ntaagaaggg 660
 agcacagcat gtaatatntt tcaaattatc agccttgca accttcatta gtttctctta 720

cgcagctggg	ngtgggtggg	tgtaccttta	atctcagcac	tgaggaggca	cngatatctc	780
catctctgtg	acttccagac	cggcntcgcc	agagcaagtt	ccaggccacc	cagatgagat	840
gctcacagag	gggacctttt	tntgatgacc	aacgnagnat	gcaagtaagg	a	891

<210> 87
 <211> 974
 <212> DNA
 <213> Rattus norvegicus

<400> 87						
aaaanaanat	attccgnntc	tnntagenna	gaagttntnc	gagcnntccc	cngtnttttt	60
aaaaacccnc	ggattccggn	nntcgggntt	taanngnntt	tttaanggcc	cnaagncccn	120
nttattgccg	ncntttcccc	cccgcntttg	cncctcttta	cttngagant	ngtgntncna	180
agattttnaag	gttnttgccc	ccccggcttt	tnttcccttn	nttttcccn	nagntttaaa	240
accggtntgg	gttncnantt	nnttgnancc	ncnattggg	gtttccgntt	accnggggtt	300
ttccccatgn	ccgttccctc	caatnttgna	cttccenggt	cnggggtccna	atnccnngna	360
acngntcnan	ccttattgac	aattaatttt	tccttgngna	ntctgncccc	cngnantttg	420
gggttcttgg	gngcagggcc	tttttttctt	tggnggcaan	cncataaatn	ttaccagntt	480
gattgctaag	gaagtancca	tgggtgngaa	cccccccttn	ttntctccca	gatggaaccc	540
aggattttgg	aactgcagag	gcttcagggg	cttggaagc	ggaggcaggn	aaagattgga	600
gtgcactgtc	cttttgcaat	atgggggttt	cctgcctgct	ggctcntctc	ctgctntntc	660
agatgggtgac	tgaggctact	tcngcaggac	tnggaataat	catgtccagg	tggctgccct	720
tccgagcaga	aagggaacaga	cgtggggcga	tgaagtgtct	atcgtttntt	tttttttctg	780
cacagactgc	aaagtgtgca	gagggaggga	ggctgtgcaa	aaaaaaaaaa	aaaaaaaaaa	840
aaaaaaaaaa	ccgaggacgc	agaagttaga	ctgctgaccc	atttggtgca	tgtgtgccca	900
tggagggagg	ggaccttntt	taaagggttc	acgcggcacg	cantgggnaa	nngnncctnt	960
acgnnctcc	caga					974

<210> 88
 <211> 850
 <212> DNA
 <213> Rattus norvegicus

<400> 88						
anttttccct	caagnaaant	ntggtttggg	caacttgaag	acgcttnnac	cnaaaaccct	60
tgngggagntt	ggngaccttn	ttaccgnaan	gagtgggaaa	cgttttccctc	cgggttnang	120
gttaggggga	cccgnnggaa	aattttaaaa	ccnngngggc	tttttcgaat	taaggggaaa	180
ngcggtttng	gtnnntgaag	ggcgggnggt	tggagtcnna	gtccagagtt	gatttccacc	240
cacaaatntg	ggaggtgncg	gggaatgntg	ncnttttctt	gngatgaggg	ntgccgtnc	300
ggantaacag	ngnttgcntt	gtntngcnna	acgaagagtn	tcctgnttgg	aataggngtt	360
cngttcggang	ganccagatt	tangngntgg	agnaaggatt	nggcagataa	angcntgaga	420
natgnancnt	ggancaggtc	nggncnnagn	ntacagatga	tgnnccana	canganataa	480
ntncagatca	cagtcgtacc	cngggctggg	ccatgaanag	ggcatcccca	gacnnacaca	540
ngccttnana	antgntcaga	gaaccancag	tggntanggg	ntgccnnnnn	naccagggaa	600
gacccggggc	gtgncggata	ttgacacanc	agatnnccatt	tggggngcgg	tcgaggggtt	660
atgntcnccg	agtacnagan	angatcntcc	aacccggaat	ncgggtgctc	ngtcgtccga	720
tgnaatgagt	cgnccggnaa	cctcatatcc	aagaaacnat	acagcagtgg	nntccgagtc	780
tcgtatantc	nttgcgggng	gaggctatnt	tcagaggnc	agattaccgt	tagcgggana	840
aagtngaana						850

<210> 89
 <211> 531
 <212> DNA
 <213> Rattus norvegicus

<400> 89						
ttgngggcngg	gtctcctctg	ngtgngngtn	tccccnanag	gggggggtctc	acagtgttng	60
ngtctnntgt	ctgtgtngtg	cccctgtccn	catctctcac	nccagggaga	gagatgtgag	120
ananacatca	gagatctctn	gnacagtgtt	tcacaagagt	ctatcnana	gagcacatct	180
gcccggggng	anacacaact	ctaaatgtgt	ctcanntgat	ctctctnttg	tgtctctnac	240
atatgnggac	atgctctcag	agtatnggnt	ctcttgngcn	cttntgcaca	cacacacaca	300

cacacacaca	cacacacaca	cacncttctc	tctggcacag	ggntatggca	nagcacatnt	360
tnngagntca	nagctntata	tgagtgtgtg	gcgaaaggng	tnatnanann	gacnncccca	420
gcnnatatag	gggggngnnc	tctngggctc	tcttnggnaa	tntgngggng	agtctgenca	480
cacaggcgct	cnnacccanc	nnnttggggc	ccccaggng	tttttcnccc	c	531

<210> 90
 <211> 572
 <212> DNA
 <213> Rattus norvegicus

<400> 90						
tttttntgtg	gcccttttaa	ctctgngtgn	ccgtntnccc	nagagggggg	gtctcacaag	60
gagacancgg	nnacacagag	gttttgngnn	tattgngagt	ctctgcgcac	nccananttt	120
aaccncgggg	netentgttt	tattttaaaa	aaaaagagtc	ncatgtntat	ttctctnatg	180
tgaaaatcnc	attcanagtt	ntgggggtttc	ccntgaggag	anatagagtt	tcacactctt	240
ctctccgagg	ggtcntenca	tgtntctccc	caatgtgngn	ggnacacaca	tgngggcccn	300
aggggggtng	ctctctctgc	ncagggcnc	ccccaanang	tagaganaca	ntgtgggtgt	360
tcacaacaca	attcncgaga	nattntgttc	cncantggnn	gtctnagntc	ncatgttgtg	420
gngacangtt	agnncncccc	atnttcnccc	ccctttcaca	ctgccccnag	agagagaaan	480
tctngggccc	ctctanannt	ntttttaaat	cnncccnac	cacaggtntt	cccagggtat	540
gngacntcnc	cnncccnncn	aaagatntgc	nc			572

<210> 91
 <211> 906
 <212> DNA
 <213> Rattus norvegicus

<400> 91						
tgggagtctc	tctcatatgg	cgcnttcncc	aaaggggngt	ctctntccng	agnccganac	60
gcgagaanac	tctgtnnant	ngtctcccc	cncnccnaca	gngtganant	caaaacctct	120
agagcccccc	agaaancccc	tntctcaaan	aaagagaaag	agaagancca	gnagnagaga	180
gananagaga	gagagagtgt	gganctntnt	cctcngancc	ccannnanan	ngtgngggcnc	240
actcncnngt	gnngngnacc	ccnggggatt	tncgogtgtc	cccttgngct	ctgtntanga	300
gananatatg	tntagtctct	ctntcgcccc	ctccgntgtc	acgtgtgcgg	ggcccnngag	360
acacagacac	ntctctcang	gggaacacat	anngactcnc	acntgtgttt	atattcnccc	420
ctcccnctca	cacanacaca	cacacagnag	atattnngct	actctctctc	tgtcacaggg	480
gtacanattt	antctnggcc	anaccctctc	cngaagnngn	ggcanngtaa	accccgcccc	540
ctctcngaga	angngagggc	gntttacntt	ccngtgggcg	tgtnccngcc	cccagagactc	600
cccttngnac	ccccctntna	accctctntt	tgaacncaac	ncacntccc	cnttttctcg	660
gggnnggncc	ngcncccnct	ctcncaaaaa	aaatttnaan	ttngtccctt	ncccnctntt	720
ttcnggnana	aaccgtgtcc	ggggggggan	nactcttttt	tgnccttaaa	atcaantttt	780
ttcccttttt	ccngggggacc	cccgnnttcc	tttttaaaaa	aaaanaaccc	tttctccctt	840
ttaaaagnac	ccnttttttc	naaaaccgtt	ccgnatttaa	ttcctaattt	cccttcccn	900
ncccgg						906

<210> 92
 <211> 914
 <212> DNA
 <213> Rattus norvegicus

<400> 92						
gggatgngcc	ctcagatcaa	tacaccctc	ngggggngtc	tctctctatc	tcccncagna	60
gactcccatc	tctntntntn	ccccaganc	tggngaacgg	ngtgtggnga	nccntntctg	120
ttctcnantc	tctaaaagng	cnaaaagcgc	ananacacgn	gcctctctat	anatctcacg	180
tgtcccnngn	netctcngac	ccctnntctg	tntgagagac	accctntctc	aaaatatagt	240
gtacacgngc	tttgnggctc	tccccttttc	tctccactnt	tgagngngaa	acgcggngtt	300
ntctctgaga	tgtaganagn	gtcccctnct	cnatatatgt	gttnccact	ccnnaggngg	360
tctcataaaa	atcncntntc	tcaacaccac	cncctcnacc	ccccncacga	gaacacntcn	420
ccaccnncan	gacacaaana	naaggngtnn	anaaccccan	aaaaactnng	ntntcngntt	480
tacacacaca	cacacncacn	ctcncncaca	ccccacnna	aatgggagaa	aaaacagaga	540
ggngtgggtg	ttngnntcaa	caccntntta	cctctctgnt	gnnanttgag	aaaatatattc	600

tntncttacc	cctctcccct	ctctgtgtgt	ngannatate	ngntctagat	gtcctnacc	660
tcccaaaacc	tttctcnggn	agagacntct	ctntnttttt	ccccncttc	catttgaaan	720
anangagaag	gnccaaaaag	gnnggngtct	tctcggaat	ncnccctttt	ggccccccaa	780
cctgggtttt	tttccccctt	ccttttaatn	antttttcna	nacaaanctt	tnngngtttn	840
ggaaaangcc	tttnnctggn	nnttttttcc	cttccccctt	tnnangggnt	tccccccccc	900
ccngaatttt	tttt					914

<210> 93
 <211> 400
 <212> DNA
 <213> Rattus norvegicus

<400> 93						
ttcctgggtg	cgggtctcctc	tgagatagtg	tatcccctat	aggggggggtc	tcacttttagc	60
acagttttatg	aataattatta	catatttcac	aagactttat	attgttataa	tatgcctcat	120
gtgagatata	tgtgattctg	tggtgggtgt	ctcagagggg	gtttgggtta	ttggggataa	180
tagtttgccc	ctcgcggggt	ctatatattat	atatgtgaca	caatatatta	gagagatttt	240
tggttatata	tatttccctt	cgcgggggtg	gagatttatc	acagggggag	agcttttccc	300
ttgttagcaa	aagtccctgg	tctcgcccc	catctcccaa	aaaaaaaaaa	atgtgaaaaa	360
aaaaaaaaaa	agggccctc	ttgagtgatg	tccccctctt			400

<210> 94
 <211> 880
 <212> DNA
 <213> Rattus norvegicus

<400> 94						
acccaatctt	nanggtggca	gtgnggnnga	tcttaacggt	ttttnagaaa	aaaaantnct	60
tgcctcncac	cccgaagcct	ccntttctta	ncagcttttt	tatangaaaa	aagatgataa	120
cgaaatttta	aaaaccgtcg	ttagaggaaa	tgaaggttca	gccgaccatt	acctganagt	180
aatgaaggtn	ttccggaggg	ttgccttcca	atcccagatg	gatttgagtt	tcaggatcaa	240
ttcagttacc	gntgaccatc	caccnncctc	cngtataatc	attngatgag	gatgaatggg	300
gagttagtgat	tgatgatgat	gatgatgatg	aagggatgag	aagnacacta	tgataacaag	360
tgtctcagtc	cacattaagg	tttgcctgna	aattagtgc	taagccatgg	gagacaaatt	420
cttttcnnac	acaattaata	gtntcttant	ccttcccac	ttctctgccc	cattctgttt	480
tccaccacag	gtctgcagcg	ggctacagct	tccagtctcc	aagcaaatac	cagaactgga	540
ggagaaaatt	ccagtccagt	gagtcattgg	cagggggagg	ggtggggtaa	gggcagtggc	600
gctcattcct	nacatgggtg	cttctcttgc	ctagcctggg	atctgagggc	aagagaacct	660
gtaagcttga	tttgatttcc	actgctgact	ggagtcactg	ccaagggatt	tgggacttct	720
ccatctctct	ctctaacctg	aaatccttag	gattctatta	tttcaccgga	ccagagctgt	780
agcagagatg	agctccaagt	ttgaaatgag	aaaggggaaa	ttgagagcta	tgagctaggn	840
gcgaaagncc	ccacaaagnn	tttggcaagt	agaaaagncc			880

<210> 95
 <211> 909
 <212> DNA
 <213> Rattus norvegicus

<400> 95						
cgngagnngg	cagggannna	ggnggggagcn	ngagaggaga	aggagaaggn	nnggnaggng	60
nngngagnaa	cgggcgggan	cnnngacga	gagaangggg	aggggancga	agngcggngg	120
nagacggtgc	nnggggggga	ggggcaggag	nggnagagag	gcangagngg	agnggggaca	180
agcnnaaanc	gaggaggnan	gangngangg	nngngngnc	gaaggcgcn	aagnnggtcg	240
gngagcgga	gnggnnaaac	tggggaacga	gacagacggc	cccnncggng	gcangnggga	300
gagnnncgcc	agngagagna	gncagnanca	gancanggga	ggggggggan	ncacnggcgg	360
gagggncgan	gacggnnngn	annggnnaga	ggcannnnnc	gccnanagng	ngaagngagg	420
cangagtgn	gcnnagagnag	acaggccccg	gcncgggggg	cagacnnngg	ncaccaccga	480
gggtggnggg	ggcncggaga	naagaccaga	ggnnngaggg	cganggcnn	ggtnggcccg	540
ggccnccna	aaaaaanncc	gaaaaaaan	aaggggcgcn	gcngggcngg	ggaggagcgc	600
ntnncgtang	tngantgacg	gagggcngna	atngggccgn	gccanncnag	ggcgnagagg	660
cccaagnccg	gnaggngnaa	gnanagancc	ngnnggtngg	gagnganagn	gcnnngnncc	720

nacccccngn	gttganggcg	cccacgncgg	ngcaggccgn	nnaaagngag	tccccnaaaa	780
nntcgnggtg	tnacancgnc	ccggggncgc	cgcnnggtcc	cgncacacng	gannncggag	840
anngcctnnt	ntctncacan	ggngccanac	nngntgctat	gcaaaagggg	cgnacttcna	900
gaaaaagnc						909

<210> 96
 <211> 927
 <212> DNA
 <213> Rattus norvegicus

<400> 96						
cctttattcg	gaggcagggg	nnncttgtcc	gggaangtta	aacgtttttt	aaaagggggg	60
ncccnngggg	gggggnttnt	ccagggaant	aaaanggtgn	gttggggggg	aaaaatttat	120
tttnaaaaag	ggcgncnat	ataaangacn	ttcggggggg	tttgaanagg	gccggaannc	180
tcgacgggtt	tccggngggg	ganaaggana	agggnacgca	cgggatttct	tncccttttt	240
tngcaaattg	cngcaggana	ccaccgggtg	ggnggttttt	gttttccgtn	aagaaagcgg	300
gngtggaata	acanggataa	acgggaagan	gggttatatt	nggttagnaa	ttgnttccag	360
ngnggccagg	aaattggcct	gtccaaaatt	cttttcccng	cttttaagac	aggcaggtat	420
tatttggcag	caggttatta	cnataggnaa	gtaaataaca	atgggtaagt	gcctggcaca	480
ggccagggtg	agtagggcat	gtatggaatg	ttaaacatta	cccttcatcc	tgagaaanaa	540
aanacaagna	anaaaggctg	gtctcacata	tcccaaagct	ttatcttctt	aggtgcccc	600
tgggtgaacgt	taagccaagc	ntatgantca	caagggacga	catgggcagg	ntaggggtaca	660
gaatcagtg	tcagagactc	caggggcacc	cctgattccc	tttgctgtca	cacagacact	720
gctccaggga	caaccctccg	gatgtgagta	tatgacttcc	tgatgggtgac	gctgccgtga	780
tgggacactc	ntcgtggtag	cacacattcc	tcagtcagct	tctgagcntc	agggtcccag	840
cagagcacag	tggcaangac	tttcattctt	nttggncctt	cccagggggg	gtncccaaat	900
ggaagatttg	gcaagntaag	gaagntc				927

<210> 97
 <211> 848
 <212> DNA
 <213> Rattus norvegicus

<400> 97						
ttttccaagt	aaancanggg	anttcggtan	aagaangttt	aaanaagngt	ccaggcancn	60
gaaattttcg	nggntttggt	taacgangca	accagggggg	ggtttcaang	ggtcttctaa	120
tnatttnaan	ggngtaggtt	tctggtnggt	tcattccttn	aaaaaaaaac	aaaacaaaac	180
aaaccgnagc	ttctgcattg	gccaccngtt	gnggcaccaa	cccttnangc	attgcccttt	240
ccttcctgcc	gtgtcggngg	gcgctaagcn	gcccttgtca	ccttccattt	ntngatcatt	300
ttccatgtcc	ttgcacttct	gcttccactt	cntgttggtg	gacgagctgt	atgntcagaa	360
antgaagtac	aaggccatca	gcgaggagct	ggaccacgct	ctcaacgata	tgacttccat	420
gtaaatgttc	atgcaccctg	cctgcttgca	ccctcacent	catgcttggt	tgatgacctc	480
accgtgggtc	ccccannann	aaaananatc	catgtctgca	ccttttgttg	gctttcttgc	540
ataacctagg	ataggttatc	ttttccacgt	tgcactaaca	aggccacgcg	cattcggtcc	600
gtgaaaccac	ctcggcatcc	ttttatntca	tagaggcaaa	tntagcttgt	ttctgccgag	660
agatgacctg	gactccgaat	gggctctgag	tatntccttt	taaaacctta	aaccagantc	720
aagtaaagtt	aggaagccat	gaggcagtg	tgcaggaagt	taggaagaaa	naccgggttg	780
ttggtttcct	gggnctgggg	tgaggggacca	ttgatagacc	tttacgaaan	ganccgcang	840
atagaaaa						848

<210> 98
 <211> 896
 <212> DNA
 <213> Rattus norvegicus

<400> 98						
agagaaaaag	gaaanannga	aagaaagagg	agnaaaaana	aagaggnggn	aanaaagaan	60
agangnanaa	agaananant	nngagattac	gaantcgggg	agagngaaag	gaaacaaagn	120
ngngngnaaa	gagnnanttn	tttcaagggt	ccgnaacaaa	aagttgagng	angattccna	180
acaaggngtn	nccacccaan	ctgntaaagg	gangatttgg	ncaaacanaa	accngtattg	240
gggagttaaa	aagagtcacc	aataggggaa	aaaaagttng	ggggaggngn	aacnacnggg	300

taaaggttcc	aggaccagag	ngttcagnac	caagttttcag	tattcaggag	gacagagttc	360
aggatcnntt	tggaacattg	gggtttgggt	agcntggnaa	cacgaaccct	tttgttcata	420
aaaaggaagg	gaaaagaaag	ggngaagag	tnttcccaga	tgnattntga	gcagagaatg	480
cccgaccccc	cgaatacgt	gttccaaaat	gggattgnac	ctgtttcacc	tcaaatttca	540
ntentccttc	tngtggacag	acgcagggat	ggggtcgggg	aaggggngaa	gctgggtcgt	600
gttctgtggt	tgccggtgga	tgntctgcag	ctgnttacc	caccgaaaac	gaatggatgg	660
gatgtcactc	ccaggcagta	gggggcgcac	gcgcattgtg	ttntagagag	anttccccag	720
cctccccngg	aannacaaca	cgttntcttc	ttcttaaggt	ggtgggtggg	ggggggggga	780
agacctattg	ctttccgaga	ggatcggacc	aaacagcaga	ttntgctcaa	ggcccttgaa	840
ccctgntatc	tcactaaaca	tctgagatac	tgacattaca	gatacggata	tcgtgg	896

<210> 99
 <211> 858
 <212> DNA
 <213> Rattus norvegicus

<400> 99						
gccaatcaag	ttncggttaa	atthttggaaa	ngngggcgaat	gcnnrtgtctt	gnnggattttg	60
gagggnggaa	ngtnggtnaa	agagtthttaa	tggtcttggg	atcgcaanta	ttttcctggt	120
tcgogncttg	tacattatga	gggttgataa	cngctgtttt	tngatttttg	ttaacanggg	180
ngggngcntt	tttnggntga	cctntagtnc	ntcngngccg	ggcatttttg	ntaccttttt	240
atthttngaa	gtncagggat	gttgtgtact	gggaatatcc	cttagaagtg	accatgattt	300
tatatthttat	taaatatata	cttagattca	ntctttgcct	aagcctggat	gttgtttggt	360
tttgtthttg	tttgtgtgtt	nggagagttn	tcattttccc	aagctggctt	tgaacattca	420
cttccacaca	aacatgtcca	cacacgggca	aaggtgtatg	cacagatatg	gacataacac	480
acacagagaa	gaatnacaaa	caaacaacaa	aaatatthcn	gacagaaaca	antaaatata	540
tccagaagg	agaatattct	acaaggcatc	aaatctgttc	taaagaaaaa	gttataataa	600
agaaaaacat	tgaaaggcag	gtgaaggaga	ttgaaggcca	tagggggccac	aaaaagggtt	660
aaacagcaaa	gcaccaacgt	agatatccgg	aacgtgctaa	atatggcaca	cacaggatat	720
ccgggaacga	tgagtcagcc	agcggcacat	ataaccaacg	atgtaatctg	ttatgtaact	780
atgaatcatc	cctggcagag	tgccaccttt	gtgtgatttt	tgtataaata	tgcccttgag	840
accagaagcc	attgcctt					858

<210> 100
 <211> 551
 <212> DNA
 <213> Rattus norvegicus

<400> 100						
ttntctgtac	ccccttctca	aaaaaagtgg	ctgggtgnctt	ttctengaag	agaatcctca	60
ccnccncana	anaaatatct	ctctccccc	cttgttgntt	gtcncccnnc	ccaaaantgt	120
gngatctntc	tctctgtgca	cgaganattt	tagagggggga	tatccccggg	gtgtngceng	180
tgtctntcct	ctcgcaata	tctttangag	nctctctctc	tcganccccc	agngtaggnn	240
gagngganaa	catttttntg	tgngggcccc	ccacaananc	acnaacaana	tatttttcgag	300
aancncatgn	ganaatcggg	gggggggggg	ccngtgttna	cacnatancc	ngggngatna	360
nanagacacn	nnatatntct	ggngtgtgna	aanataanac	aagancanac	atngggagan	420
natgtgagan	tgtgcacacc	ctgttgtgac	atgtgagggt	gggggctgat	gatncctncc	480
ttctacgttn	tntcttctcc	tcnccantga	tagacnccac	ctgctggagt	gnctagctan	540
ctgggggtcgg	t					551

<210> 101
 <211> 888
 <212> DNA
 <213> Rattus norvegicus

<400> 101						
gttaaatatg	aaaaagtggg	ggtgacaggg	ggtgataccc	tttgccggcg	gctatggatt	60
tttggcaccg	ataagatttt	caggtgacat	ggaagggtgg	tggggatggg	ggaaagttht	120
gaggggcca	aaggataagg	aggatgattg	attggtttgg	gagcagtact	tggaagaggt	180
gtgtttgatc	ggtaaacac	cacgtgtagt	gtgtttttgt	tgacagagag	ataagtgaga	240
aaaagatttc	aggagatctt	gatttttttc	gggtcgagct	atgttggggg	atgtgagggt	300

acaattcaca	agatttggtc	acagggaggt	ctaggaggtg	gtcccattag	ccggtagggg	360
ggttttctca	ataaatgggt	tcagtcaggt	gtttgcctag	atctttcatt	agttcctccc	420
ttcaaaggga	ttttgaagga	gtgctttgtc	ctgtggagca	attgactcaa	tcaataaact	480
taagtaatct	cccggattac	tgttgatgcg	ttcccagaga	ggcccccggt	agttaccagt	540
gaatcacaa	ttcctaacca	tatgattttt	gttaatctca	ccacataaac	ccacaattct	600
cgcgtccttt	gtgatgggtt	caaagtctgg	aatatTTTTT	cctccatccc	tcctttcctt	660
cctcctttta	tcctcctctt	ccttttttcc	tttcacagga	tctcattatg	cagcccagtc	720
aggccttaaa	cttgtgatcc	tcctgtctca	gcctcctagg	tgtaaatgat	acccaaatgt	780
aaaccatgtc	cagttacttc	ctcctaattc	catcttcaga	tatcctttta	gaccaaatta	840
aatattaact	gaaagacccc	accagtaggt	ttggcaagct	agcaaaga		888

<210> 102

<211> 867

<212> DNA

<213> Rattus norvegicus

<400> 102

ctttttctaa	attttttaac	gggggaaatc	aaacggcaaa	aaagaggggg	gaccacctca	60
atcacccaca	gtggaaaatt	ggtgggtatc	aatcaggtgt	tattaggggg	ggaggaatgt	120
tggggaaaca	aaaaaaaaatt	ttaaaaat	ccaggggggt	tttgaaggca	ggtgatttaa	180
aaaccgcccc	tcagtttaagg	gggttttatt	ttttttta	aaaaaataaa	attaggattc	240
tgggaatagaa	tttttaattc	agggatcctt	atttttaatg	tttccagggt	aaaagggaga	300
tattcttata	aggtttctgg	aaaaagtttg	cttggtttcc	tttggcagga	gagaggttta	360
aaaaagactt	catttgaact	ttttgatcat	tgtgtaaaac	tttttttttt	gaacaaaaca	420
ataaaatgta	aaaagatata	gatcttaggt	tttttaaaag	acaaacatat	aaaatatata	480
aacagattgt	ctgtcccatg	caaagtactg	actgaccttg	taacagctcc	acagagtgtg	540
taaaaacaaa	aaaaagcccc	ctgagagcct	tgagccatca	ggttaagtct	catttattaa	600
tattttcaag	gccacaggag	acactctgtt	cccttcattt	aggagaggtg	tgaggcagcc	660
atgttttccc	agcagtgggg	gttgggcaga	gccactccag	attggccttg	aggggtgtgt	720
agctctcagt	ctgcccgga	ttggatgggt	tattttctta	aacgaaaaca	cctgcctgag	780
aaagagccct	tttcacgggg	tggccaagtc	ccagccccgc	ctgggagcca	aggtcaagtc	840
ttagcttagc	gttctaagga	cacagat				867

<210> 103

<211> 897

<212> DNA

<213> Rattus norvegicus

<400> 103

aaaggggnanc	aaaacntaa	nggggagggg	nggggaaatg	gccaaaantt	ggggttaaaa	60
aaagtttagga	tntggttgga	tccnaccac	aaggaatttg	ttnttaattt	tttaaaggna	120
aatttgggca	cttcnattgg	gaagggttaa	accagggcaa	gtgntaccgg	gntatgcaag	180
tgaacntga	ttctggnggt	ggaggggaagg	atantganat	gtgagttagt	gcagttgagt	240
gaggacttgt	gagnacaggt	catgccacc	aaagggagga	gcaaggggtg	gcagtggtag	300
gtggtgtgtg	gttcctttct	gggggntggg	cggggagaca	gatgagaacg	ntattggagg	360
acaggnacaa	gtgtactgaa	atgcaaattc	ctgtagatct	ggaaaagggt	tggnntcagg	420
cttgatgctt	gggccggcaa	ctgtgnacct	tcctgnacg	ttcagcccc	ccacccttac	480
ggaagttttc	gtcactgaag	actagtggct	aatcagagtc	ttcaatggac	ctgccaatca	540
gaaaggaagg	cgggntnttc	cgggtgcnta	ggtgtaggat	tcgctcagta	gttaagcagt	600
cttaactgg	tctggctgct	gtgctntctg	tcctgccgtt	ggattntctg	aggcatgttc	660
aggcaagctc	caaagtgtcg	acatgggtgag	cacaggggca	ggggggggcg	gcggacgggc	720
aggggactga	gcagtgggag	ctgggtgtgt	gggtctttcc	cggggctgag	ttggaatccg	780
cggctacccg	tgaggtctta	gccactcact	agaccagcg	gcagtttctg	aataactttc	840
nttgtagggg	ttggnactcn	gnaaagactt	ccacnaaggn	cttggcaagt	agaaagg	897

<210> 104

<211> 435

<212> DNA

<213> Rattus norvegicus

<400> 104

gattccagag	agaggagtga	actggcagat	aaggcagtca	gcataatggc	ttagatacca	60
tgtgctttcg	ctcactatgc	acccatgaca	caagatcaca	gggtacaggc	ctggaccatg	120
gcagagtata	cactgggttg	gtaaatgaag	aggagagaca	gagtgggaag	tcggcttagt	180
ggatatggac	ttcaaatttg	atgaacaagc	aattcaaatg	agtatcgtgg	gcttgantgg	240
tatgaagacc	cgtttgcaaa	gcagtgggtca	taagagagaa	aagagagaga	gagagagaga	300
gagagagaga	gagagagnaa	gagagagagn	gtgtgttgtt	gttggttgtt	ttgttgttta	360
ttggtnata	acaanatnta	cctttgggcn	ctttngaaag	actntncaca	aaggagcttg	420
ncaagctaga	aaggt					435

<210> 105
 <211> 894
 <212> DNA
 <213> Rattus norvegicus

<400> 105						
gaaaaaaaaa	aaannataat	tttaattttt	ccccatttn	aagggaatn	ggaaattaaa	60
natnggtttt	nagcccaatg	gaaattaaaa	ttaagaaggt	tgttttccaa	aaacctttcc	120
ctagaggana	accggccnat	aggnggggn	agnatggaag	gattttccag	agaggaatca	180
gtttggngag	agaatttgat	aaggagtcc	ttggaaccaa	ccnggagggg	gttttggttt	240
nnnggattna	tcangatggt	tgctcctggg	aagcataagg	ntggtttatt	attttggtta	300
aaggggatga	agtacctgt	gttgcaactg	gtagcccaat	gtcctgtcat	tgtgctttgg	360
atgtaggcag	ctttgaagg	attnctctg	agaggatctt	ccggatcaga	gtatatcgcc	420
ttttcttggg	gaggcccat	agtggganc	cgcacttcac	catttctttt	ccgcccggcc	480
cagttcgggt	ntaacccacc	cgcgtggcca	cgatcccagg	gacatagcgg	gacaggcccc	540
gcagtgcggg	gacacacgtg	ggcacacccc	acctgtgcag	ccggtggctc	gcgntgaagg	600
acacgaggcg	cgacaatcgc	gcgcggcgcc	gaaggccaac	cgccgcgttc	atggtnntca	660
gaccaaagac	ccacaagnta	cgggttcggg	tttcggggac	ngaggccagc	ccggttcccc	720
cgcgntgcg	cagtgcaaan	tcggccttcc	ccgccggaag	tactcctggg	agcggtttcg	780
gcgcgtggca	cttttcgggc	cacctggagg	caacactggc	gccntttcct	gtttcagttc	840
ttgntaggct	ataagtgaag	gaccccacan	gtaggtttgg	caagctagcn	aaag	894

<210> 106
 <211> 594
 <212> DNA
 <213> Rattus norvegicus

<400> 106						
ccattaatgg	ggnggggnaa	agggatagg	atthgggcn	gnnggttant	ggggaagtgg	60
gatttttaagg	aattccccaa	aaatattgat	tcttccaaag	tattttcctt	catttcccaa	120
nagagtaatt	tcaaaagccc	cagntttgtg	gaatcanttt	ttgaanatat	gaaaaggccc	180
taatggtttc	ggcattatta	aggcccgctg	aggacactgn	tcaagttact	cttgggaaggc	240
gtttntggca	gaaacagaa	agccccgttg	gcacggacag	tgtccactgt	ttatctataa	300
atcttttcaa	gcagatcttg	cagccaacta	ggtacaagag	tcggatgggg	atggggggcg	360
gggagtcaga	gaggtcggaa	caatgaggcg	gaaacaaaa	ntntgaaaca	cgccccacctg	420
aacaggacga	aagggtgggg	cttggtccac	ccagaaggaa	acctcgaact	ccacntttca	480
aggtatccgc	tccgggttag	cagccccggc	caaacgcccc	tgctggcttc	taaccaacc	540
agctacgaaa	gcaggctnga	ccactagctg	ncctcgactt	gaaagttccc	acaa	594

<210> 107
 <211> 586
 <212> DNA
 <213> Rattus norvegicus

<400> 107						
atccaatnat	tgggagtagg	acaggggatc	gggattngag	gccagttggg	ntagtgggat	60
gctgggaatc	ttaaggaatc	cccaanacat	atggattctt	ccaaagtatt	ttccatcaat	120
tccaaataga	tgtatttcaa	aagccccagc	tttgtggatc	agtttttgca	ntatatgaaa	180
aaggccttan	tgnttcggga	ttattaaggc	ccgctgagga	cactgttagg	gcgcntcaag	240
ttattcttgg	aagggtttct	ggcagaaaca	gaacagcccc	gttggcacgg	acagtgtcca	300
ctgtttatct	ataaatcttt	tcaagcagat	cttgacagca	actaggtaca	agagtccgat	360
ggggatgggg	ggcggggagt	cagagaggct	ggaacaatga	ggcggaaacc	aaaantntga	420

aacacgceca	cctgaacagg	angaaaggggt	ggggccttgggt	ccacccagaa	ggaaacctcg	480
aactccacnt	tcaaggtatc	cgctccgggt	tagcagcccg	ccaaacgccc	tgctggnttc	540
taccaacca	gctacgaaag	caggcngacc	actagctgac	ctcgac		586

<210> 108
 <211> 909
 <212> DNA
 <213> Rattus norvegicus

<400> 108						
gggggggtgn	aaattgagaa	gcccnccttt	cntctttgtt	gtgaanacat	ttncctnncn	60
gggggatccc	tnggttccgg	aagggccgcc	ttagtnttcc	ttttcctcca	cctatgaaag	120
ggnggggagc	cgattaaaag	aagggngggag	cagngaggga	agcggagctt	cgcccgtttt	180
ccgnaccctt	aaccctgctt	gttcgggggg	ggagngtgcc	accnaccctg	gngnggtggc	240
acggagatnt	gagggggagg	gatgggtttgc	cntggccgct	ngtgggtggg	cgggcaggcg	300
ccggcattcc	cggcaccttc	ngaagacnga	gccgggttca	gggacnnaca	ntccccgcca	360
agngggacca	accgcttcgg	gtgggttccc	cggttgtntg	gtgccagggc	cgnacgccgn	420
gacngaggga	gacccaagga	cntagantca	ccggtgagcg	ggccggcgcc	ggagagcgga	480
aagaggagcg	tagcacagcg	cagntcggcc	agacgttgtt	cttntaccac	ccaccgagcg	540
tttaaaaaaa	anaaaaaaan	cccgcggcag	cggacttttt	ttgtagcgga	gcccggggcg	600
gtcacttgcc	ggaagtcccc	cccntcgttt	ctgccaccgc	ccntcgggta	cctgggcaac	660
ggcgcggggg	cggagagtgg	ntgcgcccaa	gggcnttggt	gggggtggact	caggcccggg	720
ttcccgatcc	tngtagaatn	ttntagaggc	tttttcttta	tgcgagggtac	cagagggcgg	780
aagtcttgag	gtggagaggt	catgtcccag	agdcgtaagc	cggggacgag	tgctntcagg	840
cnntgtgcan	ttgggatcct	nnggnccacc	ntgagggtcn	tcacaaanga	agcngncnag	900
taaaggagt						909

<210> 109
 <211> 576
 <212> DNA
 <213> Rattus norvegicus

<400> 109						
ggcaccgggg	taanangggg	gggagtngtc	ctgggnncct	tgaacgctgg	gggaggantg	60
gtnggggggt	ccaagggggg	nggggaganc	tnaagntcnt	caanntagag	agggggaagc	120
tccccactct	acatctgttg	tcggagcacc	ccccaccca	gagggcgctg	tcagtcatag	180
actagagacc	tccctcaag	tgnctcnatc	cttccaatag	acgagccctc	ttgacgcctt	240
tttcagagaa	ttctctaate	ctcgggtcac	ttccgcccc	ctgtcaagac	ttcacatatg	300
tcctccacgc	gaggggggtg	ctagaaccat	cataagaate	tctctgtcct	cgttctttcc	360
tgtgataaaa	gccgcggggg	nttccttttg	ggcgtctaga	tctccgtgct	gagtgtctcg	420
ggagagcgcg	cgacatcgcg	tgtgaanngc	gacctgtctc	cgcggagaat	gggagtgtct	480
gtgtgcagat	gtcatagtga	gaaaccaccg	ataaggggtg	tagggtaaaa	gataactaaa	540
gggctatgaa	gaaagtgggg	aagggaggag	gggaga			576

<210> 110
 <211> 853
 <212> DNA
 <213> Rattus norvegicus

<400> 110						
aacnccctt	ncggggggng	gggaaaaana	aaggggggtng	gnggaannta	aaccctagtt	60
taaaangggg	tanangtntt	taangggcna	aaagnttggg	ttnantccca	ggnggggtccc	120
tcctttgaan	accngaaaa	attcatttnc	agaggggttg	gaagggggag	ccgaaaagaa	180
acccaacna	cttcgcaagt	aacaangggc	cnaagggagn	cagccgcacc	ttttttccnc	240
cccgcccaaa	ggccagccgc	attcaccatg	aacagataga	ngtaggaggc	aaacaattcc	300
agttaanttg	gcggttgatg	gcanttcgg	attcttgggt	gtatttcttg	cgnatttgcg	360
aggagagcgc	ggtgttcacg	atggcggtcg	gngagggcgc	ggaggcgacg	ctggagcggc	420
ggagcgacga	agttgcaaag	gntcagggtc	aaagcgnccg	gcgggggtcg	aggggtcgag	480
caccggttcc	gttcaagcac	tggtgaagca	ggaaaccgcg	gngantcttg	gcgagaangt	540
ctggcgtagg	gaccagcggg	ccgcacttta	tagcgggatc	ntgcgtcagg	cgcgntccgg	600
ccaatcagcg	cggtggggcg	cccagccccc	cttnttctct	taggcgtgtt	gcccagacca	660

gcagtgcgtg	ggcgggggagg	agcctgtgtg	attgtgaggc	gantcttggg	gttatgagct	720
gntgcaagag	cgggtgcctgg	caacaagcgg	gacgtttntg	tggcccgggg	cggacgtagt	780
tggaaaccagc	cgtactacag	aggcattctg	ggtcccagag	agtatcgata	aggttgattt	840
ttaagtccca	ccg					853

<210> 111
 <211> 825
 <212> DNA
 <213> Rattus norvegicus

<400> 111						
ggnttncagg	ggnaccccc	cccncttnn	antttgtcca	cgnaaanattn	nngccnnnna	60
agganggggn	ngggaagttt	nagggcaang	aaaagggaaa	agtttngttt	ggacaaacct	120
tgaaaggggn	tttatcgcaa	nacnccgggg	gggggttttt	ttgaaagaga	aggggaaaag	180
attcggaanc	ctgatttttt	tggnttgagt	naagnggggg	angggngna	aaaattaaan	240
ggattccngn	ggggngact	agtanttag	gggggagaaa	agggttttat	aaggncccat	300
aaagtccagc	ggaaagccgg	ntccggggaa	gaccacccat	gngttttaat	tagagtgcaa	360
cgggttgaag	agcccaggaa	gcccganac	taggggtgagt	caccgngaaa	ntaacagacc	420
ataaaaggaa	ggatgcagaa	cagaccaggg	tacnantcac	aggccacttg	gcaggaagag	480
atagccccc	gccccnga	ncagagcccc	aacctgccaa	tgnngtagnt	ataccttatt	540
acttcatcat	gtgaatagcc	aatcatatgt	gaacatgtnt	atgtgcttcg	tttgaatcca	600
ccaatccng	taantatgat	ntgttctgna	cgcccgnttn	tgttccccaa	tcntataaaa	660
agcccatgc	tggagctgct	gggcgcgcaa	gtcntccgaa	gagactgtgt	gcccgcaggt	720
acctgtgttt	tccaataaac	cctcttgctg	attgcatccg	agtggactcg	gctcgggtcat	780
tgggcgcttg	ggactcctcc	tgagggaag	tcctctctgg	ggtct		825

<210> 112
 <211> 861
 <212> DNA
 <213> Rattus norvegicus

<400> 112						
anngaaacat	ncccnncnnn	ttnatccttt	nggaaaaggg	cancceaaag	gnnnggaacg	60
gatngaanaa	ttctttcaaa	aagaganatc	gganggnnat	cgnnnnnggt	ttcaagtccc	120
cccngagnan	naaaattgag	tcagtngggg	gnaaccgacg	nananaggaa	caggtttccc	180
gggagtcctt	gggtntcngt	tcgacccccg	gaaaccgaac	tnnecgnttt	ncctttggga	240
gnggggattt	ntaaaggna	ncggnggtat	ttccattcgg	ntagttgttn	gttcaagggg	300
gntgccggac	ggaccccctt	tnagccagac	ngngncccta	tcgnaaaan	tggtggggtc	360
caaccgcgta	agacagattt	ntcgccantg	ccagcagcca	ntggtaacag	gattagcaga	420
gagaggtatg	tagacngtgn	acagattaag	gaagtgggtg	cgtaagnacg	gacacattag	480
naggacagta	tgnggtatct	gcntcgggtt	gaagccagtt	accttnggat	aanganntgg	540
tagntttnga	tcccggcaga	caaaccaccg	ttggngagcg	tggntccttt	gnntgnaagc	600
agcagantan	gcgcagaaaa	aaaggatctc	gagaagatcc	tangatatnt	tggtcggggg	660
cagacgctna	annggtntgg	natnntganc	ggntgaccat	agagcacagt	antgnngatt	720
gcagtccgcc	ccnaggacga	naggagacca	ggggcccang	ctgnagtaac	naatcaacta	780
ccctnacnag	atgnancaga	gagagagagn	accgtatant	nantgnaaga	gaggtcccgg	840
tttcnagttc	ccagnacgga	a				861

<210> 113
 <211> 149
 <212> DNA
 <213> Rattus norvegicus

<400> 113						
attngaggag	atccggttac	taaggatata	gaagaaaaaa	ataaatcgtg	tgcttgcctt	60
ttttttttta	attgcctgct	tctccccacc	cccaaattaa	gttgcttagc	aagggggaaa	120
gaggcttttc	ctcccttcag	taggtcagc				149

<210> 114
 <211> 857
 <212> DNA

<213> Rattus norvegicus

<400> 114

gatctggtct	tgcccnggan	ganntcnntn	ccgggggggn	taaaaaagaa	ttgntggngn	60
tgacnagggg	ggnaccccn	taccnggggn	cnancggaan	tnttggnac	cgnaaaaaat	120
ttccaggngn	acangaacgg	gtgcggnggg	antaggggga	aangtttgga	gtgngccaaa	180
acggaaaagn	agacgnttgt	angggttggg	aaccagnacc	ntggaaagan	tgnagttctn	240
atcngcaaca	accaccggag	gtaggggggt	ttttgtngca	gcacagatan	gcgcagaaaa	300
aaggatttca	ggagatcctt	tgatttttat	tcgggtanga	cgttcangtn	gnnggggattg	360
ggagcggana	accatttnna	cacaggattn	tatgaactat	ggtcanttgc	tttgttgtcc	420
angtcgttgt	gggattgctg	tttttagtag	ctgcaaacgg	ttcgttttnt	gctatctttg	480
ttnggataaa	tcagccccgg	gcagangana	ttcgaaagtt	cccttttagga	gcttatttan	540
acgggctcaa	ngccaccggg	ttcgtttttn	taggcacgtt	ctgcgcattt	tttttttttn	600
gnatnttttg	atcgcgtttc	gtgggatctt	aaaaaccgtt	ttctgtgatt	ggcacgcaag	660
aaanactcat	gagctgggtc	ctgtttgtgc	tctcaggacc	aatcaaanac	ccattttccaa	720
cggctttata	atgtctgggt	ctgtttgcac	aggaagcgaa	gtcacgggctt	gcacccgtga	780
agtctgggga	ggttcagagc	tgggaactgc	ccagaggaag	gggttcgggg	ctacagccat	840
caatcttcca	gttgttt					857

<210> 115

<211> 1630

<212> DNA

<213> Rattus norvegicus

<400> 115

ccccccccc	ccccaaaaan	aanaattacc	nttttaccat	tgngggtccc	ngtccntgat	60
aaatttttaa	ccnncntttt	tccttaaaaa	ancgnatcct	gangggattt	ccgttnaatg	120
gnnttaannc	ttttngngaa	tgtnnaccce	aatnttcccc	tnaattttga	gtnggataat	180
tgcttanagg	catttggaag	tttaacggnc	acctgagggt	gattgggtgn	tattnaacgg	240
acttngatnn	gaggaaggcc	cccaanattt	tgttccattc	cttntaagtt	tgggacttgg	300
aatcccggt	gtttagatct	tgaccgtaat	caggagtcag	cgtagaggag	gccccggaag	360
gagggccag	cgcggattcg	cccgcggcag	ggcggggacc	aacagagggc	cntcggggat	420
aggggagcgc	cgcgccccn	tcccggggaa	ggacacattg	cttggttagca	ggaagccagc	480
cagaccgga	ggaggccgct	ccagcgttgg	tggtgccggt	ccggggctag	cctgatccgg	540
gcagggtgag	ttgagacgat	cgggtgagct	tgggccgggg	acgccagcgt	cttcagtcct	600
ggggattgtc	ccaggagggc	aaggagcttg	gaggagggag	gccgcacagc	taggggagtc	660
aggtctgagt	cccagagtgt	ctctaaagcc	ggggcggtga	gagtggcggc	ccgcccgggg	720
ccgcgcagcg	ngcagtcctc	cccgcgtggg	aagtggtaac	ttaacgcaca	gccacaggat	780
tcccggcctt	tagctgctgg	agggaggggt	gcttctcccc	gaggagtctg	ttgtgaaact	840
cgggttgagg	gcaccgtggg	tgccgggcaag	ggagagatgg	ggtcgccctg	aagaagtggg	900
gggctggagt	agaaagtgga	ctttgtgcaa	acctcaccce	agagtagtta	gttaccaagg	960
ctggtttttt	tttttttttt	tttttgcetca	gacacaagga	aaatttgact	caatgttaaa	1020
atatgtaat	tggcaggaaa	acttttttcc	tagcctcctt	gctaataatag	ttggaacagg	1080
gggctcccaa	gaggtataga	gtccccccatt	ttacaaaatg	tggttcagtg	ggactgtggc	1140
ccaccagtc	gtgtatccat	ggaagagtgg	cttttatgga	gaagttcatt	ttccttaacc	1200
ttaaaaactg	taaaggatct	tgtgcttgag	aatattgttg	gccagcttta	tagtcctcat	1260
ttataaaaact	atttagacta	gagtgttata	gattataggt	cttcaagttt	ccagtcacca	1320
gtccttggct	tttttagtatg	gaaatcacca	gtaatggcaa	tataacatcc	ctgcttctgt	1380
ttcttagaag	gctaaattac	agtgtgttca	aactccgtgt	cattgcaaca	ggttaaacta	1440
actttatacg	taggacatca	gggtattgac	attctcatcc	taaagtcagt	ttgtctgttt	1500
ccagaggagg	aactgaagca	gtggttcttt	aagtaactga	ctcagggctt	tcctgcctgg	1560
cgcgcctgcc	aggcatagtg	tagcattgta	ctgcactctc	tttgaccagt	ttccccaggt	1620
gaagagcctg						1630

<210> 116

<211> 883

<212> DNA

<213> Rattus norvegicus

<400> 116

aaaaattgta	aggagttggg	ggnatccccc	ataattnaaa	nagggaacaa	nccntaaagg	60
------------	------------	------------	------------	------------	------------	----

gaggggnnggg	aanggccaan	attggnttaa	aaanagtang	tttggttgat	ccanacacaa	120
ggaatttggtt	anaatttttnn	taatggaaat	ngggcacttc	aattgggang	ataaaacccc	180
aggaagtgat	accnggggtta	tcaagtnaaa	cntgattctt	ggngnngagg	gaaaggatat	240
tgaatttgag	tgagtgcagg	tgaagtgaga	cttggggagna	caggatcatgc	ccacccaagg	300
gaggagcaag	ggntggggcag	tgtagggtggt	gnngtggtcc	ttcctgggggt	gggcgggggag	360
acagatgaga	acgttatttg	aggacaggca	caagtgttac	tgaaatgcaa	atccctgtag	420
atntggaaaa	gttctggntt	caggcttgat	gcttggggccg	gcaactgtgn	actttccctg	480
tacgttcagc	ccccccaccc	ttacggaagt	tntcgtcact	gagantagt	gctaatacaga	540
gtcttcaatg	gacctgcca	tcagaaagga	aggcgggctt	ttccgggtgc	ntaggtgtag	600
gattcgctca	gtagttaagc	agtcttaact	ggttntggct	gctgtgctct	ctgtcctgcc	660
gttggaattnt	ntgaggcatg	ttcaggcaag	ctccaaagtt	gcgacatggt	gagcacaggg	720
gcaggggggg	cgggcggacg	ggcaggggac	tgagcagtgg	gagctgggtg	ggtgggtctt	780
tcccggggct	gagttggaat	ccgcggctac	ccgtgaggtc	ttagccactc	actagacca	840
gcggcagttt	ctgaataact	ttccttgtag	gggctgcaac	tct		883

<210> 117

<211> 913

<212> DNA

<213> Rattus norvegicus

<400> 117

ttccccccna	gaaaaatatt	tttngggacc	canaaaaaan	ggtcccnggn	cctgttttct	60
tccncccgna	aanaacttcc	ntttccntgg	ggggntttta	naaaagaana	tttcattggn	120
ggttttntcc	naggggggga	gaccccnttn	nccgcggggc	tttcgnaatt	ttttggtcca	180
ccngtnaaag	attttcccat	ggcgcaccat	gtacgggttg	cgaggngtat	taggcggnaa	240
cggttttttna	gtgggcctaa	tacggnanat	aggaggacga	tttgtnttgg	tttgtngagc	300
cagtaccttn	gnaaagagtt	gtagttttga	tccggcaacc	aaccaacngt	gtagcgnngt	360
tttttgttga	agcagcanta	acgcgcagaa	aaaaggatnt	caggagatcc	tttgattttt	420
cttcgggttc	ngacgttatg	tttgtgtggat	tgtgagcgga	taacaatttc	acacagattc	480
cgatngtagt	ccaatttggt	aaagacagga	tatntttccc	ttcaaagaaa	acagaaaaat	540
acagaaacgt	taattttcaa	atctcnaatc	tttctnttct	tcttcnntca	ttcattcntt	600
cnttctttct	tctttctttc	tntctttctn	nagaggaggc	atgctagggt	aacagtagct	660
catttttaaaa	tctggcacct	ggaattaatt	tagggacaaa	acacctttat	gcaaaaaaaa	720
gtttatgttt	ttccatggaa	cacagtaaaa	tcaaaattaa	aagaatataa	caaaggcttt	780
ggtgatttgg	taggattttt	tttttcctgg	aggggaaaac	agatgacttg	gaaagtgtta	840
ggaacatatc	aagccccagg	gaaagaaaaa	cgtttgattg	gtattaatta	aaacactgct	900
aatatattct	aat					913

<210> 118

<211> 320

<212> DNA

<213> Rattus norvegicus

<400> 118

tatgcaccca	tgacacaaga	tcacagaagt	acaggcctgg	accatggcag	agtatacact	60
ggttggggtaa	atgaagagga	gagacagagt	gggaagtcgg	cttagtggtat	atggacttca	120
aatttgatga	acaagcaatt	caaatagagta	tctgtgggctt	gactgggtatg	aagacccggt	180
tgcaaagcag	tgntcataag	agagaaaaga	gagagagaga	gagagagaga	gagagagaga	240
gagaaagaga	gagagtgtgt	gttggtgttg	ttgttggtgt	tgtttatattg	tttataacaa	300
gatntacntt	tggttaacttt					320

<210> 119

<211> 389

<212> DNA

<213> Rattus norvegicus

<400> 119

gggggggngc	naaaagggtc	tttctttttna	naaaaatcnn	ggangggaggc	cncnanacgg	60
ctnttanann	tnttcnggg	gtncctcncc	gntgtgggga	atganatntc	gntctcgaca	120
tcaggggatt	ggagattntc	tgngctcncc	nctcacnacc	cagaagaagc	gcacagagan	180
cagagtanca	catcatacac	acctnttcag	ctacagagcg	antnctctan	aaggggactc	240

ggggganaac	acaaccctcc	tcctcttctg	actgngagng	ccgentgtag	gntctgtcta	300
cccancaagn	cttgtgcagn	ntgngaacct	ctctntgggg	tagagtgtgt	tgngggagca	360
gggcgtantg	ttccaggnc	agnctttca				389

<210> 120
 <211> 882
 <212> DNA
 <213> Rattus norvegicus

<400> 120						
agnaacgcgg	ncggnggnnc	tcncccgccg	gagcnggncc	nccccnngn	ncccagaana	60
gnagcgctcg	gngannnccc	acngnagac	nnnggctgcc	ccncgngncc	anggcnttnn	120
nccnnccccc	cgnatccggn	ncnccccccc	ctccctnggg	gngcgggggg	cccngngccg	180
nggngatacc	nggcganncn	ttgtgcccc	gcnnnggggg	naggaccccc	ggcaccggcc	240
cngacccana	ncagnngctt	ngtggggggc	cccccgcca	nagaacgaat	tncgcnccg	300
gccgcggcca	tcggaacncn	cctagcagng	cgtcntgcta	ggcnggnna	cggnatccg	360
caancccncc	cttngtaccg	ggacagccgn	gggnccgtat	gggctgngcg	ntnggccgta	420
gccanntncc	tttngaaang	acncggnagc	tnttcacccg	cctcacaac	cncngggncn	480
gnggggggctn	tntcntgngc	cgcccgccgc	gtgngcgcan	aaaaaaaaa	aanncgcccn	540
tcnccccctc	ttttggccng	ggtnccccgc	ncaccccgctg	ccgagtnccn	nnccccccac	600
aacctcacac	cgatcccngt	gggttcccn	ngggagtcgc	ncngncnnag	cnggnattctc	660
cccatnnccg	gngcttnag	cgngccnnnn	cacngtttgt	nnngnntgc	ctccccctcn	720
tccttgaggg	aaaagcccg	acngtntctg	tggaccacnn	tgctgaggng	ctggggcccn	780
cgntctctct	ctctctcnct	ctctctctct	ctctatctct	ctttctctct	ctggggcccc	840
tcccttgntg	nngccanaag	nnngcnnacc	cgtaaagtaa	gt		882

<210> 121
 <211> 975
 <212> DNA
 <213> Rattus norvegicus

<400> 121						
aatttngnca	ataanggcc	ttcccttgag	tgngggganc	ncnctgttc	anaaggtagc	60
tttagcgngg	ttctcnagtt	natggtaacc	nagtacttaa	ttggcncnct	tgataaatgc	120
tngatcctna	naatttcaac	aaccgcagga	ccatttttga	acttggcggn	ngtttaccct	180
tnatgnnctt	tcnnaaaat	ggcttccttt	gncatcnaat	agtngtgccc	ctaaccctn	240
ggttccggag	gatgcattng	tggntgtgng	tttgnccctg	agcatgcngt	tcgtnacgg	300
gancaagntt	ntcaatgttc	cntcacncca	tacttnggct	tggggtacaa	nttgatatc	360
ttcgggatta	tatnagttta	tgtctgnttt	tcataaaatc	acttgtggat	ttggctttta	420
ngttaggaca	acttnccaca	gtttcttgga	tctcctca	catgttaacg	ccattttgtt	480
cttgatatact	aaagtgcacat	gtcnttntng	acactaaca	tcacaaatta	ggagtaccaa	540
tcaactttga	gaaaatttta	aagatgcccc	atctcttgta	tcagcaagta	ttcagccagg	600
atttaattct	ttatgtaaaa	attagcaagc	atctctatnt	cattcacgtg	caaattttct	660
ttgattgtta	attaagattg	aagtgcattg	tatggcccaa	ataagtctca	ctttaaaaaa	720
tatttcttta	tgaattatta	tccatgaatg	tttgatctgt	atagctatnt	tatataagta	780
tatgcaagga	ttgctaaaac	aatttttgag	tgaaaaaaga	tcctaggtag	aaaatgttta	840
agactaccta	taccgtcatt	aaaaactcct	caccagcatt	tactatgggt	ggactttcag	900
agatctcaat	caactctttc	ccaccagtc	tactgaaagn	ttccacctgt	agcggcccaa	960
gcaaactgag	atntt					975

<210> 122
 <211> 850
 <212> DNA
 <213> Rattus norvegicus

<400> 122						
ggggaaaccc	acggtnaagg	gnngganaac	naggtanctn	tttctccggg	ttccaanaat	60
ngaangcctt	ccngagggcc	ngaaaancat	tncttcngga	gccgttcaag	ccagnagggtg	120
ggtttcaaac	aatgcttaag	ttgtggggag	aacnagnacg	tcggttceng	accngttta	180
tcntaaagga	gacggnggtt	aaaggtagg	gggttngaca	gtcctgctgg	tggtcaagga	240
ggaggagaca	agttgncatc	caggngngca	ggaanacctg	ttaaattcct	gaccnaccgg	300

atgnttggag	agcnaaggcg	gattcttccg	gcagtggcca	gatttcaacc	caggteccgc	360
ccngcttttc	ttggtttaggc	aagcaggcct	tagtccgnga	ggacgcccct	tgggtggccag	420
ggtatcacgg	ccccctngg	gtttccattt	gcagtttgta	ttggaccatg	gatcactgct	480
tccttntgcc	ggaagttcca	gattccaaac	tgtgngantc	ccatntgcaa	ctcccatggt	540
tgccgntggg	actttttnta	atatcntggg	acccgcttcc	catttcccca	cccccntgnt	600
cccttcggga	ggaatcacccg	cccagtgtgt	cacttccctgt	aggnacttcc	aaggntagat	660
gagtgagtgg	caggcctcac	nttggcccag	ttantcagtg	cccacagagt	agcttttttg	720
agacgntagt	aaggtcttag	gggaaggaat	gtagtcgatc	cttctccttg	gtggccctca	780
gcactgtgag	tagaccccac	acatcagggc	tgtgtcgtaa	ggatctctgg	gagggttgaa	840
agtttcgagg						850

<210> 123

<211> 889

<212> DNA

<213> Rattus norvegicus

<400> 123

ggggtttcca	aaaatttggg	gntttggana	aaccttcggg	gaataaaaaca	acngnnnaaa	60
attaaggggg	gccgggggaa	aaaggagatt	nattaaancn	ccaccggaat	tnaaacnccc	120
nccgggaccg	naaccgtttt	tggccnaaan	ncgagaagtg	ccttccnggc	aaagtagggg	180
accaaaggtn	gggggagaga	attgggggtt	gtncagngtt	ccggttcnac	ggaaggagcc	240
ggttggtggg	attgtttcca	aggagnngt	ttgngaccgg	agcacctcng	ggnggaccat	300
ggggnttgcc	tgttagagac	cngcngatg	ttttgggttc	gnattcgggg	agggatttcg	360
ggggcctcag	acnggggagg	agtccecntgc	gttcccnatg	ggaccgggtg	tcgggcgggt	420
gcagtttcgc	tgctgtcctt	tggcaatgng	cntgggnatt	ngtgggcaga	ngagattccc	480
cngccccgc	natttcccn	gttccagttc	ntaggnacca	gaggttttcc	gcagtgtgat	540
tcagggagnt	agantntagc	gtctgtnttn	tntgcgtttt	ccccctcatg	attctcagtt	600
atthtttagg	agaaaagggtg	cgtggaaaca	gagcgtccct	gttccgtgct	gtttctcnta	660
gccccaaaata	cagatttaat	tctgaagrea	tcgaccccca	tatccacttc	ccgccctctc	720
ataaacgtgt	aatatggctt	gctttttcct	tgtaacgttt	catccaacca	tagtggttagc	780
ggccacctgg	catcttgagg	tgggttgcca	atgagtgaat	gaatgagtga	gtgaatgaat	840
gaatgaatga	atgaatgaag	caagcttcag	ggagattttc	agagaagtg		889

<210> 124

<211> 929

<212> DNA

<213> Rattus norvegicus

<400> 124

aatgcccntn	aggggnnttt	ccccgnattt	naaaatgggn	tncnngnttc	caaagtttcc	60
taaaaatttn	cantttccgt	ttttaccngg	tttatggttt	ncagcctact	cctgttcgan	120
ttccaaatcg	gtttaantgg	ncccnccgaa	ncntntnttn	tttggcagaa	ggtgaanttc	180
nttggggccc	ttgtttaagg	gttttnagcc	ttaaattgnt	tgntnagnnt	ctccntaatt	240
agttcattcc	tttgaccatc	ttttgnccct	ccatcttgta	aacanttaag	tctattgcat	300
tccactttnc	tntcagttnc	cgtttnaccc	tcctnagcag	aacccgnttc	tcagctntgg	360
atggttccaa	anggtttccc	aacctatgct	caataccaca	ggcagcttgc	aggagggaga	420
antggatagt	atttaacagc	atthttgacc	aaacttttag	gagcagagag	gactttacc	480
aggacaggaa	ggcaaaaagac	ttgaatctta	aacaaaggat	taagaacagg	atgtcatctg	540
tgagcctgtc	acagtgggtt	tgcagagcag	gagaacacag	acaggattag	ctataaagtt	600
gttacattag	ttattntatt	ggagcatata	atacttaaat	agttctaggg	caagagaaat	660
gaacagaaat	gacctataa	gagccagagc	tgtagccaca	gctttctttg	tgcttagttt	720
gctagttcac	tctttccagg	gcagtctggg	ggattacacc	aaattgctta	gaaaatgcta	780
gctctactgt	ccctgtctat	tgtcagcttt	gcaatgtgca	tagtgacagg	agttgcctgg	840
gaagcttggg	gcttatgttt	tgcagatcca	ttgtaattaa	aaaagaattg	taaggagatg	900
gaggcacggg	gtgaggggtga	gggtgagtg				929

<210> 125

<211> 943

<212> DNA

<213> Rattus norvegicus

<400> 125

ttggaaaccc	caacctggaa	aangngtntt	nccgggaaat	tcaacctgcg	ggcnaatggt	60
gtaaaagggc	ctaccttggc	ttngaaggga	atntcctgaa	ggnnnaatcc	caannttgtg	120
natcccaatt	aaggntnaac	nggtttaatt	tgtnttcnc	ntaccnaccn	ggtttnccgt	180
tatactaaag	ggctaacaat	taaatgctca	naagggaccc	ccaatcctng	gcnagaactt	240
gggttaaggn	ttccattagg	atttgccatc	ctntaccgtg	atcctgaaca	tntnttgaac	300
tgntttgcca	aggaacngaa	ggttttncct	naagntagca	cacagcagng	accaaggatt	360
ggaaccacgc	nagtgccttg	aggtaaaaga	tcacttcctt	ntcccttagt	caggancntt	420
agggagtggg	ggcatcaccc	acacattccc	cagtttgnac	gtaggtttca	gccagcaanc	480
cgtccactaa	agctgcctcc	aattcaaact	ggattgagtg	acaagtggct	tgggtgtctc	540
tcaaagattt	ataggtggca	atggccactc	ctctgtgtaa	ttaccctnta	tgcacgtctt	600
tttntttctc	cccactccat	ccccacccc	tctttgtttc	ttnttcctnt	cctntccctc	660
ctgttgactt	tttctctccc	tgcaaacagt	tccaggcacc	gnntagcatn	tgccactctg	720
gctntagaaa	gctttgcttc	ccctctgctc	cctggctggc	tggaaactcag	cctccggtgt	780
gggcagactg	gctcatcctc	tgtgtttctc	tgagtgtgga	ctgctgcctt	ccacacagac	840
tctctgaagt	caaggagccg	caccagcact	tcagttgtgg	gccataatca	agnccangact	900
gaaagttgcc	acctgtagn	gccgcaagca	aactgagatn	ttg		943

<210> 126

<211> 867

<212> DNA

<213> Rattus norvegicus

<400> 126

aggaaacnt	tttaaaaaaa	aggggggggg	gggggggggn	ntagnngcaa	aaaagatgan	60
accctcaagn	cggggggggg	taaaanaagg	atcggattcg	ggctttgnac	aaataaagga	120
gttttgnng	nattttcccc	ntggtcgttt	tntgnacgat	ccacggttga	ccgacgacgn	180
acggaccgac	aaccaanacg	taaaggggaa	ttgtggaggg	gttggaagtt	tagatgcccc	240
gaccacagg	gtgcggccan	cttcgggaga	cccacctttc	ttgtnggccc	ggncggggcg	300
cagcgnagcc	atttccaccc	gatccctata	gcnngccagc	ctagcaggcn	gaacaccagc	360
gggaagttga	ntnggacctc	ggagagcgcd	cgccttcccg	gcggaagtnc	taattccaaa	420
gcggcccgcg	gcngagtttc	ccatacaggt	tggttccgtc	tcggagtgcg	gtggcttgaa	480
ggacgggtct	cgcgcgagaa	gagtaccctg	cctttcaggt	gcgggagtta	cntcagcctg	540
ctgcacaccc	ggctgtgcgc	antcttctgg	tgtggccggg	acggttcacc	cagaggagtc	600
tctgtagtct	ggagcaagat	gtcgggttaa	tctggcagga	aaatgccttc	tatgctcatn	660
tatatattcc	tgcttccctc	agcttgcttt	cgacttagta	aggtaacatt	tcagagcggt	720
gcacttagta	ctttttggca	ctgtgctgta	taaatataaa	tgttccacac	ttaacatctt	780
agatgttata	tctaaagata	tgcactctta	aacttcgaaa	gcgcataccc	taaaatttca	840
tatttttgca	tacattggtc	agctgtg				867

<210> 127

<211> 303

<212> DNA

<213> Rattus norvegicus

<400> 127

ggaaatgatt	agtccaagaa	atatttgagc	agaagggagt	taggggttttc	aaattaggaa	60
agtggaatcc	acagagttcc	cttgacagag	aatataaaaa	ggactctggg	gtgtcagaat	120
ggtgggcatt	aacctgatct	tccacttgag	ggtaagggaa	atgattagtc	caagaaatat	180
ttgagcagaa	gggagttagg	gttttcaaat	taggaaagtg	gaatccacag	agttcccttg	240
acagagaata	taaaaaggac	tctgggggtg	cagaatgggt	ggcataaacc	tgatcttcca	300
ctt						303

<210> 128

<211> 840

<212> DNA

<213> Rattus norvegicus

<400> 128

aaaccggng	aanaaaaaan	gaaanngang	gcnnnaaaaa	agttnnngaca	gaaaaaactt	60
tnngaaaaaa	gganggggan	aaggcaggng	nccnactnaa	aanggncttt	tcnaagnng	120

anagagntgg	naatnagna	naggacattc	ttnnaacctc	cnangngngn	nggaannaat	180
ngggattgag	cngccaccat	tagggangaa	gttngaattn	nggggcccgn	gngagttaaa	240
angattcccn	ggttttttaa	aacagagaa	acctncaggn	acagatnaac	ccgagattgg	300
ttccctngaa	aattnnngan	aaagataaan	gtaggagcat	tcaaagtagn	anggtaaaa	360
taatgggaga	catagacacc	aaaaaaagcc	agttcagtgg	gccccgaagg	ngcattaagg	420
gaggaccagg	aaacggcagc	anagccacng	gcagccgcct	gccccnacac	cagtnattcc	480
cgcacntaga	tccaggcgnt	gggggcccgg	cggggcccgc	ntgngcagng	aagntnngcg	540
gcaacaantt	tgcntagacc	ggntggaacc	ggttagaacc	ggccgcgccg	gaccggccgc	600
ccgttccgga	ttntgcgttc	acaaagggag	gcgggactca	cgacntgngt	atcnttgnng	660
tcccaacccc	ggcccccna	cccnaccccc	nttgtccctg	tggcattcgc	gttctttccg	720
ccgtctccct	cgcgggcccgn	ttntctgcgc	ctgggtgatcc	tttcgccatg	gtcctntgga	780
gaaagaaaaa	atctttaatt	tnctagggac	gtccttttcc	tgtagtcgta	attgtagaaa	840

<210> 129

<211> 893

<212> DNA

<213> Rattus norvegicus

<400> 129

gagaaggann	aggnggggng	agngaagana	gaggagggaa	gaaangaagg	tggaganaag	60
tggannaaaa	agagggagan	ggagggagaa	ntaaaganag	ganaagagng	gggaggaggg	120
gnagnatagg	agaggaaaga	aagganggan	agaagagaaa	agaanganga	gagaaaggaa	180
agaggaaaga	aagaggggag	aagaggaaga	aanagaggag	gggangagag	ggaggataag	240
agaggaaaga	gggaganagg	nttgaaaagg	gaaagagaag	gagaaaggna	gnaggngngg	300
aagagaggna	agggagaggg	gganaanggt	aagggggnaa	agaangagaa	gtatnggggg	360
aaaggaggag	angaaagaag	aaagaganga	ggaggagagg	gagagtgagg	aataaagggg	420
agggaaaagg	angagaaaga	gagagaggga	gagggaaaga	nagagaagga	tagnggggtg	480
gagaaggaga	aaggagagaa	ggagaaggng	agaggagaa	tgaagaagga	gggagtaaga	540
aaggantgag	naggaaagga	ganagagagg	tagagagaaa	anaaagaggg	aaanggaggg	600
gaggagggng	nanaaggaat	agagggngga	aanangagag	aggggaaang	gggaaggaaa	660
ggaggaaaaa	aagnagagaa	gaagagnaat	gggaaggang	nagtagnaaa	agaaaagnag	720
aggggagagg	gggangangg	ggganacggg	ggggaanaga	aaaagtgaag	gaggccccc	780
nacccccccc	ccccacacac	acacacagcc	ttttcgccgg	cgggaagtga	ggttggtcca	840
ggagcctgtg	gtcaatccag	tcagtagtgg	gagaggtgta	acatctgtgt	ccg	893

<210> 130

<211> 789

<212> DNA

<213> Rattus norvegicus

<400> 130

taaaananng	gnngannanc	tnnaaaaaan	tntcttngga	attnnacagga	nggaggntaa	60
tngggcgggc	ancatcaatg	gtanaaatth	gggggggngg	annaaaatca	tnaanncaac	120
cgtttccana	gncaaccatt	ctggngngnc	caaggttnga	ngagntccgn	tcaaggngaa	180
accttttcaa	gaccaattaa	ctaggggatn	agagggcggn	tggttnttga	ggggcgggct	240
gctgagaaga	ttcgttgggg	gacccaggag	tgaaggtttt	tnacctgtgt	ntntcgggaa	300
ggtcggatnt	attatantcc	tgctgttgga	ggagttcggt	ggttcaaggg	ccggacccgg	360
agcgtttact	ttttnttgnc	cgcagccaat	ttgttntgct	tggtttcttc	ngaateccgg	420
ggcggggagg	gggaagcggg	gggcccacac	accacgatcc	cggcagccac	cgcgaaattg	480
ttccggcagn	tacgantctt	caacaagagc	cagagaaggc	gggtgcagag	nttcattagg	540
acgntcgga	acccggcggt	acttactttt	tccaagccca	ttgggtgatg	agaatgatga	600
ctgacaggga	ggcgtgggtc	cgctgtcgcg	ggcgggagcg	acgggtggag	ttaacgacga	660
aagctgcgcg	cgcagccatg	acccctcaca	gccacntatc	ggagggaggg	gcgggacagc	720
tttagcttgg	tgctgtcgca	gccggacgtg	aggcagttgg	tggctttcca	tcgtcgatth	780
ctggttacc						789

<210> 131

<211> 872

<212> DNA

<213> Rattus norvegicus

<400> 131

gggggnggct	tttttnggag	gcatanatng	gggnnngtcc	ggnaaacccc	attggtcggc	60
cggggaagga	aaanggggct	ctnaaaatan	gttantggga	tggngcctta	agggggggcc	120
catgngccag	gaangcagat	tcaaaaatgt	tccaagtggg	aaaccanggt	tggnanaggc	180
cctccnggnc	gtnaaggagg	agaggagaga	tggagtttca	ggtgtgtttc	ccacccagtg	240
ttcccaggga	acacaaaacg	gataggtcac	cntcaatgna	caaggaatta	aaagcttggg	300
tgtatnggga	ggcctgcttc	caaagccacc	agaaaatccg	gagagccggn	ggatcntacn	360
cacccagagg	ttcatagggg	gggcantatt	aggggtgtgc	ccttgtgaga	ggaagtgtgg	420
cacngtgggg	ctgggtttga	gatntcagat	gntcaagcca	ggcccatntt	ntctctctca	480
gtntctctcg	gtctctttct	cngtctctnt	tcagtctntt	cagtctctct	cagactctct	540
ctctctctct	ctctctctnt	ctctctctct	ctctctctct	ctctccnngc	tgcnttcaga	600
tatagacgta	gaantctcnt	ntatccagca	ccatgtctgc	ntgcatgctg	ccattnttcc	660
caccangacg	ataataggct	aaacttntga	actctaagcc	agcctcaatt	aaattnttan	720
gagtcaaacc	agcctcaatt	aatgttttcc	atttctatga	gtcacagtgg	tcattggcatt	780
tctttacagc	aatagaaacc	ctaactaaga	cttgccgaaa	cctcaaccac	aacttcagcc	840
ctcagaagcc	caagagggaa	aagaccttga	at			872

<210> 132

<211> 785

<212> DNA

<213> Rattus norvegicus

<400> 132

tcgtaanttt	tnatccaccn	gtanangatn	ttccatgcca	ccatgtacgg	ttacgaggng	60
tatagcgtgn	acngtttttg	agtnggctaa	aaggaaatgg	agacntattg	tnttggtttt	120
gtgacccata	acttcggaaa	ggttgtgttt	tatccggcaa	caaccacngt	gtagcgggtg	180
tttttgtttg	cagcagcaga	taacgcgcag	aaaaaggatn	tcaggagatc	ctttgatattt	240
ttnttcgggt	tctgacgntc	atgttgtgtg	gaattgtgag	cggataacaa	tttcacacag	300
aattcaaagg	agaggagcca	atatagaggg	ggaaaaaaa	agaaggggaa	agcattagtt	360
taaaaagttg	agagaacaaa	gtatgttttg	cttggatggg	caaccaaaga	agcntgccag	420
gaatggctcg	taaaagggtg	aagagtcatt	aaacgtcttc	tgtccaaccg	ttaccggaaa	480
catgcaagga	atttcttaga	ctggccagga	ttggattgtg	ggaaaggtct	cttcaagcnt	540
ccccttggct	tttatggcaa	gaaaatagtg	cggactatag	agagcgtcgt	tctcaaagct	600
tgtccccaat	agcagaaaag	cattgtccta	aattccttaa	aaggcaccgt	gaaataaata	660
ttacgaggac	acgatggcac	aagaaggagc	tttcaactct	gccaccagaa	cagttatact	720
tcataagtaac	catgttgccc	tgttcaatga	caaggcacgc	tctccagcag	aaagggaaaa	780
ggagc						785

<210> 133

<211> 889

<212> DNA

<213> Rattus norvegicus

<400> 133

nttnnaaagc	ganccggccn	ggngggtttg	gncggcgctt	tatacnaagn	cgngccaatn	60
ggcttttgggn	gggntttcat	anggnntgn	tttaccceat	tcagtttttt	attggtnttt	120
natgggcgca	gggatagngn	gttcnggntt	cccacangaa	tttgatttnt	ggaatcacaa	180
gtnaccagtn	gccgnaatca	cgagtttgcc	gctttntttc	ctaccttana	ttcataatan	240
gaatgagtan	ttttttttta	ttgagnaang	tttnnacagg	tttagtaaag	atgaggacag	300
aggtttttaag	ttgangatta	ggaaggagag	ttccggggga	cagaatgtgt	gtattntcag	360
tcagtgcact	acccggaaga	gttgacgtca	ggttgaggaa	gggagcggat	ttcctggagg	420
ttttaaccaa	cagagagaaa	aagcatttac	tactgattaa	gcacacaatc	tctggattca	480
gagaagggtg	tttaccttta	tataaaatgt	ctcctaactg	cgtgactgtg	tgactttgtt	540
gaagtcaact	gagcactgac	tgtgttgtgt	gcaacatggg	aagaggacca	actttnttct	600
taaattttat	ttattattta	tgtcacgtgn	acacttggtg	cttttgtttt	tgttctaatt	660
ttatctgcat	atatgtctgc	ataccacgtg	catttctgat	gcntacagat	gccagaaaag	720
gacaccgagt	ttcccctggg	antggagtta	tagatgggtta	taagtctctg	agtaggtact	780
gggaagtga	cttcagtttc	ctctggaagg	gcagaaagcg	cttttcaaat	gctgggcat	840
gtattttcagc	ccctacttaa	tttataaatt	tatttttagag	gatgtgctc		889

<210> 134

<211> 947
 <212> DNA
 <213> Rattus norvegicus

<400> 134

anaaaaaatng	agaagangag	accccagaga	agaagnanga	gaganaacag	agaagaagag	60
agnaagggng	anaaantaga	gaaaggaaaa	gntcttaaag	aggcnanaaa	ntancnatnn	120
aaggagaaga	nggaaggnta	acataggagn	caagaatana	aaganaaaaa	gaggtagaga	180
anncagagaa	cgagaaaaga	tgaaanaaaag	antanaangg	aagaaagang	nccagnanaa	240
anaaggcaga	aanaagatgn	cgtaaaaanaa	gagagaagat	aggnaaaata	gaggagaagg	300
ccnaacagga	ngggaagagc	agcgaattnn	agataaaaacc	ggagganagn	nagagaagggn	360
agagntngnn	aaggcaaaga	cagnanngag	nacggtacnt	gccccagag	gnngaagaan	420
gncnagangg	tgagggngng	cacngncnt	tccccttagg	aggncgccc	cccagagatc	480
aggtttcnag	gncaccgagt	tggatacnag	attatncacc	naggcaggaa	angantatng	540
caaaangatt	cggggngggg	tcacggggtg	agaaataaan	tcannaaana	gaggacgngg	600
aggagggngg	gaaactctng	acagaaatng	caagcangaa	gccagccnca	cccaagcccc	660
nacngaagca	gcngagangt	tgcanggcgg	naggtccaaa	tcancgnagt	catggagnga	720
gcttcgggng	ggcccnaganc	cantgaggaa	gggcaggaaa	ccatatcnag	ccgagccnng	780
ngangngtgc	cctganacac	cgggagaggt	aattttttatt	tnacgggaag	cgtccagnca	840
agttcgtggg	ccggaagaga	cgggtacttta	gtatacancg	ctnntgctnc	gagttgtngg	900
nccttntnat	gnnagatctc	acaaangaag	ctnanaagta	gatatgt		947

<210> 135
 <211> 860
 <212> DNA
 <213> Rattus norvegicus

<400> 135

aagggaatnt	ttaccccggg	tnccttttgn	cnggggggna	aaaaaannaa	aaaataatnt	60
tttaaaatta	aagggngngg	angtttttcc	ggttctattn	ngccnattcg	gggttacact	120
tttatccanc	ntttgntttt	ttanccggcc	gggttaaaaa	tgggggggga	ttagttcggg	180
tagnggttnc	cnacagcaca	gccctgtttn	tcttcggttc	ngaaaaaaa	aaattttgct	240
ggtntcacaa	ttttnttaaa	caggatttnc	ttcaaccatg	gattaataca	tttccggtgc	300
agnttgcccc	gtttgttttt	tggntggata	gggatgccag	caggattcag	ggatgcccat	360
tgtgnttagt	ntctggccct	ttaggagagc	tttgggctaa	ttatgtgacc	gattttaaga	420
agtgggtgtg	ttgtgggttc	agggactcac	ggatcagcct	ttattttata	aggacactgt	480
ggaggagaga	cagaggctga	gctgcattct	gatgtcattt	gtgctgctgt	ggaagttaaa	540
gaaaagctgc	agaagtcagc	aaaacagatg	aataccaaga	agggcagtg	gagtacagga	600
atggagagaa	aagtcagagt	ccagcttttg	ttaactccct	aggatcagac	anttctgcgt	660
aaggacgggt	ctacagttta	acagaccaca	gagcaangtc	aaacagcaaa	gtgggtttcat	720
ggcaggcagg	aaatggaaca	tttaactgga	aacactgaac	ccacccatgg	caaacttagc	780
aatgaagctg	ggtgtggtgg	cacatgcctt	taattccaac	actcagggga	cagatntaat	840
gagtttgagg	ctagactggt					860

<210> 136
 <211> 191
 <212> DNA
 <213> Rattus norvegicus

<400> 136

aggtctgacc	acttggaagc	ttgccctgan	tcatagatga	gccactgtct	tcttcccctc	60
aattcctcag	gatggggaac	agccattggg	cttttagtag	aggagggaca	ggcccttttg	120
cagcaacagt	tctcctctga	atgttggatc	tccacctata	cacatggggg	acttagcctt	180
atggatgccc	c					191

<210> 137
 <211> 988
 <212> DNA
 <213> Rattus norvegicus

<400> 137

ttnttggnna	cgggtntccg	nantatgaan	ccnttcccgg	ggttttttaa	aancccnnga	60
tattcgggga	tttgggtttt	nnacggcctt	tttttnagag	gccaaatncc	cntntnaang	120
ccttttatcc	ttcentttnt	gccccncttc	naattaggaa	gcntggtttg	nccgantntt	180
aaggttttta	gtcntccttc	gttnntnttt	cccttntttt	ttccctnaag	ttataaagcn	240
ggatatntgg	ttgccaggnt	tctnttgtac	ccgtcatngc	gggttncggn	ttaccaggn	300
tttgttcctn	ggccggtncc	ttccaatttt	ggantntccn	ggtcngnggt	ccnattncct	360
tgnaacngtt	ccacacntna	tgacaattaa	ttgtttcctg	tgtaatttgt	ccccggactt	420
ntggattcct	gngancaggg	cctntgtttc	atggaagcaa	actcccttaa	ntatttacca	480
ggttgattga	ttaagaaagt	antcatgntt	gggaaacca	cntgtttntt	tcccaggatg	540
gaancccagg	attttggaac	tgcagaggct	tcagggtctg	ggaagcggag	gcaggcaaag	600
aatggagtgc	actgtccttt	tgcaatatgg	ggtttgcttg	cctgtctggc	cctctcntgc	660
tntctcagat	ggtgactgag	gctacttcag	caggactagg	aataatcatg	tccagggtggc	720
tgcccttccg	agcagaaagg	gacagacgtg	gggcatgaa	gttgctatcg	tttttttttt	780
tttctgcaca	gactgcaaag	tgtgcagagg	gagggaggct	gtgcaaaaaa	aaaaaaaaaa	840
aaaaaaaaaa	aaaaaaccga	ggaogcagaa	gtagactgc	tgaccatttt	ggtgcatgtg	900
tgcccatgga	gggaggggac	cttctcaaaa	gggttcacgc	agcangcatt	gaaagtnccc	960
cacntgtagg	gncgcaagca	actgagat				988

<210> 138

<211> 665

<212> DNA

<213> Rattus norvegicus

<400> 138

gaaaaagatt	caggaanctt	atttttntcg	gttcgacttc	agtnngggaa	tgggcggana	60
catttcacac	ggatttgtaa	anacngtnac	ngaaacttgg	nggttcgtag	atccactttt	120
tttagacctg	agagtagttt	ttaaaatatt	tnaattaaag	gtttcctgca	cccacttttt	180
tttttatccc	taacttttca	tccagtatgg	tttttcaata	tcacanttta	atctaggact	240
ccttgcttaa	agcaattaca	agttaaatta	aaagtaagag	atggcctnata	gctctcatta	300
ctgggatgca	ggtgtgaaac	aagtgatttg	tgtagaagct	ggcaggatgg	gtataaacia	360
gaacacgtgc	ccagaggatg	tattgaaagt	tggatttaag	tctctgagta	gtttatgcta	420
ggcggtagca	ttgaacaaga	tgaantctct	gntcatagag	gtagaaactn	cccagattct	480
gaggaagtgt	gagggagagc	attagatgtt	actgttgggg	atttggaag	gccaggaaac	540
gttactccat	gccaaggag	ggtaggagaa	aggtttgggc	ttagctttga	ggacggaggg	600
aactggtggg	tggatatgag	gatggttatg	ctaaaagcag	agtggttttc	aactattgtt	660
cttct						665

<210> 139

<211> 857

<212> DNA

<213> Rattus norvegicus

<400> 139

aaaaaaagaa	aggaaagggg	agananaaaa	annangngan	aaaanagana	ganagaggna	60
agaggaagng	aggngaaaa	gagaggagan	aaanaagagg	aaggagaann	gaggaaaang	120
aaaggaacaa	aaganaagng	anggaagana	aaggagagaa	aaanaagagg	gagaaangga	180
ggagggaaan	agagaanaga	gggggagaga	anncagagaa	nagaannag	aaaaggngga	240
gacnaanana	gagggaagaa	aagngaggag	aagagagggg	agaanaaant	tgaagaagaa	300
gaagangaga	agangagnag	aggaaganga	ggggaagaag	aagaggngga	ggagaagaag	360
aggagaggag	gaggaaggag	aaggaggagg	aagagaagga	ggaggaagag	gagaggagaa	420
ggaggaggat	actanggagg	ttgtttcaat	aaaagagngg	gatntaagat	taananaagn	480
aataatgccg	gtttntatct	gttcgggggg	ggtccttggt	ctccaaacac	aganntgggc	540
cagtttntca	aaattnaant	gngaagattt	cttggnntnga	gagcagntca	gattnantng	600
nattnttttc	tagtttttnaa	cacaancttt	gtgntaacia	agagnganga	ttcnaggana	660
actcgnnttt	ntttgggagg	agactttgtt	cctttcnatg	aagatgcagg	acngngaaga	720
cgcagggtgt	gaacaggaca	cagnnacgct	tnngtntntg	tcngcntcag	cngcgtggga	780
atgagtcaga	gcagcacggg	gaggtgcctg	gatntaagct	ttctggtagg	gagaacagag	840
tgcaggcngc	ggcccag					857

<210> 140

<211> 902

<212> DNA

<213> Rattus norvegicus

<400> 140

aaaggggng	ggaagaanga	aaagggnaaa	cnttngtttg	gaagccnca	nnaaagna	60
gncgaattta	anaaggggt	agggaaaaa	aaaacanaa	attccntcct	tagccatnaa	120
ccgaacttcc	ngcaaggaaa	aaaaatttg	ngggngtaaa	gggcaccncn	tcccacaaaa	180
ttttgntaan	tttgggcgca	aattcangca	ggntttngtt	ggaaaggngn	ananaccaa	240
gggatttngg	ggatttnaaa	atcngngttt	nnggcaggnn	atccngaagt	tngaatecga	300
cgncnaccct	ttatttnagc	agttatttan	gggaacatgg	gagggnacca	tttcaaacca	360
nggatcgggc	cnggagtntg	agtgttcagc	ccacngcctt	cnaacantac	cgggataagt	420
ttttccctgn	gccagagacc	catccangtt	ccagcaaaag	gntgggtcatc	tngggcnagc	480
tccnngagtc	atcnnggggt	tctcccagcc	nggggccaat	ggtcgaaggc	aggttntttt	540
tgtctccagc	ttgttccna	ccnggggagc	ctgtcaaggc	tgcacagnac	cagantagtg	600
gtcatntcng	gctagctccn	ttagctccnt	gtccagggga	cttcctggca	ctggattagt	660
ggnggactca	ggcttgcttt	tttttcagga	gaggttagat	tactaatcat	tcagatgttc	720
ataagtcaga	acactgagca	aagcaatagn	ttctcctcca	cntactgant	cacacgtgca	780
caacagccac	acccgcaatg	cttntaggag	caggtccagn	gnacttttgt	tttaactatt	840
tntggctctt	tattaatcag	cacataaata	cgcttcgttt	ctcctttttc	aatatgnatg	900
tg						902

<210> 141

<211> 852

<212> DNA

<213> Rattus norvegicus

<400> 141

acagaggggg	gggggngtg	gaattttngg	naggangttt	tnggaaggcc	nctaaaaaag	60
aaatgttccc	agaccaaag	gggggggna	gttnaattca	nggatcctna	ngaggnggaa	120
attttttnnn	tattnaggat	caggataaat	angaaaangg	gnanattttt	nnnangnggg	180
tttttttttt	tttttttttt	tttttnngng	gnnnnannan	annnnnaaat	ggcgncgggc	240
atggntaatg	gggaanttgg	gganaattac	agagatttnt	ttttcccatg	ggnttccagg	300
atgaattcag	ntaccaacca	ggttggtacc	agcattttta	cattcgagtt	agacatcaat	360
ggtaggtcag	ggagtgagag	gttcggggcc	ngacatatat	tcntgggtgaa	cccagtgcac	420
cttntggttt	ntacaaggag	cttgaggtag	tcgcccacca	gtagctgtca	ggcagggtggc	480
ttaagttcag	aaccgnttcg	tgggaaccga	gaagcagaaa	aagacataag	ttntgcngct	540
tcanaatcca	ctcntgaata	cananatctc	ggccaaagaa	gcacagccag	tctttccggt	600
nacangaggc	cgggagcaac	aantccacag	ccagcccaag	ganatacaaa	ggacttgggt	660
cagttctgna	ccagttggag	tcagagatgg	ggcctcaaaa	gtcccagcag	tgaagggcac	720
ggtctccagc	nnacagtggg	acctttaaga	ggtgggggact	tgtaggagga	gtagagataat	780
tgggggtgtg	ctttgtcccc	nacntcggtc	tttccctctt	tatggccttg	atgtggacaa	840
gattgtttct	gc					852

<210> 142

<211> 884

<212> DNA

<213> Rattus norvegicus

<400> 142

aaaaaaaatt	ntttttccna	ggnaaataac	ccngccttaa	ccgggcgggg	gagatcaatt	60
ntttgtngtt	gtttccctcng	aggcggagng	tcaaaanaga	acacnctgg	naaaccccc	120
ttaaaanaca	aaaatttgan	ggggnngng	ngttacaaaa	agacaggatg	ttttccgagt	180
cggattcaat	cccaccacaa	catgggggtc	acaccatngt	aaggaatcgn	tgcctttttg	240
gggggtatcct	aggggggtana	nttccaaata	nngataanaa	tttttttaaa	aattttaattg	300
tanatatatta	ttanataatt	taataaataa	tatttggana	nantnatgtt	ctngcgcctt	360
gnggactggg	agttttttnt	ccnnatttna	actttcccag	nactnggtag	cctatgtgnt	420
tatgcaaccc	nttagaagct	gccttcanta	ttnaactcat	actgtttctc	gataatcngg	480
ggagtagctc	cagttngcta	tgaagctgcg	gaaaggtagg	cggacatccc	aggcttagac	540
agagttcagg	ttatttggaa	cttttnnaaca	gaagtgtgtt	cntgcacggc	agcaagacna	600
tntgggtccc	gtagttccgg	tcgccaggag	tagtgtattg	cttaggacca	ttctgggtgg	660
aatgcatctg	gtgggtctta	aannatgtca	ggcagggcct	ggcaccaggg	tctggcgagg	720

agcctcacat	accgttntaa	tgacttcac	tgcttagaat	ttgtggggaa	acgatgcaga	780
aaaatctaac	cagggatggt	tctgggccag	tcattgttggg	gatgcctcag	tcattgtaaaa	840
ttgagctccc	cctggagcac	accttaaaac	atcttctgtt	taat		884

<210> 143
 <211> 955
 <212> DNA
 <213> Rattus norvegicus

<400> 143	
cccntggaaa accnaana atangnnan anaaanactc cncceattga gggaaacnttt	60
tagggnttcc nnnntttccc gganccgcca aatgngacac caaaanngac cgnantcttt	120
ggnggttgc tctcttggan cgcnttttgt tgcaccgggg tgactaaggc catgtngggg	180
acgantaaat gtttccgggg gcngntcggc acctccnan gngngngngg tttggttctg	240
gaagncggaa nnggcattgt ttaagatttg ccatccatt tagggttcgt tcaacgcctt	300
atctttnag tttntggagt ttgggtgggg aggggagatt tagtggagga gtaaatTTTT	360
agtagggaga gaggaagg agatagacc ggagacagag aaggaggga ggaaggagg	420
gattatcctg taggatgtga gccagacnt gtctgtggtt tcttccatg acacaagaga	480
cttnttgcct gtccctagaa tgcttcattt tntagtgtct caaacttaaa gggctagtgt	540
aaagttagac tgtgaacann tngtaaacac aggtgacagg aatgtntgtc agctgggccc	600
nttatatgcc acggcagagt ggtacgtgat gcccacacat gttatgtgga agtntcatg	660
cagggttca gaacacagta gatggagatt gtgaaaatct gttgttnact taagagactg	720
gcccgaagga tccatgtgat gntacttctg ttgcttgtgc tttaaaatct tatgtgatgt	780
tttgacagact ccttccggga cccagcacaa cagctgagag tctgccctgc tggcactgct	840
gcctgtctgc tgaaggggaa cccaggcatt tgatgttggc cggcccaagg aggggctgaa	900
gctantgagc aaggacagt atagaccac acagnagttt gcaagtaaat gagnc	955

<210> 144
 <211> 1107
 <212> DNA
 <213> Rattus norvegicus

<400> 144	
caaanncaa nggtncnncn ggnccattgg ggggggttaa naatggaggg gnttnggggt	60
ttaaannttc cccnggntt caaggaaatg gggcttttga ttggcaagga aggaatgggg	120
nttccntga ancctcctga ggggccaaan attggggggg gtnacaccc ccggggaaac	180
ccttcttgac ccnagaaan gcngtttagt tcccnccca tgggntccct taccctgggn	240
tttttttga cagccnagca gccctgggtt tcttgtttt cttgggcnc gaaaatttga	300
atccagtga ttcaccatt gagecngcag aggttgatng gcaggaangg ttttaaccctt	360
ngaccaggag tgacaaattt ngngggacnc cccagtngga gtcacaaca ngtngacatt	420
gaggnccaa aggatgttg aggggatgga ttgtgtcgca gtctggttgc ctttatagt	480
ccagcatcgt tgagcccgcc ccaggagtg ttggcacgcc caaacccna cccagcgctt	540
gaggcaaggc aaacacactt cccagccct taanttnca cgccttgtt gcttggacgt	600
cccggantgg gagcaggatg aaggatttta gtgcaggaga agaccagtgc aagccggaga	660
catngagttc cctntaatc ggtgttcagt ttgccttnt ggcacgtgac tcgtaactct	720
ggtatgtgtg ctgaacctc taccagccag agatcagtgt ccttaaagt cgaatcagt	780
tgagggggac tgggaacaat actgatgctg ttgccctcta gtggcaagg caactccaag	840
cgagagggga agcagtcagt ctaccgcac ctctaagata gtggttctcg acctctctaa	900
tactgcggat taatacatc ttcattgtgt ggtgacgct caaccataaa gtgattttcg	960
ttgctgcttc ataactatat ttttgcctact gttatgaatc gtgacataaa tactgtgttt	1020
tcagatggc tcaggcaatt cctgtgaaag gggctctcca caggtttgaa agtntccac	1080
ctgtaggtgg gccaagctaa atgagat	1107

<210> 145
 <211> 92
 <212> DNA
 <213> Rattus norvegicus

<400> 145	
atggggcatc ttgtaacagg aggcctggat tgagtactgt aactgagntc ttgaaagact	60
ttacctgtag gtttggncng cttgaaagag at	92

<210> 146
 <211> 209
 <212> DNA
 <213> Rattus norvegicus

<400> 146
 aattccagcc catcctgaga cacacagtga ccctgtctca caaaaccagg gaaaagccag 60
 gtgcggagtc tcacgccttt aatctcagtc tccggaaaca gaggcagnng gatctctgtg 120
 agttcccagg cgagantttt ttgtacaggg nncctctga annncctga aagatttcac 180
 ctgtaggttg ggcenagctt aaaagagat 209

<210> 147
 <211> 97
 <212> DNA
 <213> Rattus norvegicus

<400> 147
 acagagaaac agtgtttccg ttccttaaaa cgttgctcta tcttgaataa caagcttatt 60
 acatgcgaat cgtattggga acctactgaa ttccgat 97

<210> 148
 <211> 1047
 <212> DNA
 <213> Rattus norvegicus

<400> 148
 caaggtgaat tccanttggn gtttnnaaat ngtttttnaa aaanaaat tntttgggna 60
 ttgccttnaa ngtttgggnc ctgaattcaa aattccaant tacccaaat ttcattgttc 120
 atccanaatt naattccgga aatttacaat aatttgaatt ntagttttcc caattntaat 180
 ntcagtagtt tgnntttgtg tgcccnatt ntaanatcag accegtccaa tcaccaatt 240
 gnttttttnaa attgaatngt tttccentgt accttccttg caangttgct ttaaattnga 300
 atttcagaat cccattgaa aagaatccgg gnnaagcaa caccnttaag gaccccagga 360
 aaccagaaat tngnagaaan ttggacgnag gganttnaca ttnttnccgc canaggatgn 420
 ttgggntaaa aaccgcgttt gcgcaaggct cntgtgttg cctcttttcc gccgggggcg 480
 ctgtggataa tctctgggtc agtcgaaccg ttttaccatc catttcgtta ctccgagaga 540
 ctggcgcn cn gcgggttct ccaagatggc ggcgcagagg aggagcttgc tccagagtgt 600
 gaggaaccg accgcctctc tgggctggga ggggtgggag ctccgggtgtg tcntcgggtg 660
 cagaagctgt tgtctttaga tggcagagt cggaccctc gccccagagg cntagggtg 720
 cttgcagcgc gcgcaagacc ctttccagtc tagagcctcg cctagttctg cgcgtgcgcg 780
 ccacagagcc gggcctctga ggggtcaagg cgccggggtc ctgcggaatg ggagcgtcct 840
 caagccggaa agggacatgg cgccgcccag cgggccatcc ggagggcgga caccactaat 900
 aataaatcgc cccccgcgc ccgcttgtgt aaggcgcgct gtatctctgg cattgtgtgg 960
 accgcctcac attcataagc ttcgtcagca gcagtagaga atggcttgaa agacnttnac 1020
 ctgtaggttt ggcenagctt aaaagat 1047

<210> 149
 <211> 1063
 <212> DNA
 <213> Rattus norvegicus

<400> 149
 catnggagtt cccaatggnt tccntnaann ggttntnttc aggttgggca ncnttttagga 60
 attgaaaatn ttnnttggga ttcccctaga atttgatccc attngggaaa ttttttattt 120
 ccngaacagt ccantnttaa aattgggcct nttgggatta acggattcca aggttgcaac 180
 anattggcaa gtttnnggac aggaggttc aantggntaa agtggataaa tngtgaattt 240
 tggagangga attgacttgg ttgggggcca aaantaggtg gcattttgcc cggagggttg 300
 attgcattct gttttgtgta aanatgaagn tacttgacag ctttgagata agaaggagac 360
 ntaatttgct aaacatttta agtgttctat tctgcggag ttttggagag ggtatatgcc 420
 ggtcaggaag ggagccagaa gccagtaaca ttgcaagtat ttcaacatgg aaagcttttag 480
 gttatctctt gtgcatttta tgctcggnta atgatgtaan ccaattgtaa ttctgggcac 540

agctttccca	tgtgtctttg	gaacagtctg	ggtttgtggt	tntaaaacaa	catttgtatn	600
tagttggagg	cttatctaag	gagcttctta	gcatttgggt	tgtaatttat	tttagtattg	660
tttcagctac	ccattgctac	atagtaaagt	tacaaaaatt	tagtggatta	aaataatgat	720
gtttggtttg	ctcacgaatc	tttcatgttg	gctgaagtgt	ccatttctgc	ttctctctgc	780
tgaacttggc	atcaactgag	agggttggaa	tcactctgaag	atgggggttag	ccacacctcg	840
cagttgatat	tggctgtcag	ttggaacctc	agctggggtc	agcatgcata	agtaagcatg	900
tgtcactttt	ccaggttttc	gtcttacagc	atgggtggctt	ggttctgaag	ggccatcact	960
ctaattggtg	ctgggttccc	agcgagaacc	agtgganccc	aaggatagct	tttggtgact	1020
gaaagacttt	aacctgtagg	ttggggccna	gctanaaaga	gat		1063

<210> 150
 <211> 815
 <212> DNA
 <213> Rattus norvegicus

<400> 150						
ccccccccc	aaaccttcct	tccaaaccct	tnggggtggg	gaaaacattg	ggcaangggg	60
caaattnana	ccccttgga	tngttngccn	ggnaaagttt	cngtccccca	aaagccaaag	120
gggggggggt	tccaaanatt	ccnggggttt	tttnnggggg	taaagggntt	naaaggtnaa	180
aaaatgttcc	cggngccccc	anacttccaa	aggttttccc	tttnaaaatt	ccnggccttc	240
cgggggnccn	tntgtncccc	ccnttccccc	aaatnnctt	nngaaaaggg	ttnaanantg	300
ttnaaaancc	cnaangttaa	angggnnnat	nnaaanggtt	tccctnnccn	ggggnnggna	360
aaaaggtttc	gcgcgganac	cnntgatgcc	caggttcagt	ttcccggag	cttggggcca	420
gaccgcggc	gcgccttggg	tgtggcggga	gcgcgcgggc	ttgcgccgg	acggcttctc	480
cccgcgcccg	actccctccc	gcggcggcgg	gagtaggttc	ttccggctcc	ggcttgaggc	540
ggtgcctggc	accttctgac	caggatccgc	gggtccccgt	gctgtgggtc	cgggaggcac	600
gcggggcctg	cctgctatag	cgggtttgca	gggcgagcct	ccctggagcg	gtagggtcgg	660
tttgggtgtt	gcacgctcgg	tttgacgttt	taatccggag	gagttgtggg	gttcctcgaa	720
tctcaaactg	ccttcttccc	ttttgagact	tgaataatcc	cgaagcctgc	cttgtactga	780
aagacnttac	ctgtaggttt	ggcagcttaa	aagat			815

<210> 151
 <211> 1034
 <212> DNA
 <213> Rattus norvegicus

<400> 151						
aaaaaanagg	tttccccngg	angtccctng	gggntcnttt	tnngancntn	cgttangggg	60
ncctnncct	tttccccttg	ggggaggggg	ntttttaaag	cnannntng	gtttcnntn	120
gggttaagtn	tttncccaaa	agttggtttt	tnnaaaaanc	ccctttnncc	cggacgtttt	180
ccttnncngg	anaatatntt	ttgggcccac	ccngttagn	gggatttccc	aattgcgnen	240
cccttgnaaa	cgggttnccg	gggggngtnt	tnaggggttg	aacnggggtt	taaangtgcc	300
aaaacgggta	aattggaggc	attttngnaa	tggcttttgt	tnaaccnntc	ccttgggaaa	360
gggttgtagt	tttnaacggg	naaacaacc	ccgtngtagc	gggtgttttt	tntttnccaa	420
gcgcgggnta	agccnccgaa	aaaaaggatn	ccnggagacc	ttgnattttt	nnnggggttt	480
nacgcnatnt	tttttggga	tttgggggga	taanaatttt	nnaccnga	ttttngnggc	540
cncncnnngg	gnnaaaaatc	tnannannat	tnggntattg	aacatttctt	ccntgcata	600
ttatngangt	atgacccttt	aaacaattaa	gtacttggct	tcagtgggag	agaaagtgt	660
tagcctcaaa	aagacttgaa	gtgcccaggg	tgtgtgtgtg	tgtgtgtgtg	tgtgtgtgtg	720
tatgtgtgtg	tgtgtgtgtt	tgtgtgtgtg	taaccagag	gggtgcccac	ttgctcaaaa	780
gagaaggggc	agaggaatat	gagggaagga	ttgtgggagg	gagtgaccag	tagggaaaca	840
gtgagtgtga	tgtaaagtga	ataagtaaaa	aaattaaatt	aaattaaaag	taaataaagt	900
gtctacaaag	tcaattactc	ccttcccttc	ctccaccctt	tcttctaata	ttaggcaaaa	960
acaaacncaa	aaacanaaac	aancaaaactg	aaagactnta	acctgtagg	tggncagctt	1020
gaaagagatn	tttc					1034

<210> 152
 <211> 186
 <212> DNA
 <213> Rattus norvegicus

<400> 152

agaccacctg	ggtggaaact	cctattctta	caccaagctg	cctctgtatc	cacagatacc	60
aagaagtagc	caccgttggt	ttacttaact	catgggtccac	ggggtgagct	gaggtctcct	120
tcctgagcaa	gatggaaatt	ttacttggtc	tgtaactag	cgtgcattga	atggangaca	180
tatgat						186

<210> 153

<211> 1028

<212> DNA

<213> Rattus norvegicus

<400> 153

aaagggaaacn	ttttaagcnt	tttnaattnn	gttnccnaan	aaggatttgc	atttaccacc	60
cttaaattta	ggnatttttg	aatnatttca	accnttgca	ggcagtttgt	nccatgttnt	120
gggaaagtth	taacaggatg	gttatttnga	caaaacaggt	tttttcagac	catttgtgna	180
ntatcttgaa	atttcccagt	ttttnaattn	tattntaang	atattntagt	tnnaatttna	240
tgacttcaat	ttgtatanac	aggttcttaa	caaacagtgt	gtaactgagt	accttgcccc	300
agcattttaag	gttacacaca	tcatacgaac	actgaagaaa	atgtctgntc	tttaattttc	360
cccttttctc	tgtgtaattt	ccttcaggac	tcctttgtcc	tgagtgggtca	ggcccttgat	420
aagatgggttn	atcttatttc	tgtttgccca	tgtgttgtaa	tcntgcctga	cagttcttgc	480
ttaatgcaga	aaccaagcaa	aggttcagtt	tgtactggcn	tcctttnta	gttatctgac	540
agggatcagt	tttcaagctg	tagccgtggt	cctcagagag	acctctgccc	atatacagca	600
gcagtctttc	tcattcccagc	cctgggagtt	ctagcaaaga	tttgactttc	tgagtgttgc	660
agggtcagag	accatgtatc	aagcctcggc	tctatttctt	gagtaaaatg	ggcatctggc	720
acatctactt	agatgcagaa	atagtcagaa	tgaagtgaag	atgtaggagg	agtcgtgtgg	780
agaaataggc	tctctgaaag	gaggcttctt	cttcacttta	taagctgtag	tgtcatccct	840
tcccaagtgg	ctctgaaact	gtgttagaag	acatggcctc	cccagagctt	ggggaaacct	900
taaataaggc	tgctgctcag	atgtcagcac	attttacgct	ttactggaag	acttctgctt	960
cctcttccta	tttctccaaa	tncaantgaa	agacttgtac	ctgtagggtt	gggccagctg	1020
aaaagatc						1028

<210> 154

<211> 1034

<212> DNA

<213> Rattus norvegicus

<400> 154

aaaaaanagg	tttccccngg	angtccctng	gggntcnttt	tnngancntn	cgttangggg	60
noctnncct	tttccccctg	ggggaggggg	ntttttaaag	cnannnnntg	gtttcnntn	120
gggttaagtn	tttncccaaa	agttggtttt	tnnaaaaanc	ccctttnncc	cggacgtttt	180
ccttnncngg	anaatatntt	ttgggccaaa	ccngttagnc	gggatttccc	aattgcgnen	240
cccttgnaaa	cgggttnccg	gggggngtnt	tnaggggttg	aacnggggtt	taaangtgcc	300
aaaacgggta	aattggaggc	attttngnaa	tggtctttgt	tnaaccnntc	ccttgggaaa	360
gggttgtagt	tttnaacggg	naaacaaacc	ccgtngtagc	gggtgttttt	tntttnccaa	420
gcgccgnta	agccncggaa	aaaaaggatn	ccnggagacc	ttgnattttt	nnnggggttt	480
nacgcnatnt	tttttggaat	tttgggggga	taanaatttt	nnaccngaag	ttttngnggc	540
cncncnnngg	gnnaaaaatc	tnannannat	tnngntattg	aacatttctt	ccntgcata	600
ttatngangt	atgacccttt	aaacaattaa	gtacttggtc	tcagtgggag	agaaagtgtc	660
tagcctcaaa	aagacttgaa	gtgcccaggg	tgtgtgtgtg	tgtgtgtgtg	tgtgtgtgtg	720
tatgtgtgtg	tgtgtgtgtt	tgtgtgtgtg	taaccagag	gggtgcccac	ttgctcaaaa	780
gagaaggggc	agaggaatat	gagggaagga	ttgtgggagg	gagtgaccag	tagggaaaca	840
gtgagtgtga	tgtaaagtga	ataagtaaaa	aaattaaatt	aaattaaaag	taaataaagt	900
gtctacaaag	tcaattactc	ctttcccttc	ctccaccctt	tcttctaata	ttaggcaaaa	960
acaaacncaa	aaacanaaac	aancaaactg	aaagactnta	acctgtaggt	tggncagctt	1020
gaaagagatn	tttc					1034

<210> 155

<211> 824

<212> DNA

<213> Rattus norvegicus

<400> 155

gggggntttt	cnnanmtanc	aaaaantngn	tntancann	antnnttgag	ntggttgaagn	60
aangnggaaa	angttttgaa	atcantgtaa	tgaggttcca	aaaattgagc	aggaaattgg	120
atgntgtcag	gagaaacccn	ttcagtnttg	tgcaattggt	tcgccagcag	ttaggaccgn	180
ttcccatca	cttgtgccag	cggacatcca	gntattgagc	cntgnatcat	ttatggnaca	240
aattaggaac	acacaacaga	gatccgcttt	ntgactgcca	tgttcgccaa	actcaattgg	300
gggaagtaat	cctccagacc	gttccgtttg	cacgtntagg	aagccacagt	gaaaacacaa	360
aattcgtgga	ggcgactcta	accaggaagc	ctaattccnt	agattcccgg	gacactgggg	420
caggcgctct	aaaaacagct	ttgtggggct	tcagtcctcc	gtgcgggttc	agtcggggtc	480
ttgggggatcg	ccctcgcggg	gaatgtccgg	gactccggtc	ggtatctttt	tggcctggga	540
atthccagcg	tgtggaaaaa	gtccacaaa	ttagtcctca	ctgcccgcct	cgctctctcc	600
ggcccttctc	ggtgcccacg	cacccccga	tcgaaccgga	ggatgagcat	agggtgtatt	660
ttaggcgtgc	tgggcttccc	cgccccctc	tgcccactta	gctggcaaga	agaaagccag	720
cactataaag	gaggccaggg	ccaaggactg	gcctcctctt	gctcacgagg	tcagacgcga	780
gctctgaaag	acttcacctg	taggtttggc	aagctgaaga	gatc		824

<210> 156

<211> 774

<212> DNA

<213> Rattus norvegicus

<400> 156

gagggganna	ncancaggac	caancngata	aggggggtcaa	caacntgnng	tcnccccntt	60
gagngggaaa	tgagcacngg	gcantccaac	cgntcaaggt	cccgnnttcgg	acggtcacac	120
antaggtnt	catntggatt	gccngngttc	cngttggcat	ccgggaaaan	tgagactgtg	180
tcggtaccag	agntaggatg	gccntccttc	ccngccccgg	ccttnttggc	gccttgcat	240
ccttccccga	ccggcccntg	gcgtctccgc	cttnggcact	tgacacatntg	gcggcccagg	300
atggcgcttc	cgggatggcg	ccagcgcgcg	tacgtcatca	cggagcgctc	atgtgttctt	360
tctgtccaag	cgcntaggag	cctgcgcgta	ctcccagcaa	ggaagatgta	ggaccaaata	420
gtagaagcac	ttaacatgaa	cgtcaaaaacg	atgaccaatc	acagggcgat	atatgcgcac	480
gcgcaatgtt	ccaatcatgg	ctcataagca	atccggaagt	ggccaattaa	atatactatt	540
tactaatcca	gggttacaca	gtgaaaccct	gtctcgaaaa	ataaacacag	ggctggagag	600
atggctcact	gattaagaac	actgactgct	cttccagaag	tcttgagtgc	aattccgagc	660
aagcacatgg	tggctcacia	ccatctgtaa	cagattctgg	tttatgtnga	gacaactaca	720
gtgtactcgt	attgaaagnt	nccacactgt	aggttnggca	agctaaanga	gatc	774

<210> 157

<211> 248

<212> DNA

<213> Rattus norvegicus

<400> 157

tgacacttca	tggaaactga	gaccgggagc	ttccaccaga	aggcactgcc	cagtggagaa	60
aaccgacttc	tttttgttgt	tgttctgatg	ttttgttttt	gagataaagg	tctcactgtg	120
tagctcaggc	tggttttgaa	atcaggatcc	tgaccctcag	gaatgtttaa	gtgcctaaaa	180
gtggngacaa	attattttac	gtgcctttga	aagacttcac	ctgtagggttn	ggcnagctag	240
aagagatc						248

<210> 158

<211> 833

<212> DNA

<213> Rattus norvegicus

<400> 158

aanggggtta	tnntggagan	atnctaagnt	cccaaagcaa	nttaggattg	ctnccnnnng	60
aattnttaag	cnthttgcat	aagtantaat	gccaaaatga	ccccaanata	tngntccttg	120
antgtnttaa	aaangaggat	cttctntgnc	catanacgcc	ntatatgaaa	gcaactgaac	180
aagattttaa	attggacagg	tcacaanccg	gcgtgtgcct	ttaatcccag	cactcgntgg	240
ctgatagaag	cagatgcatn	tatgtgggtt	tgaggacagn	tngnttnacg	tagagagtgc	300
ntatatcagt	agggttttgt	agagaccnta	tctcaaaaaa	caaaagcaaa	acaacagaga	360
aaaaatcaat	tgaccatgtc	ccaattacct	ttatthtatct	gtaacctatc	cttagttata	420

ctcgtaatct	ttttctctct	tcagtttgcg	tacgggacag	cagacctact	cacaacccaa	480
gctntaaatg	atgagcgtac	tcagccaggg	agcttcaccc	cacttaaccc	cataagatgg	540
cggcagcgcc	tcttcaccca	ctcagggctg	aagcacgcat	cacgtgatgc	gctccagctc	600
tcgcccgggt	ggctgacggg	aggtggagat	agaacgaggg	tgtcggccat	tttgtgtctg	660
tttcttgccg	gacgtggtgg	tggcgggttg	ttccgagaa	tgtgcgagtc	tcttctctct	720
tttttttttt	ttgtttttcg	ttttcccccc	agcttctttt	cgcctctntt	ctgcatagtc	780
tgtagtgcgc	agttgaaaga	ttccacctgt	aggttgggca	agctaaaaga	gat	833

<210> 159
 <211> 880
 <212> DNA
 <213> Rattus norvegicus

<400> 159						
aanatggntt	ggttntaaag	gttaaaattg	gggcaaaatt	tttccgcccg	ggtccttaaa	60
ccggattaac	tccaaggcca	aaattccgag	ggggaatcaa	caacaaggac	ccaaccggat	120
taaggcgggt	tcaaacaaac	ttggatttcc	ngcccttttg	ggcgggggaa	atgggcacgg	180
gngcattcca	agcngntcaa	ggttccggct	tgcggacggg	taacacaant	aggtttctca	240
tctagattgg	ccngcgttgc	ggttgagcat	ccgggaaaat	tgagattgtg	tcggtagcag	300
aggttaggatg	ggccttccct	cccngccccg	gcttccctgg	gccttgcnat	ccttccccga	360
ccggcccttg	ggtctccggc	cttggggcact	tgcacatctg	gcggccagga	tgcgcttccg	420
ggatggcgcc	agcgcgcgta	cgtcatcacg	gagcgtccat	gtgttcnttc	tgtccaagcg	480
cttaggagcc	tgcgcgtact	cccagcaagg	aagatgtagg	accaaaatgt	agaagcactt	540
aacatgaacg	tcaaaacgat	gaccaatcac	agggcgatat	atgcgcagtc	gcaatgttcc	600
aatcatggct	cataagcaat	ccggaagtgg	ccaattaaat	atactattta	ctaattccagg	660
gttacacagt	gaaaccctgt	ctcgaaaaat	aaacacaggg	ctggagagat	ggctcactga	720
ttaagaacac	tgactgctct	tccagaagtc	ttgagttcaa	ttccgagcaa	gcacatgggtg	780
gctcacaacc	atctgtaaca	gattctgggt	tatctgggnt	cnactacagt	gtannngcat	840
tgaaagatnn	tacctgtagg	ttggncagct	aaaaaggatc			880

<210> 160
 <211> 864
 <212> DNA
 <213> Rattus norvegicus

<400> 160						
aattttaant	tggttgnata	anggcttgnc	catatccttc	ctnttgtttg	ccctaagtaa	60
cagccaattg	ggggagaant	ttntngtcag	tatcatatct	ttcgtagggg	aacggaggcn	120
caggaantga	tcctnttggt	ttacagtcac	tttagcatag	gntgacagtt	ggngaccaan	180
tnatcttgcc	gtgttggaag	gagaggggan	taaggntgaa	gctcttgagt	ccnttgangc	240
ccttggaate	gggaantccc	ttaaaccaac	cccttttgcc	gttgaattgc	accaaccaga	300
ttcttccagt	ctgcttgagg	angacaggac	ttcattgctn	tggagagggg	caggagggtt	360
gggagttgac	ntnacagggc	tcagggatcc	ttttagaagg	gtccagggtc	atggcttccc	420
cccccccccag	ccaggtcaga	cactaaagtg	tcttaagccc	ctccatactt	gccgctcccc	480
cacnttgga	gaagccggcc	attaggcagg	gaccgtctct	gggagaggcc	aagccctctg	540
gctcacttgt	ggatttcctt	taagcaagac	ttcctctctg	cttccaggac	tcctgtcaaa	600
caagaggggtc	cctggcttag	agtttgggag	ctgcaggcag	aacagacatt	ccccgatgac	660
tcacaagcct	ggaactctgt	gggccagcag	gaatggggat	ggctttcttg	tcagtcaggg	720
tcaactggga	cactcactct	gagacagggg	ggcaagggag	aaacaggtca	gaggtagaga	780
gagctcagtc	ccagggactc	acgttgagg	ccctaagggtg	cgctagggag	aggnttttac	840
attcggttng	gcaagctaaa	agag				864

<210> 161
 <211> 874
 <212> DNA
 <213> Rattus norvegicus

<400> 161						
gaggttggac	cacaaggagn	ttggnggaaa	atnnaaaagt	caacctatca	gggtgtcttt	60
tagtttggaa	cagaggcttg	ggcagaaata	tgggcaagta	ttaggaaagt	acaaggggaa	120
atgttgtcaa	cgcgnttggt	ttcccagttg	ttgnactgat	ccnccagga	tgttttccca	180

cntatgntat	ggaaccntct	ctttcaggaa	gccattntna	ncntatggnt	tgcaaccctt	240
ttgggggtcgc	aacagcaggt	attaacatta	ggattcataa	cgntagcaaa	atnacagtta	300
tggagtagca	atgaaataac	tctatgnttg	ggaggggtcac	cacaacanga	gggacgggtat	360
cacaggnttt	tagcattagg	aaggttgagg	accttatttc	agagtgtcnt	gacaatcntt	420
cntggggacca	cttgacttna	tctggagccc	tttccctcac	gctcntactc	cttaccatct	480
ctgcacagct	ctntgaggct	tagagcggtc	tttcttcata	gctttccntt	ttccttcagg	540
tatgcagtca	catcttgctt	tagacccag	ggacattccg	tgtctgactc	actgcacaaa	600
atagtttccc	acatatgagt	cctcaaccgc	cccacatcac	gagacggaca	agaccggaga	660
cgccatacat	tctgtatttg	ccctccctcc	tcatttaaata	aggaatttgt	tgctgtttta	720
tttttcatta	tttgtgtgtg	tgtgtgtgtg	tgtgtgtgtg	tgtgtgtgtg	tgtgtgtgtg	780
tgcgcgcgca	cgtaaatatg	ccgctcagaa	tagtctaaaa	ctgctgggct	tgaaagacnt	840
ncacctgtag	gtttgggcna	gctaaaagag	tatc			874

<210> 162
 <211> 886
 <212> DNA
 <213> Rattus norvegicus

<400> 162						
atTTTTnaat	tgcagcaatc	ctcctgcctt	ttttcttggg	tggttaantca	caggatnttt	60
gcacacttga	ggttgaantt	gcagcaatcc	tcctgctttt	gtttnttggg	cgcttggatt	120
atagtatgtg	cataacactt	gagcagtaac	tgTTTTcttc	aatctcattt	atctcagaag	180
ttcccttgn	tgattcagac	gttattaatt	aggcaaacca	atgttgattg	tcattacca	240
tgagttgctt	ggcttgtgag	atgcatactg	tgtgttcgtg	aggcacntac	tgtgaggcat	300
gtgcccgtga	ggttcattggc	tgtgaggtgt	gtgcccgtga	ggttcattggc	tttctngacc	360
acngggagta	tgaaggagag	gaatcctacg	tttgatgcca	gccagggtta	tacagcaaga	420
tcccgctca	aaacaaaatg	aagaagtaga	gagattagt	ttaataagca	actgaggcct	480
tgaagggtg	aggctcaggcg	gtgcccgtgt	gcacacacag	aagcgtgcca	gtgacgtcag	540
acagactcag	ccctgtgtca	gacaggccgg	agggtgactg	gccatgtggc	gtgattggac	600
acattcccaa	aaaaggaact	cgatggaaga	ggctcctcnt	gctccagaca	gggcgggtgg	660
tatgtgactt	gtgcgagatt	agtctcatac	cctattgcta	gcctgtgcct	ggtaccacgg	720
acatggtaca	atccaggag	gagccgtaag	cactacaggg	gagccatcct	gaatcccagc	780
aagtccaact	tctgtttttt	cttccttccc	cgcaacatta	ggaatgactt	ctaagagngc	840
tgttgaaaga	ctttcacctg	taggttgggc	aagcttaaaa	gaggat		886

<210> 163
 <211> 865
 <212> DNA
 <213> Rattus norvegicus

<400> 163						
tggaggtaaa	agtcacaagn	ttttcaaggg	tttgagatga	cagttcaacg	tgagnattng	60
acaaggattg	attcttgnnn	acaggaaagn	tcccatccc	accaananac	accgtgttca	120
ggcccantgc	tcagagctcc	gggcgccagc	gaagggcaaa	cggccactga	ttggaaagnt	180
gcagtttaaa	gacatgtccc	aggaactggg	anccttgtgt	gactggactt	agccttgcaa	240
ntctgtctga	agcataacnt	gntgctgtct	ntgggcgagc	atttatgtgc	cccacttgag	300
acccatctca	ggacacgcag	gacacggctc	agtggagctt	tcctccaga	gagagggtgt	360
agggncatc	agtgagcttc	caaggacagg	ggaccagaac	ggtgaaaaca	aaccagggtc	420
gtgaaggaga	gcagggcggg	ggggggggga	ggggggggcg	tctntagaat	agattgaacc	480
tgcagagctg	cttgctacct	gaagttgtca	cccttttacc	cacccacntc	atctgtctct	540
gcttgaccat	ctcagcaagt	gtcacctcgc	tgccaggaca	caagtttcct	aaagcttatt	600
tcagtgtcag	ccgctgggga	gacacattca	gggcatgggc	gtcccccagc	cctcggggag	660
aatgtgggag	gtggcgatgt	gggagggatt	cgagagaaga	gaatgcttaa	gaaccatcca	720
gggaacctgt	gcgtttgaag	gtctgagtta	cacacaggct	gctcaggaag	gagctagagc	780
tccaaatagg	agctgtgatc	aggctgtgtg	tgtgtgcctg	gtgaaagact	ttnacctgta	840
ggtttgggcn	agcttgaaaa	gtatc				865

<210> 164
 <211> 859
 <212> DNA
 <213> Rattus norvegicus

<400> 164

cangagcant	ntgaancagg	catttnttga	agggctccng	agaaaacacg	tggaattnct	60
tgtctctggg	acttttagtnc	cagcnaggan	gatncagtga	gggaacacac	cgggcttttg	120
ttgtgcacgg	gaggccaggc	tcancnncct	tgggagnttg	acatccagca	ggctatanac	180
agtgatccag	gggacatgta	cacatgggga	actgnccagg	cagagaaaga	caagagaaaa	240
tctcaaanga	tgaagacaga	gangagtaat	atggccagaa	ngatacagtg	cctcntgcat	300
aacccttgag	tttaatttcc	aggggtcaact	gtattttgaa	agtataaatg	aaagttcctg	360
aagtaataaa	tttataggat	gttagtatca	cactgttcag	aatagctcaa	aaaatcctgc	420
cntgtcctct	taagtatgtg	aatcatcttt	tactgcaacg	tgtccacaat	gtatatacta	480
catacccaaa	agtcctcact	gttatcccaa	ttagtaggct	ggctgccaat	agttgtccat	540
acagagtgcc	tgctgctgtg	gccatccnta	ctgtagtaaa	cagtcatcca	aagctcagga	600
gtgaggctat	tgtagaaatg	cacttcctgg	gggccctact	gtcagtgagc	acctgagaga	660
gaaagggaca	caggcccaag	gtgggaggcc	ttagataaag	gcccatcatg	ctcaggaaag	720
gatttntaca	gatctcttag	ggaagttaca	atcaaattca	tacctcacag	cagagctcag	780
gagaagaatc	cataaagnnt	gaagacatgc	ttgtngtgnc	tgaaggacnn	tacntgtagn	840
tngggccngc	tgaaatttt					859

<210> 165

<211> 1021

<212> DNA

<213> Rattus norvegicus

<400> 165

caatngncaa	aggttttgaa	cccgngaaat	ttnaaaagtt	tgcgngantg	gttgacnttc	60
cnggtgtnaa	nggtttcccc	gttcngattg	nagggatcnc	ttttatccct	tttttnagnt	120
tttttttgag	nggaattttg	ggttcnaant	gngttaccct	taagtaacce	cattttgcan	180
ggcatggaaa	atacctaaan	tgggatngaa	agttcanatn	gaggtcagga	anggnrtggaa	240
cagggtngac	cggttngacc	gttggacctt	tgaganccat	cagatntttc	ccaggttnc	300
ccaaggactt	gaaatgaccn	tgtnccttat	ttnaantacc	caatcagttg	gtttctcgt	360
tctgttcgcg	cgtttttgtt	cccggagttc	aataaaggag	cccacaacce	ntcantnggg	420
cgccagtcct	cgatttgact	gagtcgccc	ggtagccgtg	tatccaataa	accntcttgc	480
agttgcatcc	gacttgtggt	cttcgctgtt	ccttgggagg	gtctcctctg	agtgattgac	540
taccggtcag	cgggggtcct	tcaaactgca	gttctcaagt	aagctcaacc	atccgagggg	600
cattctcaaa	gccaagtcaa	acttggggagc	cctcactcct	ggtggtcttt	caaaagaccg	660
tgcattggat	agtcagagac	tctgcaggag	cggattaagt	ccaggcctgt	ctccctgctt	720
tctgcctggg	ttctaaagtc	aagaaggcca	gatggctcag	atagttgaga	cagtggtcta	780
gctgattctc	tggggatgca	tttgggtctgc	ccaggaaacc	ctggagagtt	ttctacccaa	840
gatactaaag	ttcaaacggc	agcgcctgtc	ggcagactca	gcctatacaa	agctggcctg	900
tatctgatgg	gattntaagt	ccctggggcag	acccgggttt	gtgggcctga	agcttgagtt	960
ncaggagact	tagtggggcca	tgggattctt	ttaggatccc	gatatgggna	aacttaaact	1020
g						1021

<210> 166

<211> 1013

<212> DNA

<213> Rattus norvegicus

<400> 166

ttttgagttt	tctcngccc	nttgtgncng	aaanncagcg	ggggtntntc	actgtgnntc	60
tcacatgtnc	tcacacanat	cnggggggacn	ctcacancnn	catctcacnt	ntngnancct	120
acactcgtgt	gggntctttc	aaaacantgt	ncnntggata	cncagacact	cnnncnagnn	180
ggtntatctn	cacnngtgtc	tcngngnttt	nngcnngnnn	tcnaantca	aaagcgnat	240
nnggcacata	tntntgacac	ngnggtatat	nngnctctcn	ggnganacat	ttgntncgca	300
caaaaaancn	tggagatttn	tctacncaat	annctanttt	tcacaggnga	gcncntgttn	360
anacnncac	cntanacaan	tnnggnntgt	ntcagaggng	atcttanctc	nntggncana	420
cccgnntntg	tgnnccaaan	tnttgttttc	caagacatat	agtggnacat	gnnactctnc	480
gatntccgat	gagnananat	gtgntcngac	ntttacagcg	natacacngt	ggngcanntn	540
tcacagatat	gtgtntatnt	cnnacanaca	aatntgcnn	actcctctcg	tgtataaatc	600
aatnacggg	nggggttaaca	tnnggcncn	gttgnnacgt	natanngnga	aacacactcn	660
caagggctnc	aanttttnca	nctatacacn	cncncccgan	gggncngngc	acaaatgtgc	720

nccgaaat	ttt	tatnccgcnc	naacactctn	aaattnttcc	cgggacccta	gatataat	tttn	780
tcncattna	aaatttgcac	attnttttnc	anttgccang	gnantcgggg	gttcacccnc			840
cncnttggga	aggggnntnt	tnaacccggg	ttcnaantta	taggggggtt	tanatcnccc			900
catttttttna	aaaagngttt	accntggggc	ccntnttttn	cnaaaaaatt	tgnccccngt			960
ttancnccgg	ggttggggaa	cncgaatttc	ttngggngcc	cccctnagmn	ttt			1013

<210> 167
 <211> 1002
 <212> DNA
 <213> Rattus norvegicus

<400> 167							
aaananttna	cacggattcc	ttttcctcaa	aaccaatggg	ggaataaatg	atgtngtagg		60
gttcccngt	aatggatact	aggttgaact	tccangggga	antattat	ttt	caataagg	120
ttagagggtc	cacttgtnat	caggttattc	tgttgctttg	ggtcaagcaa	acagccnatc		180
aggattgtga	ttattngant	aaccatttta	cctnacagcn	gggagggaan	ccaangggag		240
gcttgaggaa	acggcttgtg	ggttcataaa	ctctttgaat	cataccttgg	gtgattcaaa		300
tgctttttac	taggctctcc	tttcatagta	cctctcttgt	ggacaaggac	ccagtccttt		360
gaaaagcatt	gaaaactcaa	accataccac	tatcagtttc	agctttaata	taaattagct		420
ttctaagttc	agctgaccac	nttttcaactg	gaccttcact	gatctcacag	ggaagatata		480
ttttcaacaa	ttacaaagac	atcttctgggt	tggactatgc	attccttttg	gccagattct		540
acatcctttt	tttatgccag	aatttttttag	cgttcctgta	agattgtcag	tttcccctag		600
gaaatccata	aagcttttaaa	tgccttctaa	atagccaata	ttttaatgag	aaatgtagtc		660
actgatatact	ctttgtat	ttt	aaaggttatt	ttgaggggag	ttgcttggtt	ggttggttgg	720
ttgggttggt	ggttggttag	ttgggttggt	ttggcttttg	ttttctgtcc	catggtaata		780
tgatacttat	gtcatagatt	agttaactca	aatggctctt	tcagggtggca	gtctggaaaa		840
caactaactt	gggggggaaaa	aggctgctcc	atgttctata	aaagctgtac	atgtgatttt		900
ctctgcttta	cctttttatac	tcattttattn	tgttat	ttt	gtatgaaagc	cttccgtatg	960
aaagaccntt	acctgtaggt	ttggggngct	agaaaagatc	tc			1002

<210> 168
 <211> 1031
 <212> DNA
 <213> Rattus norvegicus

<400> 168																					
caacnccat	nttttgggaat	ttngggggta	aaattttaaac	cgattc	ntttt	tcncaaacc	60														
caantggggg	atatnnatgt	atgtngtagg	gtccccngt	aatggaatat	ttaggttgaa		120														
cttacaaggg	aaatattatt	ttcacaatgg	tttagagggt	ccactgtnac	aagtattctg		180														
ttgcttttgn	ccangtcaaa	cagcccatca	ggatgggtgat	attagaatta	accattttatc		240														
caacagccag	gagaaancca	aaggggagctt	gagaaacggc	tgtgggttca	taaaactctt		300														
tgaatcatac	cttgggtgatt	caaatgc	ttt	ttattaggct	ctccttcata	gtacctctct	360														
tgtggacaaa	gaccccagtc	ctttgaaagc	attgaaactc	aaaccatacc	actatcagtt		420														
tcagcttttaa	tataaattag	ctttctaa	gt	ac	ctttttcac	tggaccttca	480														
ctgatctcac	aggggaagata	tattttcaac	aattacaaag	acatttctgg	gttggactat		540														
gcattccttt	gggccagatt	ctacatcctt	tttttatgcc	agaatttttt	agcgttcctg		600														
taagattgtc	agtttccct	aggaaatcca	taaagcttta	aatgccttct	aaatagccaa		660														
tattttta	atg	aga	aat	gt	tag	tcactgat	at	ct	ctttt	gt	at	tt	ta	agg	tt	tt	tg	agg	gg		720
agttgcttgg	ttgggttggt	gggttggttg	ttgggttggt	agttggttgg	ttttggcttt		780														
ggttttctgt	cccatggtaa	tatgatactt	atgtcataga	ttagttaact	caaatggctct		840														
tttcagggtg	cagctctggaa	aacaactaac	ttggggggaa	aaaggctgct	ccatgttcta		900														
taaaagctgt	acatgtgatt	ttctctgctt	taccttttat	actcatttat	tttgttattt		960														
gtgtatgaaa	gcccttcncc	tatgaaagac	nttcaactgta	ggtttgggcn	gctagaaagn		1020														
gacnnnaaa	a						1031														

<210> 169
 <211> 1039
 <212> DNA
 <213> Rattus norvegicus

<400> 169

aanttttgnng	agtnttttggga	atnnaacngc	ggttcccttat	gntgggnnaan	aaaccnctnc	60
nanaccccaa	taccttggat	nttttaanat	gcncctgggt	aagcnaantt	gaattatttt	120
ccntgggata	anaagtggaa	tcattgacag	ttttgtgggc	cttttnncat	ccccatgnng	180
tttnatgact	aggcacttta	tttcatggac	aaaccagtgt	tgtccctcnt	ggggactgag	240
tgggattaaa	aaaaccttcc	aaaaatgtgt	aatntgatca	aacccattga	gacaatcagt	300
gnggagtatt	agcaaattaa	actgacttgt	tcacttntga	aaantgatgt	ctgatttcgg	360
aagaatccca	gtgcctcggg	acatgaaagg	gagatgtaac	cttgagttca	tggtaggag	420
ggaattcata	gagacagttg	gtaaaaatct	gagtggaggt	gagagggttg	aggaccacat	480
tgtgtatttg	ctcatcntgt	gagggagaga	ctttgtactc	tgctctgaga	aggcagaact	540
gttaggcaga	cacttagaga	atatatgtca	tggcaaaaga	catccacca	acaagtcttc	600
agtaacaaag	cactaaacag	aaaggggttg	aagagactgg	tcagtggctg	agagctttta	660
ttgctcttac	agaggactcg	gcctgcntag	cagctcacia	cagcntgtga	cttcaacact	720
atgcctctgg	cctcaggaga	cacctgtgta	ctccaccca	gacacatata	cttaaaaata	780
aaagaaatct	tttaaacatt	gagcaaagt	aatcaggtac	taacattgaa	tatatctggg	840
gccaggaatt	attctgggtt	attgcctttt	tcggaagcct	aatatcacac	atagagaaat	900
aggcagcaca	ggcctaacag	cccataatgt	gtgctattct	atcaatagtg	ccaagtattg	960
acatggacta	ttcaaaaggc	ccaaaagtta	aatggcccag	aagtncaaca	taaagnccgg	1020
cnagctaaaa	gagatcntc					1039

<210> 170

<211> 1058

<212> DNA

<213> Rattus norvegicus

<400> 170

aaaagctttt	tttcagnttg	gccaattttt	aaccatttaa	anattgtnt	ttggaatcng	60
catttggtna	ngttattgnc	gaggaaggta	ntaagggant	ttttcccaa	ttncaccat	120
tnttggccag	ttgggatttt	gattgantgg	gaacccccca	ggntttaata	agcctttgga	180
tttgttcaca	ggggattaac	aaantccttt	gnttaatggg	gattgaattt	gggaaattgn	240
ttcctaatt	ttccaggacc	aatgcacant	ggantattag	aactgatgta	acagagtgat	300
atgggaccaa	gtaggaacaa	gggtgcaggt	ttgccgaggg	aggtaattgn	tggctctgtc	360
attgtcataa	ctttcttgaa	agtttttagga	cttggaaggga	cagaagacat	gatcattagt	420
atacttgatg	acaagtggag	atgaaaggac	aaaaattgtg	cacatcaaga	ggagaattta	480
acattgggtt	ttcttgcat	agctatccac	tcttgccctc	accctccac	ccccttaatc	540
ccagttacct	tgacgattga	ggtcattttc	tctgaacaca	ttctcttctt	ggatgttaaa	600
gtgccatttg	acactgtgtt	tagggacact	gcttagggcg	gggtggggga	attgccacag	660
aagcttgacc	ttagaagggt	gagactctgg	aagcctgaga	gagatgagat	ctgtcaaaga	720
aacgcttagc	gttggtatgg	gatgcgtagg	aggctgtact	cttgctctct	agatgctatc	780
acgggtgatg	taggagaaat	gatctcactc	agcccaagat	cattcccttc	caaagtgtct	840
catcccatca	gcaagcaaga	cctgtactga	agccagcagg	ggcgtgggtac	agagtccggc	900
attttttgca	tgccatgctg	gtttgatgtt	tgaactctaa	aggtggagac	tgttgggggc	960
agcagggcag	acagtcttct	gatgatttct	ctgccttcaa	actgaggttn	actcttgaaa	1020
gattncacct	gtaggtnggg	caagctaaaa	gagaggcc			1058

<210> 171

<211> 1043

<212> DNA

<213> Rattus norvegicus

<400> 171

attttccatt	gcgcncatt	gaacggnttt	gcgnggggtg	ttaggggttn	aanggatttt	60
nagtgtgcn	aanaaggtag	attgaaggcn	ttntttggat	ttggntttgt	aanccattc	120
ccttngaaaa	ngagttgtag	tnttaancgg	caaacaacca	ccggtttag	cgtgggtttt	180
tgttgcaagc	ngcggtagg	gcggaaaaaa	ggatntaagg	agatcctttn	ncttttcttg	240
gggtctgac	gnntcatgtt	gtgtggaatt	ntgagcgggt	acaatttcac	acngattttt	300
tatgcaaata	cacttgccaa	gttggnataa	ctgacttatt	ttaccgggaa	ntctccatgt	360
atcttctttg	gacacttacc	cttacagagc	ccaggatgaa	ttttgaccaa	gccaagtatt	420
cacacagccc	aatgtgacat	gttaccacaa	attggngatt	ttccttcagt	acactcaa	480
gacacaagct	ttttctcgat	gtctttcttg	tcattcacta	ccaggatgaa	attaatttta	540
tcttctgagg	angcaatata	cgatccaccc	aggaaaattc	actttagatc	ttcgttctca	600
tttcttggca	aacagaattt	gagctgaatt	tctcttagaa	aaatctgtcn	ttcagaaact	660

taaattcttg	ctgttccata	acagaagtca	gcaagtgact	cacctccag	atacaggtat	720
attacctcca	ctcccatcca	cagagactta	attctagtca	gcttcatgat	agtgagcctt	780
catccgtaag	gagctgtatg	gtatgggaag	gggatacaga	cagggccagg	ggtgttttta	840
aacggtaacc	cagggaccac	atccattaaa	aacactggac	tgtttgtgag	agtgtatatt	900
cctgagcatt	gcctatccct	taaggtaacta	caaaatttgg	gagtgaggct	cagcaaacta	960
ttttaacatg	cctctccacc	aacnactcaa	gattcccgtg	nacagttgaa	agtttncacc	1020
aaaggtgggc	aagctaaaga	gat				1043

<210> 172
 <211> 454
 <212> DNA
 <213> Rattus norvegicus

<400> 172						
aattcatccc	tcatttgccc	tgctagtga	aactatttca	gacctgaaga	caacatcctt	60
gaaaacttct	ctggagaatg	tgcagagatc	accatggcaa	cctgtcccgg	gccctgcctg	120
gcagggctcc	aaggcacaca	aataacgcca	ctggaatgtg	gtgcagggtc	ccgggtgggg	180
tgactagaaa	agctgccaat	tttccatgaa	aaccaccggt	gagaagcctc	agcctcagga	240
aggtgtcagt	agagagggct	gggttctctc	tagcaccaag	ggacaggctg	tgcgcaagca	300
tgcgcagaag	cacactcacc	ggcctccttt	ggggcagggc	tgcctgaaat	gaaccggctt	360
cagttttgtg	cagctcaagg	gcacaaggnt	agtgcccttt	ncttggnent	gaggcactnn	420
taaatgtagg	ttgggcgcgc	taanaagat	ccnt			454

<210> 173
 <211> 873
 <212> DNA
 <213> Rattus norvegicus

<400> 173						
gttgttattc	aatcatccac	atttgtaaaa	acacacttcg	ggtcctcctt	gtgtcnggca	60
gtaccatcca	ttgagtttca	ggaagcagaa	gtttttaaag	ctnccagcan	cntttaaatc	120
cacagctcaa	gttggtgaac	accttgggaa	actaccactt	attcaccag	aggagagttg	180
attcaagtag	ttagtacct	tntgcatcag	aanccaccag	ntactgccgg	tgagagtogg	240
taatnccang	aactcatcca	tgcaggcaaa	tttaaggaca	cacggcttga	cacagagatg	300
gttanatcgg	ctgtgacagt	tcttttagtg	gagacttttg	ctttctgaat	ccacagggct	360
tactttcttt	ctttttcttt	ttaagacaag	ctctcatttt	catcttgaga	aaatgtctga	420
tcaagccacc	aactgaaaac	ctgccattat	aaacgaggga	tttcacaatg	ctcattccaa	480
aatctgcggc	tattcatttc	tgggaagtga	tcactgagga	aggacggctg	ttgggggttg	540
gagggagaga	tcatttttag	gagaccgcct	gctctctgag	aactgagcag	aaaccccaga	600
gtggctagca	cgtgtgtgca	gcgacccag	ctcagctctc	tgagtcaccc	cctccccag	660
atgacacgcc	atgaccagtc	tcctcgtgaa	agccacttgg	tggacaaaaa	gccctttggg	720
ctgtgcaccc	agcctcacat	ctgcctctct	gggggctatt	ttcacataaa	tcaggaggga	780
ggcagcagca	gttgcccacc	tgttttngac	tcgatttgct	tggggantga	aggactttnt	840
naatgtaggt	ttgggnncngc	tnaaaagatc	cnt			873

<210> 174
 <211> 876
 <212> DNA
 <213> Rattus norvegicus

<400> 174						
gttgttattc	aatcaattct	gttgcttttg	nccangtcaa	acagcccata	cgggatgtga	60
ntatnggaac	taacccattt	atcctacagc	caggaggaaa	cccaanggga	ggctgaggaa	120
acggctgttg	nttcataaaa	ctctttgaat	cataccttgg	gtgattcaaa	tgctttttac	180
taggctctcc	ttcatagtac	ctctctgttg	acaaagaccc	agtccctttg	aaaagcattg	240
aaactcaaac	cataccacta	tcagtttcag	ctttaatata	aattagcttt	ctaagttcag	300
ctgaccacct	tttcaactga	ccttcaactna	tctcacaggg	aagatatatt	ttcaacaatt	360
acaaagacat	ttctgggttg	gactatgcat	tcctttggcc	agattctaca	tccttttttt	420
atgccagaat	tttttagcgt	tcctgtaaga	ttgtcagttt	cccctaggaa	atccataaag	480
ctttaaatgc	cttctaaata	gccaatattt	taatgagaaa	tgtagtcact	gatattctct	540
tgtattttaa	ggttattttg	aggggagttg	cttggttggt	tgggttggtg	gttggttggt	600

tggttagttg	gttgggtttt	gcttttggtt	tctgtcccat	ggtaatatga	tacttatgtc	660
atagattagt	taactcaaat	ggtcttttca	ggtggcagtc	ttgaaaacaa	ctaacttggg	720
gggaaaaagg	ctgctccatg	ttctataaaa	gctgtacatg	tgattttctc	tgctttacct	780
tttatactca	tttattttgt	tatttntgta	tgaaagccct	tccgtcctga	aagaccttta	840
cctgtaggtt	tggnccgtn	aaaagatcnc	tgggcc			876

<210> 175

<211> 459

<212> DNA

<213> Rattus norvegicus

<400> 175

aattcagaag	gatctcagaa	attgaaagca	tgtgcaaaga	taaagatttg	gggtagtagn	60
agtgggtcaaa	agggacaagg	taataatggt	aatatgcttt	tgtgtatgtg	ttctttttaga	120
gttatgttaa	aatctagaga	agcaaagtcg	attctcatag	atgcttttag	tctttggacc	180
ctgactagag	acagtttaca	ccctagacaa	gagagagaat	ggggttgagt	aaaacagtcc	240
tcccgaactc	tccacagatg	ctttggcaaa	agaaggaaat	gagcttaaac	tttttggagc	300
tctcctggga	acagaaggag	gtgggagacg	tcttgccctc	ttgctggctc	ctattggaga	360
agtgtttatt	tctggttntg	ggttttttag	gtngnttgtc	tgggttcctn	gggncctgag	420
ggcacttnna	aatgtaggtn	tggcgcgcta	aaaangate			459

<210> 176

<211> 3133

<212> DNA

<213> Rattus norvegicus

<400> 176

acccacacnc	cnancnacac	ccacacacca	anccacaccc	acacacccaa	ccacacccac	60
acacccaaacc	acacccacac	accaaaccac	acccacacac	caaaccacac	ccacacaccc	120
gagtgtggtg	tgtcctcctc	actgagtgtc	agccagccct	ttcctctact	tcaggtaaag	180
gtttctccac	tgcctcactg	tgtccctgtc	acatgggcac	aaagccatct	cagcagtcct	240
tctcaaggac	gtgggtgcca	ggtttggaag	ctggaatgcc	tacatctaaa	atcttggcca	300
tgacttgtga	caacttacat	atacatagac	atatatacat	atacagctta	catagacgca	360
gagcctcaga	ctcctctgaa	gaacgggttg	attctgtgct	ctgcagagat	gctgggagag	420
tgtataaaaa	ggtcaagaaa	gcaggcttag	aaagaagggc	aactctacct	agtgtctcct	480
tacaattttg	ttttacgtcc	tcttctgccc	acagagccct	taagacactc	cctactttct	540
gcattcattcc	tgggtgtctt	taggaacaag	ttagtgaatg	atcactctgt	aaacacatac	600
ctacaggtec	tccttacctt	gggctctgga	acacccgggt	aagtctgtgg	gtaggagggt	660
ctggctgagg	ttgagtgtat	caagtaatca	actggcagta	ccctntgggg	agtggcctgt	720
ggtttcctgc	tcccctcttt	gggtgagaaa	tcctaggggt	gtgggagcca	aggcttaggc	780
aaagggttcag	gcacagcagg	gtgtgggagg	gagttagact	atagtagagg	tgagtggagg	840
gtatggattc	gaagactttc	ggattaaaaa	aaaagcaaaa	aaaaaaaaaa	aaaaaaaaacc	900
aaaaacccaa	acaaaacaaa	aaacccaaaa	acaaaacggg	ccaaccagt	agatgtggct	960
tgctctgagt	tgctaattat	gcagggtcta	gatctcaaaa	acagtctgtg	ctctggggcc	1020
actgctgaca	tccaagtcag	gcccagaagc	tcttgggtct	catctttcct	ttccctctca	1080
ggctgcttga	agctgattga	ggtattcctt	gcttgttcag	ccggttcntg	atgggtctcn	1140
tgttcntccc	agttctctcc	atgtttcttt	tgttttgaag	tacaaaggaa	tacagttgca	1200
ggggttacat	ggcactcccn	tattcacttt	tagggttacc	acaaaagctt	gtgattcttt	1260
ccctcnttag	gactgagctt	ctacccccgc	acacaggcct	aactttgggt	tccccaccca	1320
taatggggca	cccaccccca	ccnccgcccc	acccaccccc	aagaaaaaga	aaaaagaaaa	1380
agaaagaaat	gaaacggcca	gctggctctt	acccactttg	ggcagcaggt	gtttcctccc	1440
tagcttccct	tttgcactct	atacttggtg	cttgacacac	ctcaccctc	tcttgcctgc	1500
tttttcaaat	taatagcctg	caacttccct	tgcataataga	gaatggttcc	cagggttctta	1560
ctgggattag	tgaacgctct	ttttgttgag	gaaatgcttt	taacaccacc	aagtgcctga	1620
cccctcaaag	ttggtgaagc	tctagattca	ntgggctgta	caaggacac	ttgggaaaaa	1680
tttgaacagg	acaagcctga	gggtgtgagt	ggggttggt	catctacaca	ggagctgcga	1740
ntgagaggga	aagggccccc	aaacatcttt	gctaccactg	ccttcttaag	tttggggact	1800
tggaaatccc	gttgttttaga	tcttgaccgt	aatcaggagt	cagcgtagag	gaggccccgg	1860
aaggaggggc	cagcgcggat	tgcgccgcgg	cagggcgggg	accaacagag	ggccntcggg	1920
gataggggag	cgccgccccg	ccntcccggg	gaaggacaca	ttgcttgtta	gcaggaagcc	1980
agccagaccc	ggaggaggcc	gctccagcgt	tgggtgttgcc	ggtccggggc	tagcctgatc	2040

cgggcagggg	gagttgagac	gatcgggtga	gcttggggccg	gggacgccag	cgtcttcagt	2100
cctgggggatt	gtcccaggag	ggcaaggagc	ttggaggagg	gaggccgcac	agctagggga	2160
gtcaggtctg	agtcccagag	gtgctctaaa	gccggggcgg	tgagagtggc	ggcccccccg	2220
gggcccgcga	gcgngcagtc	tccccgcgt	gggaagtggg	aacttaacgc	acagccacag	2280
gattccccggc	ctttagctgc	tggagggagg	gtggcttctc	ccggaggagt	ctgttgtgaa	2340
actcgggttg	agggcacccg	gggtgcgggc	aaggagagag	tggggtcgcc	ctgaagaagt	2400
gggggggctgg	agtagaaagt	ggactttgtg	caaacctcac	cccagagtag	ttagttacca	2460
aggctgggttt	tttttttttt	ttttttttgc	tcagacacaa	ggaaaatttg	actcaatgtt	2520
aaaatatgta	atttggcagg	aaaacttttt	tcctagcctc	ccttgctaata	tagttggaac	2580
aggggggctcc	caagagggtat	agagtccccc	atttttacaaa	atgtgggttca	gtgggactgt	2640
ggcccaccca	gtcgtgtatc	catggaagag	tggctttttat	ggagaagttc	attttcctta	2700
accttaaaaa	ctgtaaagga	tcttgtgtct	gagaatattg	ttggccagct	ttatagtctt	2760
catttataaa	actatttaga	ctagagtgtt	atagattata	ggtcttcaag	tttccagtca	2820
ccagtccttg	gcttttttagt	atggaaatca	ccagtaatgg	caatataaca	tccctgcttc	2880
tgtttcttag	aaggctaaat	tacagtgtgt	tcaaactccg	tgtcattgca	acagggtaaa	2940
ctaactttat	acgtaggaca	tcagggtatt	gacattctca	tcctaaagtc	agtttgtctg	3000
tttccagagg	aggaactgaa	gcagtgggtc	tttaagtaac	tgactcaggg	ctttcctgcc	3060
tggcgcgcct	gccaggcata	gtgtagcatt	gtactgcata	ttctttgacc	agtttcccca	3120
ggtgaagagc	ctg					3133

<210> 177

<211> 2161

<212> DNA

<213> Rattus norvegicus

<400> 177

ctggaagctc	ccttctcccc	tgtactctac	tctgcaaata	cctgcagggtg	gacactgaga	60
gaagccacac	acacctgttt	ttgtttttcca	tctctgaggg	atctgccatc	tactgtacat	120
gcagtttctg	aaaacatttg	tttggcgggt	ttctatttgt	ttactaagtt	agttcagttt	180
tcacagtggt	cacaaactag	aagtcattca	tatgagtaaa	atgtgttaaa	acgtcttcat	240
aaagttttca	gtttgagagg	agcatacaag	gaaagggctg	cttaagtggg	aaggagagcag	300
gctctgtggc	tttctcattc	taaccttgt	ttgttctctg	gaggtgtgga	gccctgctct	360
gctgctgtct	ggacagagca	gagatccttg	cagcagccac	agctctttac	tgcagatgtg	420
ttctgggggc	ctggttctga	ctccttcagc	tcctggtagt	gccctgcgtg	ataataacag	480
cctcctgctc	ccagctccag	acagctcgtc	tttctgttgc	agcagcactg	tgaacaccag	540
agtgattctg	agcttagatt	caagatgacc	tcacacttat	gggaatcctg	tgcgtggacg	600
tgttgcttsc	tgtttttact	gccavgate	ttccagctga	atgccagagt	gttgagtgtg	660
ccarcctgg	ggtarcccag	ccttgcctcc	cacctctgt	ggatactcca	cccagtctgc	720
tgttaccagg	cactggccca	gtgaaaatct	aaagggttta	ttgttttagta	gaaaattaaa	780
acacttacta	cagtttgaat	gtgttgacac	ttatgggttg	aggccaaagg	aaggtaggca	840
gaaggaaaac	aggaggcaag	gagggggaag	aagctggaga	gtctggctgg	agggcgatgc	900
cctcctgggt	ctgaaagagc	cacacccctc	tgttgccagt	tacaggccga	tctgctgctt	960
agcaccaccc	tgatgtgctc	cagcatctcc	cgttccagcg	tgggttcttg	tcgraccttt	1020
attccacggg	tacttgaggg	gtgtgtgtgc	gtgcgtgtgt	gtgtgtgtgt	gtgtgtgtgt	1080
gtgtgtgtgt	gtgtacatgt	ctgtgtcccc	atgccacagc	acttgtggag	gtcagaggac	1140
aaaggacact	aaattgcttc	tccctttcca	tcacgtgggt	ccctcaagct	tggatcttga	1200
aaacgttact	tctagtgtaa	ttgtcctaaa	agttcacgtg	gactttaagt	ctcttggtta	1260
aagtctgtag	gcagttctgt	tcccgcagca	cagttcctca	caaagccctc	tgatggctga	1320
ttctttgctc	ttggangcac	aaggctgtgc	cgtgcttaag	acaggctgca	cagcttarga	1380
cttgcaactga	gggcgttctc	gcctgggttg	ctcarcatct	ggagtatat	ggtcatggcg	1440
agtcaggggt	cagctctcgg	tatttatctt	tcagtgcatt	gatgtatttg	cccttacaga	1500
cactgtacct	gaattattta	acactgtaat	gctagtgcct	gatactgaat	tcattgactat	1560
aagttcanar	ctgcaracac	agccttaggt	gttaaacagt	atatttttaa	gagcttcaag	1620
tgcacagaac	agtaggggtg	cagttttgac	cccctaggtc	tggactttga	ggttgcattc	1680
catgaatgca	gctctgagct	gggggcgcga	tactctacat	tgtaaagtaa	tgcacctcct	1740
aactacctgc	catggtagca	agctccagcc	acctgaaaag	cagccagccc	tcttggggca	1800
gcactgcatg	aggaagcctg	aaccccagca	aaggagcatt	gggctgctat	gtctgttctg	1860
ctacagcgac	aatcccaggt	gtgcacttgc	caacagctgg	aggcatgcca	tagccagggg	1920
ttcagcatgg	ctgcccttgg	agagagggct	gcgtgtgtgt	tgtgtgtgtg	tgtgtgtgtg	1980
tgtgtgtgtg	tgtgtgtgtg	tgttagaata	agcaactact	gacaaattca	rgarcataaa	2040
cattatggaa	atttttttgt	gtatgtcatc	attttaattt	taaaagatgc	cttattttct	2100

cctcttggaa ctaaagagat tatatttcac tttataaaga aaaaaaaaaa aaaaaaaaaa 2160
a 2161

<210> 178
<211> 824
<212> DNA
<213> Rattus norvegicus

<400> 178
gggggntttt cnnanntanc aaaaantngn tntancannng antnnttgag ntggtgaagn 60
aangnggaaa angttttgaa atcantgtaa tgaggttcca aaaattgagc aggaaattgg 120
atgntgtcag gagaaaccn ttcagtnttg tgcaattggt tcgccagcag ttaggaccgn 180
ttcccatca cttgtgccag cggacatcca gntattgagc cntgnatcat ttatggnaca 240
aattaggaac acacaacaga gatccgcttt ntgactgcca tgttcgccaa actcaattgg 300
gggaagtaat cctccagacc gttccgtttg cacgtntagg aagccacagt gaaaacacaa 360
aattcgtgga ggcgactcta accaggaagc ctaatccent agattcccg gacactgggg 420
caggcgctct aaaaacagct ttgtggggct tcagtcctcc gtgcgggttc agtccgggtc 480
ttggggatcg ccctcgcggg gaatgtccgg gactccgggtc ggtatctttt tggcctggga 540
atctccagcg tgtggaaaaa gtccacaaac ttagtcctca ctgccgcct cgcctcctcc 600
ggcccttctc ggtgccacg cccccccga tcgaaccga ggatgagcat aggggtgtatt 660
ttaggcgtgc tgggcttccc cgccccctc tgccactta gctggcaaga agaaagccag 720
cactataaag gaggccaggg ccaaggactg gcctcctctt gctcacgagg tcagacgcga 780
gctctgaaag acttcacctg taggtttggc aagctgaaga gatc 824

<210> 179
<211> 774
<212> DNA
<213> Rattus norvegicus

<400> 179
gagggganna ncancaggac caancngata aggggggtcaa caacntgngt tccnccentt 60
gagngggaaa tgagcacgng gcantccaac cgntcaaggt cccgnttcgg acggtcacac 120
antaggtnt catntggatt gccngngttc cngttggcat ccgggaaan tgagactgtg 180
tcggtaccag agntaggatg gccntccttc ccngcccgg ccttnttggc gccttgcgat 240
ccttcccgaa ccggcccntg gcgtctccgc cttnggcaact tgcacatntg gcggcccagg 300
atggcgcttc cgggatggcg ccagcgcgcg tacgtcatca cggagcgtcc atgtgttcct 360
tctgtccaag cgcntaggag cctgcgcgta ctcccagcaa ggaagatgta ggaccaaaat 420
gtagaagcac ttaacatgaa cgtcaaaacg atgaccaatc acagggcgat atatgcgcat 480
gcgcaatgtt ccaatcatgg ctcataagca atccggaagt ggccaattaa atatactatt 540
tactaatcca gggttacaca gtgaaaccct gtctcgaaaa ataaacacag ggctggagag 600
atggctcact gattaagaac actgactgct cttccagaag tcttgagtcc aattccgagc 660
aagcacatgg tggctcacia ccactctgta cagattctgg tttatgtnga gacaactaca 720
gtgtactcgt attgaaagnt ncccacctgt aggttnggca agctaaanga gatc 774

<210> 180
<211> 248
<212> DNA
<213> Rattus norvegicus

<400> 180
tgacacttca tggaaactga gaccgggagc ttccaccaga aggcactgcc cagtggagaa 60
aaccgacttc tttttgttgt tgttctgatg ttttgttttt gagataaagg tctcactgtg 120
tagctcaggc tggttttgaa atcaggatcc tgaccctcag gaatgttaaa gtgcctaaaa 180
gtgngacaa attattttac gtgcctttga aagacttcac ctgtaggtnn ggcagctag 240
aagagatc 248

<210> 181
<211> 880
<212> DNA
<213> Rattus norvegicus

<400> 181

aanatggntt	ggttntaaag	gttaaaaattg	gggcaaaatt	tttccgccc	ggtccttaaa	60
ccggattaac	tccaaggcca	aaattccgag	ggggaatcaa	caacaaggac	ccaaccggat	120
taaggcgggt	tcaaacaaac	ttggatttcc	ngcccttttg	ggcgggggaa	atgggcacgg	180
gngcattcca	agcngntcaa	ggttccggct	tgcggacggt	taacacaant	aggtttctca	240
tctagattgg	ccngcgttgc	ggttgagcat	ccgggaaaat	tgagattgtg	tcggtaccag	300
aggtaggatg	ggccttcctt	ccngccccg	gcttcctggc	gccttgcnat	ccttcccga	360
ccggcccttg	ggtctccggc	cttgggcact	tgcacatctg	gcggccagga	tgcgcttccg	420
ggatggcgcc	agcgcgcgta	cgatcatcac	gagcgtccat	gtgttcnttc	tgtccaagcg	480
cttaggagcc	tgcgcgtact	cccagcaagg	aagatgtagg	acaaaaatgt	agaagcactt	540
aacatgaacg	tcaaaacgat	gaccaatcac	agggcgatat	atgcgcgatgc	gcaatgttcc	600
aatcatggct	cataagcaat	ccggaagtgg	ccaattaaat	atactattta	ctaattccagg	660
gttacacagt	gaaaccctgt	ctcgaaaaat	aaacacaggg	ctggagagat	ggctcactga	720
ttaagaacac	tgactgctct	tccagaagtc	ttgagttcaa	ttccgagcaa	gcacatggtg	780
gctcacaacc	atctgtaaca	gattctgggt	tatctgggnt	cnactacagt	gtannggcat	840
tgaaagatnn	tacctgtagg	ttggncagct	aaaaaggatc			880

<210> 182

<211> 864

<212> DNA

<213> Rattus norvegicus

<400> 182

aattttaant	tggtggnata	anggcttgnc	catatccttc	ctnttgtttg	ccctaagtaa	60
cagccaattg	ggggagaant	ttntgtcag	tatcatattt	ttcgttaggg	aacggaggcn	120
caggaantga	tcctnttggg	ttacagtcac	tttagcatag	gntgacagtt	ggngaccaan	180
tnatcttgcc	gtgttggaag	gagaggggan	taaggntgaa	gctcttgagt	ccnttgange	240
ccttggaatc	gggaantccc	ttaaaccaac	cccttttgcc	gttgaattgc	accaaccaga	300
ttcttccagt	ctgcttgagg	angacaggac	ttcattgctn	tggagagggg	caggagggtt	360
gggagttgac	ntnacagggc	tcagggatcc	ttttagaagg	gtccagggtc	atggcttccc	420
ccccccccag	ccaggtcaga	cactaaagtg	tcttaagccc	ctccatactt	gccgctcccc	480
cacnttggtg	gaagccggcc	attaggcagg	gaccgtctct	gggagaggcc	aagccctctg	540
gctcacttgt	ggatttcctt	taagcaagac	ttcctctctg	cttccaggac	tcctgtcaaa	600
caagaggggc	cctggcttag	agtttgggag	ctgcaggcag	aacagacatt	ccccgatgac	660
tcacaagcct	ggaactctgt	gggccagcag	gaatggggat	ggctttctgg	tcagtcaggg	720
tcaactggga	cactcactct	gagacaggga	ggcaagggag	aaacagggtca	gaggtagaga	780
gagctcagtc	ccagggactc	acgttgaggt	ccctaagggtg	cgctagggag	aggnttttac	840
attcggttng	gcaagctaaa	agag				864

<210> 183

<211> 874

<212> DNA

<213> Rattus norvegicus

<400> 183

gaggttggac	cacaaggagn	ttggnggaaa	atnnaaaagt	caacctatca	gggtgtcttt	60
tagtttggaa	cagaggcttg	ggcagaaata	tgggcaagta	ttaggaaagt	acaaggggaa	120
atgttgtcaa	cgcgnttggt	ttcccagttg	ttgnactgat	ccnccagga	tgttttccca	180
cntatgntat	ggaacctctt	ctttcaggaa	gccatntna	ncntatggnt	tgcaaccctt	240
ttgggggtcgc	aacagcaggt	attaacatta	ggattcataa	cgntagcaaa	atnacagtta	300
tggagtagca	atgaaataac	tctatgnttg	ggagggtcac	cacaacanga	gggacgggat	360
cacaggnttt	tagcattagg	aaggttgagg	accttatttc	agagtgtcnt	gacaatcntt	420
cntgggacca	cttgacttna	tctggagccc	tttccctcac	gctcntactc	cttaccatct	480
ctgcacagct	ctntgaggct	tagagcggtc	tttcttcata	gctttccntt	ttccttcagg	540
tatgcagtca	catcttgctt	tagaccccag	ggacattccg	tgtctgactc	actgcacaaa	600
atagtttccc	acatatgagt	cctcaaccgc	cccacatcac	gagacggaca	agaccggaga	660
cgccatacat	tctgtatattg	ccctccttcc	tcattttaa	aggaatttgt	tgctgtttta	720
tttttccatta	tttgtgtgtg	tgtgtgtgtg	tgtgtgtgtg	tgtgtgtgtg	tgtgtgtgtg	780
tgcgcgcgca	cgtaaatatg	ccgctcagaa	tagtctaaaa	ctgctgggct	tgaaagacnt	840
ncacctgtag	gtttgggcna	gctaaaagag	tatc			874

<210> 184
 <211> 886
 <212> DNA
 <213> Rattus norvegicus

<400> 184

atTTTTnaat	tgcagcaatc	ctcctgcctt	ttttcttggg	tgttaantca	caggatnttt	60
gcacacttga	ggttgaantt	gcagcaatcc	tcctgctttt	gtttnttggg	cgcttggatt	120
atagtatgtg	cataacactt	gagcagtaac	tgttttcttc	aatctcattt	atctcagaag	180
ttcccttgn	tgattcagac	gttattaatt	aggcaaacca	atgttgattg	tcattacca	240
tgagttgctt	ggcttgtgag	atgcatactg	tgtgttcgtg	aggcacntac	tgtgaggcat	300
gtgcccgtga	ggttcattggc	tgtgaggtgt	gtgcccgtga	ggttcattggc	tttctngacc	360
acngggagta	tgaaggagag	gaatcctacg	tttgatgcca	gccagggtta	tacagcaaga	420
tcccgtctca	aaacaaaatg	aagaagtaga	gagattagt	ttaataagca	actgaggcct	480
tgaagggctg	aggtcaggcg	gtgccctggt	gcacacacag	aagcgtgcca	gtgacgtcag	540
acagactcag	ccctgtgtca	gacaggccgg	agggtgactg	gccatgtggc	gtgattggac	600
acattcccaa	aaaaggaact	cgatggaaga	ggctcctcnt	gctccagaca	gggcggtggg	660
tatgtgactt	gtgcgagatt	agtctcatat	cctattgcta	gcctgtgcct	ggtaccacgg	720
acatgggtaca	atccaggag	gagccgtaag	cactacaggg	gagccatcct	gaatcccagc	780
aagtccaact	tctgtttttt	cttccttccc	cgcaacatta	ggaatgactt	ctaagagngc	840
tgttgaaaga	ctttcacctg	taggttgggc	aagcttaaaa	gaggat		886

<210> 185
 <211> 865
 <212> DNA
 <213> Rattus norvegicus

<400> 185

tggaggtaaa	agtcacaagn	ttttcaaggg	tttgagatga	cagttcaacg	tgagnattng	60
acaaggattg	attcttgttn	acaggaaagn	tccccatccc	accaananac	accgtgttca	120
ggcccantgc	tcagagctcc	gggcccagc	gaagggcaaa	cggccactga	ttggaaagnt	180
gcagtttaaa	gacatgtccc	aggaactggt	anccttgtgt	gactggactt	agccttgcaa	240
ntctgtctga	agcataacnt	gntgctgtct	ntgggcgagc	atztatgtgc	cccacttgag	300
acccatctca	ggacacgcag	gacacggtcc	agtggagctt	tccctccaga	gagaggtggt	360
agggncctat	agtgagcttc	caaggacagg	ggaccagaac	ggtgaaaaca	aaccagggct	420
gtgaaggaga	gcagggcggg	ggggggggga	ggggggggcg	tctntagaat	agattgaacc	480
tgcagagctg	cttgctacct	gaagtgtgca	cccttttacc	cacccacntc	atctgtctct	540
gcttgaccat	ctcagcaagt	gtcacctcgc	tgccaggaca	caagtttcct	aaagcttatt	600
tcagtgtcag	ccgctgggga	gacacattca	gggcatgggc	gtcccccagc	cctcggggag	660
aatgtgggag	gtggcgatgt	gggagggtat	cgagagaaga	gaatgcttaa	gaaccatcca	720
gggaacctgt	gcgtttgaag	gtctgagtta	cacacaggct	gctcaggaag	gagctagagc	780
tccaaatagg	agctgtgatc	aggctgtgtg	tgtgtgcctg	gtgaaagact	ttnacctgta	840
ggtttgggcn	agcttgaaaa	gtatc				865

<210> 186
 <211> 859
 <212> DNA
 <213> Rattus norvegicus

<400> 186

cangagcant	ntgaancagg	catttntgga	agggtccng	agaaaacacg	tggaattnct	60
tgtctctggg	acttttagtnc	cagcnaggan	gatncagtga	gggaacacac	cgggcttttg	120
ttgtgcacgg	gaggccaggc	tcancnncct	tgggagnttg	acatccagca	ggctatanac	180
agtgatccag	gggacatgta	cacatgggga	actgnccagg	cagagaaaga	caagagaaaa	240
tctcaaanga	tgaagacaga	gangagtaat	atggccagaa	ngatacagtg	cctcntgcat	300
aacccttgag	tttaattttcc	agggtcaact	gtattttgaa	agtataaatg	aaagtccctg	360
aagtaataaa	tttataggat	gttagtatca	cactgttcag	aatagctcaa	aaaatcctgc	420
cntgtcctct	taagtatgtg	aatcatcttt	tactgcaacg	tgtccacaat	gtatatacta	480
catacccaaa	agtcctcact	gttatcccaa	ttagtaggct	ggctgccaat	agttgtccat	540
acagagtgcc	tgctgctgtg	gccatccnta	ctgtagtaaa	cagtcatcca	aagctcagga	600
gtgaggctat	tgtagaaatg	cacttcctgg	gggccctact	gtcagtgagc	acctgagaga	660

gaaagggaca	caggcccaag	gtgggaggcc	ttagataaag	gcccacatg	ctcaggaaag	720
gatttntaca	gatctcttag	ggaagttaca	atcaaattca	tacctcacag	cagagctcag	780
gagaagaatc	cataaagnnt	gaagacatgc	ttgtngtgnc	tgaaggacnn	tacntgtagn	840
tnngggcngc	tgaaattttt					859

<210> 187
 <211> 883
 <212> DNA
 <213> Rattus norvegicus

<400> 187						
gggggggnnaa	naattttccca	aaaanngnng	gncccnttttt	ttatccagtt	tnngggttgaa	60
natctcnccc	cggttttnaaa	accncaatg	gggaaaaagg	tacancngat	tntttatngg	120
tttggggcgga	gggggaaatt	tttttggttt	ttttnttttn	gggatttttg	aaaaaaaaan	180
gaanttttta	ggtttcccn	angtaattta	tttcaatgga	ccattttttg	ggttctccct	240
tttgtaanan	gttaaaaaana	aggganttcc	aannttnctt	ttcagtttcc	agtttcacct	300
tcngtagcag	accagttttt	catttttgagn	tggtnccnaa	aaggnttccc	aactatgttc	360
aataccacag	gcagcctgca	ggaggagaa	tgggtatgta	tttaacagca	tttgaccaa	420
ttataagagc	agagaggagc	tttaccaggg	acaggaaggc	aaaagagctg	aatnttaaac	480
aaaagaataa	gaacaggatn	tcactctgtg	gctgtcacag	tgggtttgca	gagcaggaga	540
acacagacag	gattagctat	aaagtgtgta	cattagttat	tnatattggg	catacaatac	600
ttaaatagtt	ctagggcaag	agaaatgaac	agaaatgacc	ttataagagc	cagagctgta	660
gccacagctt	tcctttgtgt	tagtttgnta	gttcantctt	tccagggcag	tctggtggat	720
nacaccaaat	tgcttttagaa	aatgctagnt	ctactgtccc	tgtctattgt	cagctttgca	780
atgtgcatag	tgacaggagt	tgccctgggag	cttggggcctt	atgtttttgca	gatccattgt	840
aattaaaaaa	gaattgtaag	gagatggagg	cacgggggtga	ggg		883

<210> 188
 <211> 987
 <212> DNA
 <213> Rattus norvegicus

<400> 188						
canntttccc	ntanccgaaa	ntttnttttt	ggcccaaccn	gtaagacgga	tttttttncaa	60
ttgcggancc	aatggaaccg	gttttgccggg	nngtnntttg	gggtgaacgg	ttntnttaant	120
ggngccaaan	aaggtnnatt	ggaggnonta	tttgaattgg	tntgtaaanc	ntttntcttg	180
aaaaggnttg	tagcnttaan	ccggcaacaa	accaccgggt	gtacgggtgt	tttttggtgc	240
agccgcagnt	tangggcaga	aaaagaattc	aggagatcct	taancctttt	nttcgggntc	300
tgacgctcat	gttggtgtga	ttnttgagcg	gttacanttt	nacacggaat	tctattcact	360
ggcatgactc	acttccccgg	gttcatgagt	cagcagtgag	ttatctaggt	atgtgttttg	420
tgttgcaaat	tcccatatat	agaatatggt	cccggggacc	atagaaagtt	gagcagttgg	480
gcaaaattct	tccccaggag	gtgtgttcaa	gagaagaggt	tcagcccttg	aaagagcttc	540
cgtttctatc	ntcaciaaaca	tcntgaaaaa	taggctaaat	gttattctgt	gaagagtcac	600
tactggtttt	actgatgggt	gaagttctca	gactgtctag	aaaggtaatt	ttaaaacgta	660
agaaaattag	accctgtccc	ccagatctgt	tgggtgttgag	aaatctgtag	aaacttgagc	720
aggaggaagt	acaagaaagt	atgtagctat	tgtaatccct	ttcaggaagg	atgtgtttta	780
agctctattg	ttagggcctt	tcgcttgac	tgtgaagtaa	ttttttactt	tttataagct	840
taaaggatgg	cttaataaga	cgtcttagaa	atgtccacat	tatattggat	caacaaacgc	900
caaagcatca	gtttgcgtca	ggggccacgg	ggcatgggga	ctaacgggtc	attctttttg	960
aatctggatg	cctaggtgca	gtagggc				987

<210> 189
 <211> 1031
 <212> DNA
 <213> Rattus norvegicus

<400> 189						
agtccctgcc	ccntgggaag	ggtaaccttg	acctaaccct	cnaataantt	ncccttagga	60
ttgcttgga	tggnnttttac	gcgtaaccct	antaaaactt	tgangaaant	tccttccctt	120
tgattctagc	aatgnaccgg	catttttgcca	atcnattcng	ctgnantaat	tatgaagttc	180
cggtttaanc	aatttgaagt	ttaacattca	tgtatcttca	cagtcattgt	tttttgtgta	240

DEMANDE OU BREVET VOLUMINEUX

LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND PLUS D'UN TOME.

CECI EST LE TOME 1 DE 2
CONTENANT LES PAGES 1 À 244

NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets

JUMBO APPLICATIONS/PATENTS

THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE VOLUME

THIS IS VOLUME 1 OF 2
CONTAINING PAGES 1 TO 244

NOTE: For additional volumes, please contact the Canadian Patent Office

NOM DU FICHER / FILE NAME :

NOTE POUR LE TOME / VOLUME NOTE:

What is claimed is:

1. An isolated nucleic acid comprising a nucleotide sequence set forth in SEQ ID NO: 211, SEQ ID NO: 212, SEQ ID NO: 213, SEQ ID NO: 214, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 254, SEQ ID NO: 255, SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 258, SEQ ID NO: 259, SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, SEQ ID NO: 266, SEQ ID NO: 267, SEQ ID NO: 268, SEQ ID NO: 269, SEQ ID NO: 270, SEQ ID NO: 271, SEQ ID NO: 272, SEQ ID NO: 273, SEQ ID NO: 274, SEQ ID NO: 275, SEQ ID NO: 276, SEQ ID NO: 277, SEQ ID NO: 278, SEQ ID NO: 279, SEQ ID NO: 280, SEQ ID NO: 281, SEQ ID NO: 282, SEQ ID NO: 283, SEQ ID NO: 284, SEQ ID NO: 285, SEQ ID NO: 286, SEQ ID NO: 287, SEQ ID NO: 288, SEQ ID NO: 289, SEQ ID NO: 290, SEQ ID NO: 291, SEQ ID NO: 292, SEQ ID NO: 293, SEQ ID NO: 294, SEQ ID NO: 295, SEQ ID NO: 296, SEQ ID NO: 297, SEQ ID NO: 298, SEQ ID NO: 299, SEQ ID NO: 300, SEQ ID NO: 301, SEQ ID NO: 302, SEQ ID NO: 303, SEQ ID NO: 304, SEQ ID NO: 305, SEQ ID NO: 306, SEQ ID NO: 307, SEQ ID NO: 308, SEQ ID NO: 309, SEQ ID NO: 310, SEQ ID NO: 311, SEQ ID NO: 312, SEQ ID NO: 313, SEQ ID NO: 314, SEQ ID NO: 315, SEQ ID NO: 316, SEQ ID NO: 317, SEQ ID NO: 318, SEQ ID NO: 319, SEQ ID NO: 320, SEQ ID NO: 321, SEQ ID NO: 322, SEQ ID NO: 323, SEQ ID NO: 324, SEQ ID NO: 325, SEQ ID NO: 326, SEQ ID NO: 327, SEQ ID NO: 328, SEQ ID NO: 329, SEQ ID NO: 330, SEQ ID NO: 331, SEQ ID NO: 332, SEQ ID NO: 333, SEQ ID NO: 334, SEQ ID NO: 335, SEQ ID NO: 336, SEQ ID NO: 337, SEQ ID NO: 338, SEQ ID NO: 339, SEQ ID NO: 340, SEQ ID NO: 341, SEQ ID NO: 342, SEQ ID NO: 343, SEQ ID NO: 344, SEQ ID NO: 345, SEQ ID NO: 346, SEQ ID NO: 347, SEQ ID NO: 348, SEQ ID NO: 349, SEQ ID NO: 350, SEQ ID NO: 351, SEQ ID NO: 352, SEQ ID NO: 353, SEQ ID NO: 354, SEQ ID NO: 355, SEQ ID NO: 356, SEQ ID NO: 357, SEQ ID NO: 358, SEQ ID NO: 359, SEQ ID NO: 360, SEQ ID NO: 361, SEQ ID NO: 362, SEQ ID NO: 363,

SEQ ID NO: 364, SEQ ID NO: 365, SEQ ID NO: 366, SEQ ID NO: 367, SEQ ID NO: 368, SEQ ID NO: 369, SEQ ID NO: 370, SEQ ID NO: 371, SEQ ID NO: 372, SEQ ID NO: 373, SEQ ID NO: 374, SEQ ID NO: 375, SEQ ID NO: 376, SEQ ID NO: 377, SEQ ID NO: 378, SEQ ID NO: 379, SEQ ID NO: 380, SEQ ID NO: 381, SEQ ID NO: 382, SEQ ID NO: 383, SEQ ID NO: 384, SEQ ID NO: 385, SEQ ID NO: 386, SEQ ID NO: 387, SEQ ID NO: 388, SEQ ID NO: 389, SEQ ID NO: 390, SEQ ID NO: 391, SEQ ID NO: 392, SEQ ID NO: 393, SEQ ID NO: 394, SEQ ID NO: 395, SEQ ID NO: 396, SEQ ID NO: 397, SEQ ID NO: 398, SEQ ID NO: 399, SEQ ID NO: 400, SEQ ID NO: 401, SEQ ID NO: 402, SEQ ID NO: 403, SEQ ID NO: 404, SEQ ID NO: 405, SEQ ID NO: 406, SEQ ID NO: 407, SEQ ID NO: 408, SEQ ID NO: 409, SEQ ID NO: 410, SEQ ID NO: 411, SEQ ID NO: 412, SEQ ID NO: 413, SEQ ID NO: 414, SEQ ID NO: 415, SEQ ID NO: 416, SEQ ID NO: 417, SEQ ID NO: 418, SEQ ID NO: 419, SEQ ID NO: 420, SEQ ID NO: 421, SEQ ID NO: 422, SEQ ID NO: 423, SEQ ID NO: 424, SEQ ID NO: 425, SEQ ID NO: 426, SEQ ID NO: 427, SEQ ID NO: 428.

2. An allelic variant or homolog of the nucleic acid of claim 1.

3. An isolated nucleic acid encoding the protein encoded by the gene comprising the nucleotide sequence set forth in SEQ ID NO: 211, SEQ ID NO: 212, SEQ ID NO: 213, SEQ ID NO: 214, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 254, SEQ ID NO: 255, SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 258, SEQ ID NO: 259, SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, SEQ ID NO: 266, SEQ ID NO: 267, SEQ ID NO: 268, SEQ ID NO: 269, SEQ ID NO: 270, SEQ ID NO: 271, SEQ ID NO: 272, SEQ ID NO: 273, SEQ ID NO: 274, SEQ ID NO: 275, SEQ ID NO: 276, SEQ ID NO: 277, SEQ ID NO: 278, SEQ ID NO: 279, SEQ ID

NO: 280, SEQ ID NO: 281, SEQ ID NO: 282, SEQ ID NO: 283, SEQ ID NO: 284, SEQ ID NO: 285, SEQ ID NO: 286, SEQ ID NO: 287, SEQ ID NO: 288, SEQ ID NO: 289, SEQ ID NO: 290, SEQ ID NO: 291, SEQ ID NO: 292, SEQ ID NO: 293, SEQ ID NO: 294, SEQ ID NO: 295, SEQ ID NO: 296, SEQ ID NO: 297, SEQ ID NO: 298, SEQ ID NO: 299, SEQ ID NO: 300, SEQ ID NO: 301, SEQ ID NO: 302, SEQ ID NO: 303, SEQ ID NO: 304, SEQ ID NO: 305, SEQ ID NO: 306, SEQ ID NO: 307, SEQ ID NO: 308, SEQ ID NO: 309, SEQ ID NO: 310, SEQ ID NO: 311, SEQ ID NO: 312, SEQ ID NO: 313, SEQ ID NO: 314, SEQ ID NO: 315, SEQ ID NO: 316, SEQ ID NO: 317, SEQ ID NO: 318, SEQ ID NO: 319, SEQ ID NO: 320, SEQ ID NO: 321, SEQ ID NO: 322, SEQ ID NO: 323, SEQ ID NO: 324, SEQ ID NO: 325, SEQ ID NO: 326, SEQ ID NO: 327, SEQ ID NO: 328, SEQ ID NO: 329, SEQ ID NO: 330, SEQ ID NO: 331, SEQ ID NO: 332, SEQ ID NO: 333, SEQ ID NO: 334, SEQ ID NO: 335, SEQ ID NO: 336, SEQ ID NO: 337, SEQ ID NO: 338, SEQ ID NO: 339, SEQ ID NO: 340, SEQ ID NO: 341, SEQ ID NO: 342, SEQ ID NO: 343, SEQ ID NO: 344, SEQ ID NO: 345, SEQ ID NO: 346, SEQ ID NO: 347, SEQ ID NO: 348, SEQ ID NO: 349, SEQ ID NO: 350, SEQ ID NO: 351, SEQ ID NO: 352, SEQ ID NO: 353, SEQ ID NO: 354, SEQ ID NO: 355, SEQ ID NO: 356, SEQ ID NO: 357, SEQ ID NO: 358, SEQ ID NO: 359, SEQ ID NO: 360, SEQ ID NO: 361, SEQ ID NO: 362, SEQ ID NO: 363, SEQ ID NO: 364, SEQ ID NO: 365, SEQ ID NO: 366, SEQ ID NO: 367, SEQ ID NO: 368, SEQ ID NO: 369, SEQ ID NO: 370, SEQ ID NO: 371, SEQ ID NO: 372, SEQ ID NO: 373, SEQ ID NO: 374, SEQ ID NO: 375, SEQ ID NO: 376, SEQ ID NO: 377, SEQ ID NO: 378, SEQ ID NO: 379, SEQ ID NO: 380, SEQ ID NO: 381, SEQ ID NO: 382, SEQ ID NO: 383, SEQ ID NO: 384, SEQ ID NO: 385, SEQ ID NO: 386, SEQ ID NO: 387, SEQ ID NO: 388, SEQ ID NO: 389, SEQ ID NO: 390, SEQ ID NO: 391, SEQ ID NO: 392, SEQ ID NO: 393, SEQ ID NO: 394, SEQ ID NO: 395, SEQ ID NO: 396, SEQ ID NO: 397, SEQ ID NO: 398, SEQ ID NO: 399, SEQ ID NO: 400, SEQ ID NO: 401, SEQ ID NO: 402, SEQ ID NO: 403, SEQ ID NO: 404, SEQ ID NO: 405, SEQ ID NO: 406, SEQ ID NO: 407, SEQ ID NO: 408, SEQ ID NO: 409, SEQ ID NO: 410, SEQ ID NO: 411, SEQ ID NO: 412, SEQ ID NO: 413, SEQ ID NO: 414, SEQ ID NO: 415, SEQ ID NO: 416, SEQ ID NO: 417, SEQ ID NO: 418, SEQ ID NO: 419, SEQ ID NO: 420, SEQ ID NO: 421, SEQ ID NO: 422, SEQ ID NO: 423, SEQ ID NO: 424, SEQ ID NO: 425, SEQ ID NO: 426, SEQ ID NO: 427, SEQ ID NO: 428..

4. A host cell containing the nucleic acid of claim 1, 2 or 3.
5. A nucleic acid that selectively hybridizes under stringent conditions with the nucleic acid of claim 1, 2 or 3.
6. A nucleic acid having a region within an exon wherein the region has at least 50 % homology with the nucleic acid of claim 1, 2 or 3.
7. A nucleic acid having a region within an exon wherein the region has at least 60 % homology with the nucleic acid of claim 1, 2 or 3.
8. A nucleic acid having a region within an exon wherein the region has at least 70 % homology with the nucleic acid of claim 1, 2 or 3.
9. A nucleic acid having a region within an exon wherein the region has at least 80 % homology with the nucleic acid of claim 1, 2 or 3.
10. A nucleic acid having a region within an exon wherein the region has at least 90 % homology with the nucleic acid of claim 1, 2 or 3.
11. A nucleic acid having a region within an exon wherein the region has at least 95 % homology with the nucleic acid of claim 1, 2 3.
12. A protein encoded by the nucleic acid of claims 1, 2, 3, 5, 6, 7, 8, 9, 10 or 11.
13. A nucleic acid comprising a regulatory region of a gene comprising the nucleotide sequence set forth in SEQ ID NO: 211, SEQ ID NO: 212, SEQ ID NO: 213, SEQ ID NO: 214, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, SEQ ID NO: 234 SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, SEQ

ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, SEQ ID NO:246, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 254, SEQ ID NO:255, SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 258, SEQ ID NO: 259, SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, SEQ ID NO:264, SEQ ID NO: 265, SEQ ID NO: 266, SEQ ID NO: 267, SEQ ID NO: 268, SEQ ID NO: 269, SEQ ID NO: 270, SEQ ID NO: 271, SEQ ID NO: 272, SEQ ID NO: 273, SEQ ID NO: 274 SEQ ID NO: 275, SEQ ID NO: 276, SEQ ID NO: 277, SEQ ID NO: 278, SEQ ID NO: 279, SEQ ID NO: 280, SEQ ID NO: 281, SEQ ID NO: 282, SEQ ID NO: 283, SEQ ID NO: 284, SEQ ID NO: 285, SEQ ID NO: 286, SEQ ID NO: 287, SEQ ID NO: 288, SEQ ID NO: 289, SEQ ID NO: 290, SEQ ID NO: 291, SEQ ID NO: 292, SEQ ID NO: 293, SEQ ID NO: 294, SEQ ID NO:295, SEQ ID NO: 296, SEQ ID NO: 297, SEQ ID NO: 298, SEQ ID NO299, SEQ ID NO: 300, SEQ ID NO: 301, SEQ ID NO: 302, SEQ ID NO: 303, SEQ ID NO:304, SEQ ID NO: 305, SEQ ID NO: 306, SEQ ID NO: 307, SEQ ID NO: 308, SEQ ID NO: 309, SEQ ID NO: 310, SEQ ID NO: 311, SEQ ID NO: 312, SEQ ID NO: 313, SEQ ID NO: 314 SEQ ID NO: 315, SEQ ID NO: 316, SEQ ID NO: 317, SEQ ID NO: 318, SEQ ID NO: 319, SEQ ID NO: 320, SEQ ID NO: 321, SEQ ID NO: 322, SEQ ID NO: 323, SEQ ID NO: 324, SEQ ID NO: 325, SEQ ID NO: 326, SEQ ID NO: 327, SEQ ID NO: 328, SEQ ID NO: 329, SEQ ID NO: 330, SEQ ID NO: 331, SEQ ID NO: 332, SEQ ID NO: 333, SEQ ID NO: 334, SEQ ID NO:335, SEQ ID NO: 336, SEQ ID NO: 337, SEQ ID NO: 338, SEQ ID NO: 339, SEQ ID NO: 340, SEQ ID NO: 341, SEQ ID NO: 342, SEQ ID NO: 343, SEQ ID NO:344, SEQ ID NO: 345, SEQ ID NO: 346, SEQ ID NO: 347, SEQ ID NO: 348, SEQ ID NO: 349, SEQ ID NO: 350, SEQ ID NO: 351, SEQ ID NO: 352, SEQ ID NO: 353, SEQ ID NO: 354 SEQ ID NO: 355, SEQ ID NO: 356, SEQ ID NO: 357, SEQ ID NO: 358, SEQ ID NO: 359, SEQ ID NO: 360, SEQ ID NO: 361, SEQ ID NO: 362, SEQ ID NO: 363, SEQ ID NO: 364, SEQ ID NO: 365, SEQ ID NO: 366, SEQ ID NO: 367, SEQ ID NO: 368, SEQ ID NO: 369, SEQ ID NO: 370, SEQ ID NO: 371, SEQ ID NO: 372, SEQ ID NO: 373, SEQ ID NO: 374, SEQ ID NO:375, SEQ ID NO: 376, SEQ ID NO: 377, SEQ ID NO: 378, SEQ ID NO: 379, SEQ ID NO: 380, SEQ ID NO: 381, SEQ ID NO: 382, SEQ ID NO383, SEQ ID NO:384, SEQ ID NO: 385, SEQ ID NO: 386, SEQ ID NO: 387, SEQ ID NO: 388, SEQ ID NO: 389, SEQ ID NO: 390, SEQ ID NO: 391, SEQ ID NO: 392, SEQ ID NO: 393, SEQ ID NO: 394 SEQ ID NO: 395, SEQ ID NO: 396, SEQ ID NO: 397, SEQ ID NO: 398, SEQ ID NO: 399, SEQ ID

NO: 400, SEQ ID NO: 401, SEQ ID NO: 402, SEQ ID NO: 403, SEQ ID NO: 404, SEQ ID NO: 405, SEQ ID NO: 406, SEQ ID NO: 407, SEQ ID NO: 408, SEQ ID NO: 409, SEQ ID NO: 410, SEQ ID NO: 411, SEQ ID NO: 412, SEQ ID NO: 413, SEQ ID NO: 414, SEQ ID NO: 415, SEQ ID NO: 416, SEQ ID NO: 417, 418, SEQ ID NO: 419, SEQ ID NO: 420, SEQ ID NO: 421, SEQ ID NO: 422, SEQ ID NO: 423, SEQ ID NO: 424, SEQ ID NO: 425, SEQ ID NO: 426, SEQ ID NO: 427, SEQ ID NO: 428.

14. A construct comprising a regulatory region of claim 13, wherein the regulatory region is functionally linked to a reporter gene.

15. A method of identifying a cellular gene necessary for viral growth in a cell and nonessential for cellular survival, comprising

- (a) transferring into a cell culture growing in serum-containing medium a vector encoding a selective marker gene lacking a functional promoter,
- (b) selecting cells expressing the marker gene,
- (d) infecting the cell culture with the virus, and
- (e) isolating from the surviving cells a cellular gene within which the marker gene is inserted, thereby identifying a gene necessary for viral growth in a cell and nonessential for cellular survival.

16. A method of reducing or inhibiting a viral infection in a subject, comprising administering to the subject an amount of a composition that inhibits expression or functioning of a gene product encoded by a gene comprising the nucleic acid set forth in SEQ ID NO: 211, SEQ ID NO: 212, SEQ ID NO: 213, SEQ ID NO: 214, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 254, SEQ ID NO: 255, SEQ ID NO: 256, SEQ ID NO: 257, SEQ

ID NO: 258, SEQ ID NO: 259, SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, SEQ ID NO: 266, SEQ ID NO: 267, SEQ ID NO: 268, SEQ ID NO: 269, SEQ ID NO: 270, SEQ ID NO: 271, SEQ ID NO: 272, SEQ ID NO: 273, SEQ ID NO: 274 SEQ ID NO: 275, SEQ ID NO: 276, SEQ ID NO: 277, SEQ ID NO: 278, SEQ ID NO: 279, SEQ ID NO: 280, SEQ ID NO: 281, SEQ ID NO: 282, SEQ ID NO: 283, SEQ ID NO: 284, SEQ ID NO: 285, SEQ ID NO: 286, SEQ ID NO: 287, SEQ ID NO: 288, SEQ ID NO: 289, SEQ ID NO: 290, SEQ ID NO: 291, SEQ ID NO: 292, SEQ ID NO: 293, SEQ ID NO: 294, SEQ ID NO: 295, SEQ ID NO: 296, SEQ ID NO: 297, SEQ ID NO: 298, SEQ ID NO: 299, SEQ ID NO: 300, SEQ ID NO: 301, SEQ ID NO: 302, SEQ ID NO: 303, SEQ ID NO: 304, SEQ ID NO: 305, SEQ ID NO: 306, SEQ ID NO: 307, SEQ ID NO: 308, SEQ ID NO: 309, SEQ ID NO: 310, SEQ ID NO: 311, SEQ ID NO: 312, SEQ ID NO: 313, SEQ ID NO: 314 SEQ ID NO: 315, SEQ ID NO: 316, SEQ ID NO: 317, SEQ ID NO: 318, SEQ ID NO: 319, SEQ ID NO: 320, SEQ ID NO: 321, SEQ ID NO: 322, SEQ ID NO: 323, SEQ ID NO: 324, SEQ ID NO: 325, SEQ ID NO: 326, SEQ ID NO: 327, SEQ ID NO: 328, SEQ ID NO: 329, SEQ ID NO: 330, SEQ ID NO: 331, SEQ ID NO: 332, SEQ ID NO: 333, SEQ ID NO: 334, SEQ ID NO: 335, SEQ ID NO: 336, SEQ ID NO: 337, SEQ ID NO: 338, SEQ ID NO: 339, SEQ ID NO: 340, SEQ ID NO: 341, SEQ ID NO: 342, SEQ ID NO: 343, SEQ ID NO: 344, SEQ ID NO: 345, SEQ ID NO: 346, SEQ ID NO: 347, SEQ ID NO: 348, SEQ ID NO: 349, SEQ ID NO: 350, SEQ ID NO: 351, SEQ ID NO: 352, SEQ ID NO: 353, SEQ ID NO: 354 SEQ ID NO: 355, SEQ ID NO: 356, SEQ ID NO: 357, SEQ ID NO: 358, SEQ ID NO: 359, SEQ ID NO: 360, SEQ ID NO: 361, SEQ ID NO: 362, SEQ ID NO: 363, SEQ ID NO: 364, SEQ ID NO: 365, SEQ ID NO: 366, SEQ ID NO: 367, SEQ ID NO: 368, SEQ ID NO: 369, SEQ ID NO: 370, SEQ ID NO: 371, SEQ ID NO: 372, SEQ ID NO: 373, SEQ ID NO: 374, SEQ ID NO: 375, SEQ ID NO: 376, SEQ ID NO: 377, SEQ ID NO: 378, SEQ ID NO: 379, SEQ ID NO: 380, SEQ ID NO: 381, SEQ ID NO: 382, SEQ ID NO: 383, SEQ ID NO: 384, SEQ ID NO: 385, SEQ ID NO: 386, SEQ ID NO: 387, SEQ ID NO: 388, SEQ ID NO: 389, SEQ ID NO: 390, SEQ ID NO: 391, SEQ ID NO: 392, SEQ ID NO: 393, SEQ ID NO: 394 SEQ ID NO: 395, SEQ ID NO: 396, SEQ ID NO: 397, SEQ ID NO: 398, SEQ ID NO: 399, SEQ ID NO: 400, SEQ ID NO: 401, SEQ ID NO: 402, SEQ ID NO: 403, SEQ ID NO: 404, SEQ ID NO: 405, SEQ ID NO: 406, SEQ ID NO: 407, SEQ ID NO: 408, SEQ ID NO: 409, SEQ ID NO: 410, SEQ ID NO: 411, SEQ ID NO: 412, SEQ ID NO: 413, SEQ ID NO: 414, SEQ ID

NO:415, SEQ ID NO: 416, SEQ ID NO: 417, 418, SEQ ID NO: 419, SEQ ID NO: 420, SEQ ID NO: 421, SEQ ID NO: 422, SEQ ID NO: 423, SEQ ID NO: 424, SEQ ID NO:425, SEQ ID NO: 426, SEQ ID NO: 427, SEQ ID NO: 428.or a homolog thereof, thereby treating the viral infection.

17. The method of claim 16, wherein the composition comprises an antibody that binds a protein encoded by the gene.

18. The method of claim 16, wherein the composition comprises an antibody that binds a receptor for a protein encoded by the gene.

19. The method of claim 16, wherein the composition comprises an antisense RNA that binds an RNA encoded by the gene.

20. The method of claim 16, wherein the composition comprises a nucleic acid functionally encoding an antisense RNA that binds an RNA encoded by the gene.

21. A method of reducing or inhibiting a viral infection in a subject comprising mutating *ex vivo* in a selected cell from the subject an endogenous gene comprising the nucleic acid set forth in ,or a homolog thereof, to a mutated gene incapable of producing a functional gene product of the gene or to a mutated gene producing a reduced amount of a functional gene product of the gene, and replacing the cell in the subject, thereby reducing viral infection of cells in the subject.

22. The method of claim 21, wherein the cell is a hematopoietic cell.

23. A method of reducing or inhibiting a viral infection in a subject comprising mutating *ex vivo* in a selected cell from the subject an endogenous gene comprising a nucleic acid isolated by the method of claim 15, to a mutated gene incapable of producing a functional gene product of the gene or to a mutated gene producing a reduced amount of a functional gene product of the gene, and replacing the cell in the subject, thereby reducing viral infection of cells in the subject.

24. The method of claim 23, wherein the virus is HIV.
25. The method of claim 23, wherein the cell is a hematopoietic cell.
26. A method of increasing viral infection resistance in a subject comprising mutating *ex vivo* in a selected cell from the subject an endogenous gene comprising a nucleic acid isolated by the method of claim 15, to a mutated gene incapable of producing a functional gene product of the gene or to a mutated gene producing a reduced amount of a functional gene product of the gene, and replacing the cell in the subject, thereby reducing viral infection of cells in the subject.
27. The method of claim 26, wherein the virus is HIV.
28. The method of claim 26, wherein the cell is a hematopoietic cell.
29. A method of screening a compound for effectiveness in treating a viral infection, comprising administering the compound to a cell containing a cellular gene functionally encoding a gene product necessary for reproduction of the virus in the cell but not necessary for survival of the cell and detecting the level of the gene product produced, a decrease or elimination of the gene product indicating a compound effective for treating the viral infection.
30. The method of claim 29, wherein the cellular gene comprises the nucleic acid set forth in SEQ ID NO: 211, SEQ ID NO: 212, SEQ ID NO: 213, SEQ ID NO: 214, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 244, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 254, SEQ ID NO: 255, SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 258, SEQ ID NO: 259, SEQ ID NO: 260, SEQ

ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, SEQ ID NO: 266, SEQ ID NO: 267, SEQ ID NO: 268, SEQ ID NO: 269, SEQ ID NO: 270, SEQ ID NO: 271, SEQ ID NO: 272, SEQ ID NO: 273, SEQ ID NO: 274 SEQ ID NO: 275, SEQ ID NO: 276, SEQ ID NO: 277, SEQ ID NO: 278, SEQ ID NO: 279, SEQ ID NO: 280, SEQ ID NO: 281, SEQ ID NO: 282, SEQ ID NO: 283, SEQ ID NO: 284, SEQ ID NO: 285, SEQ ID NO: 286, SEQ ID NO: 287, SEQ ID NO: 288, SEQ ID NO: 289, SEQ ID NO: 290, SEQ ID NO: 291, SEQ ID NO: 292, SEQ ID NO: 293, SEQ ID NO: 294, SEQ ID NO: 295, SEQ ID NO: 296, SEQ ID NO: 297, SEQ ID NO: 298, SEQ ID NO: 299, SEQ ID NO: 300, SEQ ID NO: 301, SEQ ID NO: 302, SEQ ID NO: 303, SEQ ID NO: 304, SEQ ID NO: 305, SEQ ID NO: 306, SEQ ID NO: 307, SEQ ID NO: 308, SEQ ID NO: 309, SEQ ID NO: 310, SEQ ID NO: 311, SEQ ID NO: 312, SEQ ID NO: 313, SEQ ID NO: 314 SEQ ID NO: 315, SEQ ID NO: 316, SEQ ID NO: 317, SEQ ID NO: 318, SEQ ID NO: 319, SEQ ID NO: 320, SEQ ID NO: 321, SEQ ID NO: 322, SEQ ID NO: 323, SEQ ID NO: 324, SEQ ID NO: 325, SEQ ID NO: 326, SEQ ID NO: 327, SEQ ID NO: 332, SEQ ID NO: 333, SEQ ID NO: 337, SEQ ID NO: 338, SEQ ID NO: 339, SEQ ID NO: 340, SEQ ID NO: 341, SEQ ID NO: 342, SEQ ID NO: 343, SEQ ID NO: 344, SEQ ID NO: 345, SEQ ID NO: 346, SEQ ID NO: 347, SEQ ID NO: 348, SEQ ID NO: 349, SEQ ID NO: 350, SEQ ID NO: 351, SEQ ID NO: 352, SEQ ID NO: 353, SEQ ID NO: 354 SEQ ID NO: 355, SEQ ID NO: 356, SEQ ID NO: 357, SEQ ID NO: 358, SEQ ID NO: 359, SEQ ID NO: 360, SEQ ID NO: 361, SEQ ID NO: 362, SEQ ID NO: 363, SEQ ID NO: 364, SEQ ID NO: 365, SEQ ID NO: 366, SEQ ID NO: 367, SEQ ID NO: 368, SEQ ID NO: 369, SEQ ID NO: 370, SEQ ID NO: 371, SEQ ID NO: 372, SEQ ID NO: 373, SEQ ID NO: 374, SEQ ID NO: 375, SEQ ID NO: 376, SEQ ID NO: 377, SEQ ID NO: 378, SEQ ID NO: 379, SEQ ID NO: 380, SEQ ID NO: 381, SEQ ID NO: 382, SEQ ID NO: 383, SEQ ID NO: 384, SEQ ID NO: 385, SEQ ID NO: 386, SEQ ID NO: 387, SEQ ID NO: 388, SEQ ID NO: 389, SEQ ID NO: 390, SEQ ID NO: 391, SEQ ID NO: 392, SEQ ID NO: 393, SEQ ID NO: 394 SEQ ID NO: 395, SEQ ID NO: 396, SEQ ID NO: 397, SEQ ID NO: 398, SEQ ID NO: 399, SEQ ID NO: 400, SEQ ID NO: 401, SEQ ID NO: 402, SEQ ID NO: 403, SEQ ID NO: 404, SEQ ID NO: 405, SEQ ID NO: 406, SEQ ID NO: 407, SEQ ID NO: 409, SEQ ID NO: 410, SEQ ID NO: 415, SEQ ID NO: 416, SEQ ID NO: 417, 418, SEQ ID NO: 419, SEQ ID NO: 420, SEQ ID NO: 421, SEQ ID NO: 422, SEQ ID NO: 423, SEQ ID NO: 424, SEQ ID NO: 425, SEQ ID NO: 426, SEQ ID NO: 427, SEQ ID NO: 428 or a homolog thereof.

31. The method of claim 29, wherein the cellular gene is a gene identified by the method of claim 15.

32. A method of screening a compound for reducing or inhibiting a viral infection, comprising administering the compound to a cell containing the construct of claim 14 and detecting the level of the reporter gene product produced, a decrease or elimination of the reporter gene product indicating a compound for reducing or inhibiting the viral infection.

33. A method of identifying a cellular gene that can suppress a malignant phenotype in a cell, comprising

- (a) transferring into a cell culture incapable of growing well in soft agar a vector encoding a selective marker gene lacking a functional promoter,
- (b) selecting cells expressing the marker gene, and
- (c) isolating from selected cells which are capable of growing in agar a cellular gene within which the marker gene is inserted, thereby identifying a gene that can suppress a malignant phenotype in a cell.

34. A method of identifying a cellular gene that can suppress a malignant phenotype in a cell, comprising

- (a) transferring into a cell culture of non-transformed cells a vector encoding a selective marker gene lacking a functional promoter,
- (b) selecting cells expressing the marker gene, and
- (c) isolating from selected and transformed cells a cellular gene within which the marker gene is inserted, thereby identifying a gene that can suppress a malignant phenotype in a cell.

35. A method of screening for a compound for suppressing a malignant phenotype in a cell comprising administering the compound to a cell containing a cellular gene functionally encoding a gene product involved in establishment of a malignant phenotype in the cell and detecting the level of the gene product produced, a decrease or elimination of the gene product indicating a compound effective for suppressing the malignant phenotype.

36. A method of suppressing a malignant phenotype in a cell in a subject, comprising administering to the subject an amount of a composition that inhibits expression or functioning of a gene product encoded by a gene comprising the nucleic acid set forth in SEQ ID NO: 240, SEQ ID NO: 243, SEQ ID NO: 247, SEQ ID NO: 321, SEQ ID NO: 328, SEQ ID NO: 329, SEQ ID NO: 330, SEQ ID NO: 331, SEQ ID NO: 334, SEQ ID NO: 335, SEQ ID NO: 336, SEQ ID NO: 408, SEQ ID NO: 411, SEQ ID NO: 412, SEQ ID NO: 413, SEQ ID NO: 414 or a homolog thereof, thereby suppressing a malignant phenotype.
37. The method of claim 36, wherein the composition comprises an antibody that binds a protein encoded by the gene.
38. The method of claim 36, wherein the composition comprises an antibody that binds a receptor for a protein encoded by the gene.
39. The method of claim 36, wherein the composition comprises an antisense RNA that binds an RNA encoded by the gene.
40. The method of claim 36, wherein the composition comprises a nucleic acid functionally encoding an antisense RNA that binds an RNA encoded by the gene.
- 41) A method of treating a viral infection in a subject comprising administering to the subject a treatment effective amount of a composition that increases expression of a gene whose overexpression reduces or inhibits viral replication.
- 42) A method of screening a compound for effectiveness in treating a viral infection, comprising administering the compound to a cell containing a cellular gene functionally encoding a gene product whose overexpression inhibits reproduction of the virus, but does not prevent survival of the cell and detecting the level of the gene product produced, an increase in the gene product indicating a compound effective for treating a viral infection.
- 43) The method of claim 41, wherein the overexpressed gene is IGF2.

- 44) The method of claim 41, wherein the composition is an inhibitor of CTCF.
- 45) The method of claim 16 or 36, wherein the composition is a vector targeted to disrupt a gene comprising a nucleotide sequence selected from the group sequences selected from the group consisting of SEQ ID NO:211-428.
- 46) The method of claim 16 or 36, wherein the composition is a vector encoding a selective marker gene lacking a functional promoter.